PhIRDA 中国药促会 | 中国医疗器械行业协会 China Association for Medical Devices Industry | HKEX 香港交易所 | ineta

CBIIC 2020

第五届中国医药创新与投资大会

2020年9月27日-29日 中国 · 苏州

September 27-29，2020 SuZhou China

会议手册

Conference Handbook

2020

第五届中国医药创新与投资大会

2020 China BioMed Innovation and Investment Conference

CBIIC

2020 CBIIC will further open financing channel for pharmaceutical innovation, focus on China's latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle.

第五届中国医药创新与投资大会将继续贯彻打通医药创新投融资渠道，围绕医药创新热点问题，深度聚焦科技创新成果和全球投融资新动态、新趋势，分享我国最新医药产业政策。

路演项目审核专家名单

Expert Review Committee List

蒋华良
JIANG Hualiang

中国科学院院士、
中国药促会 2015–2016 年度会长、
中国科学院上海药物研究所研究员
Academician of Chinese Academy of Sciences
2015-2016 Annual Chairman of PhIRDA
Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences

蒋建东
JIANG Jiandong

中国药促会 2017–2018 年度会长、
中国医学科学院药物研究所所长
2017-2018 Annual Chairman of PhIRDA
Director of Institute of Materia Medica, Chinese Academy of Medical Sciences

石远凯
SHI Yuankai

中国药促会药物临床研究专业委员会副主任委员、中国医学科学院肿瘤医院副院长
Vice-Chairman of PhIRDA Clinical Research Specialty Committee
Vice President of Cancer Hospital, Chinese Academy of Medical Sciences

李　佳
LI Jia

中国科学院上海药物研究所所长、
新药研究国家重点实验室主任
Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Director of State Key Laboratory of Drug Research

陈晓光
CHEN Xiaoguang

中国医学科学院药物研究所教授
Professor of Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College

王印祥
WANG Yinxiang

中国药促会药物研发专委会主任委员、
北京加科思新药研发有限公司董事长
Chairman of PhIRDA Drug R&D Specialty Committee
Chairman of the Board, Jacobio Pharma

谭凌实
TAN Lingshi

中国药促会创新研发服务专业委员会主任委员、缔脉生物医药科技（上海）有限公司董事长兼首席执行官
Chairman of PhIRDA Innovation R&D Services Specialty Committee
Chairman of the Board & CEO, dMed Biopharmaceutical

房健民
FANG Jianmin

中国药促会药物研发专委会副主任委员、荣昌生物制药（烟台）有限公司 CEO、首席科学官
Vice-Chairman of PhIRDA Drug R&D Specialty Committee
CEO & CSO of RemeGen

杨大俊
YANG Dajun

中国药促会药物研发专委会副主任委员、亚盛医药董事长兼 CEO
Vice-Chairman of PhIRDA Drug R&D Specialty Committee
Chairman of the Board & CEO, Ascentage Pharma

CONTENTS 目 录

01

大会简介

Introduction of CBIIC

中国医药创新与投资大会（以下简称“创投大会”）是由中国医药创新促进会（以下简称“中国药促会”）于 2016 年发起创办的医药界与投资界高端对话平台。创投大会始终坚持以“推动社会资本与医药创新相结合，提高医药创新能力”为宗旨，聚焦产业政策、全球医药研发趋势和投融资动向，为业界领袖、专家、学者以及国内外医药创新企业和投资人，搭建权威、专业、多维度的对话沟通平台，深入探讨创新发展新趋势、共商投资合作新战略。

2016–2019 年中国药促会先后携手中国证券业协会、中国医疗器械行业协会、香港交易所、中国医院协会、蓝迪国际智库等机构成功举办了四届创投大会，累计参会人数超过 10,000 人，2,100 余家国内外医药相关企业和 1,500 余家投资机构到会路演，33 个创新品种在大会进行了临床数据全球首发，450 多个国内外创新项目通过路演展示，被誉为“亚太地区最受关注的医药创新与投资合作平台”。

为推动新冠疫情下全球资本与我国医药创新的深入合作，促进医药创新活力充分释放与创新成果及时、高效转化，共建后疫情时代医药产业新格局，第五届创投大会定于 2020 年 9 月 27 日 –29 日在苏州工业园区举办。

一 、贯彻推动医药创新理念，优化专场设置以满足不同参会者需求

2020 年，中央政治局常务委员会会议首次将生物医药纳入我国支柱产业范畴，全面提升生物医药产业创新发展能力。第五届创投大会将继续贯彻打通医药创新投融资渠道，围绕医药创新热点问题，深度聚焦科技创新成果和全球投融资新动态、新趋势，分享我国最新医药产业政策，设置多个热门领域路演专场，包括临床数据首发、上市及非上市、医疗器械、国际肿瘤药及国际项目、大数据 + 智慧医疗、AI+ 生物医药、创新研发服务（CRO、CMO、CDMO）等路演专场，以及投资人经验分享、融资并购和医药政策论坛等近二十场精彩纷呈、特色鲜明的交流活动，创新项目将涉及创新药、孤儿药、免疫疗法、AI 药物设计、互联网医疗、大数据 – 智慧医疗、基因检测和创新型医疗器械等前沿创新项目，满足不同参会者的需求。

二 、国家权威机构全力支持，全球顶尖机构深入合作

本届创投大会将继续与相关政府部门、国内外知名机构深入合作，邀请行业领袖、顶级专家学者热议全球医药创新及投融资政策和发展趋势，助力我国医药产业创新转化能力提升。

历届大会均得到了国内外权威机构的大力支持，包括：中国医学科学院、中国中医科学院等学术权威机构；加拿大、荷兰、澳大利亚等驻华使领馆；美国癌症研究基金会、日本制药工业协会等国际组织；香港中资证券业协会、加拿大多伦多证券交易所等国际金融机构。此外，摩根大通（J.P.Morgan）连续多届作为独家国际金融机构赞助商为大会提供全方位鼎力支持。

三 、商务洽谈邀约，深度对话为参会者提供零距离交流平台

为促进国内外医药创新与投资界的有效交流与精准合作，创投大会持续搭建更加丰富多样的展示与交流平台。本届大会将持续为参会企业提供商务洽谈邀约服务。投资人和路演汇报人可通过邀约系统寻找潜在客户、合作伙伴，在线向对方发起邀请，与会期间可与对方实现面对面交流洽谈，实现零距离无障碍沟通，深度对话碰撞出更多商机。

四、国内外媒体积极关注，见证创新与投资的融合

自 2016 年以来，创投大会得到包括《Nature》、人民网、健康报、中国医药报、医药经济报在内的数十家国内外著名杂志和权威传统媒体支持；同时吸引了包括 PharmaBoardroom、界面、36 氪、财新传媒等新媒体和医药财经类行业媒体参会，并对大会实时报道，共同见证创新与投资的融合。

在各方的共同协作与鼎力支持下，创投大会正在逐步成为解读中国医药和投融资政策、展示国内外医药创新成果和引领投资新动向的具有广泛国际影响力、权威性、多元化的成果转化及权威合作交流平台，逐渐成为亚太地区最具影响力的年度品牌盛会。创投大会将继续在社会资本与医药创新发展历程中发挥引领作用，创造更加科学、更富吸引力的医药创新投资环境，为我国经济社会发展、满足临床用药需求、打造健康中国贡献力量。



大会简介

Introduction of CBIIC

China BioMed Innovation and Investment Conference (CBIIC), as an annual grand conference to promote the communication between pharmaceutical industry and investment industry, was established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) in 2016. To promote the linkage between social capital and pharmaceutical innovation and improve the innovation capability of pharmaceutical industry, CBIIC focuses on China's latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. CBIIC was built as an authorized, comprehensive, professional and international high level platform for the industry leaders, experts, scholars, domestic and foreign pharmaceutical innovation enterprises and investors to learn the trend of innovation and discuss new investment channels and innovative cooperation strategies.

Established by PhIRDA, CBIIC was successively co-hosted by Securities Association of China (SAC), China Association for Medical Devices Industry (CAMDI), Hong Kong Exchanges and Clearing Limited (HKEX) and Chinese Hospital Association (CHA), Research and Development International (RDI) from 2016 to 2019. By the end of 2019, CBIIC has attracted over 10,000 participants, 2,100 domestic and foreign pharmaceutical enterprises and 1,500 investment institutions, and 33 new drugs made global first clinical trial data release, 450 innovative projects at home and abroad made roadshows in this events, including 80 international projects. CBIIC received extensive attention and was praised as the "most popular cooperation platform for pharmaceutical innovation and investment in Asian-Pacific region".

To promote the in-depth cooperation between global capital and pharmaceutical innovation in China under the background of COVID-19, facilitate the release of vitality of pharmaceutical innovation and timely transformation of unmet clinical needs, jointly building the new pattern of post-pandemic era for pharmaceutical industry, PhIRDA will host 2020 CBIIC in Suzhou Industrial Park on September 27-29, 2020.

I.Implement the Pharmaceutical Innovative Concept and Improve Setting of Parallel Sessions

To improve China's biopharmaceutical innovation ability in all levels, biopharmaceutical industry has been included into the national central pillar industries for the first time on the Standing Committee of the Political Bureau of the Central Committee of the CPC in 2020. 2020 CBIIC will further open financing channel for pharmaceutical innovation, focus on China's latest policies in pharmaceutical industry, explore the new trends of global pharmaceutical R&D and hot issues in investment and financing circle. 2020 CBIIC will include almost 20 fascinating and excellent parallel sessions such as Clinical Trial Data Release, Roadshows for Listed and Non-Listed Companies, Medical Devices, International Oncology Drugs, International Projects, WIT MED + Big Data, Artificial Intelligence (AI) + BioMed, Service Companies (CRO/CMO/CDMO) and Service Agencies and forums for Investors' Experience Sharing, Financing M&A and Latest Drug Policy Sharing. The roadshow projects will cover the cutting-edge areas including biopharmaceutical, oncology drugs, orphan drugs, immunotherapy, AI for drug design, biotechnology, Virtual Healthcare, medical big data, gene detection, innovative medical devices, meeting diversified needs of participants.

II.Great Supports from National Authorized Institutions & In-depth Cooperation with Global Top Leading Organizations

2020 CBIIC will make further cooperation with government departments and well-known institutions around the world, and invite KOLs in pharmaceutical industry and leading experts to discuss policies and trends of global pharmaceutical innovation and financing to improve China's capability on transformation and innovation in pharmaceutical industry.

Since its establishment, CBIIC has received great support from prestigious institutions in China and around the world, including Chinese Academy of Medical Sciences, China Academy of Chinese Medical Sciences and authorized academic institutions; Canada, the Netherlands, Australia and other embassies and consulates in China; National Foundation for Cancer Research (NFCR), Japan Pharmaceutical Manufacturers Association (JPMA) and international organizations; Chinese Securities Association of Hong Kong (CSAHK), TMX Group Limited and global financing institutions. Moreover, J.P. Morgan supports CBIIC as the exclusive international financial institution sponsor for several times.

III.One-on-One Partnering System Provides Close Communication for Participants

To facilitate effective communication and precise cooperation between domestic and foreign pharmaceutical innovators and investors, 2020 CBIIC will build a better and more diverse platform for project presentation and communication. One-on-One partnering service will be provided for participants. Investors and roadshow speakers could propose an invitation in this system online easily and efficiently. In this event, participants will have face-to-face communication and negotiation to seek potential opportunities for further collaboration.

IV.Great Attention from Domestic and Global Medias and Witness the Integration of Innovation and Investment

Since 2016, CBIIC was supported by over ten well-known magazines and traditional medias at home and abroad, including *Nature*, *people.cn*, *JKB.com.cn*, *China Pharmaceutical News*, *Medicine Economic Reporter*, and attracted new medias and healthcare financial medias including PharmaBoardroom, Jiemian.com, 36 Kr, Caixin Media, to make real-time report of the event and witness the integration of innovation and investment.

Under the great support of all parties, CBIIC is gradually becoming an international, authoritative, diversified communication platform to interpret policies on drug and financing and investment circle, present pharmaceutical innovative achievements at home and abroad, lead new investment trends. As the most influential annual grand conference in Asia-Pacific region, CBIIC will make social capital playing a leading role in the development of pharmaceutical innovation, create a more scientific and attractive investment environment and contribute to China's economic and social development to meet the clinical needs and advance the pursuit of Healthy China.

会议组织机构
Conference Organization

主办单位

中国医药创新促进会
中国医疗器械行业协会
香港交易所
艾美达（北京）医药信息咨询有限公司

独家国际金融机构赞助商

摩根大通

协办单位

华平投资
先声药业
西安杨森制药有限公司
高特佳投资

Hosts

China Pharmaceutical Innovation and Research Development Association (PhIRDA)
China Association for Medical Devices Industry (CAMDI)
Hong Kong Exchanges and Clearing Limited (HKEX)
iMeta Health Information Consulting Co., Ltd.

Exclusive International Financial Institution Sponsor

J.P. Morgan

Co-Organizers

Warburg Pincus
Simcere Pharmaceutical Co., Ltd.
Xian Janssen Pharmaceutical Ltd.
GTJA Investment Group

支持单位

中国医学科学院
南方医药经济研究所
苏州工业园区
中关村股权投资协会
香港生物医药创新协会
台湾生技医疗产业策进会
日本制药工业协会
BioCentury
中国外商投资企业协会药品研制和开发行业委员会
加拿大驻沪总领事馆

媒体支持

施普林格·自然集团
医药经济报
米内网
医学前沿

Supporters

Chinese Academy of Medical Sciences
Southern Medicine Economic Research Institute
Suzhou Industrial Park
Zhongguancun Private Equity & Venture Capital Association (ZVCA)
HK Bio-Med Innotech Association (HKBMIA)
Institute for Biotechnology and Medicine Industry (IBMI)
Japan Pharmaceutical Manufacturers Association (JPMA)
BioCentury
China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC)
Consulate General of Canada in Shanghai

Supporting Media

Springer Nature
Medicine Economic Reporter
MENET
NEJM Frontiers in Medicine

大会开幕式（主会场）
Opening Ceremony (Main Conference)

27 SEP SUN | 28 SEP MON | 29 SEP TUE

第一阶段：主办方致辞
Session I: Welcome Remarks by Hosts
主持人：宋瑞霖，中国医药创新促进会 2019-2020 年度会长
Chair: SONG Ruilin, 2019-2020 Annual Chairman of PhIRDA

任晋生 REN Jinsheng
中国医药创新促进会年度会长、先声药业董事长兼 CEO
Annual Chairman of PhIRDA, CEO & Chairman of the Board of Simcere Pharmaceutical Co., Ltd.

08:30-08:50

李小加 Charles LI
香港交易所集团行政总裁
Chief Executive of HKEX

苏州市政府领导
Senior Official of Suzhou Municipal Government

第二阶段：领导致辞
Session II: Welcome Remarks by Officials

陈德铭 CHEN Deming
商务部原部长、中国外商投资企业协会会长
Former Minister of Commerce of the People's Republic of China, Chairman of China Association of Enterprises with Foreign Investment (CAEFI)

08:50-09:05

尚福林 SHANG Fulin
全国政协经济委员会主任、原中国银行业监督管理委员会主席
Director of Economic Committee of CPPCC, Former Chairman of the China Banking Regulatory Commission

第三阶段：主旨报告
Session III: Keynote Speeches
09:05-09:10

主持人：李　燕，中国医药创新促进会候任会长、齐鲁制药集团总裁
Chair: LI Yan, Chairman-elected of PhIRDA, President of Qilu Pharmaceutical Group Co., Ltd.

沙　雁 SHA Yan
深圳证券交易所党委副书记、总经理
Deputy Secretary of the Party Committee, President & CEO of Shenzhen Stock Exchange

09:10-09:30

主旨报告 1：创业板助力生物医药产业创新发展
Keynote Speech: ChiNext Supports the Innovation and Development of Biomedicine

Elizabeth Myers
摩根大通投资银行全球主席
Global Chairman of Investment Banking, Equity Capital Markets at J.P. Morgan

09:30-09:40

主旨报告 2：生物制药行业与资本市场：回顾与展望
Keynote Speech: Biopharmaceutical Capital Market Recap

王拥军 WANG Yongjun
首都医科大学附属北京天坛医院院长
President of Beijing Tian Tan Hospital, Capital Medical University

09:40-10:05

主旨报告 3：从临床研究视角看创新药物研发
Keynote Speech: New Drug Development from the Perspective of Clinical Research

张永祥 ZHANG Yongxiang
中国药理学会理事长
Chairman of Chinese Pharmacological Society

10:05-10:30

主旨报告 4：我国新药研发历程与发展趋势
Keynote Speech: New Drug Research and Development Trend in China

第四阶段：专题讨论
Session IV: Panel Discussions

10:30-11:15

主题讨论 1: 全球医药创新发展趋势
Panel: Global Trends on Pharmaceutical Innovation R&D

主持人：宋瑞霖 中国药促会 2019-2020 年度会长

Moderator: SONG Ruilin, 2019-2020 Annual Chairman of PhIRDA

嘉　宾：蒋建东 中国药促会 2017-2018 年度会长、中国医学科学院药物研究所所长

Panelists: JIANG Jiandong, 2017-2018 Annual Chairman of PhIRDA, Director of Institute of Medicine, Chinese Academy of Medical Sciences

康　韦 中国外商投资企业协会副会长、RDPAC 执行总裁

KANG Wei, Vice Chair of CAEFI, Managing Director of RDPAC

何如意 荣昌生物首席医学官、国投创新医疗健康首席科学家、前国家食品药品监督管理总局药品审评中心首席科学家

HE Ruyi, CMO of RemeGen, CMO of SDIC, Former Chief Scientist of Center for Drug Evaluation, CFDA

李　宁 上海君实生物首席执行官

LI Ning, CEO of Shanghai Junshi Biosciences Co., Ltd.

11:15-12:00

主题讨论 2: 投资与医药创新
Panel: Investment and Pharmaceutical Innovation

主持人：黄国滨 摩根大通全球投资银行中国区主管、董事总经理

Moderator: Houston HUANG, Managing Director, Head of China Global Investment Banking at J.P. Morgan

嘉　宾：蒋华良 中国科学院院士、中国药促会 2015-2016 年度会长、中国科学院上海药物研究所研究员

Panelists: JIANG Hualiang, Academician of Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences

孙飘扬 中国药促会 2014-2015 年度会长、江苏恒瑞医药集团有限公司董事长

SUN Piaoyang, 2014-2015 Annual Chairman of PhIRDA, Chairman of the Board, Jiangsu Hengrui Medicine Co., Ltd.

方　敏 中国药促会医药创新投资专业委员会副主任委员、华平投资合伙人、中国医疗健康投资负责人

FANG Min, Vice-Chairman of PhIRDA Pharmaceutical Innovation Investment Specialty Committee, Managing Director & Head of Healthcare Investment, Warburg Pincus

鲍海洁 香港交易所董事总经理兼环球上市服务部主管

Christina BAO, Managing Director & Head of Global Issuer Services of HKEX

第一阶段 Phase I

主持人：杨大俊，中国药促会药物研发专委会副主任委员、亚盛医药董事长兼 CEO
Moderator: YANG Dajun , Vice-Chairman of PhIRDA Drug R&D Specialty Committee Chairman of the Board & CEO, Ascentage Pharma

13:30-14:00

郭明良 KUO MinLiang
中天上海生物科技有限公司资深副总裁、药物所所长
Sr. Vice President, Chief Director Institute of Pharmaceutical Research and Development, Microbio Shanghai Co., Ltd.
项目 1: 糖尿病足溃疡伤口新药 ON101 三期国际多中心临床试验数据报告
Project 1: ON101 Topline Results of Phase III MRCT in Treatment of Diabetic Foot Ulcers

14:00-14:30

宋钦辉 Tony SONG
武汉禾元生物科技股份有限公司首席医学官
CMO, Wuhan Healthgen Biotechnology Corp.
项目 2: 从稻米到血浆蛋白：重组人血清白蛋白在人体首次 I 期临床试验展示出良好的安全性和耐受性
Project 2: From Rice to Blood: the First in Human Recombinant Human Serum Albumin Presents Safety and Well Tolerated in Phase I Clinical Trial

14:30-15:00

郑向前 ZHENG Xiangqian
天津医科大学肿瘤医院甲状腺颈部肿瘤科行政主任
Executive Director, Department of Thyroid and Neck Oncology, Tianjin Medical University Cancer Institute and Hospital
项目 3: 原创新药开启甲状腺癌靶向治疗新篇章——安罗替尼治疗甲状腺癌研究数据解读
Project 3: New Chapter in Targeted Therapy for Thyroid Cancer - Interpretation of Research Data on Anlotinib in The Treatment of Thyroid Cancer

第二阶段 Phase II

主持人：李文斌，中国药促会药物临床专委会副主任委员、首都医科大学附属北京天坛医院神经肿瘤综合治疗病区主任
Moderator: LI Wenbin , Vice-Chairman of PhIRDA Clinical Research Specialty Committee Director of Dept of Neuro-oncology, Beijing Tiantan Hospital, Capital Medical University

15:00-15:30

马振坤 MA Zhenkun
丹诺医药（苏州）有限公司创建人、CEO
Founder & CEO, TenNor Therapeutics Limited
项目 4: 多靶点偶联分子抗菌新药 TNP−2092 的 II 期临床试验结果
Project 4: Phase II Results of Multitargeting Drug Conjugate TNP-2092

15:30-16:00

吴 昊 WU Hao
首都医科大学附属佑安医院主任医师
Chief Physician of Beijing Youan Hospital, Capital Medical University
项目 5: 新一代抗 HIV 非核苷一类新药 ACC007 III 期临床试验结果
Project 5: Phase III Clinical Trial Results of ACC007, a New Generation of NNRTI for HIV

16:00-16:30

肖英莲 XIAO Yinglian
广州市中山大学附属第一医院消化内科教授、主任医师
Professor and Chief Physician, The First Affiliated Hospital Sun Yat-sen University
项目 6: 原创新药引领抗消化性溃疡新征程——H008 盐酸柯诺拉赞片剂临床试验数据发布
Project 6: Novel P-CAB Create New Peptic Ulcer Treatment Paradigm Clinical Trial Data Summary of H008

16:30-17:00

孟海津 MENG Haijin
上药博康生物医药（香港）有限公司中国首席科学官
Shanghai Pharma-BIOCAD (HK) Limited Chief Scientific Officer (China)
项目 7:Netakimab 单抗的 II−III 期银屑病临床试验结果
Project 7: Results of Phase II-III Psoriasis Clinical Trial with Netakimab

医药创新城市发展论坛
暨“中国最具投资价值生物医药创新城市研究”项目成果发布会（A108-110）
Biomedical Innovation Cities Development Forum & Study Release Conference of “China Biomedical Innovation Cities with Most Investment Value”

27 SEP SUN

主持人：冯　岚，中国医药创新促进会秘书长
Moderator: FENG LAN , Secretary-General of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

14:00-14:10	**领导致辞** **Welcome Remarks**
14:10-14:15	**主办方项目介绍** **Introduction of the Study by Host**
14:15-14:25	**项目成果发布仪式** **Study Release Ceremony**
14:25-14:40	**《中国生物医药创新城市研究》排名结果公布及授牌仪式** **Study Release of “China Biomedical Innovation Cities with Most Investment Value” and Award Ceremony**
14:40-15:20	**项目评价体系及报告成果介绍** **Introduction of Assessment System and Report**
15:20-16:30	**优秀城市代表经验分享** **Experience Sharing of Representative City**

主持人：邵　蓉，中国药科大学 NDPE 研究中心执行副主任
Moderator: SHAO Rong , Executive Deputy Director, The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University

19:00-19:30

嘉宾签到
Guest Reception

19:35-19:50

宋瑞霖 SONG Ruilin
中国医药创新促进会 2019−2020 年度会长
2019-2020 Annual Chairman of PhIRDA
开场致辞 Welcome Speech

19:50-20:10

胡元佳 HU Yuanjia
澳门大学副教授，中药质量研究国家重点实验室临床研究中心副主任
Associate Professor, University of Macau Deputy Director, Clinical Research Center, State Key Laboratory of Quality Research in Chinese Medicine
开场主题报告：创新需求导向的生物医药技术扫描与专利评价
Keynote Speech:Biomedical Technology Scanning and Patent Evaluation based on Innovation Needs

20:10-21:30

圆桌讨论：数据驱动：突破医药科技转化瓶颈
Panel Discussion: Data-driven: Breaking through bottlenecks of Medical Technology Transformation

主持人：邵　蓉 中国药科大学 NDPE 研究中心执行副主任
Moderator: SHAO Rong Executive Deputy Director, The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University

讨论议题 Discussion Topics

1. 如何选择并聚焦全球前沿技术领域，通过战略布局，寻找市场突破（定向邀请）
   How to select and focus on global frontier technology areas and further find out market opportunities by strategic layout? (Directional Invitation)
2. 如何提高研发效率，降低投资风险（定向邀请）
   How to improve R&D efficiency and reduce investment risk? (Directional Invitation)
3. 如何精准对接科技与资本，促进成果转化（定向邀请）
   How to accurately connect technology and capital to promote the transformation of achievements? (Directional Invitation)

邀请嘉宾 Invited Guests

胡元佳 HU Yuanjia
澳门大学副教授，中药质量研究国家重点实验室临床研究中心副主任
Associate Professor, University of Macau Deputy Director, Clinical Research Center, State Key Laboratory of Quality Research in Chinese Medicine

张步泳 ZHANG Buyong
米内网总经理 / 首席研究员
General Manager/Chief Researcher, MENET

李　祎 LI Yi
横琴国际知识产权交易中心有限公司副总经理
Deputy General Manager, Hengqin International Intellectual Property Exchange Center Co., Ltd

上市公司专场（分会场 1）
Listed Company Roadshow (Parallel Session 1)

28 SEP MON　29 SEP TUE

主持人：杨烨辉，天风证券产业部副总监、医药联席首席
Moderator: YANG Yehui , Joint Chief Analyst of Medical Industry/Deputy Director of Industrial Services Department, Tianfeng Securities

李　靖 Jin LI
药渡董事长
Founder and Chair of Pharmacodia

08:30-09:00
开场报告：从全球抗肿瘤小分子的研发情况和资本投入层面看中国未来十年的抗肿瘤小分子药物的研发布局
Keynote Speech: Perspective of the Future Strategy in Small Molecule Anti-cancer Drug Research by Mapping both the Research Pipelines of Globle Pharms/Biotechs and China Pharms/Biotechs

姜　华 JIANG Hua
绿叶制药集团有限公司副总裁
09:00-09:25
Vice President of Luye Pharma Group Ltd.
项目 1: 绿叶制药——走出差异化的创新与国际化道路
Project 1: Luye Pharma - Differentiated Development Road of Innovation and Internationalization

王昌进 WANG Changjin
前沿生物药业（南京）股份有限公司总经理
09:25-09:50
CEO of FRONTIER BIOTECHNOLOGIES Inc.
项目 2: 原创新药 引领全球抗艾新征程 前沿生物 同创中国新药新时代
Project 2: Innovative Medicine, Leading the Global Anti-AIDS Campaign.Frontier Biotech, Creating the New Era of Chinese Medicine.

谢　炘 Hsin Tse
中国生物制药执行董事、资深副总裁
09:50-10:15
Executive Director & Senior Vice President, Sino Biopharmaceutical Limited
项目 3: 中国生物制药——以创新力构筑新护城河
Project 3: Sino Biopharmaceutical Limited - Build a New Moat with Innovation

卢　燕 LU Yan
开拓药业有限公司 CFO
10:15-10:40
CFO of Kintor Pharmaceutical Limited
项目 4: 开拓药业——中国领先的 AR 新药研发企业
Project 4: Kintor Pharmaceutical Limited - The Leading Anti-Androgen Receptor (AR) Novel Drugs Developer in China

童少靖 TONG Shaojing
北京诺诚健华医药科技有限公司首席财务官
10:40-11:05
CFO of Beijing InnoCare Pharma Tech Co., Ltd.
项目 5: 新药创制方兴未艾，诺诚健华志在千里
Project 5: InnoCare - Thriving in the Burgeoning Field of Innovative Drug Development

吴劲梓 Jason WU
歌礼制药有限公司董事长
11:05-11:30
CEO of ASCLETIS PHARMA Inc.
项目 6: 歌礼制药打造病毒性肝炎、脂肪性肝炎、艾滋病三大创新平台
Project 6: Ascletis Developed its Own Innovative Platform Focusing on Viral Hepatitis, NASH and HIV/AIDS

孟　渊 Isaac MENG
天境生物科技（上海）有限公司副总裁、医学办公室负责人
11:30-11:55
VP/Head of Medical Office, I-Mab Biopharma Co., Ltd.
项目 7: 关于天境生物——打造具有“全球首创”和“同类最优”潜力的创新管线
Project 7: About I-Mab - Building a Pipeline of Potential Novel and Highly Differentiated Medicines

非上市公司专场（分会场 2）
Non-Listed Company Roadshow (Parallel Session 2)

28 SEP MON　29 SEP TUE

主持人：杜　舟，华平投资副总监
Moderator: Joe DU, Associate Director, Warburg Pincus

张步泳 ZHANG Buyong
米内网总经理、首席研究员
General Manager/Chief Researcher, MENET

08:30-09:00
开场报告：系列新政影响下我国创新药市场表现
Keynote Speech: The Performance of China`s Innovative Drug Market Under the Influence of A Series of New Policies

陈　悦 CHEN Yue
天津尚德药缘科技股份有限公司总经理
09:00-09:25 CEO of Accendatech
项目 1: 抗脑瘤新药的开发
Project 1: New Drug Targeting Brain Tumour

罗　文 LUO Wen
索元生物医药（杭州）有限公司首席执行官
CEO of Denovo Biopharma (Hangzhou) Co., Ltd.
09:25-09:50
项目 2: 中国创新药如何从跟跑到领跑：索元生物借力精准医疗开发全球首创新药模式
Project 2: From Me-too to First-in-class: Denovo Biopharma's Disruptive Precision Medicine Approach to Developing Novel Drugs

罗　顺 LUO Shun
澳斯康生物制药（海门）有限公司董事长兼总裁
09:50-10:15 Chairman & President of Thousand Oaks Biopharmaceuticals
项目 3: 整合性 CMC 组织 – 生物制药规模化合规整体解决方案
Project 3: Integrated CMC Organization-Large Scale Solution for Biopharmaceuticals

陈晓光 CHEN Xiaoguang
中国医学科学院北京协和医学院药物研究所教授
Professor of Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
10:15-10:40
项目 4: 代谢检查点调节剂治疗重大慢病原创药物研发
Project 4: The Novel Drug Research and Development of Metabolic Checkpoint Regulators in the Treatment of Major Chronic Diseases

秦续科 Steve Chin
科望生物医药科技有限公司首席医学官
10:40-11:05 CMO of Elpiscience Biopharma Ltd.
项目 5: 深耕肿瘤免疫开发新一代创新型治疗抗体
Project 5: Driving Cancer Immunotherapy Revolution

窦昌林 DOU Changlin
山东博安生物技术有限公司首席运营官
11:05-11:30 COO of Shandong BoAn Biotechnology Co., Ltd.
项目 6: 博安生物——中国领先的全球化生物药创新企业
Project 6: Boan Biological-A Leading Global and Innovative Biopharmaceutical Company in China

王汝涛 WANG Rutao
西安力邦制药有限公司总经理
11:30-11:55 General Manager of Xi'an Libang Pharmaceutical Co.,Ltd.
项目 7: 抗癫痫一类新药 LMR-101 的 I 期临床试验结果介绍
Project 7: Introduction of Phase I Clinical Trial Results of LMR-101, a Novel Antiepileptic Chemical Drug

主持人：徐佳熹，兴业证券董事总经理，研究院副院长
Moderator: XU Jiaxi, Managing Director and Deputy Head of Research in CIS

13:00-13:30
徐佳熹 XU Jiaxi
兴业证券董事总经理，研究院副院长
Managing Director and Deputy Head of Research in CIS
开场报告：从 1.0 到 2.0 模式，创新药投资的未来新常态
Keynote Speech: New Model under 'New Normal', Takeaways for Healthcare Investors

13:30-13:55
李文斌 LI Wenbin
首都医科大学附属北京天坛医院神经肿瘤综合治疗病区主任、成都金瑞基业生物科技有限公司临床 PI
Director of Dept of Neuro-oncology, Beijing Tiantan Hospital, Capital Medical University\Principal Investigator of Chengdu Jinrui Foundation Biotech Co., Ltd.
项目 8: 和厚朴酚脂质体 JRF101：脑胶质瘤 I 期临床试验
Project 8: Honokiol Liposome JRF101: Trial For Glioblastoma

13:55-14:20
宋　燕 SONG Yan
广州领晟医疗科技有限公司首席执行官
CEO of Link Health Group
项目 9:3% 褪黑素口腔凝胶防治头颈部肿瘤患者放化疗引起的口腔粘膜炎的 II 期临床研究
Project 9: Phase II Trial of 3% Melatonin Oral Gel for the Prevention and Treatment of Oral Mucositis in H&N Cancer Patients Undergoing Chemoradiation

14:20-14:45
韦　德 WEI De
成都惠泰生物医药有限公司董事长兼总经理
Chairman & General Manager of Chengdu Huitai Biomedicine Co., Ltd.
项目 10: 靶向抑制 TGFβ 信号通路的多肽类 1.1 类创新药——抗纤维化和实体肿瘤
Project 10: Development of Synthetic Peptides Targeting TGF-beta Signaling as First-in-Class Pharma Cotherapies for Fibrosis and Solid Cancer

14:45-15:10
郭　箭 GUO Jian
浙江新码生物医药有限公司首席技术官
CTO of NovoCodex Biopharmaceuticals Co., Ltd.
项目 11: 基于非天然氨基酸定点偶联技术的大分子药物开发
Project 11: Development of Macromolecular Drugs Based on Unnatural Amino Acids-introduced Site Specific Conjugation

15:10-15:35
张世轩 ZHANG Shixuan
大连贝克林医药科技有限公司董事长
Chairman of Dalian BaicaIein Pharmaceutical Technology Co., Ltd.
项目 12: 原创抗癌药物黄芩素哌啶醇研发
Project 12: R&D of the Original Anticancer Drug Baicalein-Piperidol

15:35-16:00
郭晓宁 GUO Xiaoning
苏州苏生医药研发有限公司首席医学官
CMO of Suzhou SciClone Pharmaceuticals Research and Development Co., Ltd.
项目 13: 苏生医药研发有限公司产品管线介绍
Project 13: Pipeline Introduction-Suzhou SciClone Pharmaceuticals

16:00-16:25
王钧源 Jerry WANG
葆元生物医药科技（杭州）有限公司首席执行官
CEO of AnHeart Therapeutics (Hangzhou) Co., Ltd.
项目 14: 下一代 ROS1/NTRK 抑制剂 Taletrectinib 用于治疗 ROS1 突变的非小细胞肺癌和 NTRK 突变的实体瘤
Project 14: Next Generation ROS1/NTRK Inhibitor Taletrectinib for ROS1+ NSCLC and NTRK+ Solid Tumors

16:25-16:50
许　恒 XU Heng
中国医学科学院药物研究所研究员
Professor of Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
项目 14: 抗实体肿瘤小分子新药研发
Project 14: Small-Molecule Anti-Solid Tumor Drug Discovery and Development

16:50-17:15
程子强 CHENG Ziqiang
苏州赞荣医药科技有限公司董事长
Board of Director of Suzhou Zanrong Phrama Limited
项目 14:ZN-1041：透过血脑屏障，治疗乳腺癌脑转移的同类最佳 HER2 抑制剂
Project 14: ZN-1041: A Best-in-Class BBB Penetrable HER2 Inhibitor to Treat Breast Cancer with CNS Metastases

17:15-17:40
叶伟平 YE Weiping
广东莱佛士制药技术有限公司总经理
General Manager of Guangdong Raffles PharmaTech Co., Ltd.
项目 14: 小分子新药开发与产业化关键技术
Project 14: Key Technologies of New Small Molecule Drug Development and Industrialization

罕见病专场（分会场 3）
Rare Diseases and Orphan Drugs Roadshow (Parallel Session 3)

28 SEP MON　29 SEP TUE

第一阶段 Phase I

主持人：李林康，中国罕见病联盟执行理事长，全国罕见病诊疗协作网办公室副主任

Moderator: LI Linkang, Executive Director of China Alliance for Rare Disease, Deputy Head of Bureau of National Rare Disease Diagnosis&Treatment Network

08:30-08:50

赵　琨 ZHAO Kun

国家卫生健康委药物与卫生技术评估中心副主任

Director of Division of Health Policy Evaluation and Technology Assessment of the National Health Development Research Center

08:50-09:30

主题报告：罕见病卫生经济评估思考

keynote Speech : Considerations on Health Economic Assessment of Orphan Drugs

讨论：罕见病药物研发与医药创新发展

Panel : Rare Disease R&D vs Drug Innovation and Development

主持人：薛　群 北海康成制药有限公司董事长及首席执行官

Moderator: James XUE, Chairman and CEO of CANbridge Pharmaceuticals Inc

嘉　宾：刘军帅 国家罕见病诊疗与保障专家委员会委员

Panelists: LIU Junshuai, Committee Member of National expert consultation committee of Diagnosis and Treatment of Rare Disease

肖　啸 华东理工大学教授，信念医药董事长

XIAO Xiao, ECUST Professor, BBM President

王奕鸥 北京病痛挑战公益基金会秘书长、创始人

Yoyo Wang, Founder and Secretary-General, the Illness Challenge Foundation (ICF)

第二阶段 Phase II

主持人：刘　洋，中国医药创新促进会项目合作部主任

Moderator: LIU Yang, Director of Project Co-operation of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

09:30-09:50

张劲涛 ZHANG Jintao

捷思英达医药技术（上海）有限公司首席执行官

CEO, JS InnoPharm (Shanghai) Ltd

项目 1: 国际首创 1 类新药 Aurora A 激酶抑制剂 VIC-1911 临床开发

Project 1: Clinical Development of Aurora Kinase A Inhibitor VIC-1911 for Myelofibrosis

09:50-10:10

董　飚 DONG Biao

四川至善唯新生物科技有限公司总经理

CEO, R & B Biotech

项目 2: 利用重组腺相关病毒研制治疗 B 型血友病的基因药物

Project 2: Genetic medicine: rAAV gene therapy for Hemophilia B

10:10-10:30

郭　夏 GUO Xia

中国医疗集团有限公司执行董事

CEO, China Health Group INC.

项目 3: 应用大数据和真实世界临床研究筛选罕见病和脑科疾病新药和最佳医疗实践

Project 3: Application of Big Data and Real World Clinical Studies to Screen New Drugs and Best Medical Practices for Rare and Brain Diseases

10:30-10:50

吴振华 WU Zhenhua

杭州嘉因生物科技有限公司首席执行官

CEO, Exegenesis Bio Hangzhou Jiayin Ltd

项目 4: 开发针对罕见病的基因治疗药物

Project 4: Innovative Gene Therapy Platform for Rare Diseases

戴鲁燕 Connie DAI
天津开心生活科技有限公司战略与创新副总裁
10:50-11:10 CRO, Tianjin Happy Life Tech Co., Ltd.
项目 5: 真实世界研究助力罕见病创新药开发
Project 5: Real World Study Facilitating Innovative Drug Development Treating Rare Diseases

孔令洁 Kong Lingjie
苏州博腾生物制药有限公司首席技术官
11:10-11:30 CTO, Porton Biologics Ltd.
项目 6: 基因细胞治疗 CDMO 助力罕见病药物研发
Project 6: Gene and Cell Therapy CDMO in Rare Disease Drug Discovery

蒋　鑫 JIANG Xin
北京科信必成医药科技发展有限公司创新总监
11:30-11:50 Director, Pipeline & Strategy, CoSci Med-Tech Co., Ltd.
项目 7: 科信必成罕用药 2 类新药研发进展
Project 7: CoSci Class 2 Orphan Drug RnD Progress

第一阶段 Phase I

主持人：黄积严，深圳证券交易所上海中心江苏区域负责人

Moderator: HUANG Jiyan, Head, Jiangsu Province, Shanghai Center, Shenzhen Stock Exchange

08:30-09:30

邱凌龙 QIU Linglong

深圳证券交易所上海中心区域主任

Director, Shanghai Center, Shenzhen Stock Exchange

主题报告 1: 创业板注册制改革政策宣讲

keynote Speech 1: Regestration Reform Policy of ChiNext

09:30-10:00

谢立恒 XIE Liheng

浙江维康药业股份有限公司董事、董事会秘书、财务总监

Director & Board Secretary & CFO , Zhejiang Wecome Pharmaceutical Company Limited

主题报告 2: 抓机遇乘势而上——注册制助力医药企业腾飞

keynote Speech 2:Seize the Opportunity-Registration-based IPO System Supports the Development of Pharmaceutical Companies

10:00-10:30

汪　军 WANG Jun

普华资本合伙人

Partner, Puhua Capital

主题报告 3: 社会资本赋能医药创新企业

keynote Speech 3:Social Capital Empowers Pharmaceutical Innovation Companies

10:30-11:00

曾　信 ZENG Xin

国信证券股份有限公司首席风险官、内核负责人

CRO, GUSEN SECURITIES Co., Ltd

主题报告 4: 发扬专业优势，服务实体经济

keynote Speech 4:Serve the Real Economy with Professional Advantage

第二阶段 Phase II

11:00-12:00

主题讨论：创业板助力生物医药产业创新发展

Panel:ChiNext Supports the Innovation and Development of Biomedicine

主持人：张　凌 摩根大通全球投资银行中国区医疗健康与科技行业主管、董事总经理

Moderator: ZHANG Ling, Managing Director, Head of China Healthcare Investment Banking, J.P. Morgan

嘉　宾：邱凌龙 深圳证券交易所上海中心区域主任

Panelists: QIU Linglong, Director, Shanghai Center, Shenzhen Stock Exchange

蔡大庆 夏尔巴投资创始管理合伙人

Darren CAI, Founder & Managing Partner, Sherpa Venture Capital

林　亮 礼来亚洲基金合伙人

Stephen LIN, Partner, Lilly Asia Ventures

禤文欣 天健会计师事务所合伙人

XUAN Wenxin, Parter, PAN-CHINA Certified Public Accountants

王昭艳 金杜律师事务所合伙人

Joanne WANG, Partner, King & Wood Mallesons

当前形势下如何提高中国药物创新国际价值（分会场 5）
Leverage the Global Value of Pharmaceutical Innovations from China (Parallel Session 5)

28 SEP MON　29 SEP TUE

主持人：何如意，荣昌生物首席医学官、国投创新医疗健康首席科学家、前国家食品药品监督管理总局药品审评中心首席科学家

Moderator: HE Ruyi , CMO of RemeGen, CMO of SDIC, Former Chief Scientist of Center for Drug Evaluation, CFDA

08:30-09:00

龚兆龙 John GONG
思路迪生物医药有限公司董事长兼 CEO
Chairman & CEO of 3D Medicines Inc.
主旨报告 1：肿瘤新药临床开发全球布局的考量
Keynote Speech 1: Global Clinical Development Strategy of Oncology New Drugs

09:00-09:30

赵孝斌 Ben ZHAO
浙江海昶生物医药有限公司创始人
Founder of Zhejiang Haichang Biotech Co., Ltd.
主旨报告 2：核酸药物的技术挑战及投资机遇——守得云开见月明
Keynote Speech 2: Technical Challenges and Investment Opportunities of Nucleic Acid Drugs - Brighter Future Close at Hand

09:30-10:00

温　弘 WEN Hong
元生创投首席科学家
CSO of YuanBio Venture Capital
主旨报告 3：创新药的机遇、风险以及资本的作用
Keynote Speech 3: Opportunities, Risks and the Role of Capital for Innovative Drugs

10:00-10:30

Audrey JIA
德顺达医药咨询服务公司董事总经理
Managing Director of Data Revive LLC.
主旨报告 4：生物药研发到上市的法规挑战
Keynote Speech 4: Regulatory Challenge from R&D to Marketing for Biological Drugs

10:30-11:00

陈少羽 CHEN Shaoyu
美国安诺波特律师事务所驻上海代表处管理合伙人
Managing Partner of Arnold & Porter LLP Shanghai Rep. Office
主旨报告 5：中国药企在美国如何应对商务及法律挑战
Keynote Speech 5: How to Meet the Business and Legal Challenges in US for Chinese Pharmaceutical Companies

11:00-11:30

何如意 HE Ruyi
荣昌生物首席医学官、国投创新医疗健康首席科学家、
前国家食品药品监督管理总局药品审评中心首席科学家
CMO of RemeGen, CMO of SDIC, Former Chief Scientist of Center for Drug Evaluation, CFDA
主旨报告 6：新药研发中临床试验设计的关键要素
Keynote Speech 6: Key Considerations for New Drug Clinical Study Design

11:30-12:10

主题讨论：新药开发的国际申报策略
Panel: Global Regulatory Strategy for New Drug Development
主持人：杜　涛 汉佛莱医药顾问有限公司 CEO、首席顾问
Moderator: Tom DU, Chief Advisor & CEO of Humphries Pharmaceutical Consulting Co., Ltd.

嘉　宾：李　宁 上海君实生物医药科技股份有限公司首席执行官
Panelists: LI Ning, CEO of Shanghai Junshi Biosciences Co., Ltd.
赵孝斌 浙江海昶生物医药有限公司创始人
Ben ZHAO, Founder of Zhejiang Haichang Biotech Co., Ltd.
陈少羽 美国安诺波特律师事务所驻上海代表处管理合伙人
CHEN Shaoyu, Managing Partner of Arnold & Porter LLP Shanghai Rep. Office
龚兆龙 思路迪生物医药有限公司董事长兼 CEO
John GONG, Chairman & CEO of 3D Medicines Inc.

大数据 + 智慧医疗专场（分会场 1）
WIT-MED + Big Data Roadshow (Parallel Session 1)

28 SEP MON　29 SEP TUE

主持人：张晓夏，香港交易所环球上市服务部副总裁
Moderator: Sarah ZHANG , Vice President, Global Issuer Services, Hong Kong Exchanges and Clearing Limited

13:30-14:15

圆桌讨论：后疫情时代智慧医疗新机遇
Panel: Opportunities and Challenges of Digital Healthcare in Post Covid-19 Era
主持人：鲍海洁 香港交易所董事总经理兼环球上市服务部主管
Moderator: Christina BAO, Managing Director & Head of Global Issuer Services of HKEX

嘉　宾：匡　明 智云健康创始人 &CEO
Panelists: KUANG Ming, Founder & CEO of ClouDr
马　健 深圳晶泰科技有限公司首席执行官
MA Jian, CEO, XtalPi Inc.
游向东 浙商创投股份有限公司 / 董事、管理合伙人、执行总裁
YOU Xiangdong, Managing Partner, Zheshang Venture Capital Co., Ltd.
赵　璐 太美医疗科技董事长兼首席执行官
ZHAO Lu, Chairman & CEO, Taimei Technology

14:15-14:45

周　斌 ZHOU Bin
零氪科技首席战略官
Chief Strategy Officer of LinkDoc
主题报告 1: 大数据赋能的新药上市
Keynote Speech 1: Data-empowered Go-to-market Strategy of New Therapy

14:45-15:15

陈广宇 Leo CHEN
微医集团高级副总裁
Vice President of We Doctor Group
主题报告 2: 数字健康平台为中国医药流通价值链提质增效
Keynote Speech 2: Digital Health Platform improves quality and efficiency of China's pharmaceutical circulation value chain

15:15-15:45

罗东滔 LUO Dongtao
北京圆心科技有限公司联合创始人、副总裁、首席营销官
Co-funder, Vice President, CMO, Beijing Yuanxin Technology Co., Ltd.
主题报告 3: 互联网创新流通业运营模式浅谈
Keynote Speech 3: Brief Analysis of the Pharmaceuticals' Circulation Methods in Context of Internet Innovation

15:45-16:15

李　悦 Diana Li
医联高级副总裁
Senior VP of Medlinker
主题报告 4: 后疫情时代的互联网医疗
Keynote Speech 4: Online Healthcare in the Post-epidemic Era

16:15-16:40

张小栋 Seth ZHANG
上海镁信健康科技 CEO
CEO, Shanghai Meditrust Health Co., Ltd.
项目 1: 构建中国医药多层次创新支付模式
Project 1: Building China's Multi-layer Medical Innovative Payment Model

16:40-17:05

周　腾 David ZHOU
思派健康科技有限公司首席财务官及策略官
CFO, Chief of Staff Medbanks Network Technology Co., Ltd
项目 2: 中国的“联合健康”管理式医疗路径 – 整合医药 + 支付的科技体系
Project 2: United Health Model in China - An Integration of Providers, Products and Payors

17:05-17:30

汤　鹏 Rocs Tang
北京量子保科技有限公司品牌经理
Beijing Quantum InsurTech Co., Ltd.
项目 3: 让人人享有普惠精准的健保服务，数据智能助推定制化惠民保险
Project 3: Health and care service for everyone, Data for benefaction insurance

创新研发服务专场（分会场 3）
R&D Service Company Roadshow (CRO, CMO, CDMO) (Parallel Session 3)

28 SEP MON　29 SEP TUE

主持人：许小鸥，高盛（亚洲）有限责任公司直接投资部董事总经理
Moderator: Kevin XU , Managing Director, Goldman Sachs Principal Investment Area

甄　岭 ZHEN Ling
昆翎医药全球董事长兼首席执行官
13:30-13:50
Global Chairman and CEO, ClinChoice Inc.
开场报告：后疫情下的创新研发服务——国际化 & 本土化
Keynote Speech: Innovative R&D Services under Post-epidemic - Internationalization & localization

李　明 LI Ming
滬港中科国际生物科技有限公司首席执行官
13:50-14:10
CEO of ZSHK Laboratories Co., Ltd.
项目 1: 临床前一体化评价服务平台
Project 1: Integrated Pre-clinical Evaluation Service Platform

闻丹忆 WEN Danyi
上海立迪生物技术股份有限公司董事长兼 CEO
14:10-14:30
President & CEO, Shanghai LIDE Biotech. Co., Ltd.
项目 2:MiniPDX 小鼠体内 7 天肿瘤药敏检测的转化应用
Project 2: Translational Application of MiniPDX, a 7 Days in Vivo Oncology Drug Efficacy Test

任　峰 REN Feng
上海美迪西生物医药股份有限公司高级副总裁
14:30-14:50
Senior Vice President, Shanghai Medicilon Inc.
项目 3: 小分子化药临床前研发的陷阱与对策
Project 3: Preclinical Studies in Small Molecule Drug Discovery

郭　彤 GUO Tong
宝石花医药科技（北京）有限公司总裁
14:50-15:10
President, BaoShiHua Gem Flower Medical Technology (Beijing) Co., Ltd.
主题报告：后疫情下的创新研发服务——数字化解决方案
Keynote Speech: Innovative R&D Services under Post - epidemic - Digital solutions

徐列东 XU Liedong
缔脉生物医药科技（上海）有限公司首席商务官
15:10-15:30
Chief Operation Officer, dMed Biopharmaceutical Co., Ltd.
项目 4: 速中求稳的国际化临床研究一站式服务
Project 4: Doing Clinical Trials the Right Way – One Stop Solution

李　寅 LI Yin
北京春天医药科技发展有限公司市场营销中心总经理
15:30-15:50
General Manager of Marketing Center, Proswell Medical Company
项目 5: 创新药临床试验的“春天”
Project 5: Spring of Clinical Trials of Innovative Drugs

赵　馥 ZHAO Fu
润东医药研发（上海）有限公司副总裁
15:50-16:10
Vice President, Rundo International Pharmaceutical Research & Development Co., Ltd.
项目 6: 润东医药——打造基于高质量传统 CRO 的数字化和模式化创新平台
Project 6: Rundo – Build a Digital and Patterned Innovation Platform based on High-Quality Traditional CRO

顾继杰 GU Jijie
药明生物首席科学官兼执行副总裁
16:10-16:30 Chief Scientific Officer and Executive Vice President of WuXi Biologics
主题报告：卓越生物技术平台赋能加速全球创新
Keynote Speech: Global Premier Biologics Platforms to Enable and Expedite Innovations

董正伟 Harvey DONG
厦门艾德生物医药科技股份有限公司业务拓展部高级总监
16:30-16:50 Senior Director of Business Development, Amoy Diagnostics Co., Ltd.
项目 7: 肿瘤精准医疗伴随诊断系统解决方案
Project 7: Companion Diagnostic Solutions for Precision Oncology

郭振荣 GUO Zhenrong
浙江九洲药业股份有限公司首席技术官
16:50-17:10 CTO, Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
项目 8: 瑞博 CDMO 赋能新药研发
Project 8: Raybow CDMO, Accelerate Partner New Drug Development

蔡绪柳 CAI Xuliu
北京经纬传奇医药科技有限公司董事长
17:10-17:30 Chairman of the Board, Beijing Jingwei Chuanqi Medicine Services Co., Ltd.
项目 9: 第三方稽查与新药投资尽职调查
Project 9: Third - party Audit and Due Diligence on Investment for New Drug

投资人经验分享论坛（分会场 4）
Investors' Experience Sharing Forum (Parallel Session 4)

28 SEP MON　29 SEP TUE

第一阶段 Phase I

主持人：冯　岚，中国医药创新促进会秘书长

Moderator: FENG Lan, Secretary-General, China Pharmaceutical Innovation and Research Development Association

黄　青 HUANG Qing

高特佳弘瑞投资董事长

13:30-14:00　Chairman, GTJA HongRui Investment

主题报告 1: 健康产业创新变革下的价值再判断与投资新机遇

keynote Speech 1: Value Reassessment and New Investment Opportunities under the Reform of Health Industry

方　敏 FANG Min

华平投资合伙人、中国医疗健康投资负责人

14:00-14:30　Managing Director and Head of Healthcare Investment, Warburg Pincus

主题报告 2: 创新药板块在国际资本市场的发展趋势

keynote Speech 2: Trend of Global Capital Markets for the Innovative Pharmaceuticals Sector

黄逸宇 Sam HUANG

金杜律师事务所国际合伙人

14:30-15:00　International Partner, King & Wood Mallesons

主题报告 3: 境内外资本市场赋能中国生物医药企业创新发展

keynote Speech 3: Chinese Biopharmaceutical Companies Benefited from Innovative Development of Capital Markets

第二阶段 Phase II

15:00-16:00

主题讨论 1: 医药投资投后管理经验分享

Experience Sharing on Pharmaceutical Post Invesment Management

主持人：陈鹏辉 博远资本创始合伙人

Moderator: Kevin CHEN, Founding Partner, Biotrack Capital

嘉　宾：田　源 元明资本创始合伙人

Panelists: Lawrence TIAN, Founder, YuanMing Capital

朱忠远 通和毓承资本投资合伙人

John ZHU, Venture Partner, 6 Dimensions Capital

唐艳旻 启明创投投资合伙人

Amy TANG, Venture Partner, Qiming Venture Partners

周　浩 方圆基金管理（香港）有限公司合伙人

ZHOU Hao, Partner, Prudence Investment Management (Hong Kong) Limited

颜士翔 本草资本合伙人

Frank YAN, Partner, 3E Bioventures Capital

16:00-17:00

主题讨论 2: 二级市场牛市下的一级市场投资策略

Primary Market Investment Strategy under the Bull Market of Secondary Market

主持人：孙佳林 高特佳弘瑞投资执行合伙人

Moderator: SUN Jialin, Executive Partner, GTJA HongRui Investment

嘉　宾：宋高广 北极光创投执行董事

Panelists: SONG Gaoguang, Executive Director, Northern Light Venture Capital

吕志豪 英士律师行高级合伙人

Lui Chi Ho, Eric, Partner, Ince & Co

陈　晓 信银振华投资总经理

CHEN Xiao, General Manager, CNCB (Beijing) Investment

华　一 强生医疗新业务发展部总监

Michael HUA, Director, New Business Development, J&J Medical

毛　宁 维亚生物副总监

Daniel MAO, Associate Director, Viva Biotech

主持人：肖　慧，安永华明会计师事务所（特殊普通合伙）审计服务高级经理
Moderator: Grace XIAO , Assurance Senior Manager , Ernst & Young Hua Ming LLP

13:30-13:50

杨淑娟 Jane YANG
安永华明会计师事务所（特殊普通合伙）安永北京主管合伙人，审计服务合伙人
Managing Partner, Beijing office, Assurance Partner, Ernst & Young Hua Ming LLP
主题报告 1：生物科技企业上市财税关注重点
Keynote Speech 1: IPO Accounting and Tax Issues for Biotech Companies

13:50-14:10

毛　化 Fred MAO
弗若斯特沙利文咨询公司合伙人
Partner, Frost & Sullivan
主题报告 2: 生物科技企业赛道评估及投资逻辑分析
Keynote Speech 2: Biotech Portfolio Analysis and Investment Outlook

14:10-14:30

周成曜 Aaron ZHOU
汉坤律师事务所合伙人
Partner, Han Kun Law Offices
主题报告 3: 药品 Licence–in 和资产交易主要法律问题
Keynote Speech 3: Key Legal Issues Concerning Pharmaceutical License-in and Asset Transactions

14:30-14:50

高　元 GAO Yuan
华泰联合证券大健康行业部负责人
Head of Investment Banking/Healthcare Division, Huatai United Securities
主题报告 4: 物科技企业上市路径选择及趋势分析
Keynote Speech 4: IPO Pathway and Trend Analysis of Biotech Companies

14:50-15:50

讨论 1: 生物医药企业投融资经验分享
Panel 1: Experience Sharing of Investment & Financing of Biotech Companies
主持人：费　凡 安永华明会计师事务所（特殊普通合伙）大中华区生命科学行业联席主管，
华中地区审计部副主管，审计服务主管合伙人
Moderator: Felix FEI, Life Science Sector Co-leader, Greater China,Deputy Assurance Leader, China Central,
Partner, Assurance, Ernst & Young Hua Ming LLP

嘉　宾：毛　化 弗若斯特沙利文咨询公司合伙人
Panelists: Fred MAO, Partner, Frost & Sullivan
廖逸星 华泰联合证券大健康行业部副总裁
LIAO Yixing, Vice President of Investment Banking/Healthcare Division, Huatai United Securities
徐　荟 安永（中国）企业咨询有限公司交易咨询合伙人
Anson XU, Strategy & Transactions Partner of EY
裘育敏 尚珹资本合伙人
Benjamin QIU, Partner, Advantech Capital

15:50-16:50

讨论 2: 生物科技企业资本市场发展之路的机遇与挑战
Panel 2: Opportunities and Challenges of Capital Market Development for Biotech Companies
主持人：薛　冰 汉坤律师事务所合伙人
Moderator: XUE Bing, Partner, Han Kun Law Offices

嘉　宾：诸　斌 安永税务与商务咨询合伙人
Panelists: Raymond ZHU, Tax & Business Advisory Partner of EY
张　漓 汉坤律师事务所合伙人
陈　淼 华泰紫金投资有限责任公司合伙人
CHEN Miao, Investment Partner of Huatai Purple Gold Investment Company Limited
赵 庞 香港交易及结算所有限公司市场科环球上市服务部助理副总裁
ZHAO Pang, Assistant Vice President of Global Issuer Services in Markets, Hong Kong Exchanges and Clearing Ltd.

上市公司专场（分会场 1）
Listed Company Roadshow (Parallel Session 1)

29 SEP TUE

主持人：贺菊颖，中信建投证券股份有限公司医药行业首席分析师
Moderator: HE Juying, Chief Analyst of Healthcare, China Securities

李　盈 Lily LI
贝达药业股份有限公司战略合作副总裁
08:30-08:55 Vice President of Strategic Collaboration of Betta Pharamaceuticals Co., Ltd.
项目 1:From Insight to Foresight——贝达创新路径与布局
Project 1: From Insight to Foresight - Betta's Innovation Strategy and Pathway

俞文冰 YU Wenbing
上海君实生物医药科技股份有限公司总经理助理
08:55-09:20 Assistant General Manager, Junshi Biosciences of Shanghai Junshi Bioscience Co., Ltd.
项目 2: 围绕源头创新和患者可及的研发管线介绍
Project 2: Pipelines Development Focused on Original Innovation and Patient Access

陈　晨 Michael Chen
康方生物医药有限公司商务拓展副总裁
09:20-09:45 Business Development VP of Akeso, Inc.
项目 3: 康方生物率先驶入双抗蓝海
Project 3: Akeso and Bi-specific Antibody

张子栋 ZHANG Zidong
上海复宏汉霖生物技术股份有限公司 CFO
09:45-10:10 CFO of Shanghai Henlius Biotech, Inc.
项目 4: 复宏汉霖——可负担的创新
Project 4: Henlius - Affordable Innovation

宋郑薇 Wendy SONG
信达生物投资者关系与财务策略总监
10:10-10:35 Director of Investor Relation and Financial Strategy, Innovent Biologics
项目 5: 后疫情时代，生物创新药企的机遇和挑战
Project 5: Opportunities and Challenges: Biopharm in the Post Era of COVID19

张　甦 ZHANG Su
亚盛医药首席财务官
10:35-11:00 CFO, Ascentage Pharma
项目 6: 亚盛医药——专注细胞凋亡 研发创新药物
Project 6: Ascentage Pharma - Advancing Therapies that Restore Apoptosis

王　歈 WANG Yu
永泰生物制药有限公司首席执行官、联席首席科技官
11:00-11:25 CEO and Co-CTO of Immunotech Biopharm Ltd.
项目 7: 肿瘤细胞免疫治疗：疗效与挑战
Project 7: Cellular Immunotherapy on Tumours: Effects and Challenges

讨论：首席谈创新——从二级市场看中国医药创新
Panel: Innovation Trends in Pharmaceutical Industry: Insights from Secondary Market
主持人：贺菊颖，中信建投证券股份有限公司医药行业首席分析师
Moderator: Chief Analyst of Healthcare, China Securities
11:25-12:00 嘉　宾：徐佳嘉 兴业证券董事总经理、研究院副院长
Panelists: XU Jiaxi, Managing Director and Deputy Head of Research in CIS
罗佳荣 广发证券发展研究中心生物医药行业首席分析师
LUO Jiarong, Chief Analyst of Healthcare Sector, GF Securities
杨烨辉 天风证券产业部副总监、医药联席首席
YANG Yehui, Joint Chief Analyst of Medical Industry/Deputy Director of Industrial Services Department, Tianfeng Securities

非上市公司专场（分会场 2）
Non-Listed Company Roadshow (Parallel Session 2)

29 SEP TUE

主持人：佟梁慧，中国医药创新促进会研究部
Moderator: TONG Lianghui, Research Department, PhIRDA

08:30-08:55

胡元佳 HU Yuanjia
澳门大学副教授、中药质量研究国家重点实验室临床研究中心副主任
Associate Professor, Deputy Director of Clinical Research Center, State Key Laboratory of Quality Research in Chinese Medicine of University of Macau
开场报告：“后疫情时代”的中国医药创新：基于专利转化的分析
Keynote Speech: Chinese Medical Innovation in the Post-Pandemic Era: An Analysis based on Patent Transformation

08:55-09:20

夏献民 XIA Xianmin
武汉益承生物科技有限公司总经理
General Manager of Wuhan Yicheng Biotechnology Co.
项目 1: 针对新靶点广谱抗炎原研药伊匹乌肽滴鼻液（化药 1 类）人体耐受性和安全性良好
Project 1: PI3K Isoform Specific Inhibitor Epivotide (First-in-class) Shows Excellent Safety Properties in First Human Clinical Trial

09:20-09:45

麦俊波 MAI Junbo
深圳常元生物医学技术有限公司创始人 & 首席执行官
Founder&CEO of Shenzhen PrePharm Biomedical Tech Co., Ltd.
项目 2: 防治阿尔茨海默病生物创新药 CYPAD01 创制及产业化
Project 2: An Innovative Biological Medicine CYPAD01 for the Prevention and Treatment of Alzheimer's Disease

09:45-10:10

王　华 WANG Hua
骨新生医药科技（深圳）有限公司首席执行官
CEO of Biobone Biotech
项目 3: 骨新生医药科技（深圳）有限公司——华南地区骨修复创新领域领军企业
Project 3: Biobone Biotech (Shenzhen), the Leading Innovation Company in Bone Repair Area of South China

10:10-10:35

周国庆 ZHOU Guoqing
上海荣瑞医药科技有限公司首席执行官
CEO of Joint Biosciences Ltd.
项目 4: 溶瘤病毒疫苗驱动的 TCR−T 免疫疗法治疗实体瘤
Project 4: Novel OVV-Drive-TCR-T Combination Therapy for Solid Tumors

10:35-11:00

包　骏 BAO Jun
南京英派药业有限公司首席执行官
CEO of Impact Therapeutics Inc.
项目 5: 英派药业——小分子，大作用：打造全球领先的合成致死机制产品组合
Project 5: Impact Therapeutics – Small Molecule, Big Impact: Building Global Leading Synthetic Lethality Product Pipeline

11:00-11:25

王奎锋 WANG Kuifeng
勤浩医药（苏州）有限公司首席执行官
CEO of Suzhou GenHouse Pharmaceutical Co.,Ltd.
项目 6: 新型小分子靶向抗肿瘤药物开发
Project 6: Development of Novel Small Molecule Targeted Antineoplastic Drugs

11:25-12:00

崔华清 CUI Huaqing
中国医学科学院药物研究所研究员
Professor of Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
项目 7:hNE/IDO1 单靶及双靶抑制剂的创新药物研发
Project 7: The Development of Single and Dual Inhibitors Against Human Neutrophil Elastase and Indoleamine 2, 3-dioxygenase

主持人：罗佳荣，广发证券发展研究中心生物医药行业首席分析师
Moderator: LUO Jiarong, Chief Analyst of Healthcare Sector, GF Securities

13:30-14:00

杨红飞 YANG Hongfei
杭州火石数智科技有限公司创始人
Founder of Hangzhou AIMed Technology Co., Ltd.
开场报告：智见未来－智能医学机器人的机遇与挑战
Keynote Speech: Future is Coming: Opportunities and Challenges for Intelligent Medical Robots

14:00-14:25

张　涛 ZHANG Tao
深圳善康医疗健康产业有限公司副总经理
Vice President of Shenzhen Sciencare Medical Industries Co.,Ltd.
项目 1: 超长效戒毒药物纳曲酮植入剂临床研究进展
Project 1: The Research Progress of Controlled Release of Natrexone Implant for Drug Dependence

14:25-14:50

周文强 ZHOU Wenqiang
长沙泽达医药科技有限公司首席执行官
CEO of Zeta Pharma Inc.
项目 2: 一种治疗前列腺癌的新型 HDAC6 抑制剂小分子创新药物 Zeta55
Project 2: A Novel Small Molecule HDAC6 Inhibitor Zeta55 as Potential Drug for Prostate Cancer Treatment

14:50-15:15

钱雪明 QIAN Xueming
创胜集团首席执行官
CEO of Transcenta Holding Limited
项目 3: 创胜集团——一个专注于创新抗体药物开发的全整合型生物药公司
Project 3: Transcenta - A Fully Integrated Biopharmaceutical Company Focused on Innovative Antibody Drug Development

15:15-15:40

肖　凯 XIAO Kai
博和生物科技（成都）有限公司首席科技官
CTO of Bohe Biotechnology(chengdu)Co.,Ltd.
项目 4: 骨靶向递药系统研发及在骨科疾病治疗中的应用
Project 4: R&D of Bone-Targeted Drug Delivery System and Its Application in the Treatment of Orthopedic Diseases

15:40-16:05

张立国 ZHANG Liguo
广东旋玉健康生物科技有限公司首席科学官
CSO of Immunecent Biotechnology, Inc.
项目 5: 治疗 SLE 的新型 IFNAR1 单克隆抗体选择性阻断 IFN−ω 和 IFN−α 但保留 IFN−β 的抗病毒作用
Project 5: A Unique IFNAR1-targeting mAb that Neutralizes IFN-ω &IFN-α but Preserves the Antiviral Activity of IFN-β, as a Potential Treatment for SLE

16:05-16:30

金　晶 JIN Jing
中国医学科学院药物研究所副研究员
Associate Professor of Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
项目 6: 靶向 B 细胞淋巴瘤的小分子创新药物研发
Project 6: R&D of Novel Small Molecular Medicine for the Treatment of B-cell Lymphoma

16:30-16:55

张　洁 ZHANG Jie
成都恩沐生物科技有限公司首席运营官
COO of Chimagen Biosciences, Ltd.
项目 7: 针对 B 细胞血液肿瘤的三特异抗体临床前研究
Project 7: A Novel Tri-Specific Anti-CD3/CD19/CD20 T cell-Engaging Antibody as A Potentially Better Treatment For B-cell Lymphoma

16:55-17:20

谢单丹 XIE Dandan
江苏亚虹医药科技有限公司业务拓展副总监
BD, Associate Director of Jiangsu Yahong Meditech Co., Ltd.
项目 8: 全球首个口服治疗非肌层浸润性膀胱癌 APL−1202 项目介绍
Project 8: The First Oral Medicine to Treat NMIBC_APL-1202

17:20-17:45

肖　芳 XIAO Fang
北大未名（上海）生物制药有限公司首席商务官
CBO of Peking University V-Ming(Shanghai) Biologics Co., Ltd.
项目 9: 创新药物的最佳伙伴——全产业链的生物制药平台
Project 9: The Best Partner of Innovative Medicine -- the Whole Industry Chain for Biopharmaceutical Platform

医疗器械专场（分会场 3）
Medical Devices Roadshow (Parallel Session 3)

29 SEP TUE

主持人：王　临，中国医疗器械行业协会创新服务专业委员会秘书长
Moderator: WANG Lin, General Secretary of Innovation and Financial Services Committee of China Association for Medical Devices Industry

08:30-08:45
王　临 WANG Lin
中国医疗器械行业协会创新服务专业委员会秘书长
General Secretary of Innovation and Financial Services Committee of China Association for Medical Devices Industry
开场报告：医疗器械创新服务的资源配置与分享
Keynote Speech: Resource Allocation and Sharing in Medical Device Innovation Service

08:45-09:10
郇丹丹 HUAN Dandan
安翰科技（武汉）股份有限公司副总裁、董事会秘书
Vice President & Board Secretary of ANKON Technologies Co., Ltd.
项目 1: 安翰远程胶囊胃镜助力疫情防控
Project 1: Ankon Remote Capsule Gastroscope Helps COVID-19 Prevention and Control

09:10-09:35
张亚飞 ZHANG Yafei
迈杰转化医学研究（苏州）有限公司董事长
CEO of MEDx (Suzhou) translational Medicine Co., Ltd.
项目 2: 聚焦生物标志物和伴随诊断的精准医疗创新解决方案
Project 2: Bringing Integrated Solutions to Precision Medicine: from Biomarkers to CDx

09:35-10:00
周　曜 ZHOU Yao
科瑞百奥生物技术有限公司首席运营官
COO of Cryo Bio Technology Co., Ltd.
项目 3: 同种异体软骨材料临床技术及创新医疗器械产品
Project 3: Clinical Technology of Allogeneic Cartilage Materials and Innovative Medical Device Products

10:00-10:25
张晓冬 ZHANG Xiaodong
北京天助瑞畅医疗技术有限公司总经理
General Manager of Beijing Angel-Reach Medical Technical Co., Ltd.
项目 4: 新型普适性一体化主动脉弓修复系统
Project 4: A Novel Type of Aortic Arch Endovascular Repair System

10:25-10:50
李广成 LI Guangcheng
苏州梅德厚普医疗科技有限公司董事长
CEO of Suzhou MADEHOPE Medical Technology Co., Ltd.
项目 5: 颅内血肿清除系统
Project 5: Intracranial Hematoma Clearance System

10:50-11:15
顾　莹 GU Ying
无锡帕母医疗技术有限公司运营总监
COO of PULNOVO MEDICAL(Wuxi)Co., Ltd.
项目 6: 经皮肺动脉去神经术：治疗肺高压的创新技术
Project 6: Pulmonary Artery Denervation(PADN): Aninnovative Technique for Treatment of Pulmonary Hypertension(PH)

11:15-11:40
严光能 YAN Guangneng
暨南大学研究员
Researcher of Jinan University
项目 7:CT 引导下的穿刺定位装置系统
Project 7: CT-Guided Puncture Positioning Device

11:40-12:05
高林明 GAO Linming
索思（苏州）医疗科技有限公司总经理
Chief Executive Officer of THOTH (Suzhou) Medical Technology Co., Ltd.
项目 8: 临床级全体征医学传感器 构建数字医疗基础网络
Project 8: Clinical-Grade Medical Sensor for All Signs Constructing A Basic Digital Medical Network

科创板论坛（分会场 4）
SSE STAR Market Forum (Parallel Session 4)

29 SEP TUE

第一阶段 Phase I

主持人：黄　青，高特佳弘瑞投资董事长
Moderator: HUANG Qing , Chairman, GTJA HongRui Investment

彭义刚 PENG Yigang
上海证券交易所发行上市服务中心副总监
08:30-09:00 Associate Director of Offering & Listing Center, Shanghai Stock Exchange
主题报告 1: 科创板制度和当前运行情况介绍
keynote Speech 1: Introduction and Current Status of SSE STAR Market

盛泽林 SHENG Zelin
苏州泽璟生物制药股份有限公司董事长兼总经理
Chairman & CEO, Suzhou Zelgen Biopharmaceuticals Co., Ltd.
09:00-09:30
主题报告 2: 透过科创板，看中国创新药研发的趋势和机遇
keynote Speech 2: Trends and Opportunities of New Drug Research and Development under Reform of Capital Market in China

黄反之 HUANG Fanzhi
分享投资创始合伙人
09:30-10:00 Founding Partner, Share Capital
主题报告 3: 精准医疗时代的投资机遇
keynote Speech 3: Investment Opportunity in the Era of Precision Medicine

赵　冀 ZHAO Ji
中金公司投资银行部医疗医药组执行总经理
10:00-10:30 Executive Director, Investment Banking, Healthcare and Pharmaceutical Group, China International Capital Corporation Limited
主题报告 4: 科创思维下的生物医药企业资本运作服务
keynote Speech 4: Capital Operating of Biotech Company in STAR Market

陶旭东 TAO Xudong
君合律师事务所资深合伙人
10:30-11:00 Senior Partner, JunHe LLP
主题报告 5: 生物医药企业科创板上市法律操作要点
keynote Speech 5: Listing on STAR Market by Biotech Companies: Solutions and Tactics on Key Legal Issues

第二阶段 Phase II

11:00-12:00
主题讨论：科创板助力生物医药产业创新发展
Panel: SSE STAR Market Supports the Innovation and Development of Biomedicine

主持人：李秋实 高特佳弘瑞投资执行合伙人、PIPE 业务负责人
Moderator: LI Qiushi, Executive Partner, GTJA HongRui Investment
嘉　宾：彭义刚 上海证券交易所发行上市服务中心副总监
Panelists: PENG Yigang, Associate Director of Offering & Listing Center, Shanghai Stock Exchange
张　军 中信证券投行委医疗健康组执行总经理
Jon ZHANG, Executive Director, Investment Banking, Healthcare and Life Science Group, Citic Securities
冀　文 平安银行医疗健康金融事业部总裁
JI Wen, President, Ping An Bank's Finance SBU of Medical & Health Industry
朱　湃 倚锋资本合伙人
ZHU Pai, Partner, Efung Capital
俞文冰 君实生物总经理助理
YU Wenbing, Assistant General Manager, Junshi Biosciences

人工智能与生物医药专场（分会场 1）
Artificial Intelligence (AI) + BioMed Roadshow (Parallel Session 1)

29 SEP TUE

主持人：邓周宇，中银国际证券研究部执行董事、医药行业首席分析师、大消费组组长

Moderator: Zhouyu DENG, Executive Director of the Research Department, Chief Analyst of the Pharmaceutical Industry, and Leader of the Consumption Research Group of BOC International (China) Co., LTD

13:30-14:00

蒋华良 JIANG Hualiang
中国科学院院士、中国药促会 2015−2016 年度会长、中国科学院上海药物研究所研究员
Academician of Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences
主题报告：AI 和联邦学习助力药物研发
Keynote Speech: AI and Federated Learning Empowers Drug Research and Discovery

14:00-14:25

马　健 MA Jian
深圳晶泰科技有限公司首席执行官
CEO, XtalPi Inc.
项目 1: 拥抱人工智能，开启药物研发快进模式
Project 1: Accelerating Drug Discovery & Development with Artificial Intelligence

14:25-14:50

谭　验 TAN Yan
深圳未知君生物科技有限公司创始人、首席执行官
Founder & CEO, Shenzhen Xbiome Biotech Co., Ltd.
项目 2: 中国首家专注于肠道微生态治疗的 AI 制药公司
Project 2: The First AI-based Microbiome Drug Development Company in China

14:50-15:15

王文佳 WANG Wenjia
天士力国际基因网络药物创新中心有限公司总经理
General Manager, Genenet Pharmaceutical
项目 3: 星斗云 基于大数据与深度学习的药物机理与重定位研究平台
Project 3: Cloudphar-A Drug Mechanism and Repositioning Platform Based on Big Data and Deep Learning

15:15-15:40

沈倩诚 SHEN Qiancheng
上海宇道生物技术有限公司首席执行官
CEO, UCDOM BioTech.(Shanghai) Co., Ltd.
项目 4: First−in−Class 变构小分子研发平台与管线布局
Project 4: First in Class Allosteric Molecules: Platform and Pipeline in Drug Discovery

15:40-16:05

曹凌霄 CAO Lingxiao
苏州创腾软件有限公司首席执行官
CEO, Suzhou NeoTrident Software Ltd.
项目 5: 致力于创新与品质的数字化智能化转型——基于科学人工智能与数据驱动的 SaaS 平台
Project 5: Accelerate the Digital Transformation of Intelligent Innovation & Quality-An Artificial-Intelligence-Driven SaaS Platform

16:05-16:30

夏荣森 XIA Rongsen
深圳市青云瑞晶科技有限公司首席营销官
CMO, Shenzhen ReadCrystal Technology Co., Ltd.
项目 6: 基于 MicroED 技术的药物研发平台
Project 6: Pharmaceutical R&D Platform Based on MicroED

16:30-16:55

靳照宇 JIN Zhaoyu
明济生物制药有限公司创始人、首席执行官
Founder & CEO, futuregen biopharmaceutical company
项目 7: 计算机辅助的蛋白工程技术及生命组学驱动的创新抗体药物开发
Project 7: Development of Novel Antibody Therapeutics by Life-omics and Computer-aided Protein Engineering Technologies

16:55-17:20

许　强 XU Qiang
领星生物科技有限公司创始人、首席执行官
Founder & CEO, GenomiCare Biotechnology
项目 8: 数据驱动赋能新药临床开发
Project 8: Integration of AI & Clinico-Genomics, Accelerating Clinical Development of New Drugs

投资并购论坛（分会场 3）
Investment M&A Forum (Parallel Session 3)

29 SEP TUE

主持人：李奕莹，安永华明会计师事务所（特殊普通合伙）审计服务高级经理
Moderator: Tina LI, Assurance Senior Manager, Ernst & Young Hua Ming LLP

姜　华 JIANG Hua
绿叶制药集团副总裁
13:30-14:00 Group Vice President of Luye Pharma
主题报告 1: 涉外并购助力企业跨越式成长
Keynote Speech 1: Cross-border M&A Encourages Companies Earn a Great-leap-forward Development

王玥月 WANG Yueyue
天超资本管理合伙人
Managing Partner, T-Capital
14:00-14:30 **主题报告 2: 剧变环境下，国内 biotech 和传统药企如何突围?**
Keynote Speech 2: How to Break Out the Challenging Situation for the Biotech or Conventional Pharmaceutical Companies in China？

陈　峰 CHEN Feng
优选资本合伙人
14:30-15:00 Partner, Youchoose Capital
主题报告 3: 关于创新药投资的几点思考
Keynote Speech 3: Several Insights on Biotech Investment

王　昕 Cynthia WANG
法国施维雅药厂，亚太生物创新中心，业务拓展及许可总监
15:00-15:30 BD&Licensing Director, BioInnovation Asia, Les Laboratories SERVIER
主题报告 4: 期待成为中国创新企业的最佳合作伙伴
Keynote Speech 4: Servier, Your Partner of Choice

15:30-16:30 **讨论：医药新政和科创板下的生物医药投资**
Panel: The Biotech Investment Under New Pharma Reformation Policy and SSE STAR MARKET

主持人：谈文龙 北京朗玛峰创业投资管理有限公司合伙人
Moderator: TAN Wenlong, Partner, Beijing Everest Venture Capital Management Co., Ltd.

嘉　宾：包杨欢 薄荷天使基金合伙人
Panelists: BAO Yanghuan, Partner, BOHE Angel Fund
朱青生 泓元资本创始合伙人
Ching ZHU, Partner, Creacion Ventures
黄　潇 云锋基金执行董事
Albert HUANG, Executive Director, Yunfeng Capital

主持人：冯　岚，中国医药创新促进会秘书长
Moderator: FENG LAN , Secretary-General of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

第一阶段 Phase I

13:30-14:00

杨　胜 YANG Sheng
国家药品监督管理局药品注册管理司副司长
Deputy Director-General of Department of Drug Registration of NMPA
主题报告：近五年中国药品审评审批制度改革成果和未来改革方向
Keynote Speech : Achievement of China's Drug Evaluation System Reform in the Past Five Years and Future Trend

14:00-14:40

讨论：科学监管推动中国医药创新
Panel: Scientific Supervision Promote China's Pharmaceutical Innovation

主持人：何如意 荣昌生物首席医学官、国投创新医疗健康首席科学家、
前国家食品药品监督管理总局药品审评中心首席科学家
Moderator: HE Ruyi, CMO of RemeGen, CMO of SDIC, Former Chief Scientist of Center for Drug Evaluation, CFDA

嘉　宾：杨　胜 国家药品监督管理局药品注册管理司副司长
Panelists: YANG Sheng, Deputy Director-General of Department of Drug Registration of NMPA
宋瑞霖 中国医药创新促进会 2019-2020 年度会长
SONG Ruilin, 2019-2020 Annual Chairman of PhIRDA
邵　蓉 中国药科大学国家药物政策与医药产业研究中心执行副主任
SHAO Rong, Vice Executive Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University
冯　毅 四川科伦药业股份有限公司研发副总裁兼首席战略官
FENG Yi, Vice President for R&D, Chief Strategy Officer, Sichuan Kelun Pharmaceutical Co., Ltd.

第二阶段 Phase II

14:40-15:10

范长生 FAN Changsheng
北京医药卫生经济研究会秘书长
Secretary General of Beijing Medical and Health Economic Research Association
主题报告：医药创新背景下医保谈判准入评价研究
Keynote Speech : Research on the Evaluation of Medical Insurance Negotiation Access under the Background of Pharmaceutical Innovation

15:10-15:50

讨论：优化创新药医保动态准入探讨
Panel: Discussion on Optimizing Dynamic Access of Medical Insurance for Innovative Drugs

主持人：毛宗福 武汉大学全球健康研究中心主任
Moderator: MAO Zongfu, Director of Global Health Research Center, Wuhan University

嘉　宾：胡善联 复旦大学公共卫生学院卫生经济学教授
Panelists: HU Shanlian, Professor of Health Economics, School of Public Health, Fudan University
赵　琨 国家卫生健康委药物与卫生技术评估中心副主任
ZHAO Kun, Director of Division of Health Policy Evaluation and Technology Assessment of the National Health Development Research Center
刘军帅 国家罕见病诊疗与保障专家委员会委员
LIU Junshuai, Committee Member of National expert consultation committee of Diagnosis and Treatment of Rare Disease
夏苏建 暨南大学医学院医学统计学教研室主任
XIA Sujian, Director of the Medical Statistics Teaching and Researching Section, Jinan University of Basic Medicine

第三阶段 Phase III

15:50-16:20

陈　昊 CHEN Hao

华中科技大学同济医学院药品政策与管理研究中心主任

Director of Drug Policy and Management Research Center of Tongji Medical College, Huazhong University of Science and Technology

主题报告：创新药品在医疗机构的准入困境与患者权益保障

Keynote Speech: Access Dilemma of Innovative Drugs in Hospital and Protection of Patients' Rights and Interests

16:20-17:00

讨论：创新药医疗机构采购和临床使用面临的困难和挑战

Panel: Difficulties and Challenges in Procurement and Clinical Use of Innovative Drugs in Medical Institutions

主持人：胡　欣 北京医院药学部主任

Moderator: HU Xin, Director of Department of Pharmacy, Beijing Hospital

嘉　宾：冷家骅 北京大学肿瘤医院医疗保险服务处处长

Panelists: LENG Jiahua, Director of Department of Medical Insurance of Peking University Cancer Hospital and Institute

王晓玲 首都医科大学附属儿童医院药学部主任

WANG Xiaoling, Director of Department of Pharmacy, Beijing Children's Hospital, Capital Medical University

朱建国 苏州大学附属第一医院药学部主任

ZHU Jianguo, Director of Pharmaceutical Department, The First Affiliated Hospital of Soochow University

樊　琳 江苏恒瑞医药股份有限公司公共事务部高级总监

Lynn FAN, Senior Director of Public Affairs Department, Jiangsu Hengrui Medicine Co., Ltd.

主持人：梁燕，荷兰王国驻华大使馆生命科学和医学官员
Moderator: Sunny LIANG, LSH Officer, Department of Health, Welfare and Sport, Embassy of the Kingdom of the Netherlands

15:00-15:05

Peter A. Bootsma
荷兰王国驻华大使馆卫生、福利和体育参赞
Counselor of Health, Welfare and Sports, Embassy of the Kingdom of the Netherlands
开场致辞 Welcome Remarks

15:05-15:25

Troels Jordansen
CEO, Glycostem
项目 1: 癌症杀手：自然杀伤细胞抗癌药
Project 1: NK Cells: The Killer of Cancer

15:25-15:45

Axel Mescheder
CEO, Cristal Therapeutics
项目 2: 改善癌症和其他疾病治疗效果的纳米药物
Project 2: Customized Nanomedicines with Superior Therapeutic Profiles

15:45-16:05

Jeroen Tonnaer
BD & Licensing, PureIMS
项目 3: 可快速投放市场的低成本预装式一次性干粉吸入器
Project 3: Cyclops™, a Low-COG Innovative Preloaded-disposable DPI with Fast to Market Applications

16:05-16:25

CHEN Jiehui
Asia CEO, iDNA
项目 4: 基于肺癌的多病种一体化筛查项目
Project 4: iDNA-Providing Turn-key Solution for Lung Cancer Based Multi-Comorbidities Screening Program

16:25-16:45

Ernst Elhorst
CEO, SuperSeton
项目 5: 操作简单、安全可靠的创新型肛瘘挂线
Project 5: SuperSeton-A smooth, Simple and Safe Innovative Solution for Anal Fistula Drainage

16:45-17:05

Jeroen Kodde
CEO, Kaminari Medical
项目 6: 结合超声与光学成像技术的新型冠状动脉血管重建术
Project 6: Kaminari Medical: Combining Ultrasound and Optical Imaging to Revolutionize Coronary Revascularization

17:05-17:25

Jaap Delange
CEO, Respiosa BV
项目 7: 用于治疗阻塞性睡眠呼吸暂停综合症的微创手术植入物
Project 7: Respiosa OSA Implant Technology

国际云路演专场——加拿大
Virtual International Roadshow - Canada

22 SEP TUE

主持人：米璐璐，加拿大驻沪总领事馆商务处 生命科学商务专员
Moderator: MI Lulu, Life Sciences Trade Commissioner, Consulate General of Canada in Shanghai

09:30-09:35

Dave Murphy
加拿大驻沪总领事
Consul General, Consulate General of Canada in Shanghai
开场致辞 Welcome Remarks

09:35-09:50

Karimah Es Sabar
CEO & Partner, Quark Venture LP
开场报告：在全球大流行中，加拿大生命科学生态系统和耐力的主要优势
Keynote Speech: Key Strengths for Canada's Life Science Ecosystem and Endurance Amidst a Global Pandemic

09:50-10:10

Bill Hunter
President & CEO, Canary Medical Inc.
项目 1: Canary——智能慢病管理和虚拟医疗的交叉创新

10:10-10:30

Mohammad Qadir
President & CSO, Fusion Genomics Corp.
项目 2: 用于预防传染病的多重基因诊断技术
Project 2: Massively Multiplex Diagnostics for Infections Diseases

10:30-10:50

Karim Lalji
CEO, Microbion Pharma Corp.
项目 3: Pravibismane: 治疗生物膜感染的创新疗法
Project 3: Pravibismane: Breakthrough Therapy against Biofilm-related Chronic Infections

10:50-11:10

ZHANG Hao
CEO, Onestep Laboratories Inc.
项目 4: 独创“芯片级”免疫分析及血液分析原材料
Project 4: Raw Materials for IVD

11:10-11:30

ZHANG Zaihui
CSO & VP R&D, Signalchem Lifesciences Corp.
项目 5: SLC-391——用于癌症治疗的临床阶段小分子 AXL 抑制剂
Project 5: SLC-391 - A Clinical Stage Small Molecule AXL Inhibitor for Cancer Therapy

11:30-11:50

Michael Parr
President & CSO, Sitka Biopharma Inc.
项目 6: 突破障碍：运用纳米技术治疗膀胱癌
Project 6: Breaking through Barriers: Nanotechnology Therapeutics Platform with a Lead Program for Bladder Cancer

02

038-113

主办方介绍

Introduction of 2020 CBIIC Hosts

中国医药创新促进会

中国医药创新促进会（原名“中国医药工业科研开发促进会”，简称“中国药促会”），英文名称：China Pharmaceutical Innovation and Research Development Association（PhIRDA），成立于 1988 年，是经国家民政部登记注册的非营利性全国性 4A 级社会组织。

中国药促会秉承“创新、产业化、国际化”的宗旨，以临床需求为导向，长期致力于“产学研用资”紧密结合，促进医药行业创新发展，已经成为集医药创新研发型企业、科研机构、临床研究机构、创新服务机构和医药投资机构所组成的医药创新产业化促进平台，目前有会员单位 144 家。中国药促会已成立了药物研发专业委员会、药物临床研究专业委员会、医药政策专业委员会、医药创新投资专业委员会、创新研发服务专业委员会和心血管药物临床研究专业委员会，形成了以创新为核心，以促进创新为目标的涵盖药物研发、生产、使用以及投融资的全链条组织构架，并作为国际药品制造商协会联合会（IFPMA）的成员继续拓展国际交流渠道。

中国药促会工作内容主要包括：一是，开展医药政策研究，为我国医改事业、完善药物政策和医药产业发展建言献策；二是，通过举办各种论坛、发布会、大型会议等活动，促进会员单位乃至整个医药产业的相互交流、创新发展；三是，通过与国内外医药行业协会、企业、科研机构和外国驻华使馆合作，推动国际医药产业的多方位、多维度合作交流，为会员单位搭建国际交流平台；四是，践行国家创新驱动发展战略指导精神，为会员单位拓宽医药创新投融资渠道、搭建合作平台，推动社会资本加大对初创及研发型企业自主创新项目的投入，营造更有吸引力的医药创新投资环境；五是，为会员单位提供医药信息搜集、整理、评价服务，包括编辑每日《医药信息简报》、每周《国际医药产业发展动态与研发信息简报》等内部电子刊物以及中国药促会官方网站、微信公众号等服务平台。

中国药促会将围绕办会宗旨，不断拓展服务内涵和外延，做好政府与会员企业的桥梁和纽带，维护会员合法权益，加强行业自律，推动我国医药产业的创新和可持续发展，为加快我国经济社会发展、保障人民群众健康不断做出贡献！





PhIRDA

Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA), formerly named China Pharmaceutical Industry Research and Development Association, is registered as a non-profit 4A social organization by the Ministry of Civil Affairs of China at national level.

PhIRDA has been exerting great effort on "academia-industry-investment collaboration", which centers on the principle of "innovation, industrialization, internationalization", and persists in innovation to achieve unmet clinical requirements. As a platform facilitating the industrialization of pharmaceutical innovation, PhIRDA currently has 144 members mainly consists of pharmaceutical R&D enterprises, research institutions, clinical institutions, R&D Services companies and investment institutions focusing on pharmaceutical innovation. Moreover, PhIRDA has established the following Specialty Committees: Drug R&D, Clinical Research, Medicinal Policy, Pharmaceutical Innovation Investment and Innovation R&D Services and Clinical Research on Cardiovascular Drugs, forming a fully functional organization structure focusing on innovation, aiming to promote the development of innovation, covering the whole industrial chain, including drug R&D, manufacturing, using, investment and capital market. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.

Major work of PhIRDA includes: first, to conduct policy researches, propose valuable suggestions on healthcare reform and the development of pharmaceutical industry; second, to promote communication and innovative development of our members and even the whole pharmaceutical industry through forums, press-conferences, summits, etc.; third, to make efforts to establish an international exchange platform for our members through cooperation with foreign embassies and foreign associations to stimulate comprehensive communication between China and foreign countries in pharmaceutical field; fourth, to practice the guiding spirits of national innovation-driven development strategy, to broaden the investment and financing channels of pharmaceutical innovation, to build the cooperation platform for our members, and to promote social capitals to pay more attention on investment in innovative projects of start-up and R&D enterprises to create a more attractive environment of pharmaceutical innovation and investment; fifth, to improve the website and WeChat official account of PhIRDA and provide collecting, arranging, revising service of pharmaceutical information, which includes the following internal e-magazines such as the *daily Pharmaceutical Information Brief*, *the weekly International Pharmaceutical Development Tendency and Research Information Brief*.

PhIRDA will center on our principle, continuously expand services, build a bridge between the government and our members, maintain legitimate rights and interests of members, strengthen self-discipline, promote healthy development of Chinese pharmaceutical industry, making constant contributions to the greater economic development of the country and public health.

中国医疗器械行业协会

中国医疗器械行业协会（CAMDI）成立于 1991 年，是由从事医疗器械研发、生产、经营、投资、产品检测、认证咨询及教育培训等医疗器械产业相关工作的单位或个人在自愿的基础上联合组成的全国范围的行业性非盈利社会组织，具有社会团体法人资格。

协会的宗旨是代表并维护会员单位的共同利益及合法权益，促进中国医疗器械行业健康发展。 协会遵守国家宪法、法律、法规和国家政策，遵守社会道德风尚；业务主管单位为国务院国有资产监督管理委员会，并接受国家食品药品监督管理总局的业务指导。

中国医疗器械行业协会目前有分会及专业委员会 40 余个，拥有各类会员近 4000 家。

香港交易所

香港交易及结算所有限公司（香港交易所）是世界主要的交易所集团之一，业务范围包括股票、大宗商品、衍生产品、定息及货币产品。香港交易所是全球领先的新股融资中心，也是香港唯一的证券及衍生产品交易所和结算所营运机构，为国际投资者提供进入亚洲最活跃市场的渠道。

香港交易所透过全资子公司伦敦金属交易所（LME）和 LME Clear Limited，运营全球领先的工业金属交易市场。2018 年，香港交易所在中国深圳设立的前海联合交易中心开业，迈出大宗商品业务发展的又一步。

香港交易所是与中国内地市场互联互通的先行者。2014 年，香港交易所推出沪港通机制，让国际投资者可以通过香港直接投资中国内地股市；沪港通开启的互联互通机制先后于 2016 年及 2017 年拓展至深港通及债券通。

www.hkexgroup.com

艾美达（北京）医药信息咨询有限公司

艾美达（北京）医药信息咨询有限公司（简称“艾美达”）成立于 2014 年，是一家专业的医药行业咨询服务提供商，同时也是医药产业链资源整合服务商。公司依托强大的医药行业国内外资源，以国家产业政策对市场的影响为导向，医药卫生行业大数据为基础，通过专业的数据分析，结合药物经济学和市场准入流程，利用学术活动平台为医药企业提供整套技术及市场解决方案，并为投资机构提供技术和政策咨询服务。

CAMDI

Founded in 1991, China Association for Medical Devices Industry (CAMDI) is a non-profit social organization with corporative qualification. As a national medical devices industry association, CAMDI is established on a voluntary basis by organizations and individuals engaged in the research and development, production, operation, investment, product testing, certification and consultation, and training in relation to medical devices.

The purpose of CAMDI is to represent and safeguard the common interests and legitimate rights of its members, and to promote the healthy development of China's medical devices industry. CAMDI abides by the State's constitution, laws, regulations and policies, observes social ethnics, and receives guidance and supervision of the State-owned Assets Supervision and Administration Commission, receives guidance of China Food and Drug Administration.

Currently, CAMDI runs over 40 branches and specialized committees and has more than 4,000 members.

HKEX

Hong Kong Exchanges and Clearing Limited (HKEX) is one of the world's major exchange groups, and operates a range of equity, commodity, fixed income and currency markets. HKEX is the world's leading IPO market and as Hong Kong's only securities and derivatives exchange and sole operator of its clearing houses, it is uniquely placed to offer regional and international investors access to Asia's most vibrant markets.

HKEX is also the global leader in metals trading, through its wholly owned subsidiaries, The London Metal Exchange (LME) and LME Clear Limited. This commodity franchise was further enhanced with the launch of Qianhai Mercantile Exchange, in China, in 2018.

HKEX launched the pioneering Shanghai-Hong Kong Stock Connect programme in 2014, further expanded with the launch of Shenzhen Connect in 2016, and the launch of Bond Connect in 2017.

www.hkexgroup.com

iMeta

iMeta Health Information Consulting Co., Ltd. established in 2014, is a professional consulting provider and a service provider offering integrated resource in pharmaceutical industry chain. Relying on domestic and global rich resource in pharmaceutical industry, taking national industrial policies as guide and on the basis of big data from medical and health industry for professional data analysis, iMeta combinates market access with pharmacoeconomic and fully utilizes academic platform to provide technical service and market solutions for pharmaceutical enterprises, and offer technical suggestions and policy advice for investment institutions.

嘉宾简介
Introduction of Guests

宋瑞霖
中国医药创新促进会 2019–2020 年度会长

SONG Ruilin
2019-2020 Annual Chairman of PhIRDA

宋瑞霖，现任中国医药创新促进会执行会长、全国政协参政议政人才库特聘专家；先后取得中国政法大学法学学士、中欧国际工商学院工商管理硕士和中国药科大学社会与管理药学博士学位；澳大利亚悉尼大学访问学者。曾长期在国务院法制办公室从事卫生与药物政策、法律研究并负责卫生医药领域的法律、法规起草和审查工作；近年来，在完善我国药品审评审批制度改革、医保报销制度改革和医药创新政策方面做出了重要贡献。

现担任的其他社会职务：中国药科大学国家药物政策与产业发展研究中心执行副主任、香港联交所生物科技咨询小组成员；中国罕见病联盟副理事长、中国药学会理事、中国药师协会理事、白求恩公益基金会理事。

Dr. SONG Ruilin is the Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Advisor on Participation in and Deliberation of State Affairs for the Chinese People's Political Consultative Conference (CPPCC). He is L.L.B. of China University of Political Science and Law, EMBA of China Europe International Business School, Doctor of Social and Administrative Pharmacy of China Pharmaceutical University and Visiting Scholar of the University of Sydney. Dr. Song had served in the Legislative Affairs Office at State Council of China for a long time, engaging in health and drug policy, legal studies and in charge of law making and reviewing in the areas of pharmaceutical and healthcare industry. He has made great contribution in optimizing the reform of drug review and approval system, medical insurance reimbursement system and making policies for pharmaceutical innovation in China.

Currently, Dr. Song also undertakes several social positions, such as Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University, Biotech Advisory Panel Member of the Stock Exchange of Hong Kong Limited, the Vice President of China Alliance for Rare Disease (CARD), Director of Chinese Pharmaceutical Association (CPA), Director of Chinese Pharmacists Association and Director of Bethune Charitable Foundation.

任晋生
中国医药创新促进会年度会长、先声药业董事长兼 CEO

REN Jinsheng
Annual Chairman of PhIRDA, CEO & Chairman of the Board of Simcere Pharmaceutical Co., Ltd.

先声药业创始人，麦考瑞大学经济学硕士，高级经济师。转化医学与创新药物国家重点实验室主任，江苏省科协副主席，中国药促会副会长，全国五一劳动奖章获得者，多次入选中国医药经济十大年度人物。

Mr. Ren, founder of Simcere Pharmaceutical Group, earning his master's degree of Economics at Macquarie University, Senior Economist. Mr. Ren is the director of State Key Laboratory of Translational Medicine and lnnovative Drug Development, Vice Chairman of Jiangsu Association for Science and Technology, Vice President of China Pharmaceutical Innovation and Research Development Association, the winner of the National May 1st Labor Medal. He has been selected as one of the top ten figures in China's pharmaceutical economy by Medicine Economic News for many times.

李小加
香港交易所集团行政总裁

Charles LI
Chief Executive of HKEX

李小加先生自 2010 年起出任香港交易及结算所（香港交易所）集团行政总裁。自其担任此职以来，李先生成功推动了香港交易所历史上最为重要的多项战略举措，包括在 2012 年收购了全球最大的金属定价中心伦敦金属交易所 (LME)、在 2013 年成立场外结算公司、在 2014 年推出“沪港通”、在 2016 年推出“深港通”、并在 2017 年推出“债券通”。李先生积极寻求全方位强化香港作为离岸人民币中心的角色，亦大力推动香港上市体制的改革与发展，维持香港的竞争力和巩固香港首次公开招股中心领先的地位。
李先生出生在北京，长在甘肃。李先生离开中国深造前曾是渤海油田石油工人，并曾任英文《中国日报》的编辑记者。在美国完成法律博士学位后，李先生曾在纽约的达维 (Davis Polk & Wardwell) 与布朗伍德 (Brown & Wood) 律师事务所执业。加盟香港交易所前，李先生为摩根大通中国区主席；此前为美林证券中国区总裁。
李先生 1984 年毕业于厦门大学，取得文学士学位（英国文学）；1988 年获得美国阿拉巴马大学新闻系硕士学位；1991 年取得纽约哥伦比亚大学法学博士学位。

Charles Li has served as Chief Executive of Hong Kong Exchanges and Clearing (HKEX) since 2010. In this role, Mr. Li has orchestrated some of the most significant strategic initiatives in HKEX's history, including the acquisition of the London Metal Exchange in 2012, the launch of OTC Clear in 2013, and the introduction of Shanghai-Hong Kong Stock Connect in 2014, Shenzhen-Hong Kong Stock Connect in 2016, and Bond Connect in 2017. He has sought to strengthen Hong Kong's role as an offshore Renminbi hub and led HKEX's efforts to reform its listing regime to maintain Hong Kong's competitiveness and secure its position as a leading IPO centre.
Mr. Li was born in Beijing and grew up in Gansu. Before leaving China for further study, Mr. Li was an offshore oil worker in the North China Sea and then an editor-reporter for China Daily. After completing his Juris Doctor (JD) degree in the US, Mr. Li practiced law in New York with Davis Polk & Wardwell and Brown & Wood. Before joining HKEX, he was Chairman of JP Morgan China, prior to which he was President of Merrill Lynch China.
Mr. Li obtained a BA degree in English literature from Xiamen University in 1984, an MA degree in journalism from the University of Alabama in 1988, and a JD degree from Columbia University School of Law in 1991.

李　燕
中国医药创新促进会候任会长、齐鲁制药集团总裁

LI Yan
Chairman-elected of PhIRDA, President of Qilu Pharmaceutical Group Co., Ltd.

李燕，中欧国际工商管理学院工商管理硕士、高级工程师，现任齐鲁制药集团有限公司总裁。担任第十三届全国人大代表，全国工商联执委、中国医药企业管理协会轮值会长、中国医药创新促进会副会长、中国药学会理事等。荣获全国劳动模范、全国三八红旗手、全国优秀企业家、中国医药经济年度人物等荣誉。
李燕专心专注医药产业发展，产业报国、实业兴企，集团连续多年跻身中国医药工业百强榜前十强。主导实施创新驱动战略，实现一致性评价行业“双领跑”；建立健全中美联动五大研发中心，未来数年内将有多个创新药物研发上市。大力实施精品战略和国际化战略，产品稳定出口欧美日等全球 70 多个国家和地区，11 个人用原料药全球市场占有率第一；是国内首家对日本出口商业化包装注射剂产品的企业，累计实现 14 个制剂产品对美出口。作为全国人大代表，李燕累计提交涉及民生和医药产业高质量发展领域的建议 20 余项，推动法规和政策完善。

With a certificate of MBA at CEIBS and title of senior engineer, Ms. LI Yan currently serves as the President and CEO of Qilu Pharmaceutical Group, Co., Ltd. Ms. Li also serves as Deputy of the Thirteenth National People's Congress, executive committee member of the National Federation of Industry and Commerce, Rotating Chairman of the China Pharmaceutical Enterprises Association, Vice President of China Pharmaceutical Innovation and Research Development Association, Council Member of Chinese Pharmaceutical Association. Honors awarded to Ms. Li include but not limited to National Model Worker, National March 8th Red Banner Pace-setter, National Outstanding Entrepreneurs, Person of the Year for the Chinese Pharmaceutical Economy.
By dedicating her service to the motherland and laying the cornerstone to success of the enterprise through industrial development, Ms. Li concentrates her attention to focus on development of the pharmaceutical industry, and leads the Group as one of the top 10 enterprises among the Top 100 Chinese Pharmaceutical Industry for multiple consecutive years. Ms. Li managed to implement the innovation-driven strategy and made Qilu as the “Double Leader” in the field of quality consistency evaluation for generic drugs in China; she also lead to build and improve 5 major R&D centers connecting China and the US, with numerous innovative drugs to be developed and launched to the Chinese market. With products stablely exported to over 70 countries and regions globally and over 11 human use APIs hold the largest market share in the world, Ms. Li is also a practitioner of the strategy of product excellence and internationalization, Qilu is the first Chinese domestic pharmaceutical enterprise to export commercially packaged injectable drug products to Japan, and had exported 14 finished drug products to the US. As a deputy of the National People's Congress, Ms. Li has filed over 20 suggestions covering people's livelihood and high quality development of the pharmaceutical industry, pushing the regulation and policy improvement in such fields.

沙　雁
深圳证券交易所党委副书记、总经理

SHA Yan
Deputy Secretary of the Party Committee, President & CEO of Shenzhen Stock Exchange

沙雁女士于 2013 年 5 月起先后任中国证监会上市公司监管二部副主任，上市公司监管部副主任，证券基金机构监管部副主任、主任。2020 年 6 月起任深圳证券交易所党委副书记、总经理。

Ms. SHA Yan has served various roles in China Securities Regulatory Commission (CSRC) since May 2013, including Deputy Director of the Listed Companies Supervision Department II, Deputy Director of Listed Companies Supervision Department, and Deputy Director and later Director of the Department of Fund and Intermediary Supervision. She assumed office of President & CEO of SZSE Since June 2020.

Elizabeth Myers
摩根大通投资银行全球主席

Elizabeth Myers
Global Chairman of Investment Banking, Equity Capital Markets at J.P. Morgan

Elizabeth Myers 现任摩根大通投资银行全球主席。在之前的 7 年时间，她一直担任股权资本市场全球主管。
Elizabeth Myers 28 年前加入摩根大通。在过去的 23 年里，她在股权资本市场部为全球客户执行了大量的首次公开发行、增发和可转债交易，涉及金融、科技、房地产、工业、医疗保健、自然资源和消费品等行业。加入股权资本市场部之前，她曾在摩根大通并购部任职多年，专注于多个行业的交易。Elizabeth Myers 持有哈佛大学商学院的工商管理学硕士学位和普林斯顿大学的经济学学士学位。

Elizabeth Myers is a Managing Director and Global Chairman of Investment Banking, Equity Capital Markets at J.P. Morgan. For the prior 7 years she was the Global Head of Equity Capital Markets.
Ms. Myers joined J.P. Morgan 28 years ago. Over the past 23 years in ECM she has executed numerous IPOs, follow-ons and convertible transactions for clients across the globe, spanning a range of industries including financials, technology, real estate, industrials, healthcare, natural resources and consumer products. Prior to joining ECM, she worked for several years in J.P. Morgan's Mergers & Acquisitions group and focused on transactions across a range of industries. Ms. Myers has an M.B.A. from Harvard Business School and a BA in Economics from Princeton University.

王拥军
首都医科大学附属北京天坛医院院长

WANG Yongjun
President of Beijing Tiantan Hospital, Capital Medical University

王拥军教授，现任首都医科大学附属北京天坛医院院长，国家神经系统疾病临床医学研究中心副主任，国家神经系统疾病医疗质量控制中心主任；中华医学会神经病学分会主任委员，中国卒中学会执行副会长，中国医师协会神经内科医师分会副会长，中国医师协会毕业后医学教育神经内科专业委员会主任委员。王拥军教授开创针对高危非致残性脑血管病的治疗新方法（CHANCE 新方法）被美国《急性缺血性脑血管病管理指南（2019 更新版）》作为最高级别证据向全球推荐，成为该病治疗的国际最高标准；主持建立国内第一个标准化脑血管病病房即卒中单元，制定两部国家卫生行业标准和五部行业指南，建立国家脑血管病医疗质量控制指标、监测网络和改进平台。累计发表 SCI 论文 200 余篇，爱思唯尔 Scopus 数据库（缺血性卒中、短暂性脑缺血发作主题）近五年发文量和总被引频次均名列第一；以第一完成人获国家科技进步二等奖一项、省部级一等奖两项，获首批全国创新争先奖章。

Professor WANG Yongjun is currently the President of Beijing Tiantan Hospital affiliated to Capital Medical University, the Deputy Director of the China National Clinical Research Center for Neurological Diseases and Director of the National Center for Healthcare Quality Management in Neurological Diseases. He is also the Chairman of Neurology Branch of Chinese Medical Association, Executive Vice President of Chinese Stroke Association, Vice President of Neurology branch of Chinese Medical Doctor Association, Chairman of Neurology Specialty Committee of Medical Education after Graduation of Chinese Medical Doctor Association. Professor Wang pioneered the CHANCE research for the treatment of high-risk non-disabling cerebrovascular disease, which has been recommended to the world by the US Guidelines for the Management of Acute Ischemic Cerebrovascular Disease (2019 Update) as the highest level of evidence, and it had become the highest international standard for the treatment in this area. He presided over the establishment of the first standardized stroke unit for cerebrovascular disease wards in China, and formulated two national health industry standards as well as five industry guidelines, and established the national quality control index, monitoring network and improvement platform for cerebrovascular disease medical treatment. More than 200 SCI papers have been published attributing to as the first ranks in the number of Elsevier Scopus database (the topic of ischemic stroke and transient ischemic attack) and the total cited times in the last five years. As the first accomplice, he won the award of second prize of National Science and Technology Progress, two of first prizes of provincial and ministerial level, and one of the first national Innovation MEDALS.

蒋建东
中国药促会 2017–2018 年度会长，中国医学科学院药物研究所所长

JIANG Jiandong
2017-2018 Annual Chairman of PhIRDA, Director of Institute of Medicine, Chinese Academy of Medical Sciences

蒋建东，研究员，博士生导师。先后担任医药生物技术研究所所长、药物研究所所长、和药物研究院院长。还担任北京协和医学院药理系主任、Acta Pharmaceutical Sinica B 杂志（SCI 杂志）主编、以及《中国医药生物技术》杂志（国家核心期刊）主编。长期从事药物研究，包括心血管疾病，抗感染、抗肿瘤的药物等。发表 SCI 论文 260 余篇（如 Nature Medicine 等杂志），包括 Cell, Nature，Science，NEJM，Lancet 等。专利 43 项，转入企业 3 项；主持或参与的研究获新药证书和临床批件 7 个。获国家（及省部）级奖 4 项；国际奖 2 项。牵头抗感染团队获国家基金委创新群体。

Dr. JIANG Jiandong, received his MD degree in the Fudan University Shanghai School of Medicine. He then spent 18 years in the Department of Medicine at the Mount Sinai Hospital in New York. Dr. Jiang came back to China in 1999 and worked as an institute director in the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CAMS) / Peking Union Medical College (PUMC) in Beijing. Dr. Jiang is currently the president of the Institutes of Pharmaceutical Sciences as well as director of the Institute of Materia Medica, CAMS / PUMC. His research field on drug R&D covers infectious diseases, cancer and metabolic disorders. Dr. Jiang has published over 260 articles in journals like *Nature*, *Nature Medicine*, *Cancer Cell*, *Hepatology*, *PNAS* et al. Two accomplishments of innovative drug research have been translated into clinical use, with one for the treatment of drug-resistant hepatitis B and one for treating metabolic syndromes (berberine research). He has received 2 National Awards in China for his contribution in drug discovery. In addition, he serves as the Chair of Department of Pharmacology in the Peking Union Medical College, and Editor-in-Chief for the journal of *Acta Pharmaceutica Sinica B*.

何如意
荣昌生物首席医学官、国投创新医疗健康首席科学家、前国家食品药品监督管理总局药品审评中心首席科学家

HE Ruyi
CMO of RemeGen, CMO of SDIC, Former Chief Scientist of Center for Drug Evaluation, CFDA

何如意博士是前美国 FDA 新药审批办公室消化系统及罕见病药物审评部代理副主任，在 FDA 具有 17 年临床审评审批经验，起草多个 FDA 的工业指南，主持审批了许多新药试验申请和新药上市申请。
何如意博士 2016 年 7 月加入中国食品药品监督管理局药品审评中心，作为中国 CFDA 首位从海外引入的高级人才，担任首席科学家。在中国 CDE 期间，组织参与审评审批制度改革及技术指南撰写研讨工作，将美国 FDA 审评审批理念引入 CDE。
何如意博士毕业于中国医科大学，并获得医学学士学位和内科血液系硕士学位。于 1988 年 3 月赴美，曾在美国 NIH 国家卫生研究院从事临床研究。在美国的 Howard 大学医学院完成内科住院医师工作，目前持有美国多个州的执业医师证书。

Dr. HE Ruyi was the Chief Scientist at the Center for Drug Evaluation at the Chinese Food and Drug Administration (CFDA). Dr. He joined CFDA in July 2016, after having worked at the US Food and Drug Administration (FDA) for more than 17 years. He participated CFDA drug review and evaluation system reform in the recent years.
Dr. HE Ruyi joined the US Center for Drug Evaluation and Research (CDER) at the US FDA in 1999 as a Medical Officer in the office of New Drug. He was the Acting Deputy Director in the division of GI and Inborn error Drug Products. He chaired several working groups that were tasked with drafting and finalizing guidelines for industry. Dr. HE Ruyi has received many awards since he joined the FDA.
Dr. HE Ruyi received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. He received his clinical and research training at the National Institutes of Health (NIH) in Bethesda, Maryland. He is a licensed, board-certified physician in several States in the America.

李　宁
上海君实生物首席执行官

LI Ning
CEO of Shanghai Junshi Biosciences Co., Ltd.

李宁博士，现任上海君实生物首席执行官。在加入君实生物之前，任赛诺菲集团副总裁、亚洲区及大中华药政和医学政策主管。就职于美国食品与药品管理局（USFDA）十二年，历任评审员、资深评审员、评审主管、分部主任等职；加入 FDA 前，历任国立卫生研究院（NIH）AIDS 药物研究临床试验合作中心 WESTAT 研究员、研究主任；并任教于美国爱荷华大学医学院内科系及上海医科大学（复旦大学）。获美国爱荷华大学医学院（University of Iowa）硕士、博士，上海医科大学（复旦大学）医学硕士，医学学士等学位。发表临床试验，药物开发相关学术论文 30 余篇。受聘于美国国立卫生研究院（NIH）药物科研基金评审委员会委员，美国国立卫生研究院科研基金评审特别委员会（Special Panel）成员，及美国约翰霍普金斯（Johns Hopkins）大学和北京大学兼职教授等职。

Dr. LI Ning is currently the Chief Executive Officer at Shanghai Junshi Biosciences. Before he joined Junshi Biosciences, Ning had been appointed as Vice President and Head of Region Asia and China Regulatory Affairs and Medical Policy in Sanofi. He worked at US Food and Drug Administration for more than 12 years as a regulatory reviewer and held positions with increasing responsibilities. Dr. Li owned his medical degree from Shanghai First Medical College (Fudan University) and a doctorate degree from University of Iowa. Prior to his US FDA career, he worked at the University of Iowa, Dept of Internal Medicine and Westat /NIH DATRI Clinical trial coordinator center. He is an adjunct faculty member at Johns Hopkins University and Peking University. He has published more than 30 scientific papers in the area of clinical trial methodology.

康　韦
中国外商投资企业协会副会长、RDPAC 执行总裁

KANG Wei
Vice Chair of CAEFI, Managing Director of RDPAC

康韦女士担任 RDPAC 执行总裁，她在中国制药行业拥有近 30 年的从业经验，是一位经验丰富的专家。
自 2018 年 3 月加入 RDPAC 以来，康韦女士带领团队以“创新引领健康中国”理念为核心，致力于推动中国医药创新生态系统可持续发展，助力药品研发监管的国际接轨，促进创新产业链的国际合作，让药品和疫苗的创新成果尽早惠及全球患者，并为不断提高居民和患者生活质量做出贡献，让 RDPAC 成为中国政府实现“健康中国”目标值得信赖的合作伙伴。
在加入 RDPAC 之前，康韦女士曾历任费森尤斯卡比副总裁、诺华大中华区高级市场总监、事业部负责人等职务。康韦女士拥有澳大利亚西悉尼大学 MBA 学位及厦门大学细胞生物学学士学位。

KANG Wei is a seasoned expert who brings almost 30 years of experience working in the pharmaceutical industry in China.
Since KANG Wei joined RDPAC in March 2018, based on RDPAC Vision - “HEALTHIER CHINA THROUGH INNOVATION, she has led the team in promoting the sustainable development of China's healthcare innovation ecosystem, assisting the international integration of drug R&D regulatory, as well as promoting the international cooperation to build the innovation industry chain, which enables medicines and vaccines to benefit the worldwide patients as early as possible. KANG Wei is leading RDPAC to contribute to the continuous improvement of the quality of residents and patients' life, to be a trusted partner of the Chinese government building "Healthier China".
Prior to joining RDPAC, she held the positions of Vice President and BU Head at Fresenius-Kabi and Great China Senior Marketing Director and Co-leading & Acting BU head at Novartis. KANG Wei holds an MBA from West Sydney University and a Bachelor degree of Cell-biology from Xiamen University.

黄国滨
摩根大通全球投资银行中国区主管、董事总经理

Houston HUANG
Managing Director, Head of China Global Investment Banking at J.P. Morgan

黄国滨现任摩根大通全球投资银行中国区主管、董事总经理。他于 2015 年加入摩根大通。加入公司之前，黄国滨在高盛工作过 5 年时间，担任中国大工业部主管，负责在中国为主要客户提供全面的投资银行服务；他还在中金工作过 11 年，担任欧洲投行部主管、业务开发委员会和人力资源委员会主管，还是投行运营委员会成员。黄国滨拥有逾 20 年的投行从业经验，牵头执行了大量中国自然资源、金融服务、TMT、医疗保健等行业知名的重组、IPO、后续发行、可转债 / 可交换债、并购项目，涉及交易额超过 5,000 亿美元。此外，他曾是国务院和其它政府相关部门医疗卫生改革领域的咨询顾问。黄国滨还牵头推动 200 年投行历史中第一次系统性组织结构改革，提出并推动全新的投行服务模式的发展，开创了投行服务全面与技术和数字化接轨的新时代，为客户提供更好的支持。黄国滨是在英国金融服务管理局和香港证券及期货事务监察委员会登记注册的资质企业融资代表、经中国证监会注册登记的保荐代表人。他还是上海同济大学董事会成员。他 1997 年获英国兰卡斯特大学 MBA 硕士学位；1991 年获同济大学材料科学专业及工业管理工程专业双学士学位。

Houston Huang is the Managing Director and Head of China Global Investment Banking in J.P. Morgan. He joined J.P. Morgan in 2015. Prior to joining the firm, Houston spent 5 years in Goldman Sachs, where he was Head of China Diversified Industrial Group, responsible for industry strategy, execution, and coverage of key franchise clients. Houston also spent 11 years at China International Capital Corporation Limited (CICC), where he was Head of European Investment Banking, Head of the Business Development Committee and Head of Human Resources Committee on Investment Banking, and a member of the Investment Banking Operation Committee. With over 20 years of investment banking experience, Houston has led multiple strategic initiatives, coverage, and execution of a large number of well-known transactions including restructuring, IPO, FO, CB/EB, and M&A in the Chinese natural resources, financial services, industrials, TMT, and healthcare industries, with total transaction volume over USD500 billion. Additionally, Houston was a leading advisor to the State Council and other authorities for the Chinese Healthcare Reform Program. With extensive experience in investment banking management strategic initiatives, and project execution, Houston has also taken the leadership role in introducing the first revolutionary industry set-up in the 200-year history of the investment banking industry, where he proposed and promoted the full embracement of technology and digitalization in each industry group in order to better serve clients in the new era. He is a qualified corporate finance representative registered with the Financial Services Authority (FSA) in the United Kingdom and the Securities and Futures Commission (SFC) in Hong Kong. Houston is also registered with the Chinese Securities Regulatory Committee (CSRC) in China. Houston Huang is one of the board members of Tongji University in Shanghai. He graduated from the Management School of Lancaster University in the United Kingdom in 1997 with a MBA degree, and obtained two bachelor degrees from Tongji University in Shanghai in 1991 for Materials and Science as well as Enterprise Management and Economics.

蒋华良
中国科学院院士、中国药促会 2015–2016 年度会长、上海药物所学术委员会主任、中国科学院上海药物研究所研究员

JIANG Hualiang
Academician of Chinese Academy of Sciences, 2015 - 2016 Annual Chairman of PhIRDA, Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences

蒋华良，1987 年毕业于南京大学化学系，获得有机化学学士学位；1992 年于华东师范大学化学系获得物理化学硕士学位；1995 年于中国科学院上海药物研究所获得药物化学博士学位。目前担任 J. Med. Chem. 副主编和其他 5 种国际学刊的编委。曾任国家 863 计划专家组成员、国家重大基础研究计划“蛋白质科学重大基础研究计划”专家组成员、现任国家自然科学基金委“生物大学分子动态修饰与化学干预”重大研究计划专家组组长。

蒋华良主要从事药物科学基础研究和新药发现。系统发展了药物作用靶标发现和药物设计理论计算新方法，为新药研究提供工具，获得国际同行和工业界广泛应用。设计高效探针分子，深入阐明和确证了一系列新靶标的作用机制和药理功能。针对肺动脉高压、精神分裂症和阿尔茨海默症等国内目前尚无自主知识产权新药的重大疾病，与他人合作进行新药开发研究，数个候选新药进入临床研究或获得临床批件，并实现技术转化。曾获得国家自然科学二等奖、国家科技发明二等奖、何梁何利科技创新奖等奖项。

Dr. Hualiang Jiang obtained his bachelor's degree from the Department of Chemistry, Nanjing University in 1987. He received his master’s degree in Physical Chemistry from East China Normal University in 1992. In 1995, he obtained his Ph.D. degree in Medicinal Chemistry from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS). He was a member of scientific committees of several major research programs in China, such as 863 National High Technology Program, National Basic Research Program, and Major Research Project of National Natural Science Foundation of China. He also serves as Associate Editor of *Journal of Medicinal Chemistry* and editorial board members of several journals such as *The Journal of Biological Chemistry*.

Dr. Jiang's has been engaged in the establishment of the innovative drug research platform by integrating target discovery and drug design methods and technologies. He developed a series of new methods for drug target discovery and drug design, which have been widely used and drawn a great deal of attention from the research community. Targeting several diseases such as pulmonary hypertension, schizophrenia, erectile disorder and Alzheimer’s disease, Dr. Jiang and his co-workers obtained a number of drug candidates by using computational drug design, organic synthesis and drug development technologies. Some compounds have entered into phase I or II clinical trial. Over the years, Dr. Jiang has received the Natural Science Award of China, the National Award for Technological Invention, the Science and Technology Progress Prize from Ho Leung Ho Lee Foundation, etc.

孙飘扬
中国药促会 2014–2015 年度会长，江苏恒瑞医药集团有限公司董事长

SUN Piaoyang
2014-2015 Annual Chairman of PhIRDA, Chairman of the Board of Jiangsu Hengrui Medicine Co.,Ltd

孙飘扬，现任江苏恒瑞医药集团有限公司董事长，教授、博士生导师，享受国务院特殊津贴。中国药典委员会执行委员，十一、十二、十三届全国人大代表，江苏省工商联副主席（兼），江苏省劳动模范。先后获全国“优秀中国特色社会主义建设者”光荣称号，科技部“十一五”国家科技计划执行突出贡献奖、全国工商联科技创新企业家奖、多次被评选为江苏省优秀共产党员、优秀企业家。个人获国家科技进步二等奖 1 项，中国专利优秀奖 2 项，省部级科技进步一等奖 1 项、二等奖 2 项、三等奖 4 项，省部级以上个人荣誉 20 余项。

Dr. Sun Piaoyang is now holding the position of chairman of Jiangsu Hengrui Pharmaceutical Group. As a professor and doctoral supervisor of China Pharmaceutical University, He entitled to special grants from the National Council. He is the Executive member of the Chinese Pharmacopoeia Commission, and the representative of the 11th, 12th, and 13th National People's Congress, vice-chairman (concurrently) of Jiangsu Federation of Industry and Commerce, and model worker of Jiangsu Province. He has successively won the honorary title of "Excellent Constructor of Socialism with Chinese Characteristics", "Eleventh Five-Year" National Science and Technology Plan Implementation Outstanding Contribution Award of the Ministry of Science and Technology, and Science and Technology Innovation Entrepreneur Award of the National Federation of Industry and Commerce. He has been repeatedly selected as an outstanding Communist Party member and excellent entrepreneur of Jiangsu Province. He has won the second prize of national science and technology progress award for one time, Chinese patent Excellence Awards for two times, one first prize, two second prizes and four third prizes of provincial and ministerial level scientific and technological progress awards, and more than 20 provincial and ministerial level personal honours.

方　敏
中国药促会医药创新投资专业委员会副主任委员、华平投资合伙人、中国医疗健康投资负责人

FANG Min
Vice-Chairman of PhIRDA Pharmaceutical Innovation Investment Specialty Committee, Managing Director & Head of Healthcare Investment of Warburg Pincus

方敏先生于 2007 年加入华平投资，主要负责华平亚太区医疗健康行业的投资。加入华平之前，方先生就职于波士顿咨询集团，主要负责医药和医疗器械领域的管理咨询业务。方先生目前担任北京美中宜和妇儿医院集团、华瑭大昌商业（上海）有限公司、伊美尔医疗集团、上海海和药物研究开发有限公司、海吉亚医疗集团（6078.HK）和錦欣生殖医疗集团（1951.HK）的董事。
他持有复旦大学国际金融学士学位以及美国斯坦福大学商学院的 MBA 学位。

FANG Min is based in Shanghai, joined Warburg Pincus in 2007 and focuses on investments in the healthcare sector in Asia. Prior to joining Warburg Pincus, he worked at the Boston Consulting Group focusing on management consulting for pharmaceutical and medical device companies. Mr. Fang is a director of Beijing Amcare Women's and Children's Hospital Group, HTDK (Shanghai) Co., Ltd., Evercare (Beijing) Holding Group Co. Ltd, Shanghai Haihe Pharmaceutical Co., Ltd., Hygeia Medical Service Group (6078.HK) and Jinxin Fertility Group (1951.HK).
He received a B.A. of International Finance from Fudan University and an M.B.A. from the Stanford Graduate School of Business.

鲍海洁
香港交易所董事总经理兼环球上市服务部主管

Christina BAO
Managing Director and Head of Global Issuer Services of HKEX

鲍海洁女士，董事总经理，现担任市场发展科副主管兼环球上市服务部主管，为拟到香港上市的全球发行人提供服务，并推动香港交易所战略项目发展。鲍海洁女士于 2016 年加入香港交易所，曾担任行政总裁办公室总管，负责香港交易战略项目推动和业务综合管理。
在加入香港交易所前，鲍女士自 2001 年起曾在平安银行和深圳发展银行担任不同管理职位，包括曾任深圳发展银行董事长兼行政总裁办公室总管，负责战略项目、投资者关系和公共关系管理。鲍女士曾全面负责深圳发展银行和平安银行的两行整合项目。两行整合完成后，鲍女士担任了平安银行零售网络金融事业部总裁等职务。
鲍女士于北京大学获取工商管理硕士学位（金融系）。

Ms. Christina Bao, Managing Director, is currently the Deputy Head of Market Development Division and Head of Global Issuer Services at HKEX.
Ms. Bao joined HKEX in 2016 as the Chief of Staff and report to the CE of HKEX. She was mostly responsible for the general coordination at the senior management, planning and oversight on strategic projects.
Prior to joining HKEX, Christina held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as Chief of Staff to the Chairman and CEO from 2005 until 2010, in charge of strategic projects, IR, PR. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail E-Finance SBU for Ping An Bank.
Ms. Bao received her Master of Business Administration (Finance, General) from Peking University.

杨大俊
中国药促会药物研发专委会副主任委员、亚盛医药董事长兼 CEO

YANG Dajun
Vice-Chairman of PhIRDA Drug R&D Specialty Committee
Chairman of the Board & CEO, Ascentage Pharma

杨大俊博士是亚盛医药董事长兼首席执行官，同时兼任中山大学肿瘤防治中心教授及博导、中国药促会研发专委会副主任委员等职位。杨博士专注肿瘤学、细胞凋亡机理与新药研发近 30 年。他于 2009 年共同创办亚盛医药，并在细胞凋亡及自噬双通道调节新靶点药物开发领域内取得重大突破。亚盛医药作为全球唯一在该领域形成通道多靶点药物全布局的企业，成功将 8 项具有全球范围内“First-in-class”或“Best-in-class”类潜力原创新药推进到中、美、澳三地临床开发阶段。杨大俊博士先后承担国家“863”专项、重大新药创制专项等重大科研攻关项目近 10 项。他带领团队获得江苏省及苏州重大创新团队、首届江苏省创新争先团队奖、百华协会 2017 年度研发成就奖等多项殊荣，并荣获 2018 独墅湖杯“最具影响力药物研发领军人物奖”，在原创新药研发领域拥有广泛的影响力。

Dajun Yang, Ph.D., is the Chairman and Chief Executive Officer of Ascentage Pharma. He has concurrently served as professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center and vice director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association. Dr. Yang has dedicated his career to the research on apoptosis and innovative drug R&D for nearly 30 years. In 2009, he co-founded Ascentage Pharma and made major breakthroughs in the research of development of precision drugs targeting apoptosis and autophagy dual-channel regulation. Ascentage Pharma is the only company in the world that researches and develops innovative drugs targeting all of these pathways. Ascentage Pharma currently has eight potential “First-in-class” or “Best-in-class” innovative drug candidates in Phase I/II clinical developments in China, the United States and Australia. Dr. Yang has undertaken nearly ten National Science and Technology Major Projects such as the National High-tech R&D Program (the “863 Program”) and the Major Innovative Drug Developments program. The team led by Dr. Yang has won multiple awards such as the Major Innovation Team of Suzhou and Jiangsu, the First Jiangsu Innovation Competition Team Award, and the R&D Achievement of the Year 2017 from the BayHelix Group. Dr. Yang is the recipient of the 2018 “Dushu Lake Prize” for the Most Influential Leader in Drug R&D, an award widely recognized in the field drug R&D.

李文斌
中国药促会药物临床专委会副主任委员
首都医科大学附属北京天坛医院神经肿瘤综合治疗病区主任

LI Wenbin
Vice-Chairman of PhIRDA Clinical Research Specialty Committee
Director of Dept of Neuro-oncology, Beijing Tiantan Hospital,
Capital Medical University

李文斌，男，55 岁，主任医师、教授，博士生导师，首都医科大学附属北京天坛医院神经肿瘤综合治疗病区主任，首都医科大学肿瘤学系副主任，中国药促会药物临床研究专业委员会副主委，中国医师协会脑胶质瘤专业委员会常委，中国抗癌协会期刊出版部部长，中国抗癌协会脑胶质瘤专业委员会副主委，《Signal Transduction and Targeted Therapy》和《Cancer Biology & Medical》编委，《医学参考报神经肿瘤频道》主编，美国南佛罗里达大学名誉研究员，英国皇家医学会外籍院士，美国 GBM AGILE 国际多中心临床试验中国总协调人。善长颅内恶性肿瘤的化疗和药物临床试验研究。主持完成两项国家十三五重点创新药物 I 期临床试验和 10 余项 I–IV 期药物临床试验。

Wenbin Li, Male, 55 years old, Chief Physician, Professor, Doctoral Tutor; Director of Neuro-Oncology Department, Beijing Tiantan Hospital, Capital Medical University (CMU); Deputy Director of Department of Oncology, CMU; Vice Chairman of Drug Clinical Research Specialty Committee, China Pharmaceutical Innovation and Research Development Association (PhIRDA); Standing Committee Member and General Secretary of Glioma Specialty Committee, Chinese Medical Doctor Association (CMDA); Director of Department of Journal Publishing, Chinese Anti-Cancer Association (CACA); Vice Chairman of glioma speciality committee, Chinese Anti-Cancer Association (CACA); Editorial Board of Journal of Cancer Biology & Medical; Editorial Board of Signal Transduction and Targeted Therapy; Chief Editor of Committee of neuro-oncology channel, Chinese medical reference newspaper. Honorary Research Fellow at University of South Florida; Foreign Academician of the Royal Society of Medicine. General Coordinator of China District, GBM AGILE clinical trials. He is very skilled at chemotherapy of intracranial malignant tumors and studies on the drug clinical trials. He is in charge of two novel drugs in phase I clinical trial, which belong to National Science and Technology Major Project for “Significant New Drugs Development” during the 13th Five-year Plan period, and completed more than 10 phase I-IV clinical trials.

郭明良
中天上海生物科技有限公司资深副总裁、药物所所长

KUO MinLiang
Sr. Vice President, Chief Director Institute of Pharmaceutical Research and Development, Microbio Shanghai Co., Ltd.

郭明良为生物化学博士，美国德州大学安德森癌症中心分子细胞肿瘤学系访问学者。历任生化科学研究所教授、医学院副院长、生命科学院院长等职。具有 30 年以上学术与生技产业资历，发表国际期刊超过 100 件。
现任中天上海生物科技有限公司资深副总裁及药物所所长，领导新药研发与试验进程。

Min-Liang Kuo holds Ph.D. in Biochemistry and has extensive experience as a visiting scholar at Department of Molecular Oncology, MD Anderson Cancer Center, Houston Texas, a professor in leading universities in Taiwan, Deputy Dean of College of Medicine, Dean of College of Life Science, etc. Dr. Kuo has over 30-year experience in academic and biotech industry with 100+ publications on international journals. He is currently the Senior Vice President with Microbio Shanghai Co., Ltd., leading the research and development of company's pipelines.

宋钦辉
武汉禾元生物科技股份有限公司首席医学官

Tony SONG
CMO, Wuhan Healthgen Biotechnology Corp.

宋钦辉博士毕业于哈尔滨医科大学临床医学专业。宋博士拥有近 30 年临床及新药研发工作经验；曾担任美国诺华制药资深新药研发研究员 10 年；拥有哈佛医学院等国际顶尖科研院所药物研究经验 10 年；曾在哈尔滨医科大学附属医院从事心血管病的临床和科研工作 10 年；主持过美国 NIH 项目（编号：NIH HL0737422 QH Song），研究成果集成论文近 20 余篇；在美国波士顿大学、塔夫斯大学、哈佛大学及其附属医院等地从事医学、药学、分子生物学等相关性研究。现任武汉禾元生物科技股份有限公司首席医学官，并在美国成功指导植物源重组人血清白蛋白注射液完成了首次在人体的临床一期试验。

Dr. Song Qinhui graduated from Harbin Medical University. Dr. Song has nearly 30 years of clinical and new drug research and development experience; He was a senior scientist in new drug R&D team in Novartis /Boston for 10 years. Dr. Song also had 10 years of drug research experience in top international research institutes such as Harvard Medical School. He was a cardiologist in Affiliated Hospital of Harbin Medical University more than 10 years. He also was supported by NIH (No.: NIH hl0737422 QH); He has been working in medical research, in vivo pharmacology and cell molecular biology in Boston University, Tufts University, Harvard University and its affiliated hospitals. Currently, he is the Chief Medical Officer (CMO) of Wuhan Healthgen Biotechnology Corp. Dr. Song guided CRO-WCCT conducting OsrHSA phase I clinical trial successfully in United States.

郑向前
天津医科大学肿瘤医院甲状腺颈部肿瘤科行政主任

ZHENG Xiangqian
Executive Director, Department of Thyroid and Neck Oncology, Tianjin Medical University Cancer Institute and Hospital

郑向前教授毕业于南开大学医学院七年制临床医学专业，在美国 Moffitt 癌症中心和 MD Anderson 癌症研究中心访问学习 2 年并获得美国 Moffitt 癌症中心博士学位，从事甲状腺肿瘤外科多年，师从我国著名甲状腺及头颈肿瘤专家高明教授，全面系统掌握本专业的基础理论，专业知识以及实践操作技能，擅长甲状腺癌根治术、功能性颈淋巴结清除术及头颈部肿瘤的诊治及综合治疗。
现任中国抗癌协会青年理事会常务理事、中国抗癌协会甲状腺癌专业委员会常委兼秘书长、中国抗癌协会头颈肿瘤专业委员会常委兼秘书长、中国医药教育协会头颈肿瘤专业委员会副主任委员、天津市抗癌协会甲状腺癌专业委员会委员兼秘书长等社会职务。

Professor Xiangqian Zheng graduated from school of medicine, Nankai University, with a seven-year clinical medicine major. After graduation, Prof. zheng had studied in the Moffitt cancer center and MD Anderson cancer center in the United States for 2 years and received his doctor degree from Moffitt cancer. Prof. zheng has engaged in thyroid cancer surgery for many years with the guidance of professor Ming Gao, the well-known Chinese expert in thyroid cancer as well as head and neck cancer. Prof. zheng has an excellent performance in his field for the basic theory, professional knowledge and practical ability and is skilled in the thyroid cancer surgery such as definitive thyroidectomy and neck dissection. In addition, he is also good at the diagnosis and treatment of head and neck cancer.
Prof. zheng is the key member of many medical association, including the standing director of youth council, Chinese anti-cancer association (CACA); standing committee member and secretary-general of professional society of thyroid cancer, CACA; standing committee member and secretary-general of professional society of head and neck cancer, CACA; deputy director of professional society for the head and neck cancer, Chinese medicine education association; committee member and secretary-general of professional society of thyroid cancer, Tianjin anticancer association.

马振坤
丹诺医药（苏州）有限公司创建人 &CEO

MA Zhenkun
Founder & CEO, TenNor Therapeutics Limited

马振坤博士拥有二十多年新药研发和管理经验，曾主导多个上市和临床阶段新药产品的研发工作。曾在雅培实验室（Abbott/AbbVie）领导抗感染新药研发、参与生物制药公司 Cumbre 的创建、并在全球结核新药研发联盟（TB Alliance）任首席科技官， 2013 年创建丹诺医药，专注差异化抗感染新药产品的研发。作为评审专家，曾参与世界卫生组织、美国国家健康研究所、欧盟疾病防控中心、盖茨基金会、惠康基金会等机构的项目评审工作。发表学术论文 100 余篇，申请发明专利 70 多项。

Dr. Zhenkun Ma has more than 20 years of experience in research and development of new drug products. Previously, he led drug discovery programs at Abbott, participated in the formation of biotech company Cumbre and served as the Chief Scientific Officer of the TB Alliance. He founded TenNor Therapeutics in 2013 to develop differentiated therapies in infectious disease area. Dr. Ma served as a reviewer for the World Health Organizations, National Institute of Health, European Center for Disease Prevention and Control, Bill and Melinda Gates Foundation and Wellcome Trust. He is an author of more than 100 scientific publications and an inventor of more than 70 patent applications.

吴　昊
首都医科大学附属佑安医院主任医师

WU Hao
Chief Physician of Beijing Youan Hospital, Capital Medical University

吴昊教授，首都医科大学附属北京佑安医院主任医师、二级教授、博士研究生导师。ACC007III 期临床试验主要研究者。北京市科技领军人才、北京市高创领军人才、北京市艾滋病领域领衔专家（唯一），享受国务院政府特殊津贴。中国性病艾滋病防治协会副秘书长、中国性病艾滋病防治协会学术委员会副主任委员、中国预防性病艾滋病基金会专家委员会副主任委员、卫健委艾滋病专家咨询委员会委员、卫健委传染病标准委员会委员、卫健委应急传染病咨询委员会委员、中华医学会病毒学会常务委员。吴教授是国内最早从事艾滋病临床诊疗与科学研究的专家之一。先后 2 次获得国家科技进步奖二等奖 2 次，在 NEJM、AIDS、CID 等期刊发表 SCI 论文 100 余篇。

Professor Wu Hao, chief physician of Beijing Youan Hospital, Capital Medical University ， as well as professor, PhD tutor. Principal investigator of ACC007 Phase III clinical trial. Leading talents in Beijing science and technology, leading talents in Beijing high-tech innovation, leading experts in the field of Beijing AIDS (the only one), enjoy the special government allowance of the State Council. Deputy Secretary-General and Vice Chairman of Academic Committee of China Association for STD and AIDS Prevention and Control, Vice Chairman of Expert Committee of Chinese Foundation for Prevention of STD and AIDS, Member of AIDS Expert Advisory Committee of Health Commission, Member of Infectious Disease Standards Committee of Health Commission, Member of the Emergency Infectious Disease Advisory Committee of the Health Commission, Member of Virology for Chinese Medical Association. Professor Wu is one of the earliest experts in AIDS clinical diagnosis and treatment and scientific research. He has twice won the second prize of the National Science and Technology Progress Award, and published more than 100 SCI papers in NEJM, AIDS, CID and other journals.

肖英莲
教授，主任医师，广州市中山大学附属第一医院

XIAO Yinglian
Professor, The First Affiliated Hospital Sun Yat-sen University

肖英莲博士，教授，中山大学附属第一医院消化内科主任医师，江苏柯菲平 H008 盐酸柯诺拉赞片剂 II 期临床的 PI。
研究方向为胃食管反流病及食管动力障碍性疾病的临床与转化医学研究，研究结果被多个国内外胃食管反流病共识意见所引用。作为亚洲地区唯一专家参与胃食管反流病检测技术的国际共识意见及食管高分辨率测压国际标准的制定。为 2014 年及 2020 年中国胃食管反流病共识意见的主要作者。参编专著 3 部，发表 SCI 论文近 60 篇（一作 / 通讯作者 30 篇，5 篇 IF ＞ 10）。主持及参与国家及省部级基金近 10 项，其中作为第一主持人承担国家自然科学基金 3 项，广东省和教育部基金各 1 项。入选广东省杰出青年医学人才，DDW 杰出青年研究者（消化领域最高级的会议），青年医师研究奖（亚洲胃肠动力年会）。

Dr. Xiao Yinglian, Professor, Chief Physician of the Department of Gastroenterology, the First Affiliated Hospital of Sun Yat-sen University. She is also the phase II PI of H008 (Carenoprazan tablets) which developed by Jiangsu Carephar Pharmaceuticals.
Her research interests are the clinical and translational medicine researches on gastroesophageal reflux disease and esophageal motility disorders. Her research achievement has been cited by many domestic and international consensus on gastroesophageal reflux disease. She was the only expert in Asia to participate the international consensus on the diagnosis technology of gastroesophageal reflux disease and the criteria of esophageal motility disorder on high resolution esophageal manometry. She was the key author of the 2014 and 2020 Chinese consensus on gastroesophageal reflux disease. Participated in the compilation of 3 monographs, and published nearly 60 SCI papers (30 with first author/corresponding author, 5 IF>10). Presided over and participated in nearly 10 national, provincial and ministerial funds, including 3 National Natural Science Funds as the first host, and 1 each from Guangdong Province and the Ministry of Education. Selected as an outstanding young medical talent in Guangdong Province, an outstanding DDW young researcher (the most advanced conference in the field of digestion), and won the Young Doctor Research Award (Asian Neurogastroenterology & Motility Annual Conference).

孟海津
上药博康生物医药（香港）有限公司中国首席科学官

MENG Haijin
Shanghai Pharma-BIOCAD (HK) Limited Chief Scientific Officer (China)

孟博士拥有临床医学（中国）和分子生物学（美国）培训经历，有 20 多年药物研发全生命周期的管理经验：从临床医学应用到分子遗传学基础研究、从药物上市前 I 至 III 期临床试验到上市后 IV 期临床研究，以及在与政府及监管机构的合作方面都有丰富的实践经验。曾任辉瑞中国医学战略合作负责人，百时美施贵宝中国早期临床开发负责人，在包括肿瘤、心血管代谢等多个治疗领域有丰富的实践经历；在誉衡生物任副总裁兼首席医学官的近三年的时间里，带领团队成功完成赛帕利单抗，一款国产全人抗 PD−1 单抗，从 IND 到 NDA 申报的工作，并从零起步组建了一支 ICH 标准的誉衡生物研发团队。
孟博士现任上药博康中国首席科学官，负责管线产品在大中国区的研发，临床运营，注册引进及团队搭建工作。

Trained both as a medical doctor (in China) and molecular biologist (in US), Dr. Meng has 20+ years of experience on drug development and drug life cycle management. She understands the need and practice for doctors, drug developers and molecular biologists, and how genetic translational research can be applied to modern drug development. She had worked in medical functions for ~10 years in several multi-national companies, like Pfizer and Bristol-Meyers-Squibb, successfully managed clinical trials of different phases and NDA application with regulatory agencies, and also led an innovative medical program working with government providing a leap in improving chronic disease management in China. During the past 3 years, working as Vice President and Chief Medical Officer for Gloria Biosciences, she successfully led the clinical development of GLS-010 (Zimberelimab), a fully human anti-PD-1 mAb, from phase I to NDA submission in China and in the meanwhile established the Gloria R&D team based on ICH standards from scratch.
Dr. Meng is Chief Scientific Officer (China) of Shanghai Pharma-BIOCAD (HK) Limited, responsible for pipeline products' clinical research and development, clinical operation， local registration and establishment of local R&D team in Greater China area.

冯　岚
中国医药创新促进会秘书长

FENG Lan
Secretary-General of China Pharmaceutical Innovation and Research Development Association (PhIRDA)

冯岚，中国医药创新促进会秘书长。先后任职国家食品药品监督管理局信息中心，《中国新药杂志》有限公司总经理，2008 年参与建立中国药学会医药政策研究中心。兼任中国罕见病联盟副秘书长，北京大学光华管理学院健康协会副秘书长。
冯岚女士在企业管理、媒体运营、医药与卫生政策研究等方面拥有多年经验。毕业于吉林大学白求恩医学部，并在北京大学光华管理学院取得高级工商管理（EMBA）硕士学位。

Ms. Feng Lan, Secretary-General of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Deputy Secretary-General of China Alliance of Rare Diseases (CARD) and Guanghua EMBA Health Association. She successively served as the Associate Editor in the Information Center of China Food and Drug Administration (CFDA), General Manager of Chinese Journal of New Drugs and participated in the establishment of the Medicinal Policy Research Center of Chinese Pharmaceutical Association in 2008.
Ms. Feng Lan is experienced in business management, media operation and medical and pharmaceutical policy research. She holds a Bachelor of Medicine in Norman Bethune Health Science Center at Jilin University and EMBA of Guanghua School of Management at Peking University.

李　靖
药渡 董事长

Jin LI
Founder and Chair of Pharmacodia

中国海归留学生，连续创业者。威斯康辛－密尔沃基有机化学博士。从 2006 年到现在，参与创办的企业包括：珅奥基医药科技有限公司，欧博方医药科技有限公司， 药渡经纬信息科技有限公司，本草资本；发表论文约 30 篇，专利约 50 件；参与并主持许多国家项目：包括：重大新药创制课题研究；科技部支撑计划等；熟悉当今世界一流制药企业的药物研发流程和体系，拥有丰富的创新药物研发知识和经验。

Jin Li, Ph.D., University of Wisconsin-Milwaukee, Ph.D. in Organic Chemistry. Dr. Li has been working as the principle scientist at Pfizer's R&D headquarters over eight years. He is the founders of Shenogene, Orbiepharm as well. He has many years of experience in innovative drug research and development and corporate management. In 2013, he founded Phamrmacodia and served as chairman of the board.

姜　华
绿叶制药 集团副总裁

JIANG Hua
Group Vice President of Luye Pharma

姜华女士现任绿叶制药集团副总裁，负责集团战略发展、业务拓展，并购及合作，以及投资者关系工作。姜华女士具有多年医药相关领域的涉外合作、兼并收购和跨国管理经验。

姜华女士拥有上海复旦大学世界经济系学士学位、法国马赛 KEDGE 商学院工商管理硕士学位（MBA）及比利时联合商学院工商管理博士学位（DBA），并拥有经济师资格证书。

她是中国药品监督管理研究会流通专委会成员，法国马赛 KEDGE 商学院制药工业研究中心荣誉顾问，中美生命科学技术协会（ACLSTA）的名誉理事，从 2010−2012 年，连续三年荣获美国美中药协（SAPA）年度杰出贡献奖。

姜华女士曾多次在《医药经理人》、《中国医药技术经济与管理》等杂志上发表文章，并多次受邀参加相关学术论坛并发表演讲。她同时还是沈阳药科大学亦弘商学院和烟台大学药学院的课程讲师。

Ms. Sammy (Chinese name: Hua Jiang) is currently the Vice President of Luye Life Science Group, responsible for strategy, business development, and Investor relationship. Ms. Jiang has over 22 years of experience in pharmaceutical industry. Ms. Jiang had led over thirty of pharma and healthcare M&A, License In and License Out deals and cross boarder collaborations in the past 10 years.

Ms. Jiang holds a Doctor of Business Administration from United Business Institute, a Master's degree in Business Administration from KEDGE Business School (previously known as Euromed Management School), and a Bachelor's degree of Economics from Economy School, Fudan University. She is also an economist certified by the Ministry of Human Resources and Social Security of the People's Republic of China.

She is also the Vice Chairman of KEDGE AEMBA Alumni Association. She is the freelance writer for Healthcare executive magazine, China Pharmaceutical technology economics and management magazine, etc, and been invited to attend and make the speech in some related seminar/conference. Ms. Jiang is also the Program Professor for Yeehong Business School, Shenyang Pharmaceutical University and Yantai University Pharmaceutical College.

王昌进
前沿生物药业（南京）股份有限公司董事、总经理

WANG Changjin
Director and General Manager of Frontier BIOTECHNOLOGIES (Nanjing) Co., Ltd.

1958 年出生，美国国籍，拥有中国永久居留权，博士研究生学历。1990 年 7 月至 1995 年 1 月历任 Schering−Plough Corporation（美国先灵葆雅公司）高级科学家、副主任科学家、主任科学家；1995 年 2 月至 2001 年 1 月历任 Packard Biosciences Inc 商务开发经理、AlphaScreen 技术及系统部总监、授权并购及加盟部总监；2001 年 1 月至 2002 年 2 月任 Cellomics Co. 商务开发和市场营销副总裁；2002 年 4 月至 2004 年 8 月任 TaiGen Biotechnologies Co. 商务开发副总裁；2004 年 9 月至 2006 年 10 月任 Abmaxis Co. 商务开发副总裁；2006 年 11 月至 2008 年 11 月任 Vivus Inc. 商务开发副总裁；2009 年 1 月至 2013 年 1 月任重庆前沿首席商务官；2009 年 3 月至 2019 年 3 月任株式会社 ABsize 董事兼总经理；2013 年 5 月至 2018 年 4 月任重庆前沿总经理；2013 年 1 月至 2016 年 3 月历任前沿有限董事、总经理；2016 年 3 月至今任前沿生物董事、总经理。

Born in 1958, American nationality, with Chinese permanent residency, doctoral degree.From July 1990 to January 1995, he served as senior scientist, deputy chief scientist and chief scientist of Schering plough Corporation;From February 1995 to January 2001, he successively served as business development manager of Packard Biosciences Inc., director of alphascreen technology and systems department, and director of authorized merger and franchise Department;From January 2001 to February 2002, he served as vice president of business development and marketing of cellomics Co;From April 2002 to August 2004, he served as vice president of business development of TaiGen Biotechnology Co;From September 2004 to October 2006, he served as vice president of business development of abmaxis Co.From November 2006 to November 2008, he served as vice president of business development of vivus Inc.From January 2009 to January 2013, he served as chief business officer of Chongqing frontier;From March 2009 to March 2019, he served as director and general manager of absize Co., Ltd;From May 2013 to April 2018, he served as general manager of Chongqing frontier;From January 2013 to March 2016, he successively served as the director and general manager of Frontier limited;Since March 2016, he has been the director and general manager of Frontier biology.

谢　炘
中国生物制药执行董事、资深副总裁

Hsin Tse
Executive Director & Senior Vice President, Sino Biopharmaceutical Limited

谢炘先生是公司执行董事及资深副总裁。主要负责本集团的收购合并及融资工作，谢炘先生同时亦为本集团发言人。谢炘先生毕业于香港大学工业工程系，并获得工程荣誉学士学位。他于一九九五年八月加入本集团出任本公司主席助理并曾出任西安正大制药有限公司董事总经理之职。谢炘先生为北京潮人商会第一届理事会理事及第二届常务理事，陕西省药品医疗器械企业权益保护协会常务理事，陕西省外商投资企业协会第四届理事副会长，陕西省抗癌协会第三届理事会常务理事及世界中医药学会联合会中药药剂专业委员会副会长。曾被陕西省政府评为「陕西省外商投资企业优秀管理者」并获陕西省外商投资协会「爱员工的优秀企业家」称号。谢炘先生曾出任北京泰德执行董事，现任正大天晴监事，南京正大天晴及正大青岛董事以及正大邵阳骨伤科医院董事长。

Hsin Tse is an executive director and a senior vice president of the Company. He is mainly responsible for the acquisition and merger activities of the Group. He is also the Group's spokesman. Mr. Tse Hsin graduated from the University of Hong Kong with a Bachelor's Degree (Honors) in Industrial Engineering. He joined the Group in August, 1995 as an assistant to the president of the Company and served as the general manager of Xian C.P. Pharmaceutical Co., Ltd. Mr. Tse Hsin was a council member of the first council and the executive council member of the second council of Chaozhou Natives Chamber of Commerce Beijing. He is also an executive member of the Right Protection Association for the Medical Treatment Equipment Enterprises of the Shaanxi Province, the vice chairman of the fourth council of the Foreign Invested Enterprises Association of the Shaanxi Province, the executive member of the third committee of the Shaanxi Cancer Fighting Association and the vice chairman of the World Chinese Medicine and Pharmaceutical Professional Joint Committee. He was awarded the "Outstanding Management Award for Foreign-invested Enterprises of Shaanxi Province" by the Shaanxi Provincial Government and the "Outstanding entrepreneur who cares about his staff" by the Shaanxi Foreign Invested Enterprises Association. He was a director of CT Tianqin and Beijing Tide, and is currently a director of NJCTT and CP Qingdao, a supervisor of CT Tianqing, and the president of Chia Tai Shaoyang Orthopedic Hospital.

卢　燕
开拓药业首席财务官

LU Yan
CFO of Kintor Pharmaceutical Limited

卢燕女士，开拓药业首席财务官，主要负责公司的财务规划、投资者关系及内部控制。拥有超过 13 年的投资银行业务经验。2018 年 7 月，任职于广发融资（香港）有限公司，最后担任董事、投资银行业务主管及董事总经理。2007 年 9 月至 2018 年 7 月，任职于 UBS Securities Hong Kong Limited，离任时为亚洲医疗健康集团 (Asian healthcare group) 执行董事。自 2014 年在瑞银任职以来，一直为香港保荐首次公开发售的签署负责人。2006 年 8 月至 2007 年 8 月，于瑞士信贷（香港）有限公司担任分析师。于 2003 年 7 月于中国人民大学财政金融学院获得金融学学士学位，2005 年 7 月于中国北京大学光华管理学院获金融学硕士学位。

LU Yan, Kintor's Chief Financial Officer, primarily responsible for financial planning, investor relations and internal control of our Group. She has over 13 years of experience in investment banking business. She joined GF Capital (Hong Kong) Limited in July 2018 with her last position as the Director, head of investment banking business and Managing Director. From September 2007 to July 2018, Ms. Lu worked at UBS Securities Hong Kong Limited with her last position as an executive director in the Asian healthcare group. She has been a signing Principal for Hong Kong sponsorship IPOs since 2014, when she worked in UBS. From August 2006 to August 2007, She worked at Credit Suisse (Hong Kong) Limited as an analyst. She obtained her bachelor's degree in finance from School of Finance in Renmin University of China in the PRC in July 2003, and her master's degree in finance from Guanghua School of Management in Peking University in the PRC in July 2005.

童少靖
北京诺诚健华医药科技有限公司首席财务官

TONG Shaojing
Chief Financial Officer (CFO), Beijing InnoCare Pharma Tech Co., Ltd.

童少靖先生是诺诚健华首席财务官，负责公司的财务战略制定、风险管理及投融资等事项。
童少靖先生在医药健康领域拥有丰富的投资分析和管理经验，对创新药在资本市场的价值与发展趋势有独到见解。他曾多年在机构投资人举办的全亚洲医疗行业“最佳分析师团队”评选中名列前茅。在加入诺诚健华之前，童少靖先生在瑞银中国担任执行董事、股票分析师，负责对在 A 股和港股上市的中国医疗公司的股评分析。在此之前，童少靖先生曾在美银美林（香港）、麦他合伙人公司（纽约）从事医疗行业的投资研究。在进入金融行业之前，童少靖先生曾在 CADUS 制药公司（纽约）从事药物研发工作。
童少靖先生在中国科技大学材料科学与工程专业获得学士学位，后在美国匹兹堡大学和纽约大学分别获得化学硕士学位和工商管理硕士学位（MBA）。

Shaojing Tong is Chief Financial Officer (CFO) of InnoCare. Mr. Tong has been a leading healthcare research analyst for the Asia-market and has extensive knowledge of the industry. Mr. Tong is responsible for the financial strategy development, risk management, and investment analysis.
Mr. Tong is considered one of Hong Kong's top research analysts for the entire biopharmaceutical and healthcare sector, repeatedly being ranked in the "Best Analyst Team" of the Asian healthcare industry. Mr. Tong has many years of experience in managing investment analyst teams and has acquired comprehensive knowledge of the industries history, value chains, and developmental trends. Before joining InnoCare, Mr. Tong served as an executive director and industry analyst at UBS China, where he covered medical companies for both the Hong Kong and A-class China markets. Prior to UBS, Mr. Tong was a healthcare research analyst for Bank of America Merrill Lunch (Hong Kong) and Michael Partners (New York). Preceding his financial career, Mr. Tong worked in drug development for CADUS Pharmaceuticals (New York).
Mr. Tong received a Bachelor of Science degree in materials science and engineering from the University of Science and Technology of China. He obtained a Master's degree in chemistry at the University of Pittsburg, and a Master of Business Administration (MBA) from New York University.

吴劲梓
歌礼药业创始人 / 董事会主席兼首席执行官

Jason WU
Founder, Chairman and CEO of ASCLETIS PHARMA Inc.

吴劲梓博士，歌礼创始人、董事会主席兼首席执行官，于 2013 年 4 月创办歌礼。2018 年 8 月，在吴博士带领下，歌礼（1672.HK）成为香港交易所全球首家成功上市的未盈利生物医药企业，融资 4 亿美元。在吴博士的领导下，歌礼已发展成为一体化平台型公司，涵盖了从新药发现和开发直到生产和商业化的完整价值链。在吴博士带领下，歌礼致力于开发抗病毒、脂肪性肝炎、肿瘤相关创新药，满足国内外患者需求。

吴博士拥有超过 20 年在跨国企业和生物科技企业的新药研发、GMP 生产和商业化的经验。创立歌礼前，吴博士曾担任美国葛兰素史克（GSK）研发部门的副总裁。他还曾先后在美国诺华（Novartis）、美国安进（Amgen）/Immunex 和加拿大 Ambrilia 等制药公司研发部门担任高级科学家、副总裁等职位。吴博士在美国亚利桑那大学获得癌症生物学博士学位。

Dr. Jason WU is Founder, Chairman and CEO of Ascletis which was founded in April 2013. Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in August 2018 and raised US$400M. Under his leadership, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Under his leadership, Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally.

Dr. Wu has more than 20-year experience covering R&D, GMP manufacturing and commercialization in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex/Amgen and Ambrilia in USA and Canada. Dr Wu obtained his PhD in Cancer Biology from University of Arizona.

孟　渊
天境生物科技（上海）有限公司副总裁 / 医学办公室负责人

Isaac MENG
VP/Head of Medical Office, I-Mab Biopharma Co., Ltd.

孟渊目前担任天境生物研发部副总裁，医学办公室负责人。 在此职位上，孟渊负责监督所有早期开发和中晚期开发产品的全球医学安全和质量保证工作；与研发部及公司领导层共同领导医学安全问题的处理；推动天境生物全球 GCP/GLP/GVP 质量保证政策和流程的制定，确保公司所有的药物的发现和开发符合所有国家相关的法规以及天境公司的策略。

在此之前曾任职于多家跨国制药企业，包括美国礼来制药（2000−2003）， 惠氏制药（2003−2007），施贵宝制药（2007−2011）。孟渊毕业于上海医科大学（现复旦大学上海医学院）。孟渊在加入制药界之前在上海瑞金医院从事神经科临床医疗实践及教学工作（1997−2000）。孟渊的主要职业经验来自于临床药物安全，药物风险管理以及药物的风险受益评价等领域。 是 ICH E2D(R1) 工作组成员， 同时他也是 DIA 中国顾问委员会核心成员。

Yuan is the VP, Head of Medical Office at I-Mab Biopharma Research and Development. In this position, he ensures medical safety and quality oversight for all early and late clinical development activities globally; leads product safety issue management with R&D and company senior leaders; drives the development of GCP/GLP/GVP QA global policies and procedures within i-Mab and assuring the compliance to the company policies, the laws and regulations governing drug discovery and development.

Before he joined I-Mab Biopharma in 2018, Yuan served as China Cluster Safety Head in Johnson & Johnson and were responsible for oversight medical safety of all pharmaceutical and consumer products in China, Hong Kong and Taiwan. Before J&J, Yuan was safety risk lead in safety surveillance and risk management department in worldwide regulatory and safety division in Pfizer Company. Yuan also worked for a number of multinational pharmaceutical companies including Eli Lilly & Company (2000-2003), Wyeth pharmaceutical company (2003-2007) and Bristol-Myers Squibb Company (2007-2011). Yuan received his medical training from Shanghai Medical University (now Shanghai medical colleague in Fudan University). During 1997-2000, before joined the pharmaceutical industry, Yuan practiced as neurologist in Shanghai Ruijin Hospital.

Yuan developed his core career in the area of clinical drug safety and also developed expertise in risk management and risk-benefit assessment. He is member of ICH E2D(R1) Expert Working Group and core Member of DIA Advisory Council of China.

李　盈
贝达药业股份有限公司战略合作副总裁

Lily LI
Vice President/Strategic Collaboration, Betta Pharmaceuticals Co., Ltd.

李盈博士现为贝达药业战略合作部副总裁，主要负责带领贝达战略合作团队，进行公司项目引进、商务谈判合作以及技术转让工作， 促进公司与国内外先进企业合作，加快公司国际化进程。李盈博士拥有 15 年大型药企与初创公司药物研发、商务拓展与后期项目合作管理从业经验，在加入贝达前曾任职于美国默克、英国阿斯利康等知名跨国药企。自 2017 年至今已完成 10 余项战略合作与投资项目，其中包含最近刚刚结束的与美国 Agenus 公司总计 1.35 亿美金的 PD−1 与 CTLA−4 单抗项目的引进。合作项目中从北京天广实引进的 MIL60 于今年 6 月获得 NMPA 上市申请受理，从益方药业引进的 BPI−D0316 项目，与君实合作开发特瑞普利与 CM082 联合用药项目处于临床注册研究阶段，预计均可于 2022 年底前在中国上市。李盈博士拥有北京大学化学系学士以及美国圣路易斯华盛顿大学化学博士学位。

Dr. Lily Li is Vice President of Strategic Collaboration at Betta Pharmaceuticals Co., Ltd., where she leads the effort of expanding company's innovative pipeline through in-licensing, co-development, and strategic investment.
Lily received her Bachelor of Science degree from Peking University, China and her PhD in Chemistry from Washington University in St. Louis, US. Lily has 15 years of experience in drug development, business development and alliance management. Prior to joining Betta, Lily worked at the world's top pharmas Merck and AstraZeneca. Since joining Betta in 2017, Lily has led the BD team establishing strategic partnerships with over 10 global and domestic companies including the most recent $135M USD deal with Agenus. Other three programs are currently under BLA/registration studies and expected to be launched in China before 2022.

俞文冰
君实生物 总经理助理

YU Wenbing
Assistant General Manager of Junshi Biosciences

俞文冰先生现为君实生物总经理助理，分管投融资，是公司香港上市和科创板上市项目组主要成员之一，目前主要负责公司投资人沟通，公司的股权和债券融资，以及对外投资。俞先生拥有超过 12 年金融行业工作经验，在加入君实生物之前，曾在中海基金投资研究部，长江证券研究所，广发证券发展研究中心和光大证券金融市场部任职。在担任分析师期间，俞先生于 2011 年至 2014 年新财富最佳分析师评选中皆上榜，其中 2012 年为第一名，2013，2014 年第二名。俞先生持有上海财经大学硕士学位和同济大学学士学位。

Mr. Wenbing Yu is currently the assistant general manager of Junshi Biosciences, in charge of investment and financing. He is one of the team members of the company's Hong Kong listing and STAR market listing projects. He is currently responsible for company investor relationship, equity and bond financing, and investment. Mr. Yu has more than 12 years of working experience in the financial industry. Before joining Junshi Biosciences, he worked in the Investment & Research Department of Zhonghai Fund, Changjiang Securities Research Institute, GF Securities Development & Research Center, and Everbright Securities Financial Market Department. During his tenure as an analyst, Mr. Yu earned the New Fortune Best Analyst Awards from 2011 to 2014, of which 2012 was the first, 2013, and 2014 were the second. Mr. Yu holds a master's degree from Shanghai University of Finance and Economics and a bachelor's degree from Tongji University.

陈　晨
康方生物医药有限公司商务拓展副总裁

Michael CHEN
Business Development VP, Akeso, Inc.

陈晨博士在生物制药及全球商务拓展领域深耕多年，在研发外部创新、管线合作、商务拓展等方面有着扎实的经验和实践成果。在加入康方生物之前，陈博士曾担任默克雪兰诺医药研发外部创新亚太区负责人，并同时负责默克国际商务拓展部在中国及亚太地区的相关工作，开展各种对内引进，对外合作等业务。针对不同类型的项目，陈博士通过开放创新、许可授权、合作开发、投资及其他新颖的模式，推进商务合作。陈博士也是默克亚洲和中国研发中心的领导成员之一。陈博士也是默克在华拓展肿瘤事业和创新合作的核心成员之一。
陈博士拥有英国埃塞克斯大学细胞和分子生物学学士学位、英国诺丁汉大学癌症免疫治疗硕士学位、英国帝国理工学院生物化学博士学位。在加入默克之前，他曾在英国生物技术公司 Spirogen Ltd（后被阿斯利康集团旗下全球生物制药分公司 MedImmune, LLC 收购）领导研究项目，归国后加入药明生物和睿智化学开展商务拓展及投资工作。

Mr. Michael Chen has dedicated himself to biopharmaceutical industry and global business development for years and has extensive experience and practical achievements in external innovation, pipeline cooperation and business development. Before joining Akeso, Dr. Chen worked as Head of External Innovation APAC for Merck KGaA. Meanwhile, Dr. Chen was also responsible for the international business development department of Merck in China and APAC areas, carrying out a variety of internal and external business cooperation. This particularly involved opportunity finding and leading discussions through various approaches, including open innovation, licensing, co-development, investment, and other collaboration models. Dr. Chen was also one of the leading members of Merck Asia and China research and development center. Dr. Chen was also one of the core members for expanding Merck's oncology business and innovation collaboration in China.
Dr. Chen received his bachelor's degree of cell and molecular biology from University of Essex, a master's degree in cancer immunotherapy from University of Nottingham and a Ph.D. degree in biochemistry from Imperial College London. Before joining Merck, he has been leading research projects in the UK at Spirogen Ltd, later acquired by MedImmune, LLC (a company of AstraZeneca PLC). He then returned to China and led business development and investment activities at WuXi Biologics and ChemPartner.

张子栋
上海复宏汉霖生物技术股份有限公司 首席财务官

ZHANG Zidong
CFO of Shanghai Henlius Biotech, Inc.

张子栋博士复宏汉霖首席财务官，曾于上海复旦大学获得化学学士学位，并在波士顿大学获得生物化学硕士学位及博士学位，后于杜克大学富卡商学院取得 MBA 学位。张博士曾担任纽约瑞银集团股票分析师，关注美国医药及特种医药行业大型股。在此期间他主要关注癌症免疫疗法，自身免疫疾病，仿制药 / 生物仿制药，以及特种医药的前沿研究。他也曾在拜耳集团担任内部咨询师，处理过美国、欧洲及中国的多个项目，包括美国及中国的战略规划及市场预测、并购、组织架构设计及实施。

Dr. ZHANG Zidong, Chief Financial Officer, graduated from Fudan University for BS in chemistry, then obtained Ph.D. degree from Boston University in Biochemistry and MBA from Duke University the Fuqua School of Business. Dr. Zhang had worked as Equity Analyst for UBS in New York, covering US large Cap Pharmaceuticals and Specialty Pharmaceutical sector. He has previously worked as an equity analyst for UBS in New York, covering US large cap pharmaceuticals and specialty pharmaceutical sector with a key focus in therapeutic areas as Oncology (especially for Immuno Oncology), autoimmune diseases, and other areas. He was an internal consultant for Bayer AG, a global pharmaceutical company, where he had multiple projects across the United States, Europe and China, including strategic planning and market forecasts for United States and China, merger and acquisition, organisational structure design and implementation.

宋郑薇
信达生物投资者关系与财务策略总监

Wendy SONG
Director of Investor Relation and Financial Strategy, Innovent Biologics

宋郑薇女士于 2020 年 7 月加入信达生物，负责投资者关系管理和财务策略支持。宋郑薇女士在生物医药行业研究和财务金融分析领域有着丰富的经验，加入信达之前，曾在 UBS 任职助理总监 5 年，领导和负责健康医疗板块的分析评估，涵盖的领域包括制药、生物技术及健康医疗服务等，在此期间，她为多家上市医药公司提供了权威性的评级服务并出具了分析报告。此外，她还曾供职于美国 Siemens。宋郑薇女士本科毕业于上海同济大学，并于美国 University of Maryland 获得了硕士学位。

Ms. Wendy Song joined Innovent Biologics as the Director of Investor Relation and Financial Strategic Analysis. Prior to Innovent, she spent more than 5 years at UBS as the Assistant Director and Healthcare Analyst covering areas of pharmaceutical, biotech, commercial and healthcare service. During that period of time, she provided in-depth analysis reports for listed healthcare companies in A share and H share. Prior to her analyst career at UBS, she spent time with Siemens U.S.. Wendy graduated from Tongji University Shanghai with a BS degree and University of Maryland US for a Master Degree.

张甦
亚盛医药 首席财务官

ZHANG Su
CFO, Ascentage Pharma

张甦先生自 2019 年 8 月担任亚盛医药的首席财务官。张甦先生在金融业有超过 18 年经验，长期专注于医药行业分析，对香港资本市场熟悉。曾在普华永道、Exane BNP Paribas、渣打银行和招商证券任职。
张甦先生于 2000 年获得复旦大学国际商务经济学专业学士学位，于 2006 年获得巴黎高等商学院 MBA 硕士学位，于 2007 年获得伦敦政治经济学院会计 & 财务专业硕士学位。

Mr. Su Zhang has been the chief financial officer of Ascentage Pharma since August 2019. Mr. Zhang has more than 18 years of experience in the finance industry and has long been focused on the analysis of the pharmaceutical industry and is familiar with the Hong Kong capital market. He ever served in PWC, Exane BNP Paribas, Standard Chartered Bank and China Merchant Securities.
Mr. Su Zhang holds Bachelor degree in Economics in International Business in Fudan University in 2000 and holds MBA in HEC school of management in 2006, Master degree in Accounting & Finance in London School of Economics and Social Science in 2007. Su has 12 years of experience in overseas capital markets and

王　歆
永泰生物制药有限公司执行董事、首席执行官兼联席首席技术官

WANG Yu
Executive Director, Chief Executive Officer and Co-Chief Technology Officer, Immunotech Biopharm Ltd.

王歆博士毕业于北京大学并获得免疫学博士学位，在医学研究领域拥有逾 25 年的经验，在癌症医治领域取得了多项重要的研究成果，在癌症研究及免疫学相关学术期刊上发表了多篇科学文章，并主持了多个国家和市级科学基金项目并获得了专项支持。
王博士始终保持专业领域的前瞻性，带领团队所开发的产品从非特异性细胞免疫治疗产品到特异性细胞免疫产品，针对肿瘤患者进行不同适应证的治疗，为临床肿瘤和难治性病毒感染的治疗提供了重要的免疫治疗方法。在此基础上，从行业的先进技术方向出发，致力于免疫细胞行业尖端技术和资源储备。在王博士的带领下，团队正在建设的 T 细胞库、抗原特异性细胞库、抗原特异性识别受体基因库，是我国在细胞治疗行业齐肩于国际研究水平的重要技术积累。这些项目的实施，将为未来的中国细胞免疫治疗研究奠定重要的技术和资源基础。

Dr Wang Yu obtained a Ph.D. in immunology from Peking University. Dr Wang has over 25 years of experience in medical research. Throughout her career, Dr Wang has made significant research output in the area of medical treatment of cancer and published a number of articles in cancer studies and immunology related academic journals. She is the leader of many national and municipal science fund projects with special supports.
Dr Wang has always been forward-looking in her professional field. She led a team to develop products ranging from non-specific to specific cellular immunotherapy products, which targeted different indications for treating tumour patients. This provided an important immunotherapy method for clinic tumour and refractory viral infection treatment. On this basis, we are committed to edge-cutting technology and resource reserves in the immune cell industry from the industry's perspective of advanced technology. Under the leadership of Dr Wang, the team is currently building a T cell bank, an antigen-specific cell bank and an antigen-specific recognition receptor gene bank. It is an important accumulation of technology in the cell therapy industry in China, which is equal to the international research level. The implementation of these projects will establish an important technical and resource foundation for future research on cellular immunotherapy in China.

贺菊颖
中信建投证券股份有限公司医药行业首席分析师

HE Juying
Chief Analyst of Healthcare, China Securities

中信建投证券医药行业首席分析师。复旦大学管理学硕士，10 年以上医药行业研究经验，善于前瞻性把握细分赛道机会，公司研究深入细致，负责整体投资方向判断。
获 2013 年新财富医药行业第 3 名，水晶球医药行业第 5 名。2018 年 Wind“金牌分析师”医药行业第 3 名，2018 第一财经最佳分析师医药行业第 1 名。 2019 年 Wind“金牌分析师”医药行业第 1 名。

Juying He, Chief Analyst of the China Securities Healthcare Industry Research Team. She obtained a master's degree in management at Fudan University and has more than ten years of analysis experience in the healthcare industry. She is good at grasping opportunities in sub-industries in a prospective way through detailed and in-depth research of companies. She is responsible for the decision-making of the overall research direction of the team.
Honors: Ranked No. 3 in the New Fortune 2013 Best Sell-side Analysts in the healthcare industry, No. 5 in the Crystal Ball 2013 Best Sell-side Analysts in the healthcare industry, No. 3 in the Wind 2018 "Gold Medal Analysts" in the healthcare industry, No. 3 in the Yicai 2018 Best Sell-side Analysts in the healthcare industry, and No. 1 in the Wind 2018 "Gold Medal Analysts" in the healthcare industry.

杨烨辉
天风证券产业部副总监 / 医药联席首席

YANG Yehui
Tianfeng Securities Joint Chief Analyst of Medical Industry/ Deputy Director of Industrial Services Department

中山大学硕士，曾就职于江中药业研发部，默沙东市场销售部，招商证券、华泰证券研究所，2016 年加盟天风证券。有超过 12 年的医药行业从业 + 投资研究工作经验，作为团队成员参评获得 2011 年新财富第三名，2012 年新财富第四名，2013 年新财富入围，2014 年新财富第二名，2017 年带队参评新财富入围。

Master of Sun Yat-sen University, once worked in Jiangzhong Pharmaceutical R & D Department, Merck East Market Sales Department, China Merchants Securities, Huatai Securities Research Institute, joined Tianfeng Securities in 2016. More than 12years of experience in the pharmaceutical industry and investment research, as a team member to participate in the 2011 new wealth third place, 2012 new wealth fourth place, 2013 new wealth finalist, 2014 new wealth second place. In 2017, he led the team to participate in the new wealth and shortlisted.

陈晓光
中国医学科学院药物研究所药理室主任

CHEN Xiaoguang
Director, Department of PharmacologyInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College

陈晓光博士，研究员，现为中国医学科学院药物研究所药理室主任，天然药物活性物质与功能国家重点实验室副主任。首批新世纪“百千万人才工程”国家级人选，国务院特殊津贴专家。曾获得首届 DEBIOPHARM−CCRF 中国奖一等奖。1996 年、1997 年、2001 年作为客座教授或访问学者先后到日本、瑞士、美国相关大学和研究机构从事研究工作。长期从事肿瘤分子药理学及新药创制研究。主要研究领域为抗肿瘤药物研究新靶点、信号通路抑制剂以及与免疫治疗密切相关的新药研究。发表学术论文 150 余篇；申请国内外专利 60 余项，获得授权专利 40 项，主编研究生教材 3 部，主持多个创新药物的研发。作为项目总负责人已完成 5 个 1 类化药的成果转化，转让总额近 5 亿元人民币， 所研发的小分子肿瘤免疫治疗新药在国内外处于领先地位。在小分子新药的基础研究、新药创制与开发中取得显著成绩。

Xiaoguang Chen, Director of Pharmacology Department of IMM, CAMS&PUMC, Deputy Director of the State Key Laboratory of Active Substances in Natural Medicines. She was elected as Millions of Talent Projects National candidates and awarded the State Council Special allowance. She has won the first prize of the first DEBIOPHARM-CCRF China Award. In 1996, 1997, and 2001, she worked as a visiting professor or visiting scholar in related universities and research institutions in Japan, Switzerland, and United States. Her major is in the research of cancer molecular pharmacology and new drug development. Her main research areas are new targets for anti-tumor drug research, signaling pathway inhibitors, and new drug research closely related to immunotherapy. She has published more than 150 academic papers, applied for more than 60 domestic and foreign patents, obtained 40 authorized patents, edited 3 postgraduate textbooks and developed several innovative medicines. As the head of the project, she has completed 5 patent transfers of Class 1.1 new drugs with a total package of nearly 500 million RMB. The new drug for small molecule cancer immunotherapy she has developed is at the leading position in china and abroad. She has made significant achievements in basic research and R&D of small molecule drugs.

张步泳
米内网总经理 / 首席研究员

ZHANG Buyong
Guangzhou PICO Medicine Information Co., Ltd. +
General Manager/Chief Researcher, MENET

毕业于中国药科大学生物制药系，20 世纪 90 年代末进入医药信息行业。国内医药信息领域的第一批进入者、实践者、研究者，更是国内医药信息行业的推动者。在十八年职业生涯中，为中国 500 余家主流医药企业操盘各种类型的市场研究项目，由其领衔开发了切合国内医药市场需求的品类市场综合分析、品种筛选与企业产品梯队组建、IPO 募集资金投向可研、大品牌终端流向、大品牌终端核查项目、医药企业投资可行性等独特的产品类型。现为多家医药企业及基金证券机构担任顾问。在医药市场分析、预测以及对各大类别药物市场分析方面有着独到深入的见解，具有丰富的市场研究和营销策划管理经验。

Graduated from the Department of Biopharmaceutics of China Medicine University, and entered the pharmaceutical information industry in the late 1990s. The first batch of entrants, practitioners, and researchers in the field of medical information in China are the promoters of the domestic medical information industry. Over the past 18 years, more than 500 mainstream Chinese pharmaceutical enterprises have conducted various types of market research projects. They have led the development of comprehensive market analysis, variety selection and product echelon formation, IPO fund investment to be researched, the terminal flow of large brands, and end of large brands that meet the needs of the domestic pharmaceutical market. Unique product types such as end check items, investment feasibility of pharmaceutical enterprises, etc. He is now a consultant for several pharmaceutical companies and fund securities companies. He has unique and in-depth insights in the pharmaceutical market analysis, forecasting, and analysis of major categories of pharmaceutical market, and has rich experience in marketing research and marketing planning and management.

杜　舟
华平投资副总监

Joe DU
Associate Director, Warburg Pincus

杜舟，华平投资副总监，其在医药医疗领域具有深厚的研究、投资经验及行业资源。
在加入华平投资之前，杜舟先生曾任中国平安人寿（601318.SH/2318.HK）组合投资经理（Portfolio Manager）、医药战投主管分析师；三胞集团首席战略官、副总裁、市值管理总经理。
杜舟先生亦曾任申万宏源证券（000166.SZ/6806.HK）医药行业首席分析师、医疗大健康行业负责人。中国水晶球最佳分析师评选第一名。中国非公立医疗机构协会投融资分会委员、中央电视台首席看市金牌特邀嘉宾。其主要覆盖 A 股及 A+H 股在医药大健康行业的龙头上市公司，在医药行业二级市场有深厚的研究经验与行业资源，具有深厚的市场影响力。
杜舟先生亦曾从事投资银行、战略咨询及美国生物医学研发工作；其拥有美国密歇根大学工商管理硕士（MBA）及生物医学硕士（M.S.）的双学位。

Joe Du, Associate Director, WARBURG PINCUS
Mr. Du is the Associate Director at WARBURG PINCUS, focusing on China healthcare research and investments.
Prior to joining WARBURG PINCUS, Mr. Du worked as Portfolio Manager, Lead Analyst of Healthcare Strategic Investments at PINGAN LIFE INSURANCE (601318.SH/2318.HK); and Chief Strategy Officer, Vice President at SANPOWER GROUP.
Also, Mr. Du worked as the Head of China Healthcare Research, Chief Healthcare Equity Research Analyst at SHENWAN HONGYUAN SECURITIES (000166.SZ/6806.HK), covering leading healthcare and pharmaceutical companies in A-Share and A+H Share stock market in China, with extensive research experience and industry resources in China healthcare sector. He ranked No.1 in Crystal Ball Awards (China Sell-Side Analysts Survey).
Mr. Du also worked in investment banking and management consulting industry in China, as well as biomedicine R&D in the United States. He holds a MBA degree from University of Michigan Ross School of Business, and a M.S. degree in Biomedicine from University of Michigan, Ann Arbor.

徐佳熹
兴业证券董事总经理，研究院副院长

XU Jiaxi
Managing Director and Deputy Head of Research in CIS

兴业证券董事总经理，研究院副院长，大健康与消费研究中心总经理，医药行业首席分析师。
2011 年加入兴业证券，先后获得 2016−2019 年新财富最佳分析师医药生物行业第一名，2014−2018 年最受保险机构欢迎分析师五连冠，并多次获得水晶球、Starmine、金牛奖、福布斯最佳分析师奖项。
复旦大学生命科学学院博士，《药学进展》期刊编委，上海市青年岗位能手，对医药健康多个领域有深度覆盖，行业资源丰富。

Dr. Xu is a Managing Director and deputy head of research in China Industrial Securities Co., Ltd. (CIS). He also leads the Healthcare and Consumer Goods Research Center in CIS research institute.
As one of leading healthcare research teams in mainland China, Dr. Xu and his colleagues cover over 70 stocks in A and H markets. This team ranked No.1 in New Fortune Analyst Award in 2014 and 2016-2019 consecutively. His list of accolades also includes Starmine Award, IAMAC (Insurance Asset Management Association of China) Award, Crystal Ball Award, etc. Dr. Xu is a member of the editorial board in <Progress in Pharmaceutical Science> (Journal of China Pharmaceutical Association) and was awarded Shanghai Youth Expert, Shanghai Financial Youth Talent in 2018 and 2019 respectively.
Dr. Xu earned his B.S. degree in biological science and a Ph.D. degree in genetics from Fudan Univ.

胡元佳
澳门大学副教授 / 中药质量研究国家重点实验室临床研究中心副主任

HU Yuanjia
Associate Professor, University of Macau / Deputy Director, Clinical Research Center, State Key Laboratory of Quality Research in Chinese Medicine

澳门大学副教授，中药质量研究国家重点实验室临床研究中心副主任，博士生导师。胡博士开展医药专利与复杂系统分析超过 15 年，创建医药技术扫描与专利价值评估模型，建立基于复杂系统的药物开发平台，近年来积极推动医药科技成果转化。他的研究结果不仅在 150 余份学术作品中介绍，也在 WIPO、WTO、CNIPA、DIA 等机构会议中报告。胡博士也是世中联网络药理学专委会副秘书长，中国药理学会网络药理学专业委员会委员，国家药物政策与医药产业经济研究中心项目研究员，国家知识产权公共服务平台金融创新试点平台政策指导专家。胡博士于 2001 年获中国药科大学药事管理学士学位，2008−2009 赴奥地利研究中心访问研究，2009 年获澳门大学生物医药博士学位。

Dr. Yuanjia Hu is Associate Professor and PhD Supervisor in the University of Macau, and Deputy Director of Clinical Research Center of the State Key Laboratory of Quality Research in Chinese Medicine. Dr. Hu has researched medical patents and complex system for more than 15 years, initiatively established models of medicinal technological scanning and patent valuation, built up drug development platform based on complex system, and actively impelled the transformation of medicinal scientific and technological achievements in the recent years. His research results have been not only introduced in over 150 academic publications, but reported in conferences organized by WIPO, WTO, CNIPA, and DIA etc. Dr. Hu is also Deputy Secretary-General and Executive Council Member in Specialty Committee on Network Pharmacology of WFCMS, Commissioner of the Commission on Network Pharmacology in Chinese Pharmacological Society, Project Researcher in the Research Center of National Drug Policy & Ecosystem, and Policy Expert in Financial Innovation Pilot Platform of State Intellectual Property Operation Public Service Platform. Dr. Hu received B.Sc. degree of Pharmacy Administration from China Pharmaceutical University in 2001, studied in Austrian Institute of Technology during 2008-2009, and achieved Ph.D. degree in Biomedical Sciences from the University of Macau in 2009.

杨红飞
杭州火石数智科技有限公司创始人

YANG Hongfei
Founder of Hangzhou AIMed Technology Co., Ltd.

连续创业者
智能医学机器人整体解决方案总工程师
HSMAP 全球医健创业地图的设计者
承担过多个 863 计划，科技部、发改委产业专项
2018 年杭州唯一青年创业领军团队核心成员

Serial entrepreneur Chief engineer of Intelligent Medical Robots
Designer of “HSMAP” Global Healthcare Startup Map As the project leader, undertook many 863 programs, as well as projects with MOST and NDRC Core member of the only Hangzhou Leading young entrepreneurial team in 2018

罗佳荣
广发证券发展研究中心生物医药行业首席分析师

LUO Jiangrong
Chief Analyst of Healthcare Sector at GF Securities

罗佳荣，广发证券发展研究中心生物医药行业首席分析师，曾任申银万国证券研究所有限公司生物医药首席分析师，近十年医药行业二级市场研究经验，带领团队获得 2019 年东方财富最佳分析师生物医药行业第一名，新财富最佳分析师第五名；2018 年中国保险资产管理业最受欢迎卖方分析师第三名；2017 年中国保险资产管理业最受欢迎卖方分析师第三名，新财富最佳分析师第 5 名。对创新药、生物药、创新疫苗、CRMO、医药流通等细分子行业有相对完备的跟踪和覆盖，对恒瑞医药、药明康德、长春高新、通策医疗等行业龙头公司有长期的研究。毕业于上海财经大学财务管理硕士，南京大学化学系本科。

Luo Jiarong is the chief analyst of Healthcare Sector at GF securities, was formerly the chief analyst of Healthcare Sector at SWS Research. He has almost ten-year equity research experience in pharmaceutical industry in secondary market, and led team into winning the first place in 2019 Eastmoney Best Analyst in Biological & Pharmaceutical Industry, the fifth in 2019 New Fortune Best Analyst, the third in 2018 IAMAC Most Popular Sell-Side Analyst, the third in 2017 IAMAC Most Popular Sell-Side Analyst, and the fifth in 2017 New Fortune Best Analyst. He has relatively complete following and coverage in sub-industries including innovative drugs, biological drugs, innovative vaccines, CRMO, medicine circulation, and has long-term research experience in leading enterprises such as Hengrui Medicine, Changchun High-tech, WuXi AppTec, and so on. He obtained the master degree in financial management from Shanghai University of Finance and Economics, and bachelor degree in chemistry from Nanjing University.

李林康
中国罕见病联盟执行理事长、全国罕见病诊疗协作网办公室副主任

LI Linkang
Executive Director of China Alliance for Rare Disease
Deputy Head of Bureau of National Rare Disease Diagnosis&Treatment Network

李林康，男，法学硕士。中国罕见病联盟执行理事长、全国罕见病诊疗协作网办公室副主任、国家卫健委罕见病诊疗与保障专家委员会副主任委员兼办公室主任、中国医院协会副会长、北京罕见病诊疗与保障学会会长、《中国药房》杂志编委会主任委员等职务。
历任国家卫生健康委员会医政医管局巡视员、中纪委驻国家卫健委纪检组正局级纪律检查员等职务。在罕见病防治与保障政策领域有一定认识与研究。组织参与开展了《 2019 年中国罕见病患者综合社会调查》、《罕见病药品医保准入和动态调整影响分析》、《中国罕见病用药保障制度建设与医保基金影响分析》等研究课题。参与编写了《2019 年中国罕见病药物卫生技术评估专家共识》等著作。

Li linkang, a master of law. Executive Director of China Alliance for Rare Diseases, Deputy Head of Bureau of National Rare Disease Diagnosis&Treatment Network, Deputy Commisioner/Bureau Head of the Committee of Diagnosis&Treatment of Rare Disease, Vice Resident of China Hospital Association, President of Beijing Society of Diagnosis&Treatment of Rare Disease、Chairman of the Editorial Board of Journal of China Pharmacy.
Worked as Chief Inspector of the Medical Administration and Hospital Authority of National Health Care Commission, Chief Discipline Inspector of the Central Commission for Discipline Inspection in the National Health and Family Planning Commission, etc.
He's been devoting himself to the Diagnosis&Treatment of Rare disease, as well as the protection of the rights of the patients and their families, and become knowledgeable in this area. Led the projects of <Social Surveys of Rare Disease Patients in China 2019>, < Analysis on the Impact of Access and Dynamic Adjustment of Medical Insurance for Rare Disease Drugs >, <Analysis on the Impact of Construction of Medication Security System for Rare Diseases and the Medical Insurance Fund in China>, etc. Participated in the drafting of <Consensus of Experts on Health Technology Assessment of Rare Diseases in China 2019> and others.

赵　琨
国家卫生健康委药物与卫生技术评估中心副主任

ZHAO Kun
Director of Division of Health Policy Evaluation and Technology Assessment of the National Health Development Research Center

赵琨，研究员，国家卫生健康委药物与卫生技术评估中心副主任。现任中国卫生技术评估专业委员会副主任委员 / 秘书长、ISPOR 亚太区主席（2018–2020）、国际疾病优先控制领域咨询委员会委员、亚洲卫生技术评估联盟董事会成员。曾任 ISPOR 卫生技术评估委员会委员及 2014–2016 年亚洲联盟主席。主持开展国家卫计委分级诊疗体系建设第三方评估、世界卫生组织中国乙肝丙肝治疗经济学评价、非小细胞肺癌二线靶向治疗卫生技术评估、细胞免疫治疗技术评估、疫苗接种预防慢阻肺急性发作的经济评价、达芬奇手术机器人技术评估、质子重离子放射治疗设备技术评估等。作为第一作者及通讯作者在核心杂志上发表文章 80 余篇，作为主编出版了《卫生技术评估与政策评价—理论与方法篇》和《卫生技术评估与政策评价—实证篇》。

Dr. Kun ZHAO (professor) is the director of Division of Health Policy Evaluation and Technology Assessment of the National Health Development Research Center (affiliated to National Health Commission of China). She is currently holding several positions, including vice committee chair/ Secretary General of China HTA Committee, ISPOR AP Chair (2018-2020), member of ACE of Disease Control Priorities and HTAsiaLink board membe, Asianet HTA Chair (2014-2016). She has led several assessment programs, such as NHC third-party evaluation of tiered diagnosis and treatment regime , WHO project of Hepatitis B&C Therapy Economics in China, HTA for secondary line of targeted drug for NSCLC, cell immunotherapy, cost-effectiveness analysis of the vaccination preventing COPD from acute exacerbation, DaVinci surgical robot related therapy, proton and heavy ion therapy. Dr. ZHAO has published more than 80 articles on leading medical journals as the first and corresponding author. As chief author in the books of 《HTA & policy evaluation---theory chapter》and 《HTA & policy evaluation---practice chapter》.

刘军帅
国家罕见病诊疗与保障专家委员会委员

LIU Junshuai
Committee Member of National expert consultation committee of Diagnosis and Treatment of Rare Disease

现任国家罕见病诊疗与保障专家委员会委员、中国药促会医药政策委员会副主任委员、中国医促会健康保障分会常务理事、北京罕见病诊疗与保障学会副会长、北京病痛挑战基金会理事、罕见病发展中心高级顾问等职。

医学学士，工商管理硕士。1990 年毕业于第二军医大学，在部队医院从医十年；1999 年专业至地方政府从事医保改革工作十五年，是青岛医保众多改革创新项目的发起者与主要规划设计者。先后负责设计了医保三个目录、医保支付价、老年护理、医保社区医疗、医保 DTP 药房模式、高值药谈判及共付模式、大病救助、罕见病保障、慢病管理（烟草依赖项目）、三险合一（城乡同筹）、社保商保全面合作模式等项目。同期，参与了国家医改及相关部门的部分改革咨询与政策建议等工作。

现作为独立学者继续医改研究及健康产业研究等工作。

Mr. Junshuai Liu, Bachelor of Medicine, MBA. committee member of “National expert consultation committee of Diagnosis and Treatment of Rare Disease”, vice-Chinaman of Medicinal Policy Specialty Committee of PhIRDA, Managing director of Health care association of China international Exchange and Promotion Association for Medical and Healthcare, vice president of “Beijing expert consultation committee of Diagnosis and Treatment of Rare Disease”, Director of “Beijing Illness Challenge Foundation”, senior advisor of Center of Rare Disease

After graduation from the Second Military Medical University in 1990, Mr. Liu worked in military hospital for 10 years. In 1999, He moved to provincial government and started to lead medical care reform for 15 years. As the initiator and leading designer of multiple reform projects in Qingdao, he led the design of below major projects including “three medical insurance list”, “medical insurance payment price”, “elderly healthcare”, “medical insurance community medical treatment”, “medical insurance DTP drug store”, “high-value drug price negotiation and co-payment”, “major disease aid”, “rare disease treatment”, “chronic disease management (Tabaco dependence project)”, “unified insurance of the three major social insurance including elderly insurance, medical insurance and unemployment insurance (urban and rural co-financing)”, “comprehensive cooperation of social insurance and commercial insurance” and so forth. In the meantime, he participated in national medical reform projects and worked as policy consultant for relevant government departments

Mr. Liu currently continues the search and studies in the areas of medical reform and healthcare industry as independent scholar.

薛　群
北海康成制药有限公司董事长及首席执行官

James XUE
Chairman and CEO of CANbridge Pharmaceuticals Inc

薛群博士是一位具有国际视野和高度社会责任感并在美、中生物高科技制药领域积累了丰富实践经验的创业者和企业家。薛群博士于 2012 年创立了北海康成，一家专注于有严重临床需求的实体肿瘤和罕见病领域的新药创制企业。

在创办北海康成之前，薛群博士曾在美国健赞公司 (Genzyme) 工作长达十年之久，担任多个重要部门的高管并作为第一任总经理创建了健赞中国，领导了包括即复宁 ® 和思而赞 ® 在内的多个抗血液肿瘤和罕见代谢病特药的成功上市。

薛群博士拥有北京大学药学院学士，布朗大学生物有机化学博士，弗吉尼亚大学达顿商学院（Darden）工商管理学硕士，并从沃顿 –INSEAD 联合营销管理培训班结业。薛群博士是中国罕见病联盟副理事长，上海市罕见病防治基金会副理事长，中国药促会理事和研发专委会委员，北京大学医学部 – 密西根大学医疗系统联合学院理事会理事，百华协会会员及波士顿分会创建人。

Dr. James Xue has spent 20+ years in pharmaceutical industry and is the founder, chairman & CEO of CANbridge Pharmaceuticals Inc., a bio-tech company focused on oncology and rare disease. He holds a B.S. in Pharmaceutical Chemistry from Peking University School of Pharmacy, a Ph.D. in Bioorganic Chemistry from Brown University and a M.B.A. from Darden School of Business, University of Virginia. He is deputy director general of China Alliance for Rare Disease (CARD) and Shanghai Foundation for Rare Disease, a R & D Committee Member of China Pharmaceutical Innovation and Research Development Association (PHIRDA),a member of the Advisory Committee of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School. He is a member of BayHelix Group and founding member of BayHelix Boston Chapter.

肖　啸
华东理工大学教授、信念医药董事长

XIAO Xiao
ECUST Professor, BBM President

肖啸，现任美国北卡罗莱纳大学杰出讲席教授，华东理工大学药学院生物工程学院教授。2017 年人才引进华东理工大学药学院和生物反应器工程国家重点实验室，建立基因治疗新药研发团队。肖啸教授在基因载体的研发及应用方面取得了多项科研成果并得到广泛应用，其中包括重组腺相关病毒（AAV）基因载体的改进，简易高效的基因载体靶向技术以及遗传性病基因药物开发等。肖啸教授作为创始人创建了 Askbio、Bamboo 和信念医药科技等基因治疗公司，其发明的用于治疗杜氏肌营养不良（DMD）的基因治疗药物，已通过辉瑞制药公司实现临床转化，目前已进入 III 期临床。肖啸教授多年来担任多种国际重要学术期刊的编委和美国 NIH 基金评委，还担任过美国基因与细胞治疗学会董事会成员。

Dr. Xiao Xiao is a Fred Eshelman Distinguished Professor in Eshelman School of Pharmacy, the University of North Carolina at Chapel Hill (UNC), and professor in School of Pharmacy and School of Biotechnology, East China University of Science and Technology (ECUST). Since 2017, he has been working in East China University of Science and Technology and built up a research and development team work on recombinant adeno-associated virus (AAV) gene therapy drugs. Dr. Xiao Xiao has a lot of innovations and inventions in the field of AAV gene therapy. He has remarkable achievement in invention of tissue targeted AAV vectors, innovation of production process of AAV gene drugs, and many rare disease treatment by AAV gene drugs, etc., as well as the genetic muscle disease, hemophilia, lysosome storage diseases, heart diseases and so on. Dr. Xiao Xiao was the founder of Asklepios BioPharmaceutical, Inc. (US), Bamboo Therapeutics, Inc. (US) and Belief BioMed Co., Ltd. (CN). He developed the mini-dystrophin gene drugs that had been transferred to Pfizer for treating Duchenne muscular dystrophin (DMD), which is preparing for a global phase III clinical trial. Dr. Xiao Xiao has been the member of the editorial board of several international journals, the scientific expert of NIH foundation peer review in the United States, and the member of the board of directors of The American Society for Gene and Cell Therapy.

王奕鸥
北京病痛挑战公益基金会秘书长 / 创始人

Yoyo WANG
Founder and Secretary-General, the Illness Challenge Foundation (ICF)

王奕鸥，病痛挑战基金会秘书长、瓷娃娃罕见病关爱中心创始人、长江商学院 EMBA，罕见病人士。近十二年来一直致力于推动罕见病问题解决和罕见病社会认知的进步。2008 年，开创瓷娃娃，提高了罕见病、国际罕见病日在中国的公众认知。2014 年带领瓷娃娃团队与新浪微博共同将“冰桶挑战”成功策划并落地中国，募集上千万资金，帮助渐冻人等罕见病群体近千人。2016 年，与南都公益基金会共同发起成立了病痛挑战基金会，为罕见病领域搭建平台，探索通过跨界、创新、联合的方式撬动复杂的罕见病问题解决。

Yoyo Wang is the founder and Secretary-General of the Illness Challenge Foundation,the founder of China-Dolls Center for Rare Disorders (CCRD), and EMBA alumnus of Cheung Kong Graduate School of Business. Being one with rare disorder, she has always been working on helping people with rare disorders like herself and raising social awareness of this group of people in the past 10 years. She founded CCRD in 2008 and got more attention from the society on the Rare Disease Day. Six years later, CCRD brought the “ALS Ice Bucket Challenge” in China and raised over 10 million RMB to help Chinese people suffering from ALS. In 2016, Yoyo established the Illness Challenge Foundation, a platform to help people with rare diseases, together with the Narada Foundation.

黄积严
深圳证券交易所上海中心江苏区域负责人

HUANG Jiyan
Head, Jiangsu Province, Shanghai Center, Shenzhen Stock Exchange

北京大学法律硕士，现任深圳证券交易所上海中心区域副主任，曾任职于法院、知名互联网公司、律师事务所等，加入深交所后，先后负责华北、东北、华东地区的企业培育工作，具备丰富的企业上市服务经验。

邱凌龙
深圳证券交易所上海中心区域主任

QIU Linglong
Director, Shanghai Center, Shenzhen Stock Exchange

曾任职于证监会发行部、深交所创业板公司管理部，现为深交所上海中心区域主任，熟悉资本市场规则与企业上市筹划。

谢立恒
浙江维康药业股份有限公司董事、董事会秘书、财务总监

XIE Liheng
Director & Board Secretary & CFO, Zhejiang Wecome Pharmaceutical Company Limited

1983 年 7 月出生，中国国籍，无境外永久居留权，硕士学历，注册会计师，会计师职称。曾经在天健会计师事务所从事审计工作，参与了很多企业的上市审计业务，积累了丰富的审计经验；后又在银江股份有限公司（股票代码：300020）任职，历任财务经理、财务副总监、浙江银江智慧交通集团有限公司副总裁兼财务总监；2015 年 1 月起担任浙江维康药业有限公司财务总监；2015 年 3 月至今担任浙江维康药业股份有限公司（股票代码：300878）董事、董事会秘书、财务总监。现在兼任丽水市第五届青年联合会委员。

汪　军
普华资本 合伙人

WANG Jun
Partner, Puhua Capital

汪军：2015 年杭州十大天使投资人新科技和新商业模式践行者
汪军先生毕业于华侨大学，上海交大 MBA，浙大药学院研究生。具有十年以上股权投资经验。专注于医疗服务、智能医疗、新药和 IVD 领域的投资。曾任杭州国家高新区的科技咨询公司、经纬中国资深投资经理，现任普华资本合伙人。主要关注领域为医疗服务、器械、新药和 IVD。
主导多个医疗项目投资，如：树兰医疗、佰辰医疗、水木未来、键嘉机器人、洛启生物、胡庆余堂、好孕帮、堃博、唯强等。参与多个项目的投资决策，如：南微医学、健耕医药、国邦医药、嘉禾生物等。其中南微医学已成功在上交所上市

曾　信
国信证券股份有限公司 首席风险官 内核负责人

ZENG Xin
GUOSEN SECURITIES CO., LTD CRO

曾信先生，国信证券股份有限公司首席风险官、内核负责人，中国证券业协会风险控制委员会秘书长。曾信先生从事投行及相关业务二十多年，主持并完成了广发证券、铜陵有色、新和成等一批项目的保荐融资工作，并主持完成了公司 200 多个保荐及相关投行项目的内核工作，对投行业务制度等理解深刻透彻，并长期跟踪资本市场各项制度变更带来的机会。曾信先生经手过九州通、天士力、佰仁医疗等多个医药行业项目的资本运作，对行业特性、价值判断有一定心得。

Mr. Zeng Xin is the Chief Risk Officer and the Chief of the Internal check of Guosen Securities Co., Ltd, and the Secretary of the Risk Management Committee of the China Securities Industry Association. Mr. Zeng Xin, has engaged in the investment banking and related business for more than 20 years, presided over and completed the sponsor such as Guangfa Securities, Tongling Nonferrous Metals Group, NUH and etc, and presided over more than 200 sponsors and related investment banking projects of the internal check, baring deep understanding of the investment banking system and long-term tracking the opportunity brought by for the changing of capital market system. Mr. Zeng Xin, who has worked with Jointown, Tasly and Balance Medical various pharmaceutical industry projects in the capital operation, he is familiar with the characteristics of the industry and the value judgment.

张　凌
摩根大通全球投资银行中国区医疗健康与科技行业主管、董事总经理

ZHANG Ling
Managing Director, Head of China Healthcare Investment Banking

张凌先生于 2019 年重新加入摩根大通并担任全球投资银行中国区医疗健康与科技行业主管、董事总经理。张凌先生拥有超过 20 年的投资银行工作经验，主要专注于医疗行业。在加入摩根大通之前，张凌先生担任华大基因首席运营官，并在此期间主导完成了 2017 年华大基因于深交所的上市挂牌。在此之前，张凌先生曾担任过摩根大通中国医疗行业投资银行部主管，也曾任职于花旗银行投资银行部董事总经理。张凌先生拥有西北大学凯洛格学院 MBA 学位和南开大学经济学专业本科学位

Ling Zhang re-joined J.P. Morgan in 2019 as Managing Director, Head of China Healthcare Investment Banking. Ling has over 20 years of experience in investment banking, primarily focusing on healthcare. Prior to this, Ling worked as Chief Operating Officer at BGI Genomics, where he led the successful IPO in 2017. He also worked as Head of China Healthcare Investment Banking at J.P. Morgan and as Managing Director at Citibank Investment Banking. Ling holds Bachelor of Economics from Nankai University and MBA from Kellogg School of Management, Northwestern University.

蔡大庆
夏尔巴投资创始管理合伙人

Darren CAI
Founder & Managing Partner, Sherpa Venture Capital

在参与设立夏尔巴投资之前，他在君联资本担任董事总经理，是医疗投资团队负责人之一。
蔡大庆先生专注于健康医疗领域的投资，他主导投资的项目包括贝瑞基因 (000710.SZ)、信达 (HKE: 01801)、诺辉、Shenogen、瑞博、Axonics (NASDAQ：AXNX)、BioNano (NASDAQ：BNGO)、和美、派格、纳米维景、诺思格、志道生物、麦默真空、信念、辉大等多家领先的健康医疗企业。
蔡大庆先生曾多次被评为中国医疗健康投资前十名，2017 年及 2019 年被评为福布斯中国最佳创投百人之一，并在 2018 年当选中国医疗投资 50 人论坛 (H50) 轮值联席主席。
加入君联资本之前，蔡大庆先生在软银投资集团 (SBI Group) 与北大青鸟合资的 SBI−BDJB Investment（青鸟思倍投资）担任常务董事 (Managing Director)。蔡先生也曾在中化（香港）、美国博思咨询等公司担任高管。他还曾出任华大基因 (300676.SZ) 董事、CFO 等职务。
蔡大庆先生在美国加州伯克利大学获得博士学位，在美国耶鲁大学获得 MBA 学位，在中国科学技术大学获得理学学士学位。

Dr. Daqing (Darren) CAI is a founder/Managing Partner of Sherpa Healthcare Partners.
Before establishing Sherpa Healthcare Partners, he was a Managing Director at Legend Capital and a leader of the Healthcare investment team.
Dr. Cai focuses on investment opportunities in the healthcare sector and he led investments in companies including Berry Genomics (SZSE: 000710), Innovent (HKE: 1801B), New Horizon, Shenogen, BioHermes, Ribo, Axonics (NASDAQ: AXNX), BioNano (NASDAQ: BNGO), Hemay, PegBio, NanoVision, Leto Labs, Memoray, Belief Bio, Hui Gene, and many others.
Dr. Cai received multiple awards for Top 10 Healthcare Investors in China. He was one of Forbes Best VC Investors in China in 2017 and 2019. In 2018, he was elected Co-Chairman of Healthcare Investors 50 (H50, a top Chinese Healthcare investor organization) for 2018-19.
Prior to joining Legend Capital, Dr. Cai worked at SBI-SDJB, a joint venture fund of SBI Group and Beida Jadebird Group as a Managing Director. He also worked for SinoChem (Hong Kong) and Booz & Co. in senior management positions. He was a Board Director and CFO of Beijing Genomics Institute (300676.SZ) as well.
Dr. Cai holds a Ph.D. degree from University of California, Berkeley; an MBA from Yale University; and a B.S. degree from University of Science and Technology of China.

林　亮
礼来亚洲基金 合伙人

Stephen LIN
Partner, Lilly Asia Ventures

林　亮，礼来亚洲基金　合伙人
主导了疫苗、化学药、抗体药和 IVD 等多个创新企业的投资以及公司孵化，包括康希诺生物、凯因科技、迈博斯生物、圣湘生物、康诺亚、深圳原力、迪哲医药和典晶生物等。 此前他先后在三九医药创建了战略规划部并领导公司战略规划与业务拓展，在默克－雪兰诺（中国）负责核心产品的市场营销，在葛兰素史克（中国）从事企业收购兼并以及产品的引进和对外授权。拥有中国药科大学化学制药学士学位和药物化学硕士学位、中欧国际工商学院 MBA 学位及执业药师资格。

Stephen Lin, M.S., MBA
Stephen, the Partner at Lilly Asia Ventures, led the investments in companies of vaccine, small molecule, large molecule and IVD, including CanSino, Kawin, MabSpace, Sansure Biotech, ConMed, IonovaBio, Dizal, and Elumienx, et al. Before that, he worked as BD at GlaxoSmithKline (Great China), covering M&A and product licensing. Previously, he managed the marketing of a core product at Merck Serono (China). In Sanjiu Medical & Pharmaceutical, he set up and headed the Strategic Planning Department, driving corporate strategic planning and business development.
Stephen's education includes a Master of Science in Medicinal Chemistry and a Bachelor of Pharmaceutical Chemistry, both from China Pharmaceutical University. He also earned a Master of Business Administration degree (finance direction) from China Europe International Business School. A Licensed Pharmacist in China.

禤文欣
天健会计师事务所 合伙人

XUAN Wenxin
PAN-CHINA CERTIFIED PUBLIC ACCOUNTANTS PARTER

禤文欣女士，1979 年 1 月出生、2001 年 7 月参加工作，清华大学 EMBA、中山大学会计硕士、中山大学会计管理学士，资深中国注册会计师、注册税务师、国际注册内部审计师、财政部会计领军后备人才，现任天健会计师事务所（特殊普通合伙）合伙人。成功主持星期六、西陇科学、浩云科技、广弘控股、原尚股份、方邦电子、通达电气、若羽臣等多家企业的股份制改制上市或再融资审计业务，目前服务的拟上市企业包括瑞博奥生物、科方生物、华银健康、朗肽制药、慧智微电子、万丈金数等十余家，拥有丰富的 IPO 审计经验。

Ms. Xuan Wenxin, born in January 1979, started her career in July 2001. She was once an EMBA at Tsinghua University, master of accounting at Sun Yat-sen University, and bachelor of accounting management at Sun Yat-sen University. She is a senior Chinese certified public accountant, a certified tax accountant, an international certified internal auditor, and an accounting elite selected by the Ministry of Finance. Ms. Xuan is currently a partner of Tianjian Certified Public Accountants (Special General Partnership). She successfully handled auditing tasks for the shareholding restructuring IPO or refinancing by many companies such as Saturday, Xilong Scientific, Haoyun Technologies, Guanghong Holdings, Gensho Logistics, Fangbang Electronics, Tongda Auto, and Ruoyuchen Tech. She currently serves more than ten to-be-listed companies including Raybiotech, KOFA Biotechnology, Huayin Health, Longtime Pharmaceutical, Smarter Micro, and Infinite. She has extensive IPO auditing experience.

王昭艳
金杜律师事务所合伙人

Joanne WANG
Partner, King & Wood Mallesons

王昭艳律师的主要执业领域为企业上市、基金设立、基金投资、投融资等法律服务。
王律师曾为多家公司境内外上市提供法律服务，能够参与设计重组、改制方案，协助客户规范公司治理，并能从资本市场运作的角度为不同阶段的客户提供整体建议。
王律师在私募股权基金领域有非常丰富和独特的经验，熟悉基金设立、基金投资以及基金投资后管理的全流程；曾多次代表基金管理人和投资者设立或投资人民币私募股权基金，为多家私募基金的架构设计、风险控制和投资运作提供意见，并曾在诸多私募股权融资、风险投资项目中为投资人或融资方提供法律服务。王律师还担任多家知名投资机构、母基金的常年法律顾问。
王律师熟悉生物医药、先进制造、互联网、教育、消费品等多个行业。

Ms. Wang specializes in IPOs, fund formation, PE/VC investment, investing and financing.
Ms. Wang has provided legal service and advice on numerous enterprises' domestic and overseas IPOs. Ms. Wang also can advise on the company's restructuring and reorganization, help clients with corporate governance and provide comprehensive advice to customers from the perspective of capital market.
Ms. Wang has extensive practical experience in private equity funds, and is familiar with the whole process of fund formation, PE/VC investment and post-investment management. She has represented many fund sponsors and investors in their formation or investment of RMB private equity funds. She also has advised a number of funds on fund structure design, risk control and fund operation. Besides, Ms. Wang has provided legal service to PE/VC investors or the target companies in quite a few PE/VC investment transactions. Moreover, she has served as the external legal counsel for a number of investment institutions and FOFs.
Ms. Wang is familiar with the legal service regarding the industries such as bio-medicine, high-end manufacturing, TMT, education, consumption products.

龚兆龙
思路迪医药董事长兼 CEO

John GONG
Chairman & CEO of 3D Medicines Inc.

龚兆龙博士 1984 年毕业于北京医学院，1996 年获美国纽约大学博士学位。1996 至 1998 年在美国国立卫生研究院（NIH）从事博士后研究工作，1998 至 2008 年任美国食品药品监督管理局（FDA）新药审评员，2008 年回国先后担任昭衍新药研究中心首席技术官、北京莱博药业 CEO、百济神州新药开发和药政事务副总裁。龚博士专注于创新药研发二十余年，从审评审批、CRO 服务，和企业自主研发不同角度参与创新药研发和审评全过程，并带领团队开展多项处于临床及商业化阶段的创新药研发工作。龚博士是 DIA 中国区顾问委员会委员，中国临床肿瘤学会（CSCO）临床研究专家委员会委员，中国医药创新促进会药物临床研究专业委员会委员，中国新药杂志编委，药学进展杂志编委。

Prior to joining 3DMed, Dr. Gong served as VP of Drug Development and Regulatory Affairs of BeiGene, CEO of BL Pharma, and CTO of JOINN Laboratories. Dr. Gong has spent the last 20 + years focused on new drug R&D, and has extensive experience with the new drug review and approval process, CRO services, and research and development. He has led multiple new drug development programs into clinical stage and commercial phase. From 1998 to 2008, Dr. Gong worked as a reviewer for 10 years at the US FDA. He is a committee member of DIA China, CSCO and the Chinese Pharmaceutical Association, and a member of the editorial board of the Chinese Journal of New Drugs and the Journal of Progress in Pharmaceutical Sciences. Dr. Gong received his Ph.D. from New York University in 1996 and a medical degree from Beijing Medical College in 1984.

赵孝斌
浙江海昶生物医药有限公司创始人

Ben ZHAO
Founder of Zhejiang Haichang Biotech Co., Ltd.

赵孝斌，浙江海昶生物医药有限公司创始人，2010 年受聘为 FDA 药审中心资深审评员，主管复杂药物制剂审批，重点审查核酸、多肽、脂质体等复杂药物的 CMC 一致性评价及其 cGMP 质量系统，并参与了 FDA 的纳米药物法规指南协调工作组，制订多项脂质体相关药物的申报指南。拥有 FDA Level III（最高级别）药物现场核查员资格证书，2013 年获 FDA 药审中心特别成就奖、FDA 风险评估试验项目组奖。为 NSF 国家纳米中心专家组成员。赵博士毕业于俄亥俄州立大学获药学博士，曾工作于上海医工院、雅培、James 肿瘤医院等机构，其主要研究领域为小核酸药物、肿瘤靶向治疗等。

Ben Zhao is founder and CEO of The WhiteOak Group Inc. (TWG). Prior to TWG, Dr. Zhao is a CMC reviewer and GMP inspector specialized in complex drugs at the US FDA. In 2014, he founded TWG and devoted to developing high-quality liposomal drugs with rational design. Previously, Dr. Zhao was a group leader in developing small interfering RNA (siRNA) at Abbott Laboratories. In China, he developed the first generic liposomal doxorubicin (Libaoduo®) in 2008. Dr. Zhao is an inventor of 12 patents and has published over twenty peer reviewed articles. He also serves as an Advisory Board member for the NSF Nanotechnology center. Dr. Zhao was trained as a medical doctor at Norman Bethune University of Medical Sciences and received a Ph.D. degree from the Ohio State University.

温　弘
元生创投首席科学家

WEN Hong
CSO of Yuanbio Venture Capital

温弘，同写意法规俱乐部理事、元生创投首席科学家、中国临床肿瘤学会转化医学专委会常务委员。在药物研发转化医学领域有丰富的经验。加入元生前，任丽珠医药集团首席科学家。2013 年到 2018 年，担任美国 FDA 科研领头人和资深审评，负责法规制定、复杂药物综合审评、药物上市后调查及 NDA/ANDA/DMF/CP/CC 审评，以及相关领域的科研项目立项、审核和指导。加入 FDA 前在美国医药工业（诺华和惠氏）的 11 年中，主持或参与了 32 个临床阶段药物的研发和申报，有 9 个新药已获得批准上市（其中多个年销售额超过 10 亿美元）。温弘博士于 2002 年获得美国普度大学药学博士，发表超过 70 论文 / 专利 / 学术报告，于 2010 年编辑出版了控释制剂专著。温博士曾在 FDA 多次获奖，也得到诺华的最高科学奖 Novartis Leading Scientist。

Dr. Hong Wen, Director of Tongxieyi Regulatory Sciences Club, CSO of Yuanbio Venture Capital, Executive Member of Translational Medicine Committee of Chinese Society of Clinical Oncology (CSCO) . Dr. Hong Wen has extensive experiences in drug R&D especially translational medicine. Prior joining Yuanbio, he has been the CSO of Livzon Pharmaceuticals Group. From 2013 to 2018, he was a scientific lead and senior reviewer for the US FDA, responsible for FDA Guidance development, complex drug product reviews, and post-marketing investigations, as well as NDA/ANDA/DMF/CP/CC reviews. He was also responsible for the initiation, audition and guidance of relevant research grants and contracts. Prior to joining FDA in 2013, Hong has worked 11 years in pharmaceutical industry (Novartis and Wyeth) and has led and contributed to the clinical development of 32 new drugs, of which 9 NDA approvals in Europe and USA. In 2002, he received his Ph.D. in Industrial and Physical Pharmacy from Purdue University. Dr. Wen has been recognized multiple times at the FDA, and has received “Novartis Leading Scientist” award, Novartis’ highest scientific recognition.

Audrey JIA
德顺达医药咨询服务公司董事总经理

Audrey JIA
Managing Partner of DataRevive USA LLC

Audrey JIA，北京大学医学学士，约翰霍普金斯大学生物法规硕士，埃默里大学分子遗传学博士，具有美国医生执照。贾博士在生物药物开发和监管审查方面拥有 20 年的综合经验，曾在 Pfizer, AbbVie 和 PDL BioPharma 从事单克隆抗体的工程、人源化、亲和力成熟、工艺开发长达十年。在美国 FDA 期间，贾博士是评估生物制品的全职 CMC 评审员，进行过大量 IND、BLA 评审，以及美国和国际 cGMP 上市申报核查，特别是新型蛋白质、抗体和生物仿制品的评审。贾博士也是 FDA 在突破性治疗政策发展方面的重要成员，对于快速通道、突破性疗法的法规要求，及通过快速途径开发药物非常熟悉。2016 至今，贾博士任中美知名法规咨询公司 DataRevive 的首席法规专家，成功为许多亚美欧公司申报美国的临床 IND、上市申报及 GMP 核查。

Dr. Jia holds a Master degree in Bioscience Regulatory Affairs from Johns Hopkins University, and a Ph.D. degree in Microbiology and Molecular Genetics from Emory University. Prior to that, Dr. Jia obtained her Bachelor degree of Medicine from Peking University.

Dr. Jia has 20 years of combined experience in biologic drug development and regulatory review. Dr. Jia spent 10 years from year 1999 to year 2009 in the biopharmaceutical companies working on monoclonal antibody engineering, humanization, affinity maturation, expression, and purification. During her time in US FDA from year 2009 to 2015, Dr. Jia was a full time CMC reviewer for IND/BLA review of biological products including antibody fragments, fusion proteins, antibody drug conjugate, combination products, and radiolabeled antibodies. She performed numerous IND reviews, BLAs (including post approval reviews), and several US and international cGMP pre-approval inspections (PAIs). She is specialized in both novel proteins/antibodies and biosimilar products reviews.

Dr. Jia currently leads a regulatory consulting firm (DataRevive USA LLC) for drug and biologic products. She has helped many companies filed their US INDs/BLAs successfully.

陈少羽
美国安诺波特律师事务所驻上海代表处管理合伙人

CHEN Shaoyu
Managing Partner of Arnold & Porter LLP Shanghai Rep. Office

陈少羽律师是美国安诺波特律师事务所驻上海代表处管理合伙人，律所总部在美国首都华盛顿，拥有超过 1000 名律师，在美国，欧洲，和亚洲共有 14 个办公室，为客户提供全球性的法律服务。

陈律师曾经在美国 FDA 马里兰总部担任助理首席律师 (2000−2004), 以及在美国安进公司加州总部担任高级法律顾问 (2006−2010)。陈律师毕业于北京大学，目前持有美国首都华盛顿的律师执照。

陈律师精通中美两国的药品和医疗器械的监管法律，拥有 20 年的丰富经验，擅长为制药企业和医疗器械公司在中国和美国的业务活动保驾护航，通过解决各种重大法律问题，帮助公司制定关键战略方向和实施方案，进行融资上市、合资合作、技术转让、专利许可，以及产品开发注册、生产和销售等重要业务活动。

Andrew Shaoyu Chen is the managing partner of the Shanghai office of Arnold & Porter LLP, which is a large international law firm headquartered in Washington DC, with over 1000 attorneys providing full legal services from 14 offices located in the US, Europe, and Asia.

Mr. Chen has 20 years of experience in food and drug law, including serving in the US Food and Drug Administration (2000-2004) in Rockville, Maryland, as Assistant Chief Counsel, and Amgen (2006-2010) in Thousand Oaks, CA, as Senior Counsel. Mr. Chen was born and grew up in China, graduated from Peking University, and received attorney license from Washington DC.

Leveraging this very unique experience, Mr. Chen has been effectively assisting life sciences companies doing business in China and the US, ranging from Fortune 500 to midsize and small startups, to help them resolve the most challenging legal and regulatory issues.

杜　涛
汉佛莱医药顾问有限公司 CEO、首席顾问

Tom DU
Chief Advisor & CEO of Humphries Pharmaceutical Consulting Co., Ltd.

杜涛博士现任汉佛莱医药顾问有限公司 CEO 和首席顾问（合伙人）。杜博士毕业于天津医科大学，获得加拿大 McGill 大学病理学／药理学博士学位、美国哈佛大学博士后学位。杜博士曾在美国食品药品管理局（FDA）担任了将近 7 年的高级审评官员，审评过一百多个药品的 IND 和 NDA。

杜博士离开 FDA 后，曾先后担任过美国联合健保中国区首席代表和全球医药产品注册部高级总监，以及香港和记黄埔医药的临床和注册部高级总监。杜博士于 2004 年进入顾问行业，并参与创立了美国汉佛莱医药顾问有限公司（HPC)。近年来曾为多家中美医药风险投资企业和欧美大型投资机构提供过医药投资咨询服务（如：摩根斯坦利，KKR,EQT 等）。他曾在两家北美的上市公司担任过独立董事，并参与了多家公司在北美的融资、并购和上市。

Dr. Du is currently the CEO and chief consultant (partner) of Humphrey Medical Consulting Co., Ltd.Dr. Du graduated from Tianjin Medical University, and then successively received a PhD degree in Pathology/Pharmacology from McGill University in Canada and a postdoctoral degree from Harvard University in the United States. Dr. Du served as a senior review officer in the US Food and Drug Administration (FDA) for nearly 7 years and reviewed more than 100 drugs IND and NDA.

Since Dr. Du left the FDA, he served successively as the chief representative of United Healthcare China, the senior director of the global pharmaceutical product registration department, and the senior director of the clinical and registration department of Hutchison Whampoa Pharmaceuticals in Hong Kong. Dr. Du has provided pharmaceutical investment consulting services for many Chinese and American pharmaceutical venture capital companies and large European and American investment institutions (such as Morgan Stanley, KKR, EQT, etc.). He has served as an independent director of two listed companies in North America and participated in the financing, mergers and acquisitions and listings of many companies in North America.

张晓夏
香港交易及结算所有限公司环球上市服务部副总裁

Sarah ZHANG
Vice President, Global Issuer Services, Hong Kong Exchanges and Clearing Limited

张晓夏女士于 2011 年加入香港交易所上市部首次公开招股交易组，主要负责审阅新上市申请及相关上市政策研究工作。张女士于 2015 年 8 月转至北京代表处，现任环球上市服务部副总裁，服务于中国大陆地区拟上市企业，并与相关政府机构、行业协会及金融业界保持密切联系。

Ms. Zhang joined the Listing Department of HKEx in 2011 and was responsible for processing applications for IPO listing application, and coordinating listing policy initiatives and developments. Ms. Zhang internally transferred to Beijing Representative Office since August 2015. Her key focus is on market development introducing and promoting the HKEX IPO platform to corporates, investors and financial institutions in Mainland China.
Ms. Bao received her Master of Business Administration (Finance, General) from Peking University.

匡　明
智云健康创始人、CEO

KUANG Ming
Founder and CEO of ClouDr

智云健康创始人，毕业于上海交大与剑桥大学。曾任职强生亚太市场部负责人、全球战略部负责人；强生大中华区年度销售冠军。智云健康成立于 2014 年 12 月，是中国领先的一站式慢病管理和智慧医疗平台。目前，智云健康正通过自主研发的医院 SaaS 系统、药店 SaaS 系统以及先进的互联网医院平台，为全国近 2000 家医院，数万家药房提供服务，辐射 5 亿慢病患者。2019 年，智云健康联合中电数据建立国家级慢病大数据中心，以技术驱动智慧医疗进步，赋能医疗健康产业，让数字健康走进千家万户！
智云健康企业成就：荣获 2020 西湖论坛最佳智慧医疗平台奖；荣登胡润百富 2020 胡润中国瞪羚企业；荣登爱分析 2019 中国医疗科技创新企业榜 50 强榜；智云健康被评为 2019 国家高新技术企业；荣登 2019 德勤高科技高成长 50 强榜单第 14 名。

Founder & CEO of ClouDr. Graduated from Shanghai Jiao Tong University and the University of Cambridge. Former head of Johnson & Johnson Asia Pacific Marketing & Global Strategy Department and Annual Top Sales of Johnson & Johnson Greater China. Established on December 12, ClouDr is the leading one-stop chronic disease management and smart healthcare platform in China. Currently, ClouDr is serving nearly 2,000 hospitals, tens of thousands of pharmacies and 500 million patients with chronic diseases throughout the country with its independently developed SaaS systems for hospitals and pharmacies and advanced e-Clinic platforms.
In 2019, in collaboration with CEC Data, ClouDr launched a national big data center for chronic diseases, promoting progress of smart healthcare and empowering medical and healthcare industry with technology, and bringing digital healthcare to every household.
Company's achievements:Honored with the best smart medical platform by 2020 iFHi;Listed among the Hurun China Mountain Goats 2020 by Hurun Report;Listed among the top 50 medical technology innovation enterprises in China 2019 released by digital consultancy ifenxi;Honored with the title of a national high-tech company;Ranked 14th in the list of top 50 fast-growing high-tech companies released by global consultancy Deloitte;

马　健
晶泰科技首席执行官

MA Jian
CEO, XtalPi Inc.

马健是晶泰科技的联合创始人、CEO，浙江大学理论物理学博士，美国麻省理工学院博士后，在量子计算领域有丰富的研究成果。2014 年，他与合作伙伴共同创立药物研发科技公司晶泰科技（XtalPi），带领团队将学术成果产业化，基于前沿量子物理、计算化学、人工智能与云计算技术，为全球创新药企提供智能化药物研发服务，通过提高药物研发关键环节的效率与成功率、降低研发成本，为患者带来更多优质的药物。

在马健的带领下，晶泰科技与数十家跨国药企及科研机构建立深度合作，被摩根士丹利列为亚太地区数据驱动药物研发的标杆，全球人工智能药物研发公司的典型。2019 年，马健被评为《麻省理工科技评论》“35 岁以下科技创新 35 人”并获得首届 AI 新药开发者大会“中国 AI 新药开发最佳 CEO”称号。

Jian Ma is the co-founder and CEO of XtalPi, a PhD in theoretical physics from Zhejiang University, and a postdoctoral fellow at Massachusetts Institute of Technology. He has rich research results in the field of quantum computing. In 2014, he co-founded XtalPi, a drug research and development technology company with his partners, and led the team to industrialize academic achievements, based on cutting-edge quantum physics, computational chemistry, artificial intelligence and cloud computing technology. XtalPi's vision is to provide intelligence for global pharmaceutical companies, by improving the efficiency and success rate in drug research and development, and reducing research and development costs, bringing more high-quality drugs to patients in the future.

Under the leadership of Jian Ma, XtalPi has established in-depth cooperation with dozens of multinational pharmaceutical companies and research institutions. XtalPi was also listed by Morgan Stanley as a pioneer for data-driven drug R&D in the Asia-Pacific region and a representative of global AI drug R&D companies. In 2019, Jian Ma was named "35 Under 35 in Innovation & Technology" by "MIT Technology Review" and was awarded the title of "Best CEO of China's AI New Drug Development" at the first AI new drug developer conference.

游向东
浙商创投股份有限公司董事、管理合伙人、执行总裁

YOU Xiangdong
Managing Partner, Zheshang Venture Capital Co., Ltd.

游向东，浙商创投股份有限公司董事、管理合伙人、执行总裁，浙商总会大健康委员会执行主席，主任医师、教授、硕士生导师，原任浙江大学医学院附属第二医院副院长、心脏中心副主任、心脏超声主任。自 2016 年 1 月加入浙商创投股份有限公司以来，成功投资了千麦医疗、明视康、阳光眼科、太美医疗、术创机器、浙江归创、和铂医药、联川生物、普罗亭、遂真生物、捷诺飞等 20 多个医疗项目。荣获第二届万物生长大会“2017 杭州投资人物”。2020 年，作为执行事务合伙人委派代表管理杭州启真未来创新股权投资合伙企业（有限合伙），重点投资领域包括浙江大学医学中心（包括浙大校友发起）创新临床技术、生物医药、医疗器械等，推动浙大医学中心创新项目产业化，打造国际医学创新高地。

The director, managing partner and executive president of Zheshang Venture Capital Co., Ltd. The executive chairman of the general health committee of General Association of Zhejiang Entrepreneurs, the chief physician, professor and master's supervisor. He was the vice president of the Second Affiliated Hospital of Zhejiang University Medical College, the deputy director of the heart center, and the director of cardiac ultrasound. Since joining Zheshang Venture Capital Co., Ltd. in January 2016, it has successfully invested in more than 20 medical projects, including Chain Medical, Bright vision, Yangguang Ophthalmology, Taimei technology, SS Innovations, Zylox, Harbour Biomed, LC Bio Tech, Plt tech, Life real, Regenovo etc. It was awarded the "2017 Hangzhou investment figure" of the second world growth conference. In 2020, as an executive partner, he appointed a representative to manage Hangzhou Qizhen future innovation equity investment partnership (limited partnership). The key investment fields include innovative clinical technology, biomedicine, medical devices, etc. of Zhejiang University Medical Center (including those initiated by Zhejiang University Alumni), so as to promote the industrialization of innovation projects of Zhejiang University Medical Center and create an international medical innovation highland.

赵　璐
太美医疗科技董事长兼首席执行官

ZHAO Lu
Chairman & CEO, Taimei Technology

赵璐，太美医疗科技创始人，毕业于吉林大学分子生物学系与沈阳药科大学制药系，生物技术制药专业学士学位；复旦大学管理学院 / 台湾大学管理学院 EMBA 学位。2019 年加入第五期湖畔大学。
赵璐先生曾于上海医药集团和先灵葆雅公司从事销售管理、市场推广等工作，业绩杰出。2008 年，创立上海捷信医药科技股份有限公司，在国内患者管理领域业绩斐然，并挂牌新三板（股票代码 834294）。
2013，赵璐先生再次创建太美医疗科技。至今，公司成为生命科学产业数字化运营平台，获得众多国内外领先制药企业、医院 / 机构的青睐，多个产品市场占有率居全国第一。公司获得腾讯投资，经纬创投，元生资本，北极光创投，软银中国、凯风创投等顶尖 VC 的多轮投资。

Mr. Zhao holds the bachelor degree of biotechonolgy pharmacy from Jilin University - China / Shenyang Pharmaceutical University and EMBA from Fudan University/Taiwan University management college. Member of 2019 Hupan University.
Mr. Zhao has 10-year working experience in Shanghai Pharma Group and Schering Plough.
In 2008, Mr. Zhao established Jsure Health. With outstanding achievements in the field of patient recruitment, Jsure Health was listed on the new OTC Market (Symbol: 834294).
Mr. Zhao subsequently started Taimei Medical Technology in 2013 to develop digital operation platform in life science industry. Till now, Taimei has been obtained multiple rounds of investment from top VC such as Tencent, Matrix Partner, Genesis Capital, Northern Light, etc.

周　斌
零氪科技首席战略官

ZHOU Bin
Chief Strategy Officer of LinkDoc

周斌担任零氪科技首席战略官。他负责公司真实世界数据洞察部门，服务了多家临床阶段及上市阶段的药企客户。在加入零氪科技之前，周斌是麦肯锡医疗行业的咨询顾问，并且是麦肯锡数字化团队的早期创始团队之一。

Bin Zhou is Chief Strategy Officer of LinkDoc. He leads the RWD division and has served several clinical- and commercial-stage pharma clients. Prior to joining LinkDoc, Bin was part of the McKinsey's healthcare practice and one of the founding members of McKinsey Digital.

陈广宇
微医集团高级副总裁

Leo CHEN
Vice President of We Doctor Group

陈广宇先生目前任职微医集团高级副总裁，分管集团全国区域拓展及医疗器械事业群。拥有近 14 年医疗器械相关工作经验，10 年以上器械流通经验，擅长采购、分销，涉及骨科、心内介入、外科、麻醉科、眼科、神经外科等众多领域。

他曾担任华润医药集团医疗器械有限公司 CEO，管理近 2600 人团队，开展全国医疗器械业务布局，实施 LAP 新渠道项目，应对政策变化，通过渠道深耕，进行产品深度覆盖，运营管理 150 亿业务规模。并有效地在 2014 年引入带量招标采购理念，为医院做供应链服务，制定招标规则，成功实施招标，有效执行落地采购及分销管理制度。

Chen Guangyu currently serving as the senior vice president of We Doctor Group, in charge of the group's national regional expansion and medical device business group. He has nearly 14 years of medical device related work experience and more than 10 years of device circulation experience. He is adept in purchasing & distribution, covering many fields such as orthopedics, intracardiac intervention, surgery, anesthesiology, ophthalmology, neurosurgery, etc.

He was employed as the CEO of China Resources Pharmaceutical Group Medical Devices Co., Ltd., managed a team of nearly 2,600 people, carried out the national medical device business layout, implemented the LAP new channel project, responded to policy changes, deepened the channel, conducted in-depth product coverage, successfully operated and managed a 15-billion business. And he effectively introduced the concept of mass bidding procurement in 2014, providing supply chain services for hospitals, formulating bidding rules, successfully implementing bidding, and effectively implementing the procurement and distribution management system.

罗东滔
北京圆心科技有限公司联合创始人、副总裁、首席营销官

LUO Dongtao
Co-funder, Vice president, CMO, Beijing Yuanxin Technology Co., Ltd.

罗东滔，毕业于广东药科大学，中国人民大学医药行业 MBA。任中国医药物资协会常务理事；任中国医药物资协会院边及单体药店分会副会长；任中国卫生信息与健康医疗大数据学会健康服务与技术推广工作委员会常务委员。

2016.01−2017.07 期间，就职于三生制药，历任电子商务及患者管理部总监；互联网医疗公司 − 上海澳曦科技总经理。负责三生制药集团产品线上销售，患者管理及互联网医疗战略推进工作。

2008.10−2016.01 期间，就职于上海中信国健药业，历任南区商务经理 / 全国商务总监。负责商业渠道管理、政府事务、市场准入等工作。

1998.06−2008.09 期间，就职于三九医药，历任贸易公司销售主管、投资经理、连锁药房省级公司总经理助理、商品中心总监、分公司总经理等职务。负责临床推广、商务渠道、投资并购、医药批发 / 零售连锁公司运营管理工作。

Luo dongtao, graduated from Guangdong Pharmaceutical University and finished MBA degrees in pharmaceutical business in Renmin University of China.Luo not only is the managing Director of China Medical Materials Association,but also the vice President of the Hospital–neighboring and Independent Pharmacies Branch of Medical Materials Association.He is standing committee member of the Health Service and Technology Promotion council of China medical information and big data Association.

Luo was as hired as the Director of the online-business and patients management departments of 3SBio Inc. and the Chief Manager of Shanghai Aoxi Technology respectively. Responsibilities: in charging of the online sales of the products, patients management and strategic planning of online businesses.

Luo was as hired as the commercial Manager of Southern region and then the Chief Commercial manager of Shanghai CITIC Guojian Pharmaceutical Industry Co., Ltd. Responsiblities: managing commercial channels, government–related issues and market access.

He had been employed as the Director of Sales, Manager of investment, Manager Assistant of province-scaled chain Pharmacies, Director of Commercial Products and the Chief Manager of the trading subsidiary company of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd respectively. Responsibilities: in charge of clinical Promotion, Business Networking, investment M&A, wholesales and retail.

李　悦
医联高级副总裁

Diana LI
Senior VP of Medlinker

李悦女士拥有 20 余年医药行业经验，曾任默沙东中国副总裁、华北分公司总经理。
2018 年 1 月，李悦女士加入医联并担任高级副总裁一职，致力于推动互联网医疗领域创新模式在中国的实践与落地。在医联慢病管理业务的起步阶段，李悦女士创立了业务团队并与产业链上下游包括药企、药店、医院等诸多合作方一起，构建更加丰富的互联网医疗生态圈。

Ms. Yue LI has more than 20 years of experience in the pharmaceutical industry. She was previously Vice President of MSD China and General Manager of MSD North China.
In January 2018, Ms. Yue LI joined Medlinker and served as Senior Vice President, dedicated to promoting the practice and implementation of the innovative mode in the field of telemedicine in China. In the initial stage of chronic disease management business of Medlinker, Ms. Yue LI established a business team and worked with many partners in the upstream and downstream of the industry chain, including pharmaceutical companies, pharmacies, hospitals and so on, to build a more rich Internet medical ecosystem.

许小鸥
高盛（亚洲）有限责任公司直接投资部董事总经理

Kevin XU
Managing Director, Goldman Sachs Principal Investment Area

许小鸥先生现任高盛直投部董事总经理，负责亚太区（日本除外）的私募股权投资，主要关注医药、器械、诊断以及医疗服务领域的增长型和控股型投资。许先生 2010 年加入高盛，曾担任高盛中国投资银行部执行董事，负责国内外机构的战略并购以及资本市场业务。在加入高盛之前，许先生就职于美国康涅狄格州的对冲基金巴索资本（Basso Capital Management）。许先生持有英国剑桥大学的金融硕士学位以及美国马里兰大学的学士学位。

Kevin Xu is currently a Managing Director of Goldman Sachs Principal Investment Area (PIA), responsible for private equity investments in Asia (ex-Japan), with a focus on growth and buyout opportunities in pharma, device, diagnostics and healthcare services. Mr. Xu joined Goldman Sachs in 2010, and previously served as Executive Director for Goldman Sachs Investment Banking Division in China, where he was responsible for M&A as well as capital markets transactions for Chinese and foreign institutions. Prior to joining Goldman Sachs, Mr. Xu worked with Basso Capital Management, a Stamford Connecticut based hedge fund. Mr. Xu received his Master of Finance degree from the University of Cambridge in the UK and his B.A. from the University of Maryland in the US.

甄　岭
方恩医药董事长兼首席执行官

ZHEN Ling
Chairman and CEO, Fountain Medical Development

甄岭先生现任方恩医药的董事长兼首席执行官。方恩医药是一个致力于临床研发的为国内外创新医药企业提供全方位服务的临床 CRO。方恩在全球有 25 年运营历史，共计 1700 员工遍布全球 7 个国家 50 多个城市。

甄岭先生曾就职于德丰杰龙脉基金担任合伙人，负责医药健康领域的投资及投后管理。甄先生还曾就职昆泰医药 12 年 (Quintiles 全球最大的临床 CRO，后与 IMS 合并成立了全球最大的健康数据公司 IQVIA)，并担任全球高级副总裁兼大中华区总经理，负责其在大中华区的临床研发，数据，及咨询业务。

早年，甄先生曾分别就职于全球知名财务与咨询公司安勇，国际知名医药企业葛来素素史可和礼来的美国总部。

甄先生分别获得中国科技大学生物学士，美国印第安纳大学生化硕士和管理硕士，以及美国北卡罗莱那州立大学法学博士，并拥有北卡州律师执照。

Currently Ling serves as the Chairman and CEO of the Fountain Medical Development, a global full-service CRO headquartered in China with 1700 clinical research professionals in more than 50 cities and 7 countries around the world.

Previously, Ling was a partner at the Draper Dragon Venture Group , focusing on the investment and management of life science and healthcare companies in China and the US. Earlier, Ling had spent 12 years in Quintiles (the largest clinical CRO in the world and later merged with IMS Health to form the world leading human data science company called IQVIA), where he served as a global Senior Vice President and the General Manager in Greater China (including China, Hong Kong and Taiwan), to oversee clinical operation, data and consulting service in the region.

Prior to Quintiles, Ling also served in the Life Science Strategy Group of Ernst & Young in the US, Eli Lilly and GlaxoSmithKline in the US.

Ling received his Bachelor of Science degree from the University of Science and Technology of China□his Master of Science degree in biochemistry and Master of Business Administration degree from Indiana University at Bloomington in the US. Ling also holds a Juris Doctor degree from the Law School of North Carolina Central University and is a licensed attorney in the state of North Carolina in the US.

郭　彤
宝石花医药科技（北京）有限公司总裁

GUO Tong
President of Gem Flower Pharma Tech. (Beijing) Co., Ltd.

宝石花医药科技（北京）有限公司总裁。加拿大麦吉尔大学生物统计学博士，DIA 中国顾问委员会委员，大数据及人工智能领域专家及召集人，清华大学医学院健康领导力硕士班授课导师，中国药科大学硕士专业学位研究生校外导师。曾任艾昆纬副总裁及大中华区商务发展负责人，拥有 20 多年跨国制药公司及 CRO 临床运营，业务拓展，生物统计领域的管理经验。

Dr. Tong Guo is the CEO of Gem Flower Pharma Tech., an ARO based in Beijing. Dr. Guo was trained as a biostatistician with M.Sc. and Ph.D. degrees in Biostatistics from McGill University Canada. He was Vice President and Head of Business Development at IQVIA Greater China Region. Prior to his BD role, Dr. Guo was the Head of Biostatistics Africa & Asia and managed the off-shore Biostatistics functions at legacy Quintiles. Dr. Guo has more than 20 years of experience in managing teams in clinical operations, business development and biostatistics for multinational pharmaceutical companies and CRO. Dr. Guo serves as the member of the DIA Advisory Committee China (ACC). He is teaching at the Master Degree of Health Leadership Program at Tsinghua University School of Medicine.

黄 青
高特佳弘瑞投资董事长

HUANG Qing
Chairman, GTJA HongRui Investment

黄青女士是上海交大 MBA，中国私募股权投资领域的杰出代表。曾在西门子等多家知名企业任重要管理职位，拥有超过十五年的私募股权投融资经验，管理上百亿人民币基金的投融资业务，在上市资本运作、企业管理等方面具有丰富经验，对健康医疗、IT 信息等领域有极深刻的理解。

部分经典投资案例：复宏汉霖（02696）、贝斯达医疗（833638）、飞荣达科技（300602）、多普泰制药（831057）、京泉华科技（002885）、信质电机（002664）

个人荣誉：2020 年中国优秀女性直投基金投资人 TOP10、2019 年医疗健康中国最具公众影响力创业投资人物 TOP100、2016 年投中 −FT 中国卓越投资人 TOP100、2015 年中国风险投资榜单之新锐魅力领袖

Ms. Huang Qing holds an MBA degree and graduated from Shanghai JiaoTong University. She is an outstanding representative in the field of private equity investment in China, has held important management positions in many well-known enterprises such as Siemens. She has more than 15 years in private equity investment and financing experience. She has managed the investment and financing business of more than ¥ 10 billion funds. Ms. Huang Qing has rich experience in listed capital operation and enterprise management, and has a profound understanding of health care, IT and other fields.

黄逸宇
金杜律师事务所国际合伙人

Sam HUANG
International Partner, King & Wood Mallesons

黄逸宇先生的执业领域包括为上市及非上市公司的企业融资，证券发行、债券发行、私募股权投资和企业并购。

黄律师曾代表过众多客户成功完成其在亚洲区的重要资本市场交易，其中代表性的客户包括：腾讯、百济神州、中金公司、基石药业、万科集团、中国信达等。黄先生在金融服务、保险、能源、生物制药、技术及通讯领域等行业均有丰富的经验。自香港联交所开辟生物科技 18A 章节以来，黄律师参与了信达生物，基石药业，启明医疗，康方生物和诺诚健华的上市。

黄律师撰写的多篇文章曾被《中国法律评论》、《凤凰周刊》、《法制日报》、《北京青年报》等报刊杂志刊载发表并广受好评。

Mr. Yiyu Huang specializes in public and private corporate finance transactions, including initial public offerings, debt offerings and private equity investments, and mergers and acquisitions.

Mr. Huang has worked on some of the most significant capital markets transactions in Asia, including with companies from the TMT (Tencent), healthcare (Beigene), FIG (CICC), Oil and Gas (Sinopec), real estate (Vanke), financial services (CINDA), and other sectors. Mr. Huang's experience covers a wide variety of industries, including aviation, Energy, financial services, insurance, pharmaceuticals, technology and communications. Since the introduction of Chapter 18A (Biotech) at Hong Kong Stock Exchange in 2018, Mr Huang has participated in the IPOs of Innovent Biologics, CStone Pharma, Venus MedTech, Akeso Inc, and InnoCare Pharma.

陈鹏辉
博远资本创始合伙人

Kevin CHEN
Founding Partner, Biotrack Capital

陈鹏辉先生是博远医疗基金创始合伙人。在创立博远医疗基金之前担任红杉资本中国基金合伙人，负责医疗领域的投资。之前任职于光大控股，组建了光大控股首期医疗基金，担任基金负责人，全面负责基金的管理和投资。
代表性的投资项目包括华大基因（300676），浙江贝达医药 （300558），鱼跃医疗 （SZ002223），再鼎医药（Nasdaq ZLAB），美中宜和，微医等近二十多家国内医疗领域的领先企业。
在进入医疗投资领域之前，在国内领先的医药研发外包公司尚华医药研发服务集团担任总裁，COO, CFO. 领导了公司的快速发展， 并于2010 年领导公司在纽约证交所上市 . 曾任美国圣地亚哥生物技术公司 Ligand Pharmaceuticals（NASDAQ LGND）的研究员，从事新药研发工作。
本科毕业于南京大学化学系，是美国杜兰大学药物化学硕士和美国西北大学凯洛格商学院 MBA。

Kevin （Penghui）Chen is the founding partner of Biotrack Capital. Prior to Biotrack, he was a partner at Sequoia Capital China, responsible for healthcare investment. Before Sequoia, Mr. Chen was the founding member of the first healthcare fund at Everbright Holdings and served as head of Everbright Healthcare Fund I.
At Sequoia and Everbright, Mr. Chen led investments in over 20 leading healthcare companies in China including BGI; Betta Pharma; Zai Lab; Yuwell and We-Doctor。
Before Everbright, he was the President, COO & CFO of ShangPharma Corporation, one of the top three preclinical CRO companies in China and took the company public at NYSE in 2010.
Prior to ShangPharma, Mr. Chen also worked in the M&A and BD function at multinational companies and worked as research scientist at Ligand Pharmaceuticals in San Diego, California.
Mr. Chen holds a bachelor's degree in chemistry from Nanjing University, master degree in medicinal chemistry from Tulane University and an MBA from Kellogg School of Management, Northwestern University.

颜士翔
本草资本合伙人

Frank YAN
Partner at 3E Bioventures Capital

颜士翔博士作为本草资本合伙人同时也是本草八达的首席执行官，拥有 17 年中美两地药物研发，管理，以及运营的经验，先后在诺华，罗氏，GSK 任要职，在广泛的疾病领域内具备充分的经验包括癌症，神经退行性疾病，疼痛，传染性疾病，眼科疾病，以及代谢类疾病，并有丰富的对外合作和商务拓展经验。颜士翔博士发表了近 50 篇学术论著及专利，并拥有纽约大学生物化学博士学位。
颜士翔博士投资了靶向蛋白降解领域全球第一梯队领先公司 C4 Therapeutics（已提交纳斯达克上市申请）、全新机理靶向周围神经病变新药公司 Regenacy 及其在中国落地本草孵化运营的公司本草瑞生、致力于靶向过脑治疗神经系统疾病新药公司 Orpheris、治疗脑部肿瘤全球首创新药公司本草八达。

Dr. Frank Yan is a Partner at 3E Bioventures Capital and the Chief Executive Officer of N.B. Quadriga, who has 17 years of pharmaceutical R&D, management, and operation experience in both U.S. and China, having held positions in Novartis, Roche, and GSK. He has broad experience in various disease areas such as oncology, infectious diseases, neurodegenerative diseases, pain, ophthalmology, and metabolic diseases, as well as deep experience in external innovation and business development. Dr. Frank Yan has close to 50 publications and patents including those in Nature, Science, and has a Ph.D. degree in Biochemistry from New York University.
Dr. Yan has led investments in several biotech companies including C4 Therapeutics, Regenacy, Orpheris, N.B. Quadriga.

田　源
元明资本 创始人

Lawrence TIAN
Founder, YuanMing Capital

田源博士是元明资本创始人，迈胜医疗科技集团董事长。元明资本专注大健康领域投资并打造中美两国新药研发、创新医疗器械和高端医疗服务行业领军企业，投资组合包括百济神州、亚盛医药、迈胜质子科技、联影医疗、长风药业、药明巨诺、阿诺医药、神州医疗等多家生命科学行业优秀公司。

在创立元明资本之前，田源先生曾创立中国国际期货公司，联合创立物美超市联锁企业和亚布力滑雪场，还担任过中国诚通集团董事长，2010 年以来，田源先生致力于推动中国资本投资中美两国生命科学创新企业，具有扎实的实战经验。

田源先生是中国企业家论坛的创始人、主席，是中美商业领袖圆桌会议的创始人和会议主席，是各种中美企业家高端会议的核心组织者，在中美两国商界具有非常广泛的社会影响力。田源先生是中国医药创新促进会投资委员会副主任委员，香港联交所生物科技咨询小组成员。

田源先生获得武汉大学经济学硕士、博士学位，获得过中国经济学最高奖 ––– 中国经济理论创新奖。

Dr. Lawrence Tian is the Founder of YuanMing Capital, Chairman of Mevion Medical Systems, Inc. YuanMing Capital focuses on the investment in pharmaceutial research and development, innovative medical devices and high-end medical services in both China and the United States. YuanMing has successfully invested in a dozen of leading biopharma companies including BeiGene, Ascentage Pharma, Mevion Medical Systems, United Imaging, CF PharmTech, JW Theraperutics, Adlai Nortye and Digital China Health.

Prior to founding YuanMing Capital, Dr. Tian established China International Futures Corporation, co-founded Wu Mart Supermarket and Yabuli Ski Resort. He also served as Chairman of China Chengtong Group. Since 2010, Dr. Tian has been committed to promoting China's capital investment into US life science innovative companies, and has accumulated solid experiences and an outstanding track record.

Dr. Tian is the Founder and Chairman of China Entrepreneurs Forum and China-U.S. Business Leaders Roundtable. As a core organizer of various high-end meeting for entrepreneurs of both countries, Dr. Tian is an influential figure in the Sino-China business scene and has extensive social influence. He serves as Vice Chairman of Investment Committee of China Pharmaceutical Industry Research and Development Association, and he is a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong Limited ("HKEX"). Dr. Tian obtained his master's degree and doctoral degree from Wuhan University. He was the recipient of China's highest prize for economics: China Economics Theory Innovation Award.

朱忠远
通和毓承资本投资合伙人
映恩生物创始人和首席执行官

John ZHU
Venture Partner, 6 Dimensions Capital
Founder & CEO, Duality Biologics

朱忠远博士，通和毓承资本投资合伙人、映恩生物创始人和首席执行官。朱忠远博士在医疗健康领域拥有超过十五年行业经验。在加入通和毓承之前，朱忠远博士曾任职毓承资本，景林投资，美国应用生物系统等公司。其主要投资案例包括：基石药业、凤凰医疗、华大基因、甘李药业等二十余家公司。朱先生拥有美国麻省大学医学院博士学位和加州大学伯克利分校商学院 MBA。

Dr. John Zhu, Venture Partner of 6 Dimensions Capital and Founder&CEO of Duality Biologics. Prior to that, he worked for Wuxi Ventures, Greenwoods Asset, Applied Biosystems etc. Dr. Zhu has over 15 years of experience in healthcare industry. He has led more than 20 private equity investments, including CStone Pharma, Phoenix Healthcare Group, BGI, Gan&Lee etc. He earned his MBA from University of California at Berkeley and PhD from University of Massachusetts Medical Center.

唐艳旻
启明创投投资合伙人

Amy TANG
Venture Partner, Qiming Venture Partners

沈阳药科大学获得学士、中科院硕士、长江商学院 EMBA 硕士。现任启明创投医疗健康投资合伙人。
唐女士加入启明前，在晨兴创投工作 13 年 (2002−2015)，担任晨兴北京办公室负责人。在此期间，独立投资并在董事会层面管理超过 20 家早期生物医药公司。 其中大部分均已通过上市或并购途径成功退出，回报丰厚。加入晨兴之前，唐女士在葛兰素史克工作七年，其中五年做新药注册，两年做产品经理。
投资项目包括神州细胞，义翘神州，加科思，科州和克睿基因。

Amy earned her master's degree in Chinese Academy of Sciences and a bachelor's degree from Shen Yang Pharmaceutical University. Amy is also a graduate of EMBA course of Cheung Kong Graduate School of Business (CKGSB).Ms. Amy Tang is a Venture Partner at Qiming Venture Partners.
Amy previously worked in Morningside Ventures for 13 years (2002~2015). in charge of its Beijing office. Amy invested and managed dozens of early stage biotech portfolios during this period. Up till now, most of the investments have exited via IPOs or M&A with multiple returns.
Prior to joining Morningside, Amy worked in GSK as a regulatory manager for five years and product manager for two years. She had participated in the investment on Sino Cell Tech, Sino Biological, Jacobio Pharma, KeChow Pharma, and Cure Genetics.

周　浩
方圆基金管理（香港）有限公司合伙人

ZHOU Hao
Partner, Prudence Investment Management (Hong Kong) Limited

周浩，方圆基金合伙人、Mevion Medicine Systems 董事，武汉大学人才引进基金理事会理事，武汉大学企业家联谊会长三角分会的常务副会长。1993 年毕业于武汉大学国际金融专业。香港中文大学 MPAcc 专业会计硕士。中国人民银行武汉分行外汇交易中心任职 8 年。2000 年华为技术有限公司市场部财经经理。2001 年深圳一体智能技术有限公司副总经理。2002 年中西药业总经理助理。2004 年至 2011 年，伽马星医疗集团董事副总经理。2011 年至今以合伙人身份加入方圆基金管理（香港）有限公司。

Mr. Zhou Hao, Partner of Prudence Investment Management (Hong Kong) Limited and Director of Mevion Medical Systems, INC. Mr. Zhou also serves as a member of the Board of Directors of Wuhan University Talents Import Fund and a Vice-President of the Yangtze River Delta Branch of Wuhan University Entrepreneurship Association. Mr. Zhou received his bachelor's degree in International Finance from Wuhan University in 1993. Later, he received master degree in MPAcc from Chinese University of Hong Kong. Mr. Zhou worked in Foreign Exchange Trading Center - Wuhan branch of The People's Bank of China for 8 years. In 2000, he worked as a Financial Manager of Marketing department in HUAWEI Technology Limited. In 2001, he has been appointed as Deputy General Manager of Shenzhen ETI Intelligent Technology Co., Ltd. In 2002, he served as the General Manager Assistant at Shanghai Zhongxi Pharmaceutical Co., Ltd. From 2004 to 2011, Mr. Zhou served as the Director and Deputy General Manager of Gamma Star Medical Group. Mr. Zhou has joined Prudence Investment Management (Hong Kong) Limited as a Partner since 2011.

孙佳林
高特佳弘瑞投资执行合伙人

SUN Jialin
Executive Partner, GTJA HongRui Investment

孙佳林，高特佳弘瑞投资执行合伙人，苏州大学国际经济法硕士。
拥有多年投资经验，部分经典投资案例：方舟制药（002513），华韩整形（430335），新百药业（300294），之江生物（834839），维亚生物（01873），长风药业，罗益生物，美华医疗，济诺医院等。2018 年荣获中关村股权投资协会“青年投资人 100”

Sun Jialin, Executive Partner of GTJA HongRui Investment Co.,Ltd, MASTER of International Economic Law, Suzhou University.
With many years of investment experience, Sun Jialin has many classic investment cases: ARK PHA(002513), ARSMO(430335), XINBAI Pharmaceutical (300294), SHANGHAI ZJ Bio-Tech (834839), VIVA biological (01873), CF PharmTech, ROYAL Bio- Pharmaceutical, etc.

宋高广
北极光创投执行董事

SONG Gaoguang
Executive Director, Northern Light Venture Capital

宋高广博士毕业于协和医科大学，目前是北极光执行董事，对生物制药产业的发展有着深刻的认知，拥有丰富的产业经验和投资经验，曾任舒泰神生物制药战略部总监。目前主要集中在生物医药和生物技术等方面的投资。主要投资案例包括：泽璟制药，康乃德医药，信念生物，怡道生物，兰晟制药，麦科奥特医药，康朴生物，鑫康合生物，Teon Therapeutics，NGGT 等。

Dr. Gaoguang Song graduated from Peking Union Medical College (PUMC). He is currently serving as the Vice President at Northern Light Venture Capital (NLVC). Dr. Song has a profound understanding for China’s pharmaceutical industry. Prior to NLVC, Dr. Song served as the Director of Strategic Research at Staidson Biopharmaceutical Co., Ltd. His major achievements are focused on the early stage investments on biopharmaceuticals and biotechnology, which includes Zelgen, Connect, Belief, ImmunPath, Lansson, Micot, Kangpu, Kanova, Teon Therapeutics□NGGT and other biotech startups.

吕志豪
英士律师行高级合伙人

Lui Chi Ho, Eric
Partner, Ince & Co

吕志豪律师对银行及金融交易事务有着丰富的经验，特别是专门为跨境项目融资担任顾问工作，并为企业提供咨询及收购合并等法律服务。吕律师拥有香港和英格兰及威尔士执业资格，并协助客户就担保贷款及无担保贷款所涉及的各个方面问题提供专业的法律意见及支持，覆盖的项目包括双边贷款、联合贷款、建筑贷款及并购贷款。

在企业融资方面，吕律师协助多家企业进行改组，就有关企业申请在香港及海外的证券市场首次公开发售及上市后的交易和持续合规提供意见。吕律师亦曾参与众多涉及中港两地合资和收购的项目。此外，吕律师代表中国企业和公司在香港经商，为客户提供一系列的法律服务，包括银行、保险、证券、房地产投资等。

吕律师熟悉中国业务， 他被中华人民共和国司法部任命为中国委托公证人。吕律师是第一批获准在深圳前海合作区成立中港合伙联营律师事务所的香港律师，并获得广东省司法厅授予港澳律师工作证，可以在中国境内执业香港法律的香港律师。

Mr. Lui is a banking and corporate finance specialist. He has extensive experience in corporate finance, cross-border project finance and general corporate advisory and M&A. Dual qualified in Hong Kong and England & Wales, Eric advises clients on all aspects of secured and unsecured loan transactions including bilateral loans, syndicated loans, building loans and acquisition finance.

On corporate finance front, Eric advises a number of companies on their restructuring and subsequent IPOs in Hong Kong and foreign securities markets, as well as continuing obligations post-listing. He also works on numerous joint ventures and M&A transactions in Hong Kong and China. Additionally, Eric represents leading Chinese companies and organizations doing business in Hong Kong and provides advice in a range of areas including banking, insurance, securities and real estate investment.

Eric is familiar with China business and he is a China Appointed Attesting Officer appointed by the Ministry of Justice of the People's Republic of China. He is also part of the first batch of Hong Kong lawyers who set up joint venture law firm in Shenzhen Qianhai Cooperation Zone, and obtained a working permit issued by Guangdong Ministry of Justice which allows him to practise Hong Kong law in mainland China.

陈　晓
信银振华（北京）股权投资基金管理有限公司总经理

CHEN Xiao
General Manager, CNCB (Beijing) Equity Investment Fund Management Co.,Limited

具备 10 年以上商业银行投行业务经验，近 10 年境外股权项目投资经验。曾任职于信银（香港）资本有限公司副总经理，参与管理的香港夹层基金 Darby 基金多年位列亚太区排名首位。南京大学硕士。主导锦欣医疗 Pre-IPO 融资、新世纪儿童医院基石投资。

Chen, Xiao has more than 10 years of investment banking business experience in commercial bank, and nearly 10 years of overseas private equity investment experience, led the investment to Jinxin Fertility. He has served as deputy general manager of CNCB (Hong Kong) Capital Limited, and has played an important role in the Darby Fund which is the Top 1 in asia pacific area for many years. Mr. Chen also has a Master's degree from Nanjing University.

毛　宁
维亚生物副总监

Daniel MAO
Associate Director, Viva Biotech

芝加哥大学布斯商学院，MBA
复旦大学，硕士
在 2016 年加入 VBI 之前，毛宁先生曾于华兴资本和蓝峰集团任职，两家专注于早期创业融资和跨境并购的精品投资银行。
在 VBI，毛宁先生主导并参与了 Bonti、Arthrosi 和 Versa 等投资项目。

MBA, The University of Chicago Booth School of Business
Master, Fudan University
Before joining VBI in 2016, Daniel worked at China Renaissance and Bluepeak Group, two boutique investment banks focused on early-stage startup fundraising and cross-border M&A, respectively.
At VBI Daniel led the investments into Bonti, Arthrosi, and Versa, among others.

华　一
强生医疗新业务发展部总监

Michael HUA
Director, New Business Development, J&J Medical

华一先生负责强生医疗在华的并购、投资、战略合作业务。他深入参与了包括辛迪思收购及手术机器人项目在内的，强生医疗近年来一些主要外部创新项目。加入强生之前，华一先生在海外从事企业并购重组及战略咨询工作。华一先生持有皇家特许会计师及美国特学金融分析师等专业证照。

Michael Hua, Director, New Business Development, is responsible for J&J Medical's M&A, licensing, distribution and strategic alliances in China. Some of the key transactions that Michael has been involved in at J&J include the Synthes acquisition and surgical robot projects. Michael has a cross-border M&A and corporate strategy consulting background. He holds Chartered Accountant qualification and is a Chartered Financial Analyst Charterholder.

肖　慧
安永华明会计师事务所（特殊普通合伙）审计服务高级经理

Grace XIAO
Assurance Senior Manager, Ernst & Young Hua Ming LLP

肖慧女士拥有逾 14 年的审计经验，现为安永审计服务高级经理。她对审计大型国有企业，民营企业及中外合资企业等均有丰富的经验，服务的项目涉及多个行业，包括生物医药行业、汽车业、制造业、批发零售业、港口运营及物流业等。

肖女士近年专注于服务生命科学及医疗健康领域的客户，对于生物医药、医药流通、医疗器械及医疗服务等，有较为完整的理解和相关的财务专业服务经验。在汽车行业也有丰富的经验。

肖女士拥有丰富的不同市场的 IPO 审计和年报审计经验，熟悉中国企业会计准则、美国会计准则以及国际财务报告准则，熟悉资本市场披露规定和内部控制审计的实务操作。

Ms. Grace Xiao has more than 14 years of audit experience and is now an assurance senior manager of Ernst & Young Hua Ming. She has rich experience in auditing state-owned enterprises, private enterprises as well as multinational joint ventures, covering industries including pharmaceuticals and biotech, automotive, manufacturing, retail and logistics industry.

Grace has focused on serving clients in life science industry in recent years. She has relatively complete understanding of biopharmaceuticals, medicine circulation, medical device and medical service industries, and has accumulated rich experience in providing relevant professional services.

Grace has rich experience in IPO audit and annual audit for clients in different markets. She is familiar with Chinese Accounting Standards, International Financial Reporting Standards and US Generally Accepted Accounting Principles, and the corresponding listing rules and internal control practice.

杨淑娟
安永华明会计师事务所（特殊普通合伙）
安永北京主管合伙人，审计服务合伙人

Jane YANG
Managing Partner, Beijing office, Assurance Partner,
Ernst & Young Hua Ming LLP

杨淑娟女士拥有逾 25 年的审计经验，目前是安永北京主管合伙人、大中华区政府及公共事业部主管合伙人，同时还兼任中国人民大学商学院客座教授及会计专业硕士企业导师、财政部政府会计准则咨询委员会委员及 PPP 专家委员等职。杨女士曾于 2012 年至 2016 年四年间连任中国证监会并购重组审核委员会审核委员。

杨女士对审计大型国有企业，民营企业及中外合资企业等均有丰富的项目管理经验，所审计的公司覆盖各种行业，主要包括制药及生物科技业、消费品制造业、大型制造业、建筑业及零售业。杨女士在协助中国企业在 A 股及海外上市审计和财务报告方面有丰富经验，曾成功协助沈阳三生、甘李药业、中国圣牧、中国通号、中国铁建、铁建高新装备、西部矿业及京客隆在内的众多企业成功在香港及国内上市，并协助株洲时代新材顺利完成海外并购。她目前还担任华润医药和中国建筑年度审计及多个生物医药企业 IPO 审计项目的负责合伙人工作。

Ms Jane Yang has over 25 years of audit experience. She is the Managing Partner of Beijing office and the Government & Public Service Market Segment Leader of EY Greater China. She is also a guest professor and an enterprise coach for MPACC students of Renmin University of China, a Ministry of Finance PPP Center Expert and a member of Ministry of Finance Government Accounting Standards Consultancy Committee. Ms Yang was a member of China Security Regulation Committee (CSRC) Merge & Acquisition Review Committee during the period from 2012 to 2016.

Ms Yang has rich experience in the audit and project management of a number of state owned companies, privately owned companies as well as multinational joint ventures. Industry coverage ranged from pharmaceuticals and biotech science, consumer products industrial products, construction, mining and retail. She also has extensive audit experience in sizable Chinese engagements with domestic and overseas listing/listed company financial reporting requirements. Ms Yang has assisted her audit client including 3SBio Inc., Gan&Lee Pharmaceutical Co.,Ltd., China Shengmu Organic Milk Limited, China Railway Signal & Communication Corporation Limited, China Railway Construction Corporation Limited, CRCC High Tech Equipment Corporation Limited, West Mining Co.,Ltd. and Beijing Jingkelong Co., Ltd.in successfully completing IPO in Hong Kong and Mainland China. She also assisted in the completion of overseas acquisition by Zhuzhou New Times Materials Co., Ltd.. She is the partner in charge of annual audit of China Resource Pharmaceutical Group Ltd.,and China State Construction Engineering Corporation Limited and a number of Biotech company IPO audit engagements currently.

毛　化
弗若斯特沙利文咨询公司合伙人

Fred MAO
Partner, Frost & Sullivan

毛化先生负责弗若斯特沙利文大中华区的医疗咨询服务，项目服务对象包括医药、医疗器械及医疗服务三大板块的多家中国及国际领先的企业，掌握了丰富的产业经验。尤其在医药领域，见证了中国医药产业近年来从仿制药、me-too、fast-follow 到 first/best-in-class innovation 的演进趋势的同时，通过投融资服务、IPO 行业咨询服务、研发管线的开发策略咨询、商业尽调及市场准入等多种项目类型深入了解中国市场的动态，积累了丰富的专业知识。毛先生持有上海交通大学硕士学位。

Mr. Mao takes charge of the healthcare consulting service of Frost & Sullivan in Greater China. He possesses a wealth of industry experience in three major healthcare sectors including pharmaceuticals, medical devices and healthcare services, covering a number of clients that are leading companies in the field, in China or around the globe. Particularly in the field of pharmaceuticals, he has witnessed the trend in China pharmaceutical industry that evolves from generic drugs, "me-too", "fast-follow" development mode, toward the innovation of first/best-in-class drugs; at the same time, he keeps abreast with the dynamics of China market and accumulates a wealth of professional knowledge through investment and financing services, industry consulting services for IPO, strategic consulting for pipeline development, commercial due diligence, market access, as well as other projects. Mr. Mao holds a master degree from Shanghai Jiaotong University.

周成曜
汉坤律师事务所合伙人

Aaron ZHOU
Partner, Han Kun Law Offices

周律师专长于技术 / 知识产权授权、跨境和境内兼并收购、私募股权投融资、风险投资、外商投资、合资。周律师协助多家境内外知名医药企业完成旨在实现医药产品在大中华区的商业化和开发的授权事宜和药品资产和权益买卖交易。周律师曾代表多家境内外知名企业完成跨境和境内的兼并收购项目，且代表多家境内外基金及公司完成跨境和境内的私募股权融资和风险投资项目。周律师还担任多家企业的常年法律顾问，并在法律合规和反贿赂合规方面有着丰富的经验。

周律师有超过 16 年法律执业经验，包括之前在顶级美国华尔街律师事务所工作近 5 年及担任《财富》世界 50 强公司的亚太地区法务主管近 3 年。周律师现为中国保险资产管理业协会股权投资专业委员会的委员。

周律师被 Legal 500 评为“亚太区推荐的公司和并购律师”和“明日之星”，并被《亚洲法律杂志》(ALB) 评为“2018 年十五佳律师新星”。

Mr. Aaron Zhou's practice focuses on technology/IP licensing, cross-border and domestic mergers and acquisitions, private equity investment, venture capital investment, foreign direct investment (FDI) and joint ventures. Mr. Zhou has helped top-tier multinational and PRC pharmaceutical companies in their out-licensing/in-licensing for the commercialization and development of pharmaceutical products in the greater China region. He has also represented many renowned multinational and PRC companies in their cross-border and domestic merger and acquisition transactions, and has acted for many foreign and domestic funds and companies in their private equity financing and venture capital investment projects. In addition, Mr. Zhou is well-experienced in handling general corporate, FCPA-related and compliance matters.

Mr. Zhou has over 16 years' legal experience, including five years at a top-5 Wall Street law firm and 3 years as the Asia Pacific legal head of a Fortune Global 50 company. Mr. Zhou is a current member of the Equity Investment Committee of the Insurance Asset Management Association of China.

Mr. Zhou is ranked as a “recommended corporate, merger & acquisition lawyer” by Legal 500 Asia Pacific and was recognized as one of the "2018 China Top 15 Rising Lawyers" by Asian Legal Business (ALB).

高　元
华泰联合证券大健康行业部负责人

GAO Yuan
Head of Investment Banking/Healthcare Division, Huatai United Securities

高元先生系现任华泰联合证券有限责任公司大健康行业部主管，具有超 15 年投资银行业务经历。曾主持及参与的项目有：迈瑞医疗下市重组及首发上市、奥赛康药业重组上市项目、药明康德首发上市、艾迪药业科创板首发项目、苏宁环球并购及非公开发行、宝胜股份并购及非公开发行、鹏鹞环保首发项目、雅克科技首发项目、国科微首发项目、江南嘉捷首发项目等数十家企业融资、并购等资本运作。

Mr. GAO Yuan is the head of Investment Banking/Healthcare Division of Huatai United Securities Co., Ltd., with over 15 years of investment banking experience. He has in charge or participated in the following projects: the IPO of Mindray medical, the restructuring and IPO of Aosaikang pharmaceutical, the IPO of Wuxi Apptec, the IPO of Aidi pharmaceutical, Suning global M&A and non-public offering, Baosheng's M&A and non-public offering, the IPO of Pengyao environmental protection, the IPO of Yake technology, the IPO of Guokewei, the IPO of Jiangnan Jiajie and other dozens of enterprises financing, M&A and other capital operations.

费　凡
安永华明会计师事务所（特殊普通合伙）大中华区生命科学行业联席主管，华中地区审计部副主管，审计服务主管合伙人

Felix FEI
Life Science Sector Co-leader, Greater China, Deputy Assurance Leader, China Central, Partner, Assurance, Ernst & Young Hua Ming LLP

费凡先生现任安永大中华区生命科学与医疗健康行业联席主管合伙人及审计服务主管合伙人。负责对客户提供高质量、一体化的审计、税务、咨询及财务交易服务。

费凡先生现任安永中区审计服务副主管，协助主管合伙人领导审计部门在中区的市场活动和运营。

费凡先生专注于服务生命科学与医疗健康领域的客户，包括生物科技、制药、医药流通、医疗器械及医疗服务等行业。其在零售及消费品及汽车行业也有丰富的经验。

费凡先生一直专注服务民企的收购重组、资本募集及上市；对于中国、香港、国际及美国会计准则及公司架构重组、兼并收购有深刻认识和丰富的实际操作经验。其职业生涯中成功帮助多家民企在各主要资本市场成功上市。

费凡先生是中国注册会计师资深执业会员，上海安泰经济与管理学院导师委员会副主任委员、会计硕士和审计硕士项目导师。

Felix is the co-leader of Great China Life Science sector, leading EY Great China's assurance, tax, advisory and transaction services for life science clients.

Felix is the deputy assurance leader of China Central. He assists assurance leadership team to drive marketing strategy and operational excellence.

Felix has 20 years' experience in providing assurance service to clients in life science, consumer products and automotive industry sectors.

Felix also specialized in providing exceptional services to private-owned companies' IPOs. Focus on China domestic, US and Hong Kong capital market.

Felix is also a guest lecturer of Shanghai Jiao Tong University's Master of Professional Accountants ("MPACC") Program and a deputy director of the Career Mentor Committee of Antai Economics and Management Colleague of Shanghai Jiao Tong University.

廖逸星
华泰联合证券大健康行业部副总裁

LIAO Yixing
Vice President of Investment Banking/Healthcare Division, Huatai United Securities

廖逸星先生系现任华泰联合证券有限责任公司大健康行业部副总裁。负责医疗行业A股及港股IPO，拥有丰富的医疗医药行业资本运作经验。曾经负责或参与的项目包括但不限于药明康德 A 股及 H 股 IPO、爱尔眼科再融资及重大资产重组、三生制药分拆三生国健科创板 IPO、荣昌生物 H 股 IPO、美年健康借壳上市、奥赛康借壳上市等。

Mr. Liao Yixing is the vice president of Investment Banking/Healthcare Division of Huatai United Securities Co., Ltd. Responsible for IPO of A-share and H-share in healthcare industry, with rich capital operation experience in healthcare industry. He has in charge or participated in the following projects: the A-share and H-share IPO of WUXI APPTEC, the refinancing and major asset restructuring of Aier Eye Hospital Group, the spin off of 3SBIO Inc., the IPO of Sunshine Guojian, the H-share IPO of Remegen, the backdoor listing of Meinian Onehealth, the backdoor listing of Aosaikang, etc.

徐　荟
安永（中国）企业咨询有限公司交易咨询合伙人

Anson XU
Strategy & Transactions Partner of EY

徐先生是一位财务交易咨询领域的资深人士，他拥有近 20 年在中国从事评估业务的经验。
徐先生参与的项目涉及多个行业，涵括生物医药、制造业、食品饮料、金融服务、房地产、汽车、信息技术、日用消费品等。
徐先生具有的丰富专业知识和行业经验，使其非常了解国内及国际评估方法的惯例。其业务涉及广泛，评估标的内容包括企业价值、不良资产、无形资产，不动产，厂房设备及衍生金融资产等。
徐先生曾为许多国内外客户提供投诸如企业并购中对权益价值的评估、企业合并引起的购买价格分摊和核心资产的减值测试以及不良资产评估等，其精益求精的工作态度深受客户好评。

Anson is a Partner of the Valuation and Business Modeling Group in China with around 20 years experience in valuation, financial modeling and other transaction related areas.
Anson has rich experience in valuation and business modeling, including broad knowledge of different sectors, expertise of valuation methodologies and professional understandings of accounting standards.
Anson has provided business valuation for companies in different industries, including life science, diversified industrial products, F&B, financial services, real estate, auto, information technology, consumer products, etc.
Anson is familiar with the valuation of business, tangible and intangible assets for tax purpose.

裘育敏
尚珹资本合伙人

Benjamin QIU
Partner, Advantech Capital

裘育敏先生现任尚珹资本合伙人。尚珹资本由于剑鸣先生于 2016 年 1 月成立，关注创新驱动的成长型投资机会，主要投资于医疗医药健康服务业、科技与创新领域。裘育敏先生主要关注医药、医疗服务、医疗器械等行业的投资机会。

裘先生拥有逾 15 年的医疗医药投资、咨询与医院管理经验。自 2013 年加入新天域资本以来，裘先生主导投资了康宁杰瑞、东曜药业、益方生物、兴盟生物、再鼎医药、和铂医药、山东亨利药业、导明医药、泛生子医疗、瑞尔齿科、上海力康生物医疗等项目。

加入新天域资本之前，裘先生作为专注医疗产业投资的德福资本的核心团队之一，主导了温州康宁医院等项目的投资。裘先生还曾是普华永道医疗咨询服务团队的创始成员之一，早年亦在加拿大温哥华总医院供职多年。

裘先生拥有英属哥伦比亚大学 MBA 学位和华东工业大学学士学位。裘先生亦持有特许金融分析师（CFA）和美国管理会计师（CMA）证书。

Mr. Qiu is Partner at Advantech Capital, a private equity fund founded by Mr. Jianming Yu in January 2016. Advantech Capital focuses on innovation-driven growth capital, on investments in Healthcare, TMT, and E-services sectors in China. Mr. Qiu's main focus areas are Pharmaceutical, Medical Devices and Healthcare Services.

Mr. Qiu has aggregated over 15 years of experience in healthcare investment, consulting and hospital management. He joined New Horizon Capital in 2013 and has since taken a leading role in investments in AlphaMab Oncology, TOT Pharma, Synermore Biologics, InventisBio, Zai Lab, Harbour BioMed, KBP, DTRM Pharma, Arrail Dental and HealForce Biotech etc.

Before joining New Horizon Capital, Mr. Qiu worked at GL Capital, a healthcare-dedicated investment fund, where he led multiple deals including Kangning Psychiatric Hospitals Group. Mr. Qiu also worked at the PwC Healthcare Advisory Team as a founding member and at Vancouver General Hospital as a business analyst.

Mr. Qiu holds an MBA degree from the University of British Columbia and a Bachelor's degree in Engineering from the Eastern China University of Technology. He is also holder of designations of CFA (Chartered Financial Analyst) and CMA (Certified Management Accountant – US)

薛　冰
汉坤律师事务所合伙人

XUE Bing
Partner, Han Kun Law Offices

薛律师主要从事私募和风险投资、兼并收购、境内外上市重组、外商投资以及中国税务法律咨询等业务。薛律师曾代表众多的投资基金、跨国公司、国有企事业单位、初创及成长型公司、上市公司和科研机构处理各种法律事务；薛律师的业务领域涉及众多行业，包括生命医药、高新技术、电子科技、环境技术、电信、互联网、广告、能源、教育、房地产和财富管理等。

薛律师在中国税务合规及税收规划相关法律服务领域还有着丰富的实践经验。在加入汉坤前，薛律师曾在普华永道及另外一家中国领先律师事务所有多年的中国税务及法律服务从业经验。薛律师还曾在一家投资并购基金担任并购咨询部门的执行总裁。

薛律师被 Legal 500 评为“亚太区推荐的公司和并购律师”。

Mr. Xue Bing's practice focuses on venture capital and private equity investment, mergers and acquisitions, capital markets transactions, foreign direct investment and PRC tax advisory services. Mr. Xue has represented and provided legal services to numerous investment funds, multinational companies, state-owned enterprises, start-ups and emerging companies, public companies and research institutions in relation to their various PRC legal matters, covering the life science and pharmaceutical, high-tech, electronic technology, environmental technology, telecommunications, internet, advertising, energy, education, real estate and wealth management industries. Mr. Xue also has solid knowledge of and practice experience with China tax compliance and tax planning-related legal services.

Before joining Han Kun, Mr. Xue practiced tax and law for several years with PricewaterhouseCoopers and another leading PRC law firm. Mr. Xue also had one-year working experience at a buyout fund where he served as CEO and was responsible for M&A transactions.

Mr. Xue is ranked as a "recommended corporate, merger & acquisition lawyer" by Legal 500 Asia Pacific.

诸　斌
安永税务与商务咨询合伙人

Raymond ZHU
Tax & Business Advisory Partner of EY

诸斌先生是安永税务部华中区合伙人，同时担任安永大中华区政府及公共项目服务主管合伙人。在过去逾十九年的专业服务中，他致力于为各级政府部门、大型国有企业、全球跨国企业以及高成长民营企业提供优质的税务咨询协助。拥有丰富的服务经验。

在此期间，诸先生为客户提供过如下主要服务：IPO 上市、企业兼并、集团重组、跨境投资运作相关涉税事宜、税务咨询 / 筹划、税务申报等服务。

诸先生拥有众多行业经验，特别擅长为制造业、金融业、医药及医疗器械、分销 / 零售业、互联网行业、矿业、物流、电子商务等行业客户提供专业的税务服务。

诸斌先生担任上海市外资委外商投资咨询企业协会委员，国家会计学院特聘硕士生导师。

Raymond is a tax partner with over 19 years of Chinese and international tax experience serving Fortune 500 multinationals and private equity firms investing in China.

Raymond has led many studies that involve formulation of investment strategies, restructuring of Chinese operations, advice on merger and acquisition (including tax due diligence, tax structuring and post-deal integration), tax compliance assessment, design and implementation of cash repatriation schemes, tax negotiations and etc.

Raymond is also frequently engaged in providing advice on tax issues faced by Chinese companies listed/ to be listed in and outside China equity market. All of these assignments have created significant value to clients and have covered around parts of China including Beijing, Guangzhou, Shanghai, Shenzhen and so forth.

Raymond has worked with a wide spectrum of clients in industries with a focus on TMT (Technology, Media, Telecom) sector, internet, manufacturing and retailing, pharm & electronic commerce.

王　临
中国医疗器械行业协会创新服务专业委员会秘书长

WANG Lin
General Secretary of Innovation and Financial Services Committee of China Association for Medical Devices Industry

王临，中国医疗器械行业协会创新服务专业委员会秘书长，临床医学专业，科技部医疗器械重点专项课题评审专家。多年临床放射诊断工作经验和医疗器械企业管理经验。参与了我国第一台数字 X 线机（DR）研发与临床应用和国家“十五”、“十一五”数字 X 线机重点专项课题研究。熟悉国内外医疗器械行业及市场，熟悉大型医疗设备的采购和商业运营及医院合作、医院设置配置及管理，熟悉多种医疗设备、器械、耗材等产品，尤其是大型影像设备、内窥镜、高值耗材等。对于各种医疗器械的技术性能、临床应用、市场和发展趋势具有较强的判断和把握。近年来主要从事医疗器械的创新服务工作，熟悉医疗器械行业发展现状、趋势和特点，拥有医疗器械创新成果转化、科技金融对接的丰富经验与资源，兼任多个园区和机构的专家顾问。

WANG Lin, General Secretary of Innovation and Financial Services Committee of China Association for Medical Devices Industry. Clinical medicine major, expert for the Evaluation of Key Topics on Medical Devices in the Ministry of Science and Technology. Years of experience in clinical radiodiagnostic and enterprises management. Participated in the R&D and clinical application of China's first digital X-ray machine(DR), part of the main digital X-ray machine research group of the national “Tenth Five-Year” and “Eleventh Five-Year” plans. Familiar with domestic and international medical device industry, especially in procurement and commercial operation of large-scale equipment, and cooperation/configuration/ management inside a hospital. Familiar with various medical devices, especially like large-scale imaging equipment, endoscopes, high-value consumables, and etc. Good judgment on the technical performance, clinical application, market and development trend of various medical devices. In recent years deeply engaged in innovative services for medical devices. Intimate knowledgement of the development status, trend and characteristics of medical device industry. Enable to provide professional advice and financial docking resources in transforming innovative achievements of medical device. And also expert consultants for many science parks and institutions.

彭义刚
上海证券交易所发行上市服务中心副总监

PENG Yigang
Associate Director of Offering & Listing Center, Shanghai Stock Exchange

上海证券交易所发行上市服务中心副总监、长三角二级部门总经理，兼任长三角 G60 科创走廊建设联席会议办公室副主任、上海证券交易所公益基金会理事、上海市股权交易托管中心董事。
公职律师，上海市五一劳动奖章获得者，上海市金融人才讲师团讲师，上海市普陀区人民政府特聘企业上市专家辅导团专家。
曾借调中国证监会担任 IPO 审核员，曾任辽宁股权交易中心副总经理、上海股权交易托管中心注委会委员、审委会委员，浙江股权交易托管中心注委会委员。
参与战略新兴板制度建设和科创板市场建设相关工作，目前主要从事主板、科创板企业上市培育、培训和咨询工作，具有丰富的审核实务经验。

盛泽林
苏州泽生物制药股份有限公司董事长兼总经理

SHENG Zelin
Chairman & CEO, Suzhou Zelgen Biopharmaceuticals Co., Ltd.

盛泽林，苏州泽璟生物制药股份有限公司（简称“泽璟制药”，股票代码 688266.SH）创始人、董事长、总经理，药理学博士，美国加州大学圣地亚哥分校博士后，中欧国际工商学院 EMBA，曾就职于美国施贵宝制药公司。先后获得江苏省创新创业领军人才、苏州市杰出人才、姑苏和昆山创新创业领军人才等，拥有 30 多年的新药创新开发、项目管理和企业管理经验。
泽璟制药是中国首家采用科创板第五套标准上市的创新药企业，是一家专注于肿瘤、出血及血液疾病、肝胆疾病和免疫炎症性疾病等多个治疗领域的创新驱动型新药企业，公司在研 12 个新药的 30 项研发项目，承担了 5 项国家“重大新药创制”项目，累计申请发明专利 130 余项。

Zelin Sheng, Ph.D. the founder and CEO of Suzhou Zelgen Biopharmaceuticals, Co., Ltd. (Zelgen Pharma, 688266.SH). Dr. Sheng obtained his Ph.D. degree in pharmacology in University of Miami, FL. USA. After his postdoctoral training in UCSD, Dr. Sheng worked as a senior researcher at Bristol-Myer Squibb, NJ. Dr. Sheng also completed his eMBA training in CEBIS, Shanghai. Dr.Sheng has been committing to clinical practice, drug research and development in multiple disease areas as well as the management of companies for more than 30 years. He has also been awarded for multi honors from various areas.
Zelgen Pharma was the first public traded company for the fifth standard in SEE STAR MARKET. The company has been committed to the R&D and commercialization of more than a dozen of innovative new drugs in oncology and hematology as well as other fields.

黄反之
分享投资创始合伙人

HUANG Fanzhi
Founding Partner, Share Capital

黄反之先生是分享投资创始合伙人、分享医疗基金主管合伙人，曾在机械电子工业部从事行业管理，担任过国企财务处长、飞利浦消费通信公司财务负责人、沃尔玛中国公司财务总监、上市公司高管。

黄反之先生拥有丰富的医疗投资经验，主导投资医疗项目 70 多个，包括华大基因、美年大健康、步长制药、泽璟生物、泛生子、天臣医疗、碳云科技、诺唯赞、贝登医疗、方恩医药、索元药业、捷诺飞、迈普生物、菲鹏生物、江丰生物、张强医生、家鸿口腔等众多知名公司。

黄反之先生曾荣获：

胡润中国：年度中国最佳医疗健康产业投资人 TOP10

投中集团年度榜单：医疗及健康服务产业最佳投资人 IPO

投资家：中国医疗健康领域最佳投资人 IPO

动脉网：年度最佳医疗投资人

赵　冀
中金公司投资银行部医疗医药组执行总经理

ZHAO Ji
Executive Director, Investment Banking, Healthcare and Pharmaceutical Group, China International Capital Corporation Limited

赵冀先生拥有丰富的医药医疗行业经验及科创板业务经验，专注于创新药、医疗服务及医疗器械企业的资本运作服务，主持及主导多家创新药企业 IPO，包括泽璟制药科创板 IPO（A 股首单无收入未盈利企业 IPO，科创板首单第五套标准企业 IPO）、百奥泰科创板 IPO 等，主持及主导多家生物医药企业私募融资，包括泽璟制药 Pre-IPO 轮私募融资、瑞博生物 C+ 轮私募融资、亚虹医药 C+ 轮私募融资等，并协助多家连锁专科医院集团及医疗器械公司进行 IPO 申报；其他项目经历还包括悦心健康重大资产重组收购医院资产、益丰药房非公开发行、九洲药业非公开发行、金城医药重大资产重组等。

赵先生现为中金公司投资银行部医疗医药行业组执行总经理，拥有 12 年投资银行经验；本科及硕士毕业于上海交通大学生命科学技术学院，获生物医学工程专业学士学位及硕士学位；赵先生为 A 股保荐代表人，拥有香港和 A 股证券从业资格。

Mr. Ji Zhao is currently the Executive Director of Medical & Healthcare Team in Investment Banking Department of CICC, he has rich investment banking experience in healthcare industry, focuses on the sector of innovative drug, medical institution and medical device.

Mr. Zhao has involved in and successfully completed a numerous capital operation projects in medical and healthcare industry, including: Zelgen Biopharmaceutical's A-share IPO, Bio-Thera's A-share IPO, Yifeng Pharmacy's A-share Non-public Offering, Jiu Zhou Pharmaceutical's A-share Non-public Offering, Jin Cheng Pharmaceutical's A-share Material Asset Reorganization, EverJoy Health Group's A-share Material Asset Reorganization, etc.

Mr. Zhao graduated from Shanghai Jiao Tong University with bachelor's degree and master's degree both in Bio-Medical Engineering. Mr. Zhao is Sponsor Representative of A Share, and has Hong Kong securities qualifications.

陶旭东
君合律师事务所资深合伙人

TAO Xudong
Senior Partner, JunHe LLP

陶旭东律师拥有超过 25 年的执业经验，专注于各类企业的设立、重组、投资、并购及境内外资本市场股权及债权融资业务。在生命科学领域，他近期完成的代表性项目包括：(1) 担任采用科创板第五套标准上市的第一家企业——苏州泽璟的发行人律师；(2) 担任中国西南地区第一家科创板上市企业——成都先导的发行人律师；(3) 担任国内第一家“服务换股权”CRO 企业——维亚生物香港联交所主板上市及上市后 CB 发行、若干并购项目的发行人中国律师；(4) 在中国民营上市公司第一单中代表马德里及纳斯达克上市公司 Grifols S.A. 与 A 股上市公司上海莱士跨境换股，及代表多家知名买断型基金及私募股权投资基金进行医药企业的投资及收购项目等。
陶律师自 2012 年起连续被国际知名法律专业媒体《国际金融法律评论》及《亚洲法律》评选为兼并收购及资本市场业务的“领先律师”。

Mr. Tao has over 25 years of practicing law in China, with focuses on formation, restructuring, investment, mergers and acquisitions, and equity and debt financing in domestic and overseas capital market by various types of enterprises. His most recent representative deals in life science sector include: (a) acting as the issuer counsel to Suzhou Zelgen, the first listed biotech company by adopting Criteria 5 of STAR Market listing rules; (b) acting as the issuer counsel to Chengdu HitGen, the first company listed on STAR Market in southwest China; (c) acting as the issuer's PRC counsel to Vivo Biotech in its listing on HKEX and post-listing financings and M&A transactions; (d) representing Madrid and NASDAQ-listed Grifols S. A. in its cross-border share swap with A-share listed Shanghai RAAS. Mr. Tao also represented a number of buyout and PE funds in their investment and acquisition projects in pharmaceutical and device business.
Mr. Tao has been selected as a “Leading Lawyer” in mergers and acquisitions and capital market practice by IFLR and Asialaw since 2012.

李秋实
高特佳弘瑞投资执行合伙人、PIPE 业务负责人

Li Qiushi
Executive Partner, GTJA HongRui Investment

李秋实，高特佳弘瑞投资执行合伙人、PIPE 业务负责人。曾任国泰君安证券首席医药行业分析师，平安银行医疗健康事业部董事总经理，曾获“新财富”、“水晶球”最佳分析师。毕业于北京大学医学部，美国西北大学 Kellogg 商学院 EMBA。拥有十五年丰富的医疗健康产业一二级市场投资经验。

Li Qiushi, Executive Partner of GTJA HongRui Investment Co.,Ltd, and Head of PIPE Business. He once served as the Chief Pharmaceutical Industry Analyst of GUOTA JUNAN SECURITIES, the Managing Director of the medical and health business department of PINGAN BANK, and the Best Analyst of "new wealth" and "crystal ball". He has 15 years of rich experience in primary and secondary market investment of medical and health industry.

张　军
中信证券投资银行管理委员会医疗健康组执行总经理

Jon ZHANG
Executive Director of Investment Banking, Healthcare and Life Science Group, Citic Securities

张先生现任中信证券投行委医疗健康组执行总经理，立项委员会委员，投资决策委员会委员，拥有逾 10 年的医疗健康行业投资银行与投资经验，先后为以岭药业、步长集团、甘李药业、绿叶制药、三生药业、金域医学、艾德生物、联影医疗、泰格医药、国药集团、益丰药房、康宁医院、博瑞医药、艾力斯等数十家知名客户提供融资、境内外上市、并购重组等全方位服务。在企业战略咨询、资本策略选择、交易结构设计、交易高效执行、行业资源整合等方面拥有丰富的经验。

Mr. Zhang is the current executive director and member of the Project Establishment Committee and the Investment Decision Committee of the Healthcare Group of CITIC Securities. He has over 10 years of investment banking and investment experience in the healthcare field, and has successively provided all-round services including financing, IPO in domestic and overseas market and M & A, for dozens of well-known companies, such as Yiling Pharmaceutical, Buchang Pharma, Gan & Lee Pharmaceuticals, Luye Pharma Group, 3SBio Group, Kingmed Diagnostics, AmoyDx, United Imaging Healthcare, Tigermed, Sinopharm, Yifeng Pharmacy, Kangning Hosptical, BrightGene Bio-Medical Technology, Allist Pharmaceutical technology etc. He has rich experience in enterprise strategic consulting, capital strategy selecting, transaction structure designing, efficient transaction executing, and industry resources integrating.

冀　文
平安银行医疗健康金融事业部总裁

JI Wen
President, Ping An Bank's Finance SBU of Medical & Health Industry

冀文，现任平安银行医疗健康金融事业部总裁。
近二十年商业银行从业经验，深耕医疗健康行业，在私有化、跨境并购、产业基金等投行领域具有丰富项目经验。
平安银行医疗健康事业部是国内唯一一家总行级医疗健康产业专营机构，依托平安集团综合金融优势，致力于为医疗健康行业客户提供“全产业链 + 全生命周期 + 全流程”的综合化金融服务。
作为国内最领先、最专业、最具特色的医疗健康金融品牌，曾获得中国并购公会“年度最佳并购融资奖”等奖项。
成功案例包括：药明康德、绿叶制药、罗欣药业、正大天晴、智飞生物、泰邦生物、迈瑞医疗、乐普医疗等。

Ji Wen is the President of Ping An Bank's Finance SBU of Medical & Health Industry.
With nearly 20 years of experience in commercial banking, he has been deeply involved in the medical and health industry, and has extensive project experience in investment banking fields such as privatization, cross-border mergers and acquisitions, and industrial funds.
Ping An Bank's Finance SBU of Medical & Health Industry is the only head office-level medical and health industry franchise institution in China. Relying on the comprehensive financial advantages of Ping An Group, it is committed to providing customers in the medical and health industry with integrated financial services of "full industry chain + full life cycle + full process" .
As the most leading, most professional, and most distinctive medical and health financial brand in China, it has won awards such as the "Best M&A Financing Award of the Year" by the China M&A Association.
Successful cases include: WuXi AppTec, Luye Pharma, Luoxin Pharmaceutical, Chia Tai Tianqing, Zhifei Biological, Taibang Biological, Mindray Medical, Lepu Medical, etc.

朱　湃
倚锋资本合伙人

ZHU Pai
Partner, Efung Capital

美国加州大学圣地亚哥分校经济学学士（UCSD），发起和铂医药、万春医药及 Apexigen 等项目投资，曾任国信证券资产管理总部项目经理，主导多项上市公司股票质押，负责银证合作相关项目，包括但不限于委托贷款、基金直投、信托收益权等相关业务，总规模约 300 亿人民币。

With a bachelor's degree in Economics from the University of California, San Diego (UCSD), Mr. Zhu Pai initiated and invested in Harbour BioMed, Beyondspring Pharma and Apexigen Inc. He was once a project manager in headquarters of Guosen Securities Asset Management. He led a number of stock pledge of listed companies, and was responsible for Bank-Securities cooperation and related projects, including but not limited to entrusted loans, direct investment fund, trust benefit right and other related businesses, with a total scale of about 30 billion RMB.

邓周宇
中银国际证券研究部执行董事、医药行业首席分析师、大消费组组长

DENG Zhouyu
Executive Director of the Research Department , Chief Analyst of the Pharmaceutical Industry, and leader of the Consumption Research Group of BOC International (China) Co., Ltd,

曾供职于国信证券、国海证券。曾获得 2013 年金融界最佳分析师第一名；2014 年新财富最佳分析师第三名（团队）、金牛奖最佳分析师第三名（团队）、水晶球最佳分析师第四名（团队）；2017 年水晶球最佳分析师第五名（公募组）；2017 年、2018 年金翼奖最佳分析师第五名。邓先生毕业于上海财经大学获得经济学硕士学位。

He has won the first place for the Best Analyst in financial industry in 2013.
In 2014, He has achieved the third place in “2014 New Fortune Best Analysts“ , the third place for the Best Analysts of Golden Bull Awards , and the fourth place for the Best Analysts in Crystal Ball Awards ;
He also got the fifth place in “2017 Crystal Ball Awards Best Analysts” (Public Offering Fund Group); and the fifth place in “Golden Wing Award Best Analysts” in 2017 and 2018
Mr. Deng graduated from Shanghai University of Finance and Economics with a Master degree in Economics.

李奕莹
安永华明会计师事务所（特殊普通合伙）审计服务高级经理

Tina LI
Assurance Senior Manager, Ernst & Young Hua Ming LLP

李奕莹女士拥有逾 11 年的审计经验，现为安永审计服务高级经理。她对审计大型国有企业，民营企业及中外合资企业等均有丰富的经验。服务的项目涉及行业包括生物医药行业、大型制造业、金融业等。

李女士为企业提供专业审计与咨询服务，尤其专注于为中国境内企业在国内外证券市场的融资提供专业服务，曾多次领导或参与 IPO 审计、上市公司审计项目并参与长期证监会现场核查。拥有丰富的不同市场的 IPO 审计和年报审计经验，熟悉中国企业会计准则以及国际财务报告准则，熟悉资本市场披露规定及监管机构核查要求。

李女士近年专注于服务生命科学及医疗健康领域的客户，对于生物医药、医药流通、医疗器械及医疗服务等，有较为完整的理解和相关的财务专业服务经验。

Ms. Tina Li has more than 12 years of audit experience and is now an assurance senior manager of Ernst & Young Hua Ming. She has rich experience in auditing state-owned enterprises, private enterprises as well as multinational joint ventures, covering industries including pharmaceuticals and biotech, manufacturing and finance industry.

Tina has rich experience in IPO audit and annual audit for clients in different markets. Specialized in providing exceptional services to private-owned companies' IPOs. Focus on China domestic, US and Hong Kong capital market. She is familiar with Chinese Accounting Standards, International Financial Reporting Standards, and the corresponding listing rules and internal control practice.

Tina has focused on serving clients in life science industry in recent years. She has relatively complete understanding of biopharmaceuticals, medicine circulation, medical device and medical service industries, and has accumulated rich experience in providing relevant professional services.

王玥月
天超资本管理合伙人

WANG Yueyue
Managing Partner, T-Capital

上海交通大学生物学本科、博士，清华大学 MBA，高级工程师。

深根医疗大健康战略投资 10 余载，曾任国药集团金融投资平台国药投资产业发展总经理、现代制药（A 股 600420）资深战投总监、美国礼来（ELI LILLY）亚太区对外研发与合作。

案例：信达（01801）、微芯（688321）、浙江贝达（300558）、南通联亚、海尔生物（A19054）、益诺斯等；宝迪康与澳大利亚上市企业 cochlear 出售与整合；Amgen、和记黄埔、德国 SCHEBO、德国 ATERNA ZENTRIS 许可与合作等。

擅长：投资、并购、跨境并购、合资、许可、技术转移等。

Dr. Linda Wang, Managing Partner, T-Captial
• SJTU-Chinese Ph.D
• Tsinghua MBA
Work Experience
• Managing Director, China National Pharmaceutical Investment Co. Ltd
• Head of Global Business Development, Senior Director, Shyndec Phamaceutical Co. Ltd (600420)
• Senior Manager, Global External R&D, Eli Lilly
CASE
• Innovent Bio(B1801), Betta Pharma(300558), Haier(1169), Novast, InnoStar, etc,
• Eli Lilly vs. Hutchison, BodyCare vs. Cochlear, etc.
Expert
• Investment, Fund Raising, M&A,License-in/-out, Technology Transfer, JV, Co-development, etc.

陈　峰
优选资本合伙人

CHEN Feng
Partner, Youchoose Capital

曾在中金公司、中植集团从事投资管理工作。“投资家”网专栏作家，NMPA 直管《中国医药报》撰稿专家，新药创始人俱乐部会员，目前负责优选资本直投 biotech 团队。其主办的新媒体”Biotech VC”有上万名国内外新药华人科学家、投资机构关注和阅读，其坚持原创分享创新药投资领域的独立见解和思考。其热门文章《创新药尽调漫谈》系列、《星辰和大海》、《给 China market only 新药算笔帐》等深受业内人士高评。

Used to hold investment management position in CICC and Zhongzhi group. Columnist of "master of investor" website. Contributing authors of "CN pharm", a newspaper managed directly by NMPA Member of New drug founders club.Currently in charge as leader of Youchoose Capital biotech team.

王　昕
法国施维雅药厂，亚太生物创新中心，业务拓展及许可总监

Cynthia WANG
BD&Licensing Director, BioInnovation Asia, Les Laboratories SERVIER

王昕女士于 2015 年 7 月加入施维雅中国，任职业务发展总监，专注于以中国地区的业务发展；自 2020 年 4 月起，任职法国施维雅药厂亚太生物创新中心业务拓展及许可总监，致力于通过合作和共同创造推动中国及亚太地区医疗创新。

王昕女士在中国的生命健康及制药领域工作超过 19 年。加入施维雅之前，王昕女士曾经任职辉瑞中国高级业务拓展经理，负责全球疫苗业务拓展和辉瑞中国对外许可项目管理。过往任职经历还包括西安杨森，安捷伦科技，施耐德电气等公司的业务发展，新产品引进及上市准备，战略联盟管理，业务规划及运营等职能。王昕女士专注于药品业务发展领域多年，拥有丰富的项目经验，同时兼任 CHBD 协会（中国医疗健康产业 BD 协会）副主席。

王昕女士的教育经历包括北京大学 MBA，美国福坦姆大学国际金融硕士，北京大学医学部药学学士。

Cynthia Wang Joined Servier China as Business Development Director since July 2015.

Cynthia brings with her over 19 years of Healthcare/pharmaceutical industrial experience in China. Prior to Servier China, Cynthia worked as Senior BD manager for Pfizer in Vaccine BD global M&A projects and managing full TAs of out-licensing BD activities. Before joining Pfizer, Cynthia held a series of positions in Business Development, New Product Introduction, Product launch, Strategic Alliance Management, Business planning and Operational Management at Janssen/Johnson & Johnson, Agilent Technologies and Schneider Electric. Cynthia has broad BD network in China serving as Vice Chairman of CHBD(China Healthcare BD) organization, Cynthia has proven BD track records of closing multiple BD deals.

Cynthia holds a Master of Business Administration from Peking University, a Master of Global Finance from Fordham University in NYC, a Pharmacy degree from Peking University Health Science Centre.

谈文龙
北京朗玛峰创业投资管理有限公司合伙人

TAN Wenlong
Partner, Beijing Everest Venture Capital Management Co., Ltd.

免疫学专业，上海交通大学医学院博士 , 军事医学科学院博士后。曾在抗体药物国家工程研究中心，中国人民解放军总医院肿瘤中心，军事医学科学院，华控基金，朗玛峰创投工作学习。多年的交叉工作经历，其对创新药、医疗器械及 IVD 诊断领域有深入的理解与思考。
投资案例：瑞博生物，天广实亿腾景昂，艾美疫苗，数坤科技，兰度生物等。

Immunology major, doctor of Medical School of Shanghai Jiaotong University, postdoctoral of Academy of Military Medical Sciences. He has studied in the National Engineering Research Center of antibody drugs, cancer center of the General Hospital of the Chinese people's Liberation Army, Academy of Military Medical Sciences, Tsinghua Holdings Capital, and Everest venture capital. Due to years of cross work experience, he has a deep understanding of innovative drugs, medical devices and IVD diagnosis.
Investment cases: Ribo Life Science, Mabworks, EOC Pharma, Aim vaccine, Shukun technology, Lando Bio, etc.

朱青生
泓元资本创始合伙人

Ching ZHU
Partner, Creacion Ventures

朱青生博士是泓元资本（Creacion Ventures）创始合伙人，负责中国投资业务。在创业和从事风险投资前，朱博士有在美国 Guidant 公司（现属波士顿科学）10 年的工作经历，担任过创新疗法研究的部门经理等职务，拥有 200 多项美国发明专利。
泓元资本（Creacion Ventures）是一家跨境风险投资机构，专注于由生命科学和健康行业的创新而带动的早期投资机会。泓元资本的投资团队由一批在海内外生命科学及医疗领域具备丰富的风险投资和管理实战经验的专业人士组成。我们对于中国的制药、生物技术、医疗器械和其他相关领域有着深刻的理解，尤其在扶持初创公司方面积累了丰富的经验。

Dr. Qingsheng Zhu is a founding partner of Creacion Ventures, where he leads the China investment business. Prior to start a business and engaging in venture capital, Dr. Zhu had 10 years of work experience in Guidant (now Boston Scientific) in the United States, where he served as a department manager of innovative therapy research, and owned more than 200 US invention patents.
Creacion Ventures is a cross-border venture capital firm focused on early stage investment opportunities driven by innovation in the life sciences and healthcare industry. The investment team of Creacion Ventures consists of a group of professionals with rich experience in venture capital and management in the field of life sciences and medical care which from China to worldwide. We have a deep understanding of Pharmaceuticals, biotechnology, medical devices and other related fields in China, especially our experience in supporting start-ups.

包杨欢
薄荷天使基金合伙人

BAO Yanghuan
Partner, BOHE Angel Fund

曾在美国冷泉港实验室神经生物学系从事基础科研工作多年，并参与创立和运营一家从冷泉港实验室和麻省理工学院分离出来的神经生物学新药研发服务公司。回国后先后在君联资本和元生创投从事生物医药医疗创投工作，参与投资、投后管理、创建及指导 20 余家公司。拥有丰富的从科研院所发掘原始创新成果的实战经验和案例，并致力于协助教授和科学家开展成果转化和商业化。

获得的行业认可包括：百华协会（BayHelix）会员、《创业邦》创业导师、新药创始人俱乐部 “新药投资百人圈”成员、浙江大学（余杭）基础医学创新研究院专家咨询委员会成员、西交利物浦大学校外导师、2016−2019 连续三年中国创新创业大赛生物医药行业决赛评审。

美国俄勒冈州立大学遗传学硕士，长江商学院 MBA。

Mr. Bao is a venture capitalist and an entrepreneur in biotech and life-science industries. He currently works as Partner at BOHE Angle Fund.

Before returning to China, Mr. Bao worked as a research scientist at the Cold Spring Harbor Lab (CSHL) in New York. He participated in the founding and early operation of a CSHL and MIT spin-off company providing mouse brain mapping services for drug discovery in neuroscience.

Mr. Bao started his career as a venture capitalist at Legned Capital and Sungent Bioventure in China. Since then he has participated in over 20 deals of venture investment and venture creation in biotech and life-science industries.

Mr. Bao received a M.B.A degree from Cheung Kong Graduate School of Business, and a M.S. degree in Molecular Genetics from Oregon State University.

邵　蓉
中国药科大学教授、
国家药物政策与医药产业经济研究中心执行副主任

SHAO Rong
Professor, Vice Executive Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University

邵蓉教授现任中国药科大学国家药物政策与医药产业经济研究中心执行副主任，社会与管理药学博士生导师，江苏省教学名师、执业律师。从事药事管理政策与法规的教学与科研，曾获江苏省教学成果一等奖、二等奖多项，主持、完成国家社科基金重大项目和面上项目、国家各部委及企业研究课题百余项。

任工业和信息化部安全生产专家组成员、国家中药品种保护评审委员会审评专家、国家执业药师工作专家、NMPA（原 CFDA）仿制药质量和疗效一致性评价专家委员会专家、国家药品监督管理局《药品管理法》修法专家组成员、《药品管理法》和《疫苗法》两法宣讲团成员等职。

任《中国药房》、《中国新药杂志》、《中国卫生政策研究》等十多家杂志编委。

Shao Rong, Professor, Vice Executive Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University, doctoral advisor of Social and Administrative Pharmacy, Legal Practitioner.

Shao is engaged in the education and research of the policies and regulations on Pharmaceutical Administration and won the first and second prizes of Provincial Excellent Teaching Result in Jiangsu. Theory and Practice of Chinese Pharmaceutical Law, edited by Shao Rong, is one of the national 11th and 12th Five-Year Planning textbooks, the project—establishing and elaborate textbooks and the key textbooks of Jiangsu province. Shao has taken charge of and completed over 100 major projects and general projects from the National Social Science Fund of China, and research subjects from Chinese ministries and commissions and enterprises.

Shao is a member of the Safety Production Expert Group of the Ministry of Industry and Information Technology, an expert of the National Committee on the Assessment of the Projected Traditional Chinese Medicine Products, a national licensed pharmacists work expert and a member of Expert Committee on the Consistency Evaluation of quality and efficacy of Generics of NMPA (formerly CFDA), etc.

Shao also serves as the editor of dozens of journals, including China Pharmacy, Chinese Journal of New Drugs and Chinese Journal of Health Policy and so on.

胡善联
复旦大学公共卫生学院卫生经济学教授

HU Shanlian
Professor of Health Economics, School of Public Health, Fudan University

胡善联，复旦大学公共卫生学院卫生经济学教授，博士生导师。现任国家新型冠状病毒肺炎专家组成员，国家消灭脊髓灰质炎认证小组成员，“沪苏浙皖闽”四省一市综合医改联席会议专家指导组副组长，中国社会保障学会医疗保障专业委员会常务委员、中国卫生经济学会卫生技术评估专业委员会副主任委员，中国中药协会药物经济学专业委员会顾问，中国研究型医院学会药物经济学专业委员会顾问，中国药科大学国家药物政策与医药产业经济研究中心研究员，“国际临床药物” 杂志主编。

Dr. Shanlian Hu. MD. MSc. Professor of Health Economics, School of Public Health, Fudan University. At present, he has several social responsibilities, such as, member of national COVID-19 Expert Committee, member of China Eradication of Poliomyelitis Leading Confirmation Group, Deputy Guiding group leader of comprehensive health system reform in Shanghai Municipal and Jiangsu, Zhejiang, Anhui, Fujian four provinces, member of Advisory Committee of Public Policy in National Health Commission, member of Steering Committee of China Social Security Association. Deputy Director of Health Technology Assessment Sub-Committee, Chinese Health Economics Association, senior consultant of Pharmacoeconomics Sub-Committee of China Association of Traditional Chinese Medicine and senior researcher Of National Drug Policy & Pharmaceutical Industry Economic Research Center in China Pharmaceutical University. Chief Editor, Journal of World Clinical Drugs in China.

胡　欣
北京医院药学部主任

HU Xin
Director of Department of Pharmacy, Beijing Hospital

胡欣，沈阳药科大学药物分析专业博士，北京医院药学部主任，药物临床风险与个体化应用评价北京市重点实验室主任，国家药典委员会委员，卫计委合理用药专家委员会委员，CFDA 药品一致性评价专家委员会委员，北京药学会副理事长，中国药师协会副会长，中国药房杂志主编、中国新药杂志副主编、中国药物警戒杂志副主编、药物临床治疗杂志副主编。中国药学杂志、中国临床药学杂志、中国临床药理学杂志、中华老年医学杂志编委。主持多项国家科技重大专项课题、国家自然科学基金、卫生行业科研专项课题等，发表 100 多篇 SCI 和中文核心期刊文章，参编多部专业书籍。获得 2019 年药师紫晶奖，学术影响力获得药学各界的认可。

Hu Xin, graduated from shenyang pharmaceutical university professional pharmaceutical analysis, Ph.D., Director of Department of Pharmacy, director of Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, Member of the Chinese Pharmacopoeia Committee, Member of the Expert Committee on Rational Drug Use of the NHFPC, Vice President of Beijing Pharmaceutical Association, Vice President of Chinese Pharmacists Association. Editor-in-chief of Chinese Pharmacy Magazine, Deputy editor of Chinese Journal of New Drugs, Chinese Journal of Pharmacovigilance, and Chinese Journal of Drug Clinical Therapy. Editorial Board of Chinese Journal of Pharmacy, Chinese Journal of Clinical Pharmacy, Chinese Journal of Clinical Pharmacology, Chinese Journal of Geriatrics. He has presided over a number of national science and technology major special projects, national Natural Science Foundation of China, special research projects in the health industry, etc. He has published more than 100 SCI and Chinese core journal articles and participated in the compilation of many professional books. Won the Amethyst Award for pharmacists in 2019, and the academic influence was recognized by all circles of pharmacy.

王晓玲
首都医科大学附属北京儿童医院药学部主任

WANG Xiaoling
Director of Department of Pharmacy, Beijing Children's Hospital, Capital Medical University

首都医科大学附属北京儿童医院药学部主任、临床研究中心副主任。国家卫生健康委儿童用药专家委员会委员兼办公室主任；国家卫生健康委罕见病诊疗与保障专家委员会委员；中国药理学会 TDM 专业委员会儿科 TDM 学组组长，中国药学会儿科药学组副组长；中国医药教育协会儿童用药评价分会副主任委员；福棠儿童医学发展研究中心药学专委会主任委员；中国研究型医院学会感染性疾病询证与转化专委会常务委员；中国医学会细菌感染与耐药防治分会委员等；《中国临床药理学杂志》、《药物不良反应杂志》、《中国药房》、《中国医药导报》、《儿科药学杂志》等学术期刊编委及审稿专家；致力于儿科临床药学、临床药理及儿童合理用药工作。

Director of Department of Pharmacy and Deputy Director of Clinical Trial Research Center, Beijing Children's Hospital, Capital Medical University; Committee Member and Director of the Expert Committee on Pediatric Drugs of National Health Commission; Committee Member of the Expert Committee on Diagnosis and Protection of Rare Diseases, National Health Commission; Leader of the Pediatric Group, Therapeutic Drug Monitoring Professional Committee, Chinese Pharmacological Society; Deputy Leader of Pediatric Pharmacy Group, Chinese Pharmaceutical Association; Chairman of the Pharmacy Professional Committee of Futang Research Center of Pediatric Development; Standing Committee Member of the Specialty Committee of Inquiry and Transformation of Infectious Diseases Committee Member of Chinese Society of Bacterial Infection and Drug Resistance Prevention, Chinese Medical Association etc. She is also the Editorial Board of academic journals such as Chinese Journal of Clinical Pharmacology, Adverse Drug Reactions Journal, China Pharmacy, China Medical Herald and Clinical Remedies, Journal of Pediatric Pharmacy.
She is committed to pediatric clinical pharmacy, pediatric clinical pharmacology and rational drug use for children. She has undertaken and completed more than 10 important national and provincial projects related to children's drug use. She has published more than 100 papers as the first author and corresponding author, and edited and co-edited 10 monographs.

冷嘉骅
北京大学肿瘤医院医疗保险服务处处长

LENG Jiahua
Director of Department of Medical Insurance of Peking University Cancer Hospital and Institute

冷家骅，现任北京大学肿瘤医院医疗保险服务处处长。北京大学医学博士，Johns Hopkins 大学 医学院博士后，Johns Hopkins 大学 彭博公共卫生学院 DrPH 在读。
CHS-DRG 临床论证肿瘤组执行组长，CHS-DRG 试点专家组专家，上海医保支付方式改革咨询专家，中国卫生经济及医疗保障联盟（CASHE）发起人。中国卫生经济学会医保专委会常委，北京抗癌协会大肠癌专委会常委，中国医疗保健国际交流促进会 NEN 青委会副主任委员，健康保障分会常务理事。

Leng Jiahua is the director of Department of Medical Insurance of Peking University Cancer Hospital and Institute, Doctor of Medicine at Peking University, Postdoctoral Research fellow at Johns Hopkins University School of Medicine, PhD student at Johns Hopkins University Bloomberg School of Public Health.
He is the executive director of CHS-DRG clinical demonstration tumor group, expert of CHS-DRG pilot expert group, consultant expert of Shanghai medical insurance payment mode reform, initiator of CASHE□member of the standing committee of China Health Economics Association Health Insurance Special Committee, member of standing committee of Beijing Anti-cancer Association Colorectal Cancer Special Committee, vice director of China International Exchange and Promotive Association for Medical and Health Care NEN Youth Committee and Executive Director of Health Security Branch.

范长生
北京医药卫生经济研究会秘书长

FAN Changsheng
Secretary General of Beijing Medical and Health Economic Research Association

社会职务：
中国药学会药物经济学专业委员会 委员
北京药学会药物经济学专业委员会 委员
主要从事卫生技术评估和医疗领域的政策分析

Social Position:
Committee Member of Pharmacoeconomics Specialized Committee of Chinese Pharmaceutical Association
Committee Member of Pharmacoeconomics Specialized Committee of Beijing Pharmaceutical Association
Specialty in health technology assessment, medical industry policy and data analysis.

陈　昊
华中科技大学同济医学院药品政策与管理研究中心主任

CHEN Hao
Director of Policy and Management Research Center of Tongji Medical College, Huazhong University of Science and Technology

陈昊，华中科技大学，同济医学院药品政策与管理研究中心，原中文核心《医学与社会》编辑部，主任，高级经济师；上海创奇健康发展研究院，资深研究员；广东卫生经济研究院，研究员；执业药师，中国社会保障学会医疗保障专业委员会常务委员，中国药品监管管理研究会委员，国家医保局药物经济学专家。
主要研究方向：卫生事业管理、药品质量监管体系、药品政策与管理。近 30 年的医药行业工作经历，多项国家药物政策主要研究和设计者，多省药品集中采购方案设计者、咨询专家。著有《制药企业质量体系与最新 GMP 实务》、《药品互联网销售国际监管研究》、《药品购销两票制政策透视》、《药品管理学》、《中国药品监督管理体制研究》等。

Dr. Chen Hao who has the long-term research job qualifications in the field of drug price policy and GXPs, serves as a researcher in Drug Policy and Management Research Center of Tongji medical college, Huazhong University of Science and Technology. He has ever served in several multinational pharmaceutical enterprises for many years. He has significant experience in providing strategic consulting and training services to pharmaceutical industries and distributors. He is the designer or important consultant of essential drug policy and drug bidding projects in many provinces. He also is a licensed pharmacist, senior economist and magazine columnist and freelance writer of several famous medical medias in China. His latest position is the director of editorial department of the journal of Medicine and Society.

毛宗福
武汉大学全球健康研究中心主任

MAO Zongfu
Director of Global Health Research Center, Wuhan University

毛宗福教授，武汉大学全球健康研究中心主任，社会医学与卫生管理学博士生导师，健康经济学博士生导师。发表论文 100 余篇，其中，SCI 或 SSCI 论文 30 余篇；出版专著或教材 12 部，先后获湖北省人民政府成果奖励 7 项，多项政策咨询报告得到国家领导人、湖北省和武汉市主要领导同志批示，入选全国“2018 年度十大最受关注医改专家”。

曾挂职湖北红安县人民政府副县长（2003−3004 年）、湖北咸宁市人民政府副市长（2009−2011 年）；曾任政协湖北省教科文卫体专委会副主任（2012−2017 年）。第十一届、第十三届全国人大代表，被聘为国家卫生健康委员会药物政策专家，国家医疗保障局 DRG 付费国家试点专家组成员，武汉市人民政府参事等。

Professor Zongfu Mao, director of Global Health Research Center, Wuhan University, doctoral supervisor in social medicine and health management, as well as doctoral supervisor in health economics, has published more than 100 papers, including more than 30 SCI and SSCI papers; and has published 12 monographs or teaching materials, has been awarded 7 achievement awards from government of Hubei province. His policy consultation reports have been approved by national leaders, leaders of Hubei Province and Wuhan city, and he has been selected into the "top 10 Medical reform experts of 2018".

He had served as deputy head of government of Hongan county , Hubei province (2003-2004) and deputy mayor of Xianning city, hubei province (2009-2011),and was deputy director of Hubei special committee of education, science, culture, health and sports of the CPPCC (2012-2017). He was deputies to the 11th and 13th NPC, and had been appointed as a drug policy expert of the national health commission, as well as a member of the national DRG pilot expert group of the national healthcare security administration, a counselor of the Wuhan people's government.

夏苏建
暨南大学医学院医学统计学教研室主任

XIA Sujian
Director of the Medical Statistics Teaching and Researching Section, Jinan University of Basic Medicine

博士、副教授、硕士生导师，暨南大学基础医学院医学统计学教研室主任，兼社会医学与卫生事业管理教研室主任。

主要研究领域为社会医疗保险政策研究、社会医学与卫生事业管理、药物经济学研究等。主持了四十多项各级科研项目，累计课题经费超过 1000 万元。已发表学术论文 80 余篇，其中 SCI 文章 4 篇。为政府相关行政部门完成了多部重要规划文件与研究报告。其中作为项目负责人和广州市城市勘测设计院共同承担的《广州市医疗卫生设施布局规划 (2011−2020 年)》，经广州市第十四届人代常委会审议通过，由广州市政府颁布实施。2019 年研究成果《广东省基本医疗保险按病种分值付费工作指南》为广东省医疗保障局全面采用，并正式出版。

Xia Su-jian, PhD, associate professor and master supervisor of Jinan University of Basic Medicine, is currenty the director of the Medical Statistics as well as the Social Medicine and Health Management Teaching and Researching Section.

His main research fields are social medical insurance policy research, social medicine and health service management, pharmaceutical economics research, etc.He has presided over more than 40 scientific research projects at all levels, with a total project fund of more than 10 million yuan. He has published more than 80 academic papers, including 4 SCI articles. He has also completed a number of important planning documents and research reports for relevant government administrative departments, which including Guangzhou Medical and health Facilities Layout Planning (2011-2020), undertaken jointly by the project leader and Guangzhou Urban Survey and Design Institute which is approved by the 14th Standing Committee of Guangzhou Municipal People's Congress and promulgated and implemented by the Guangzhou Municipal Government. The research results of the 2019 study "Guangdong Provincial Basic Medical Insurance Paid work Guide based on Disease Classification points" was fully adopted by The Guangdong Provincial Medical Security Administration.

冯　毅
四川科伦药业股份有限公司研发副总裁兼首席战略官

FENG Yi
Vice President for R&D, Chief Strategy Officer, Sichuan Kelun Pharmaceutical Co., Ltd.

冯毅先生现任四川科伦药业股份有限公司研发副总裁兼首席战略官
加入科伦前，他曾担任方恩医药大中华区总裁 3 年，并于此任职前担任科文顿 * 伯林律师事务所（Covington & Burling LLP）药品法规事务高级顾问 2 年。加入工业界之前，他曾在 CFDA 药物评价中心（CDE）任职 17 年。期间担任过多个领导职务，包括 CDE 主任助理和国家重大新药发现项目实施办公室副主任。从第四军医大学毕业后，他担任过矫形外科医生。
冯先生在药品评价、法律法规方面积累了深厚的知识和专业知识。1997−2013 年间，他参与了在中国首次上市的多个治疗领域创新药品的科学决策和监管决策。他领导参与了许多与药品监管相关的法律、法规和指南的起草工作，并深入研究了欧美等国的监管体系。他还带头将国际监管机构普遍认可的 GRP（Good Review Practice）纳入中国的审评流程。

Yi Feng, MD Vice President of R&D & Chief Strategy Officer, Sichuan Kelun Pharmaceutical Co., Ltd.
Dr. Yi Feng is the Vice President of R&D & Chief Strategy Officer at Sichuan Kelun Pharmaceutical Co Ltd. He previously served as a president of Great China of Fountain-Medicine for 3-years and a senior consultant of drug regulatory affairs at Covington & Burling LLP for 2-years. Prior to that, he had held several leadership positions during his 17 years' tenure at the CFDA Center for Drug Evaluation (CDE), including Assistant Director of the CDE and Deputy Director of the Office of the National Major New Drug Discovery Program Implementation. He also worked as an orthopedic surgeon after graduating from Fourth Military Medical University. Dr. Feng has accumulated profound knowledge and expertise in drug evaluation, laws and regulations. He has been involved in making regulatory and scientific decisions for the first approval of many drugs in China in various therapeutic areas. He has led or participated in drafting and formulating many laws, regulations and guidelines in China, and has had in-depth studies in the regulatory systems of Europe, the United States and other countries. He also led the effort to bring the concept of Good Review Practice commonly recognized by international regulatory authorities into China's evaluation process.

朱建国
苏州大学附属第一医院药学部主任

ZHU Jianguo
Director of Pharmaceutical Department, The First Affiliated Hospital of Soochow University

主要从事医院药事管理、药事质量控制、院内药品物流信息化建设、合理用药管理与监测、个体物药物治疗、药物经济学评价等工作，社会任职有中国研究型医院学会药物评价专业委员会委员，中国医促会药学信息化分会委员，江苏省医院协会药事管理专业委员会委员兼秘书，江苏省医疗保险研究会医疗保障与药物评价专业委员会秘书长，江苏省老年医学学会临床药学专委会副主任委员，江苏省药师协会临床药师分会副主任委员，苏州市中西医结合学会临床药学专业委员会副主任委员、《中国现代应用药学》杂志特约编委，主持与参与国自然、省市课题多项，以第一或通讯作者公开发表论文 20 余篇。

Mainly engaged in the works of hospital pharmacy management, quality control of drugs, hospital medicine logistics information construction, management and monitoring for the rational use of drugs, individual drug treatment, and pharmacoeconomic evaluation.
Membership in professional associations include committee member of Professional Committee for Drug Evaluation of Chinese Association of Research Hospitals, committee member of Pharmaceutical Information Branch of China Medical Association, committee member and secretary of Professional Committee of Pharmaceutical Administration of Jiangsu Hospital Association, secretary-general of Medical Care and Drug Evaluation Professional Committee of Jiangsu Institute of Medical Insurance, vice chairman of Clinical Pharmacy Special Committee of Jiangsu Geriatrics Society, vice chairman of Clinical Pharmacists Branch of Jiangsu Pharmacists Association, vice chairman of Professional Committee of Clinical Pharmacy of Suzhou Integrated Chinese and Western Medicine Society, and the contributing editor of Chinese Journal of Modern Applied Pharmacy. Leaded and participated in a number of National Natural Science Funds ,Provincial and municipal projects, and published more than 20 papers as the first or corresponding author.

博　沛
荷兰王国驻华大使馆卫生、福利和体育参赞

Peter A. Bootsma
Counselor for Health, Welfare and Sports, Embassy of the Kingdom of the Netherlands

博沛先生，医学博士，2014 年任荷兰驻华大使馆卫生、福利和体育参赞。1999 至 2003 年、2010 至 2014 年，任荷兰驻华盛顿大使馆卫生参赞，负责美国和加拿大区域。自 2006 年，任荷兰卫生监察局地区主任。2003 至 2006 年，任荷兰卫生部创新、职业和道德处处长。赴华盛顿之前，他是荷兰国家公共卫生研究院国际合作局副局长，负责对西欧、东欧和前苏联国家的技术援助项目和卫生发展项目。1985 至 1991 年，他负责对中东、亚洲和非洲发展中国家的卫生保健和技术援助项目。他曾在中东及其他国际机构做过 5 年的全科医生。

Peter A. Bootsma, M.D. is the Counselor for Health, Welfare and Sports at the Embassy of the Kingdom of the Netherlands in Beijing since 2014, liaising with the Chinese Government and Chinese private sector in health, welfare and sports. Previously, Mr. Bootsma was Counselor at the Royal Netherlands Embassy in Washington D.C. from 1999-2003 and 2010-2014, representing Dutch health, welfare and sports interests in the United States and Canada. Mr. Bootsma was Regional Director at the Netherlands Health Care Inspectorate as from 2006 and (Deputy) Director for Innovation, Professions and Ethics at the Netherlands Ministry of Health from 2003-2006. Prior to this Washington D.C. assignment, he was Deputy Head of the Bureau for International Cooperation at the Netherlands' National Institute of Public Health. In that position, he was responsible for technical assistance projects and health development projects in Western and East-European countries and countries of the former Soviet Union. From 1985-1991, he was responsible for health care and technical assistance projects in a variety of developing countries in the Middle East, Asia and Africa. Mr. Bootsma started his career as a General Practitioner in the Middle East and other international settings.

梁　燕
荷兰王国驻华大使馆卫生、福利和体育处生命科学和医学官员

Sunny LIANG
LSH Officer, Department of Health, Welfare and Sport, Embassy of the Kingdom of the Netherlands

梁燕，生命科学和医学官员，自 2007 年底任职于荷兰王国驻华大使馆卫生、福利和体育部门。她主要负责荷兰驻华使馆生命科学和医学、养老和体育行业的相关工作。她工作的重要内容之一是积极促进相关行业中荷产业界的商业对接，包括协助荷兰中小企业在华寻找研发、市场，投融资等合作伙伴。

梁燕毕业于大连医科大学第二附属医院肾内科专业，曾先后就职于首都儿科研究所附属儿童医院，国际 SOS 救援中心，马士基（中国）航运有限公司，以及无国界医生组织 MSF 等。

Sunny Liang, Life Science and Health Officer. She is part of the Department of Health, Welfare and Sports (VWS) of the Embassy of the Kingdom of the Netherlands since the end of 2007. Sunny is the focal point at the Embassy for the Life Science & Health (LSH), elderly care, and sport sectors. One important part of her work focuses on actively assisting relevant Dutch SME's in reaching out to potential Chinese partners, including R&D, marking partners, and investors, etc. Sunny has a master degree of Nephrology from the Dalian Medical University. She used to work at the Beijing Children's Hospital of Capital Institute of Pediatrics, International SOS, Maersk China, and MSF, etc.

穆大纬
加拿大驻上海总领事

Dave Murphy
Consul General, Consulate General of Canada in Shanghai

穆大纬先生于 2019 年 10 月被任命为加拿大驻上海总领事。在来上海之前，穆大纬先生担任加拿大驻华大使馆商务公使，这是他在北京的第二个任命。穆大纬先生的海外任职经历包括：在布宜诺斯艾利斯担任经济和贸易参赞和在台北加拿大贸易办事处担任贸易与投资主任。穆大纬先生于 1991 年加入加拿大外交及国际贸易部，曾先后担任媒体关系官员，中国和蒙古司的副主任，和投资合作项目主任。此外，穆大纬先生曾担任加拿大国际开发署产业合作项目总干事并在蒙特利尔国际的国际组织部担任副总裁。
穆大纬先生在麦吉尔大学获得农业工程科学学士学位。他拥有在蒙特利尔的卡夫食品公司担任项目工程师的私营部门工作经验。穆大纬先生会说普通话和西班牙语。

Dave Murphy was named Consul General of Canada in Shanghai in October, 2019. Most recently, Mr. Murphy was Minister (Commercial) at the Canadian Embassy in Beijing, his second assignment to that mission. He has also served overseas as Counsellor (Commercial-Economic) in Buenos Aires, and as Director (Trade and Investment) at the Canadian Trade Office in Taipei. Mr. Murphy joined the Canadian Public Service in 1991, and served in the Department of Foreign Affairs and International Trade as Media Relations Officer, Deputy Director in the China and Mongolia Division, and Director of the Investment Cooperation Program. He was seconded to the Canadian International Development Agency as Director General, Industrial Cooperation Program, and to Montreal International as Vice President (International Organizations).
Mr. Murphy holds a Bachelor of Science in Agricultural Engineering from McGill University, and gained private sector experience as Project Engineer with Kraft General Foods in Montreal. He speaks Mandarin Chinese and Spanish.

Karimah Es Sabar
Quark Venture 首席执行官兼合伙人
加拿大政府经济战略委员会（健康与生物科学）主席
加拿大政府工业策略委员会成员

Karimah Es Sabar
Chief Executive Officer & Partner, Quark Venture LP
Chair, Health & Biosciences, Economic Strategy Table (Government of Canada)
Member, Industry Strategy Council (Government of Canada)

Karimah Es Sabar 女士是加拿大生命科学领域公认的领袖，拥有丰富的全球经验，她是药物研究与发展中心（CDRD）的首席执行官兼总裁；曾担任过 BC 省生命科学行业协会首席执行官兼总裁。她不仅在大型制药公司担任高级管理职位时有杰出的表现；她还成功培养、孵化了多家初创公司。
Es Sabar 女士因卓越领导力和开创性贡献数次荣获表彰，包括加拿大 Top100 最具影响力女性。Es Sabar 女士在众多健康科技公司董事会以及研发 / 非营利组织任职。

A highly-recognized Canadian life sciences leader with global experience, she was CEO & President of the Centre for Drug Research and Development (CDRD); CEO & President of LifeSciences BC; she has had a distinguished record of senior management positions in big pharma; and she helped found and lead several startup companies internationally.
Ms. Es Sabar has received multiple awards and recognitions for her leadership and pioneering work, including Canada's Most Powerful Women: Top 100 Award. Ms. Es Sabar serves on numerous boards of health technology companies as well as R&D and not-for-profit organizations.

米璐璐
加拿大驻沪总领事馆商务处 生命科学商务专员

MI Lulu
Life Sciences Trade Commissioner, Consulate General of Canada in Shanghai

米璐璐自 2016 年起任职于加拿大驻沪总领事馆商务处。作为加拿大商务专员服务（TCS）的一员致力于推动和促进加中双边在学术、产业、贸易及投资等层面和领域的双向互动合作，以及两国之间企业和商业机构之间的专业对接；特别是协助加拿大中小型创新企业和机构在华寻找合作伙伴，拓展研发、商业转化和投融资机会。她取得乔治华盛顿大学商科硕士学位，此前曾就职于毕马威管理咨询。

MI Lulu has been a member of the Canadian Trade Commissioner Service (TCS) global network since 2016. With presence in more than 14 cities across China and over 120 years of professional experiences, TCS facilitates Canadian companies' in-market professional development and strategic bilateral engagements with on-the-ground business stakeholders. She graduated from The George Washington University with a master's degree in business, and worked in KPMG's Management Consulting practice.

03

116-177

临床数据全球首发项目介绍
Introduction of Clinical--Trial Data Release of Innovative Drugs

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
马振坤 MA Zhenkun	丹诺医药（苏州）有限公司创建人、CEO Founder & CEO, TenNor Therapeutics Limited	多靶点偶联分子抗菌新药 TNP−2092 的 II 期临床试验结果 Phase II Results of Multitargeting Drug Conjugate TNP-2092

项目简介

TNP−2092 是一个专门针对医疗器械相关生物膜感染设计的新分子实体，通过抑制细菌 RNA 聚合酶、DNA 旋转酶和拓扑异构酶三个靶点的协同作用产生对生物膜的杀菌活性。TNP−2092 已经在美国获得 FDA 合格抗感染产品、快速通道和孤儿药的资格认定。在美国 IND 和 I 期临床试验的基础上，丹诺医药近期完成了一项由 120 例急性细菌性皮肤和皮肤组织感染患者参加的多中心、随机、双盲、万古霉素对照的 II 临床试验，结果表明 TNP−2092 拥有良好的安全有效性。丹诺医药目前正开展一项 TNP−2092 在人体关节组织分布的研究，为启动针对人工关节感染的 III 期临床试验做好准备。

Project Introduction

TNP-2092 is a new molecular entity specifically designed for the treatment of medical device associated bacterial biofilm infections. TNP-2092 exerts its biofilm bactericidal activity by synergistically inhibiting three essential drug targets associated with bacterial biofilms - RNA polymerase, DNA gyrase and topoisomerase IV. TNP-2092 has received qualified infectious disease product, fast track and orphan drug designations form the US FDA. Under a US IND and building on the phase I results, TenNor has recently completed a phase II multicenter, randomized, double blind and vancomycin controlled clinical trial in 120 patients with acute bacterial skin and skin structure infections. This study demonstrated the safety and efficacy of this drug product. TenNor is currently conducting a TNP-2092 drug distribution study in joints in humans, in preparation for a phase III clinical trial in patients with prosthetic joint infections.

吴　昊 WU Hao	首都医科大学附属佑安医院主任医师 Chief Physician of Beijing Youan Hospital, Capital Medical University	新一代抗 HIV 非核苷一类新药 ACC007 III 期临床试验结果 Phase III Clinical Trial Results of ACC007, a New Generation of NNRTI for HIV

项目简介

抗艾滋一类创新药 ACC007 是全新一代的非核苷类逆转录酶抑制剂，能够快速降低患者体内病毒载量，有效减少中枢神经系统不良反应。2017 年被列入国家十三五“重大新药创制”和优先审评品种。目前已经完成了 III 期临床试验 48 周观察，试验结果良好，符合预期，已于 2020 年 6 月提交新药上市申请。具备未来上市后可能逐步替代目前国内一线治疗方案中普遍使用的非核苷类逆转录酶抑制剂的重大市场前景；上市后有望填补该细分领域国产创新药物空白、有效提高临床先进用药的可及性。ACC007 和 ACC008 作为升级版的创新药物和三合一单片复方制剂，对标国际先进，着眼中国现实，形成产品组合梯队，同时打造诊疗一体化战略。

Project Introduction

ACC007, an innovative anti-HIV drug , is a new generation of non-nucleoside reverse transcriptase inhibitors, which can quickly reduce the viral load of HIV infected patients and effectively reduce the adverse reactions of the central nervous system. In 2017, it was listed in the national "13th Five-Year" "Major New Drug Creation" and priority review varieties. The 48-week observation of the phase III clinical trial has been completed. The test results are good and in line with expectations. NDA has been submitted in June 2020. It has a major market prospect that it may gradually replace the non-nucleoside reverse transcriptase inhibitors commonly used in domestic first-line treatment plans after going on the market in the future. After launch, it is expected to fill the gap of domestic innovative drugs in this segment and effectively improve the accessibility of advanced clinical drugs. As upgraded generation of innovative drugs and its combo , ACC007 and ACC008 are benchmarking internationally advanced, focusing on Chinese reality, forming a product portfolio echelon, and at the same time creating a diagnosis and treatment integration strategy.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
宋钦辉 Tony SONG	武汉禾元生物科技股份有限公司首席医学官 CMO, Wuhan Healthgen Biotechnology Corp.	从稻米到血浆蛋白：重组人血清白蛋白在人体首次 I 期临床试验展示出良好的安全性和耐受性 From Rice to Blood: the First in Human Recombinant Human Serum Albumin Presents Safety and Well Tolerated in Phase I Clinical Trial

项目简介

HSA 约占血浆总蛋白 40−50%。二战以来用于临床至今均从血浆提取，我国市场需求约为 700 吨 / 年，60% 依靠进口。自 1981 年以来，试图使用重组 DNA 技术来替代血浆来源，其安全性、成本和规模化面临巨大挑战。禾元生物利用自主开发的 Oryz^{HiExp} 和 Oryz^{Pur} 技术平台，从稻米生产 OsrHSA 获得美国 FDA 批准临床并完成首次在人体的临床 I 期试验。研究结果表明 : OsrHSA 安全性和耐受性良好；胶体渗透压随 OsrHSA 浓度增加而显著增加；所有轻度不良反应与药物无关；没有受试者因不良反应而退出；没有不良反应与异常实验室检测结果有关；没有具有临床意义的生命体征、心电图和体检变化；PK 参数在亚裔和非亚裔可比较；没有受试者产生抗药抗体（ADA）；没有受试者在给药后产生抗 HCP 抗体。仅有一个受试者检测到增加。

Project Introduction

Human serum albumin (HSA) is constituting 40%-50% of plasma proteins and used in clinic since World War II, which is only sourced from human plasma. Market demands of HSA in China is estimated about 700 tones/year and ~ 60% of HSA is imported. Since 1981, Scientists attempt to replace of pHSA by rHSA using recombinant DNA technology. However, the huge challenges of safety, cost-effective and large scale to produce rHSA due to large dosage. Healthgen Biotechnology Corp. developed Oryz^{HiExp} and Oryz^{Pur} platforms to produce OsrHSA from rice seed. It was approved by the US FDA for clinical trials and completed a first in human of phase 1 trial in USA. The main results are: 1,OsrHSA was safe and well tolerated; 2, the colloid osmotic pressure significantly increased with increased OsrHSA concentration; 3, All TEAEs were mild, not serious, and not related to treatment. 4, No subject withdrew from the study due to a TEAE; No TEAEs related to abnormal laboratory results; 5, No clinically significant changes in vital signs, ECGs, or physical examinations; 6, The OsrHSA PK parameters were comparable across doses and between Asian and Non-Asian subjects; 7, No subjects developed ADAs; 8, No subjects developed anti-HCP antibodies post-infusion. However, an increase in anti-HCP antibodies was detected in one subject.

郑向前 ZHENG Xiangqian	天津医科大学肿瘤医院 甲状腺颈部肿瘤科行政主任 Executive Director, Department of Thyroid and Neck Oncology, Tianjin Medical University Cancer Institute and Hospital	原创新药开启甲状腺癌靶向治疗新篇章 ——安罗替尼治疗甲状腺癌研究数据解读 New Chapter in Targeted Therapy for Thyroid Cancer-Interpretation of Research Data on Anlotinib in The Treatment of Thyroid Cancer

项目简介

盐酸安罗替尼是 1 类口服、新型小分子多靶点酪氨酸激酶抑制剂。不仅拥有多靶点，而且对这些靶点均具有较强的抑制活性，能有效抑制 VEGFR、PDGFR、FGFR、c-Kit 等激酶，具有抗肿瘤血管生成和抑制肿瘤生长的作用。目前国内对于晚期无法手术的局部晚期或转移性甲状腺髓样癌患者没有很好的治疗手段。2016 年，安罗替尼治疗甲状腺髓样癌 IIA 期临床研究结果首次在 ASCO 进行口头报道，受到全球关注。基于这一可喜结果，开展了 IIB 期研究，并再次取得阳性结果。目前，安罗替尼已递交申请用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗，有望填补国内甲状腺髓样癌靶向治疗领域的空白。

Project Introduction

Anlotinib Hydrochloride, an oral and new micro molecule multi-targets RTK inhibitor that is designed to primarily inhibit kinase such as VEGFR, PDGFR, FGFR and c-Kit. It has a broad spectrum of inhibitory action on tumor angiogenesis and growth. At present, three indications for non-small cell lung cancer, small cell lung cancer and soft tissue sarcoma have been obtained. No excellent therapy is available in China for inoperable local advanced or metastatic medullary thyroid carcinoma patients. Anlotinib has shown single-agent activity, orally presented phase IIA study for medullary thyroid carcinoma at 2016 ASCO, which drew attention globally. Based on such satisfying result, phase IIA study has been implemented and achieved positive again. Anlotinib is the only targeted drug with high-quality clinical evidence in China. Currently Anlotinib has submitted application for the treatment of inoperable local advanced or metastatic medullary thyroid carcinoma and is expected to fill the blank of MTC targeted therapy domestically.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
郭明良 KUO MinLiang	中天上海生物科技有限公司资深副总裁、药物所所长 Sr. Vice President, Chief Director Institute of Pharmaceutical Research and Development, Microbio Shanghai Co., Ltd.	糖尿病足溃疡伤口新药 ON101 三期国际多中心临床试验数据报告 ON101 Topline Results of Phase III MRCT in Treatment of Diabetic Foot Ulcers

项目简介

ON101 为治疗糖尿病足伤口溃疡之创新药，药理机制为诱导伤口组织产生特定趋化因子，促使免疫细胞浸润，尤其是 M2 巨噬細胞的聚集，可抑制伤口发炎、刺激血管增生，及癒合伤口。其特殊药理作用机制，使复杂的糖尿病慢性伤口，转化成正常伤口愈合程序，加速愈合。ON101 三期国际多中心临床通过美国 FDA、中国 NMPA、台湾 FDA 之审查，于上述三地收案共 236 位糖足溃疡受试者。结果充分显示 ON101 之完全愈合率在不同的伤口状态下，与对照组相比，达到優越临床效果。在伤口次族群分析，显示其疗效之一致性，且对较困难愈合之伤口有显着之療效差異。ON101 也于三期临床试验之期中展现极佳的安全性，无严重药物不良反应。

Project Introduction

ON101 is an innovative new drug for the treatment of diabetic foot ulcers. Its pharmacological mechanism is to induce specific chemokines in wound tissues and promote infiltration of immune cells, especially the aggregation of M2 macrophage, which can inhibit wound inflammation, stimulate vascular proliferation, and ultimately heal ulcers. This special pharmacological mechanism of action allows complex diabetic chronic inflammatory wounds to be converted into normal wound healing procedures, accelerating chronic wound healing.The ON101 Phase III MRCT under IND of the US FDA, China NMPA, and Taiwan FDA, has recruited total of 236 subjects with diabetic foot ulcers from US, China and Taiwan. The results have demonstrated ON101's clinical superiority in complete healing rate to the control group under different ulcer conditions. The subgroup analysis shows that ON101 achieved robust and consistent complete healing performance across subgroups and even in hard-to-heal groups, ON101 has healed more ulcers with statistical significance. The safety profile of ON101 has been good and clean without serious adverse events.

肖英莲 XIAO Yinglian	广州市中山大学附属第一医院 消化内科教授，主任医师 Professor and Chief Physician, The First Affiliated Hospital Sun Yat-sen University	原创新药引领抗消化性溃疡新征程 ——H008 盐酸柯诺拉赞片剂 临床试验数据发布 Novel P - CAB Create New Peptic Ulcer Treatment Paradigm Clinical Trial Data Summary of H008

项目简介

化 1 类新药盐酸柯诺拉赞片（H008）是柯菲平自主研发的钾离子竞争性酸阻滞剂（P-CAB），拟用于治疗十二指肠溃疡、反流性食管炎、胃溃疡和幽门螺旋杆菌感染等。2 项中国 III 期已启动，美 IND 已获批。中国 II 期结果表明，H008（20 mg）内镜下溃疡愈合率较兰索拉唑肠溶胶囊有更快愈合趋势。临床 I 期研究显示，与富马酸伏诺拉生相比，20 mg 剂量的 H008 可表现出相当的药效。同时，最长疗效持续可达 24h，可避免常规 PPIs 的夜间酸突破现象。这是中国自主研发的首个 P-CAB 制剂。目前，柯菲平已取得中日欧发明专利授权，其美国专利也即将授权。一旦获批上市，将填补常规 PPIs 无法满足的巨大临床需求。

Project Introduction

H008 (Carenoprazan tablets) is novel, potent oral potassium ion competitive acid blocker (P-CAB) developed by Jiangsu Carephar pharmaceuticals. It provides a potentially best treatment for duodenal ulcer, non-erosive reflux disease, gastric ulcer, eradication of h. pylori. H008 already launched 2 phase III clinical trials in China, one of which for duodenal ulcer will complete enrollment in 2020. Moreover, USA FDA approved its IND with exemption of a part of clinical studies. The results of phase II clinical trials in China showed that the ulcer healing rate of H008 (20 mg) under endoscope has a tendency to heal faster than Lansoprazole enteric-coated capsules (96.36% vs 92.19%). The ulcer healing rate under the endoscope in the fourth week, H008 also tended to heal faster than lansoprazole. After multiple doses in phase I clinical trials, H008 at a dose of 20 mg showed considerable efficacy compared to Vonoprazan fumarate tablets. Furthermore, the efficacy of H008 can last up to 24 hours, avoiding the Nocturnal Acid Breakthrough of conventional PPIs. This is the first P-CAB independently developed by Chinese pharmaceuticals. Its patents were authorized in China, Japan and Europe. Moreover, its US patents is estimated to be authorized this year. Once approved for marketing, it will fill the huge clinical needs that conventional PPIs cannot meet.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
孟海津 MENG Haijin	上药博康生物医药（香港）有限公司 中国首席科学官 Shanghai Pharma-BIOCAD (HK) Limited Chief Scientific Officer (China)	Netakimab 单抗的 II–III 期银屑病临床试验结果 Results of Phase II-III Psoriasis Clinical Trial with Netakimab

项目简介

Netakimab（Efleira®）为重组人源化抗白介素 -17（IL-17）单克隆抗体。IL-17 是一种炎症相关的细胞因子，其过表达会引发炎症损伤，与多种自身免疫病的发病有关。Netakimab 由 Biocad 公司研发，是首个俄罗斯上市的原研单抗药物，其研发历程备受 RMH 关注，并已分别于 2019 年和 2020 年获 RMH 批准，用于斑块状银屑病、强直性脊柱炎及银屑病关节炎的治疗。其在银屑病患者中的 II、III 期研究共计纳入 436 例患者。其中，在俄罗斯及白俄罗斯开展的多中心临床 III 期试验（BCD-085-7/PLANETA），纳入中重度银屑病患者 213 例，治疗周期及随访长达 3 年。治疗后第 12 周随访发现，83.3% 的患者达到银屑病面积与严重性指数（PASI）改善 75%，有 1/3 的患者彻底实现皮肤康复。Biocad 公司认为，随着 Netakimab 上市，重度银屑病的治疗费用会下降 25%-30%。

Project Introduction

Netakimab (Efleira®) is an original humanized anti-interleukin-17 (IL-17) monoclonal antibody. IL-17 is an inflammation-related cytokine, and its overexpression can cause inflammatory damage and is related to the pathogenesis of a variety of autoimmune diseases. Netakimab, developed by Biocad, is the first original monoclonal antibody marketed in Russia. Its development has attracted the attention of RMH. In 2019 and 2020, it has been approved by RMH for plaque psoriasis, active ankylosing spondylitis and psoriatic arthritis. A total of 436 patients were included in the Phase II and III studies in patients with psoriasis. A multi-center phase III clinical trial (BCD-085-7/PLANETA) carried out in Russia and Belarus enrolling 213 patients with moderate to severe psoriasis with treatment period and follow-up up to 3 years. At week 12 after administration, 83.3% of patients achieved PASI 75, and 1/3 of the patients got clear. Biocad believes that with the lauch of Netakimab, the cost of treatment for severe psoriasis will drop by 25% to 30%.

路演项目介绍
Introduction of Roadshow Projects

国际云路演专场——荷兰
Virtual International Roadshow - Netherlands

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Troels Jordansen	CEO, Glycostem	癌症杀手：自然杀伤细胞抗癌药 NK Cells: The Killer of Cancer

项目简介

Glycostem 成立于 2007 年，一直专注于自然杀伤细胞（NK）疗法的研究，目前有约 40 名员工。基于脐带血干细胞 CD34+，Glycostem 开发了可以现货供应的自然杀伤细胞产品 oNKord®。I 期临床试验的结果表明 oNKord® 安全无副作用；追踪存活率，第一年达到 80%；五年达到 50%。针对急性粒细胞白血病（AML）和多发性骨髓瘤（MM）的临床试验预计于十月、十一月间启动。

Glycostem 拥有 GMP 车间洁净室，其独特的封闭式制造系统确保最终产品达到最高标准。生产过程中不需要癌细胞作为饲养细胞，因此最终产品没有包含癌症 DNA 片段或癌细胞的风险。

Glycostem 是自然杀伤细胞和 CAR-NK 细胞领域公认的领导者，oNKord® 已经授权给日本和韩国经销商，同时 Glycostem 也在积极开发和准备 CAR-NK 和 TCR-NK 前期临床活动，已经在这一领域达成了两项全球交易。

Project Introduction

Glycostem has developed NK-cells therapies and a solid GMP manufacturing process. Our NK-cell therapies include naked NK-cells (oNKord - un-manipulated) and several CAR-NK products. We are about to (October) take oNKord into pivotal trials for AMlL and MM patients. oNKord is already out-licensed in Japan and Korea but we are looking for potential partners for China and other Asian territories and are interested in exploring territory specific cancers such as liver and lung cancer. For CAR-NK we already have two global partners for whom we are developing CAR-NK products and expect to be in phase I clinical trials by 2021/2022. We are actively looking for partners for co-development of future CAR-NK products.

Since June 2019 we have had GMP license for our in-house cleanroom. In this cleanroom we have a completely closed manufacturing system which we believe is the first of its kind. This means that we will not have any contamination and can operate in a class-C environment which is less capital intensive that class A/B.

Glycostem is currently raising $40/$50 million in a cross over found raise and by 1st half 2021 we expect to be listed on NASDAQ.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Axel Mescheder	CEO, Cristal Therapeutics	改善癌症和其他疾病治疗效果的纳米药物 Customized Nanomedicines with Superior Therapeutic Profiles

项目简介

CriPec® 纳米药物平台通过改善药物动力学与生物学分布，提高药物的耐受性与组织靶向性。CriPec® 可与小分子、多肽、寡核苷酸药物结合，既可调控药物释放速率，也可经靶向配体功能化提升选择性。CriPec® 纳米药物生产步骤简易、成本低，大规模（GMP）生产成熟且可制备冻干剂型。

先导产品 CPC634（CriPec® 包埋的抗肿瘤药多西他赛）已进入实体瘤 II 期临床试验。临床数据证实相较传统多西他赛，CPC634 延长了药物体循环时间、提高了安全性并显著提升药物的肿瘤摄取。

公司的点击化学专利技术 CliCr® 可高效合成各类新型偶联物，CriVac® 平台则可通过模拟病毒特性，快速提供应对不同病原体的疫苗方案。

Project Introduction

Cristal Therapeutics is a clinical stage company developing innovative products for improved treatments of cancer and other diseases. The CriPec® nanomedicine platform improves tolerability and enabling selective tissue targeting of therapeutic agents via prolonged pharmacokinetics and improved biodistribution. CriPec® can be combined with small molecules, peptides and oligonucleotides, with tuneable drug release kinetics and option to increase selectivity by functionalizing CriPec® surface with targeting ligands. The manufacturing of CriPec® nanomedicines is a straightforward with low cost of goods, and large (GMP) scale production is already in place including freeze-drying.

The lead product CPC634 (CriPec® entrapped docetaxel) is in clinical phase 2 for the treatment of solid tumors. The clinical data so far have demonstrated prolonged systemic circulation, improved safety and significantly enhanced tumour uptake as compared to the conventional docetaxel.

The click chemistry platform "CliCr®" generates superior and novel conjugate products, whilst CriVac® platform can generate virus mimics and thereby offers a prophylactic vaccination strategy readily adaptable to different pathogenic threats.

Jeroen Tonnaer	BD&Licensing, PureIMS	可快速投放市场的低成本预装式一次性干粉吸入器 Cyclops™, a Low-COG Innovative Preloaded-disposable DPI with Fast to Market Applications

项目简介

PureIMS 是一家进行临床阶段研究的公司，基于其专有的、预装和一次性 DPI（干粉吸入器）平台 Cyclops™，开发了一系列快速创造价值的许可机会。Cyclops™ 是经 CE 认证的医疗器械。它的设计和功能性具有低成本的特点，并受专利保护，直到 2034 年。现已上市一种 Cyclops™ 产品（用于囊性纤维化）并在同情用药方案下予以报销。

PureIMS 成立于 2014 年，是格罗宁根大学和医疗设备制造商 IMDS 的子公司，总部位于荷兰 Roden。该公司是在种子资金的基础上成立的，目标是进行约 2500 万欧元的 A 轮融资。通过融资的收益，公司将实施其两个牵头项目（神经学和过敏症研究的第二阶段），并通过 505(b)(2)/10(3) 条规定获得市场许可。此后公司将开发三个符合第 505(b)(2)/10(3) 条规定的后续项目，直至达到人类试点 –PK 里程碑，并将获得许可。Cyclops™ 平台可进行半独家许可。

Project Introduction

PureIMS is a clinical stage company developing a portfolio of rapidly value creating licensing opportunities based on its proprietary, preloaded and disposable DPI (dry powder inhaler) platform Cyclops™. Cyclops™ is a CE-marked medical device. Its design and functionality imply low COG and are patent protected until 2034. One Cyclops™ application (colistin for the indication cystic fibrosis) is on the market and reimbursed under a compassionate use regimen.

PureIMS was established in 2014 as a spin-off from the University of Groningen and medical device manufacturer IMDS and is based in Roden, The Netherlands. The company was founded on the basis of seed funding. The company is aiming at a Series A financing round of ~EUR 25M. Through the proceeds of the financing round the company will pursue its two lead programs (Phase 2 in neurology and allergy) to market authorization via the 505(b)(2)/Article 10(3) pathways, and develop three follow-on 505(b)(2)/Article 10(3)-qualifying programs in different indications until the human pilot-PK milestone upon which they will be out-licensed. The company's platform Cyclops™ is available for semi-exclusive licensing.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
CHEN Jiehui	Asia CEO, iDNA	基于肺癌的多病种一体化筛查项目 iDNA-Providing Turn-key Solution for Lung Cancer Based Multi-Comorbidities Screening Program

项目简介

iDNA 是唯一一家负责欧洲最大的肺癌筛查实验项目——4ITLR 的私人研究所。iDNA 依托国际领先的 NELSON 肺癌筛查方案，以及对肺癌、慢阻肺、冠脉病、肺炎患者胸部 CT 影像的深度理解，可以为医院 / 体检中心提供低假阳性、高精准度的肺癌筛查全流程解决方案。在筛查肺癌的同时，允许单次扫描辅助筛查慢阻肺、冠脉病、肺炎（包括新冠肺炎），提升筛查项目的成本效益。iDNA 的全流程解决方案包括且不限于：高危人群的筛选与招募、信息系统数据管理、CT 设备调试与校准、现场 / 远程 CT 影像数据评估、医护人员的标准化培训、流程管理以及全球领先的 AI 筛查软件。

Project Introduction

iDNA is the only private institution who is responsible for the CT imaging in a biggest European Lung Cancer screening project within Horizon 2020 program. iDNA has the experience in carrying out lung cancer screening programs in large population. In reliance on iDNA's advanced lung cancer screening method based on NELSON study, as well as its deep understanding in CT images of lung cancer, COPD, coronary artery disease and pneumonia (also Covid-19), iDNA can provide hospitals, health check centers with low false-positive and highly accurate turn-key lung cancer screening solution allowing diagnosis of lung cancer, COPD, coronary artery disease and pneumonia with only one scan. iDNA's turnkey solution includes but not limited to implementing high-risk population profiling, recruitment, (ICT) data management, CT calibrating technology, on-site/remote evaluating CT imaging data, training on-site personnel on SOPs, and state-of-the-art AI software.

Ernst Elhorst	CEO, SuperSeton	操作简单、安全可靠的创新型肛瘘挂线 SuperSeton-A smooth, Simple and Safe Innovative Solution for Anal Fistula Drainage

项目简介

SuperSeton 是一种用于肛瘘管引流的光滑、简单且安全的解决方案，可显著减轻患者在手术中的疼痛感和术后的不适感。相比于现有肛瘘管引流手术中常用的带有绳结的挂线，SuperSeton 没有绳结且表面光滑，同时配备了拥有专利设计的创新连接头和一次性连接器，使用起来安全、灵活，可以在几秒钟内手动完成闭环动作。该产品已在欧洲获得 CE 认证 IIA 类证书，并已在欧洲市场销售。SuperSeton 目前已经在欧洲、美国、印度、日本和中国申请专利保护。与此同时，我们准备从中国寻求合作伙伴（和投资者），使我们也能够为中国患者提供服务。

Project Introduction

SuperSeton is a smooth, simple and secure solution for fistula drainage that prevents unnecessary irritation and discomfort for patients. Knotless and smooth, SuperSeton features an innovative closure that is secure and flexible, and can be applied manually in seconds with the patented disposable applicator. The product is registered in Europe as a CE Class IIA device and is available on the European market. Currently patients are treated and enjoying the comfort provided by SuperSeton

As we have filed for patent protection in Europe, US, India, Japan and China, we are ready to seek partnerships (and investors) from China, enabling us to also serve the Chinese patients. In the end, the SuperSeton has been developed and designed with the patient in mind, providing comfort where needed.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Jeroen Kodde	CEO, Kaminari Medical	结合超声与光学成像技术的新型冠状动脉血管重建术 Kaminari Medical: Combining Ultrasound and Optical Imaging to Revolutionize Coronary Revascularization

项目简介

Kaminari 通过将超声和光学成像结合到血管内光声（IVPA）设备中，开发出了一种血管内窥镜来对冠状动脉内部进行成像。Kaminari 的 IVPA 系统包括一个用于信号生成和分析的控制台，以及一个带有远端尖端的导管，该导管置于冠状动脉之中。

导管的总长度约为 1.80 m，由一个外套（直径 1 mm）和一个内芯组成，远端带有光声换能器（直径 0.6 mm）。在冠状动脉的数据采集过程中，末端带有换能器的内核被拉回大约 10 厘米，并以每分钟 1200−3000 转的速度旋转。在概念验证的演示中，我们使用了原型导管，该导管达到预期的效果。利用这种技术，可以确定斑块的结构和组成。IVPA 是唯一可以实现此目的的技术。

Project Introduction

Kaminari develops an intravascular catheter to image the coronary arteries by combining ultrasound and optical imaging into an Intra Vascular Photo Acoustic (IVPA) device that will significantly reduce major adverse cardiac events and recatherizations.

Kaminari Medical's IVPA system consists of a console for signal generation and analysis, and a catheter with a distal tip that is placed in one of the coronary arteries.

The catheter has an overall length of ca. 1.80 m and consists of an outer sheath (diameter 1 mm) and an inner core with the photo-acoustic transducer (diameter 0.6 mm) at the distal end. During data acquisition in the coronary artery, the inner core with the transducer at the end is pulled back ca 10 cm and rotated at 1200 - 3000 revolutions per minute. In the proof of concept demonstration we used a prototype catheter that performed sufficiently for the purpose. With this technology the structure and the composition of the plaques can be determined. IVPA is the only technology that can achieve this.

Jaap Delange	CEO, Respiosa	用于治疗阻塞性睡眠呼吸暂停综合症的微创手术植入物 Respiosa OSA Implant Technology

项目简介

Respiosa OSA 植入术（CE 认证 II B 类医疗器械）是一种简单、微创的外科手术植入解决方案，可为由于舌头造成的阻塞性睡眠呼吸暂停症提供最佳治疗。当患者仰卧睡觉时，Respiosa 可防止舌头塌陷入气道。手术可在 30 分钟内完成，有效减少患者创伤，且术后恢复快。术后，植入物可以通过配套的全套仪器进行完全去除。由于 Respiosa 使用了纯天然的材料，患者不会感觉到植入物的存在，材料也不会与身体产出排异反应，因此在附着力方面不存在问题。此外，Respiosa 还可以用于治疗由于舌头阻塞导致的打鼾症状。Respiosa 的设计经过了严格的产品测试、临床专家认可以及广泛的临床前动物研究以及早期的 2 期临床试验。

Project Introduction

Respiosa OSA Implant Technology (Class IIb); a simple, minimally invasive surgically implanted solution to provide optimal therapy for tongue based OSA. Respiosa prevents the tongue from collapsing into the airway when patients sleep on their backs. Designed and tested by world-class developers with ENT surgeons, the novel Respiosa implant system promises to deliver effective, durable and adjustable therapy. The implant can be placed with a 30-minute procedure, offering low trauma and quick recovery. Respiosa's effect is optimized with an in-office adjustment procedure post-surgery. The implant can be completely removed. A removal kit includes all instruments required for a removal procedure. Since Respiosa is natural and unobtrusive, patients don't feel the implant, or interact with it, thus adherence is not an issue. Respiosa's indications will also include tongue-based snoring. Respiosa's design has been refined with robust bench testing, KOL feedback, and extensive preclinical (animal and cadaver) studies as well as an early stage Phase 2 clinical trial.

国际云路演专场——加拿大
Virtual International Roadshow - Canada

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Bill Hunter	President & CEO, Canary Medical Inc.	Canary——智能慢病管理和虚拟医疗的交叉创新

项目简介

Canary Medical 的首个产品是装备有 Canary 健康植入报告处理器（CHIRP）的智能胫骨延长器，与全膝关节置换（TKA）系统配合使用。CHIRP 收集患者一天的步态指标，通过家庭基站将其上传到 Canary 符合 HIPAA 标准的云中，分析后提供给临床医生和患者。它能为外科医生提供大量数据参考，以较低的成本增强医疗团队管理、患者沟通和长期疾病管理。Canary 向 FDA 提交了 CHIRP 及其相关生态系统的 De Novo 510K 申请，被 FDA 授予首个全关节产品“突破性设备”。预计 2020 年下半年提交并在 2021 年上半年获批。

Project Introduction

Canary Medical's first product, the Canary Health Implanted Reporting Processor (CHIRP) smart tibial extension, is designed to be used in conjunction with its world-leading othopaedic partner's Total Knee Arthroplasty (TKA) system. The CHIRP collects patient gait metrics, range of motion, recovery and complication data and uploads this to Canary's HIPAA compliant cloud via a home base station for analysis and presentation to the Clinician and Patient. This rich data set provides Surgeons with the ability deliver healthcare passively and remotely for up to 20 years after surgery resulting in better disease management and lower costs. Canary has received Breakthrough Status from the FDA for the TKA product, a first in total joint products. It is targeting to submission for H2 2020 and anticipates an approval in H1 2021.

Mohammad Qadir	President & CSO, Fusion Genomics Corp.	用于预防传染病的多重基因诊断技术 Massively Multiplex Diagnostics for Infections Diseases

项目简介

Fusion Genomics Corp 的 ONETest™ 泛病原体测试可以响应包括未确诊（特发性）感染在内的众多诊断应用场景，其测试平台的核心技术均已突破概念验证和临床研究阶段。每年因该感染需要入院治疗的美国患者达数百万计，而目前的分子方法无法有效诊断这些感染，导致治疗效率低下、住院治疗负担居高不下以及与抗生素耐药性叠加。由此导致的医疗成本总计超过 270 亿美金。

Fusion Genomics 已经与包括加拿大 Sunnybrook Health Sciences Centre、佛罗里达大学、西雅图儿童医院等多家杰出研究机构合作验证并探索 ONETest™ 的商业转化问题。公司的愿景是提供基于基因组信息的准确诊断，以经济有效、及时并低成本的方式，指导治疗、检测抗生素耐药性和识别宿主（人类）疾病易感性标记，从而造福有需要的患者群体。

Project Introduction

Fusion Genomics's product, ONETest, has broad application and would reduce hospital costs and save lives by diagnosing diseases that are currently impossible or difficult to detect. Today, this category of diseases represents a surprising percentage of hospital admissions and costs the US healthcare system $27 billion each year. All technologies necessary for such a test have been developed to the proof-of-concept or clinical study stage and are now being commercialized by Fusion Genomics.

Fusion Genomics has partnered with world class institutions, such as Sunnybrook Health Sciences Centre, University of Florida, Dutch National Institute and Seattle Children's Hospital, to validate the ONETest and plans to commercialize it soon. Fusion Genomics' mission is to make these genomic tests for infectious diseases as ubiquitous and cost-effective, as today's PCR and antibody tests. The ultimate aim is to have an automated, easy to use, rapid test that costs just $100 and can spot novel viruses as they emerge in humans.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
Karim Lalji	CEO, Microbion Pharma Corp.	Pravibismane： 治疗生物膜感染的创新疗法 Pravibismane: Breakthrough Therapy against Biofilm-related Chronic Infections

项目简介

Microbion 是一家临床阶段的制药公司，重点开发突破性的疗法，用于治疗耐药性和危及生命的感染。Microbion 的主要药物为 Pravibismane（普拉维比斯曼）一首个已知的广谱抗感染药物，能够对抗各种耐药细菌 / 超级细菌、高度耐药真菌物种，可高效破坏细菌生物膜，并防止其形成。

Microbion 的药物开发项目针对医疗需求高度未满足的专业市场，预计销售额峰值超过 40 亿美元。Microbion 的局部 / 部分 Pravibismane 试验处于临床 II 期，用于治疗糖尿病足部溃疡（DFI）和整形外科植入物感染。在超过 325 个受试者中，该局部试验已被证明耐受性良好，具有疗效。

Microbion 正在募集资金，用于 DFI 中的 II 期概念验证，以及推进囊性纤维化（CF）患者的第 1b 期吸入临床试验。

Project Introduction

Microbion is a clinical-stage pharmaceutical company developing breakthrough therapies for treatment of drug-resistant and life-threatening infections. Our lead drug candidate, pravibismane, is a new class of broad-spectrum anti-infective with combined potency against a wide range of resistant bacteria, highly resistant fungal species, and an unprecedented ability to prevent and eradicate bacterial biofilms.

Microbion's topical/local pravibismane program is in Phase 2 for the treatment of diabetic foot ulcer (DFI) and orthopedic infections while the inhaled program for cystic fibrosis (CF) related- and non-tuberculous mycobacterial- lung infection, has been awarded over $17M in funding from CARB-X and the Cystic Fibrosis Foundation and Orphan Drug designation (for CF-related infection) from the FDA, is expected to start phase 1 studies in H2 2021. Microbion's drug development program targets specialty markets with high unmet medical need and represent over $4B in peak sales opportunity.

Microbion is seeking funding to complete Phase 2 proof of concept in DFI and advance inhaled program through Phase 1b.

ZHANG Hao	CEO, Onestep Laboratories Inc.	独创“芯片级”免疫分析及血液分析原材料 Raw Materials for IVD

项目简介

Onestep Lab 公司是一家致力于研发世界最前沿的医疗诊断试剂原材料的创新公司，目前已拥有多项“芯片”级发明，应用在各个不同的领域。例如，美国发明专利 US9714939 是应用在酶免疫分析方法学上，可应用在传染病检测，癌症检测，抗体药筛选；美国发明专利 US10597352 是应用在水中的氯监测，可应用在肾病透析病人的透析水监测。公司的目标是成为世界一流的医疗原材料公司，为科学家们提供更好的产品和服务，从而造福人类。

Project Introduction

Onestep Laboratories Inc. draws upon years of experience in biochemistry and diagnostics to develop leading-edge reagents for biological laboratories. Our goal is to provide fellow scientists with high quality, cost effective products. Onestep Laboratories Inc. has developed several products including QuickBlu TMB substrate (US 9714939) for ELISA, TMB solution (US 10597352) for monitoring total chlorine in dialysis water and QuickRedTM Nucleus Stain for live cell imaging.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
ZHANG Zaihui	CSO & VP R&D, Signalchem Lifesciences Corp.	SLC-391——用于癌症治疗的临床阶段小分子 AXL 抑制剂 SLC-391 - A Clinical Stage Small Molecule AXL Inhibitor for Cancer Therapy

项目简介

SLC-391 是具有高活性、高选择性、低毒性和药物性质优异的临床阶段的小分子 AXL 抑制剂，具有适合的半衰期和很高的生物利用度 (>50%)。在非小细胞肺癌动物模型实验中，它与厄洛替尼和紫杉醇联用在抑制肿瘤生长方面显示出强大的协同作用。在 AML 白血病模型和 PDX 模型中，与 BCL−2 抑制剂 venetoclax 的联用显示出在减少白血病负担和增强白血病动物存活率方面的强大协同效应。在 CT−26 结肠癌同基因癌症动物模型实验中，该化合物显示具有调节和提高机体固有性免疫功能以及继发性免疫功能的能力。该化合物在与 PD−1 单克隆抗体的组合治疗中表现出很强的协同效应。目前，SLC−391 正在加拿大的多个癌症中心进行 I 期安全性临床实验，剂量扩增实验阶段预计将于 2020 年底完成。

Project Introduction

SLC-391 is clinical stage small molecule AXL inhibitor with good potency and selectivity with desirable pharmaceutical properties. The pharmacokinetic studies in rodents and dogs indicated that SLC-391 has high bioavailability with a simple suspension formulation (>50%). Moreover, it has exhibited a strong synergistic effect in tumour growth inhibition in combination with erlotinib and paclitaxel in NSCLC xenograft models and demonstrated a strong synergistic effect in decreasing leukemia burden and enhancing survival of leukemic animals in a novel combination approach with BCL-2 inhibitor venetoclax in aggressive xenotransplant AML leukemic models and PDX models. In a CT-26 colon cancer syngeneic model, SLC-391 played a role in modulating both the innate and adaptive immune responses and demonstrated a synergistic effect in tumour growth inhibition and overall survival in combination with an anti-PD-1 antibody. Currently, SLC-391 is under phase I safety clinical evaluations in multi-cancer centres in Canada and the dose expansion phase is anticipated to be complete by the end of 2020.

Michael Parr	President & CSO, Sitka Biopharma Inc.	突破障碍：运用纳米技术治疗膀胱癌 Breaking through Barriers: Nanotechnology Therapeutics Platform with a Lead Program for Bladder Cancer

项目简介

云杉（Sitka）生物制药公司是一家临床前生物技术公司，专注于开发具有突破性的纳米粒子平台技术，以增加药物在难以穿透的组织中的吸收。我们正在开发的领先药物（STK-01），最初针对肿瘤适应症，以解决膀胱癌膀胱内化疗的吸收挑战，以及卵巢癌腹腔内给药的问题。

我们的纳米粒子平台技术用途广泛，与其他纳米输送系统相比具有独特的优势，特别适合于治疗目前无效或不安全的相对局部疾病。膀胱癌被选为我们的治疗目标，因为该病症具有有限的吸收和疗效、或有重大耐受性问题和副作用等挑战。Sitka 的新产品（STK-01）旨在通过将更高浓度的化疗多西紫杉醇直接输送到膀胱壁中，从而克服这些问题并改善治疗效果。

Project Introduction

Sitka Biopharma is a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues. Initially targeting oncology indications, we are developing our lead candidate (STK-01) to address the absorption challenge of intravesical chemotherapy for bladder cancer, and later intraperitoneal delivery for ovarian cancer.

Our nanoparticle platform technology is highly versatile, offers unique benefits over other nano-delivery systems, and is particularly well-suited for treating relatively localized diseases where local administration of the therapeutic is possible but is currently ineffective or unsafe. Bladder cancer was chosen for our lead program because it is characterized by therapies that exhibit limited uptake and efficacy, or are associated with significant tolerability issues and side effects. Sitka's novel product (STK-01) is designed to overcome these issues and improve treatment outcomes by delivering a much higher concentration of the chemotherapeutic docetaxel into the bladder wall.

上市公司专场
Listed Company Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
姜　华 JIANG Hua	绿叶制药集团有限公司副总裁 Vice President of Luye Pharma Group Ltd.	绿叶制药——走出差异化的创新与国际化道路 Luye Pharma - Differentiated Development Road of Innovation and Internationalization

项目简介

绿叶制药是致力于创新药物的研发、生产和销售的国际化制药公司。绿叶制药在中国、美国和欧洲设有研发中心，拥有超过 40 个中国在研药物和 10 多个海外在研药物，在中枢神经和肿瘤领域已有多个创新制剂和创新药在欧洲、美国、日本开展注册及临床研究。绿叶制药在微球、脂质体、透皮释药等先进药物递送技术领域达到国际先进水平，并在生物抗体、细胞治疗、基因治疗等领域进行了积极布局和开发。 绿叶制药已在全球建有 8 大生产基地，超过 30 条生产线，并建立了与国际接轨的 GMP 质量管理和控制体系。公司现有 30 余个上市产品，产品覆盖肿瘤、中枢神经、心血管、消化与代谢等治疗领域；业务遍及全球 80 多个国家和地区。

Project Introduction

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 40 drug candidates in China and more than 10 drug candidates in other international markets. Along with a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. Europe and Japan, Luye Pharma has reached high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems, as well as actively making strategic developments in the fields of biological antibodies, cell therapies and gene therapies, among others.Luye Pharma is developing a global supply chain of 8 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as in fast growing emerging markets.

王昌进 WANG Changjin	前沿生物药业（南京）股份有限公司总经理 CEO of FRONTIER BIOTECHNOLOGIES Inc.	原创新药 引领全球抗艾新征程 前沿生物 同创中国新药新时代 Innovative Medicine, Leading the Global Anti - AIDS Campaign.Frontier Biotech, Creating the New Era of Chinese Medicine.

项目简介

前沿生物是一家立足中国、面向全球，具有国际竞争力的创新型生物医药企业，致力于研究、开发、生产及销售针对未满足的重大临床需求的创新药。

公司核心产品为国家一类新药、中国首个治疗艾滋病的原创新药、全球首个长效 HIV 融合抑制剂 -- 艾可宁，于 2018 年 5 月获得新药证书。公司正在加速新药产品线的全球开发，其中，艾可宁 +3BNC117 联合疗法是一款聚焦全球市场的抗艾新药，拟每 2 周 -4 周给药一次，旨在替代现有口服疗法，且有望探索艾滋病功能性治愈，其中联合疗法维持治疗适应症处于美国 II 期临床阶段。新型透皮镇痛贴片 AB001 已于 2020 年 3 月完成中国桥接 I 期临床试验，I 期临床试验结果达到预设的终点指标。

Project Introduction

Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health. Our medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management.

Frontier Biotech's first commercial product was approved by the National Medical Product Administration (NMPA), which is the counterpart of the Food and Drug Administration (FDA) in China, in May 2018 through a priority review process and has gained accelerated approval. Two additional drug candidates are currently undergoing multiple clinical trials in Phase I and Phase II in both China and the United States. Frontier Biotech brings together many of the best scholars, scientists, and professionals in R&D, senior management, marketing, international business development, and manufacturing. At Frontier Biotech, our long-standing commitment to excellence is in everything we do throughthe entire development cycle from drug discovery, preclinical research to global clinical development. This approach has enabled Frontier Biotech to emerge in the global market as a competitive player in the field of HIV long-acting treatment and immunotherapy.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
孟　渊 Isaac MENG	天境生物科技（上海）有限公司副总裁、医学办公室负责人 VP/Head of Medical Office, I-Mab Biopharma Co., Ltd.	关于天境生物——打造具有“全球首创”和“同类最优”潜力的创新管线 About I-Mab - Building a Pipeline of Potential Novel and Highly Differentiated Medicines

项目简介

天境生物是一家富有活力的国际生物科技公司，聚焦肿瘤免疫和自身免疫疾病领域差异化创新生物药的研发，以“持续开发创新生物药，真正改变患者生活”为使命。天境生物在“快速产品上市”和“快速概念验证”的双轮策略驱动下，通过自主研发和全球合作等多元化模式，迅速建立起拥有十多个具有全球竞争力的创新药研发管线。天境生物凭借优秀的药物研发团队、倍受认可的临床前及临床开发实力，以及世界一流的 GMP 生产能力，正快速成长为覆盖全产业链的综合性全球生物制药公司。

Project Introduction

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on developing biologics of novel or highly differentiated in the therapeutic areas of immuno-oncology and autoimmune diseases. Company's mission is to bring transformational medicines to patients through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven preclinical and clinical development expertise, and world-class GMP manufacturing capabilities

卢　燕 LU Yan	开拓药业有限公司 CFO CFO of Kintor Pharmaceutical Limited	开拓药业——中国领先的 AR 新药研发企业 Kintor Pharmaceutical Limited - The Leading Anti-Androgen Receptor (AR) Novel Drugs Developer in China

项目简介

开拓药业专注发展潜在“best−in−class”和“first−in−class”创新药物的研发及产业化，致力成为创新疗法研究、开发及商业化的领军企业。公司以雄激素受体 (AR) 相关疾病为核心，研发多通道产品组合，产品覆盖全球高发病率癌症及其它未满足临床需求的疾病领域，包括前列腺癌、乳腺癌、肝癌和脱发等。开拓药业前瞻性布局了包含小分子创新药、生物创新药及联合疗法的多元化产品管线，包括 5 款正在开展临床研究的产品雄激素受体（AR）拮抗剂、ALK−1 单抗、mTOR 激酶靶向抑制剂和 Hedgehog 抑制剂，以及正在进行临床前研究的 AR−Degrader、c−Myc 抑制剂和 IDO 抑制剂等。

Project Introduction

Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialisation of “best-in-class” and “first-in-class” innovative drugs, and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. The Company was founded by national-level talents, after years of development, centered upon androgen receptor (AR) related diseases and researched and developed product portfolios in multiple channels covering cancers with a globally high incidence and illnesses yet to meet their clinical requirements, such as prostate cancer, breast cancer, liver cancer and hair loss. Kintor Pharmaceuticals has prospectively deployed a diversified product pipeline that includes small molecule innovative drugs, bioinnovative drugs and combination therapies, including 5 products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as AR-Degrader, c-Myc inhibitors and IDO inhibitors that are undergoing preclinical research. Globally, the Company owns more than 60 patents, many of which are listed as the “Major New Drugs Discovery” in National 12th and 13th Five-Year Plans. On 22 May 2020, the Company was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
宋郑薇 Wendy SONG	信达生物投资者关系与财务策略总监 Director of Investor Relation and Financial Strategy, Innovent Biologics	后疫情时代，生物创新药企的机遇和挑战 Opportunities and Challenges: Biopharm in the Post Era of COVID19

项目简介

信达生物成立于 2011 年，致力于开发、生产和销售用于治疗肿瘤等重大疾病的创新药物。2018 年 10 月 31 日，信达生物在香港联交所主板挂牌上市，股票代码：01801。公司已建立起一条包括 23 个新药品种的产品链，覆盖肿瘤、代谢疾病、自身免疫等多个疾病领域，其中 3 个产品获得 NMPA 批准上市销售，1 个单抗产品上市申请被 NMPA 受理并被纳入优先审评，4 个产品进入 III 期或关键性临床研究，另外还有 15 个产品已进入或即将进入临床研究。信迪利单抗已于 2019 年 11 月成功进入国家医保目录，成为唯一一个进入新版国家医保目录的 PD-1 抑制剂。

Project Introduction

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 3 products on market, 1 assets under NDA review with priority review status, 4 assets in Phase III or pivotal clinical trials, and additional 15 molecules in or close to clinical trials. TYVYT has been the only PD-1 inhibitor included in the NRDL since 2019.

童少靖 TONG Shaojing	北京诺诚健华医药科技有限公司首席财务官 CFO of Beijing InnoCare Pharma Tech Co., Ltd.	新药创制方兴未艾，诺诚健华志在千里 InnoCare - Thriving in the Burgeoning Field of Innovative Drug Development

项目简介

诺诚健华（09969.HK）是一家处于临床阶段的生物医药公司，专注于肿瘤及自身免疫类疾病治疗领域的一类新药研制。现有多个新药产品处于临床及临床前研发阶段。公司在北京、南京、上海、广州、美国新泽西和波士顿均设有分支机构。在过去五年凭借我们管理团队的全球视野及本土专业经验，我们已建立强大的在研产品管线，其中包括一款候选药物－奥布替尼，已就两项适应症提交上市申请，并均获得优先评审，两款候选药物处于临床 I/II 期阶段，一款候选药物于近期已取得 IND 批准，还有若干款候选药物正处于 IND 准备阶段。

Project Introduction

InnoCare Pharmaceuticals is a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.In the past five years, leveraging on our management team's global vision and local expertise, we have built a robust pipeline that includes one asset - Orelabrutinib with two NDAs submitted, accepted and granted priority review by the NMPA, two assets in Phase I/II trials, one that recently obtained IND-approval and several others at the IND enabling stage.At InnoCare, we encourage innovation and creative thinking. We have adopted an open and organized R&D system with the concepts of clear and transparent communication, timely and effective execution, as well as flexible and rapid action. We believe that "common goals, mutual trust, and cooperation" will unify and strengthen our team. These principles constitute the key foundation to the competitiveness of our company and the essential elements to ensure our success in becoming a global leader in the biomedical industry.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
王　歙 WANG Yu	永泰生物制药有限公司首席执行官、联席首席科技官 CEO and Co-CTO of Immunotech Biopharm Ltd.	肿瘤细胞免疫治疗：疗效与挑战 Cellular Immunotherapy on Tumours: Effects and Challenges

项目简介

近年来，免疫治疗彻底改变了癌症的治疗方式。癌症免疫治疗旨在刺激患者自身的免疫系统，以产生或增强抗肿瘤免疫反应，从而控制或根除癌细胞。由于其能够提供相对持久的疗效，细胞免疫治疗在癌症治疗领域的应用标志着新里程碑。永泰生物是中国一家领先的细胞免疫治疗生物医药公司，14 年来专注于 T 细胞免疫治疗药物研发和商业化，其核心在研产品 EAL 是中国首款、也是目前为止唯一一款获准进入实体瘤（肝癌）治疗 II 期临床试验的细胞免疫治疗产品。除了 EAL 外，永泰生物的在研产品还包括 CAR-T 细胞系列和 TCR-T 细胞系列。永泰生物的创始人王歙博士将基于近 30 年 T 细胞的研发经验，介绍细胞免疫治疗在癌症治疗领域的疗效与挑战。

Project Introduction

Recently, cancer immunotherapy has revolutionised cancer care. Cancer immunotherapy is designed to stimulate a patient's own immune system to generate or augment an anti-tumour immune response in order to control or eradicate cancer cells. Due to its ability to provide relatively durable remissions, the application of immunotherapy in cancer in recent years have marked a milestone in cancer treatment. Immunotech Biopharm is a leading cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialisation of T cell immunotherapy for almost 14 years. EAL, the core product candidate of Immunotech Biopharm, is the first cellular immunotherapy product in China approved for entry into a Phase II clinical trial, and by far, the only that had been approved for application in a Phase II clinical trial for solid tumour (liver cancer) treatment. Other than EAL, the main product candidates of Immunotech Biopharm include the CAR-T cell series and the TCR-T cell series. The founder of Immunotech Biopharm, Dr Wang Yu, will, based on her almost 30 years T cell related R&D experiences, introduce the effects and challenges for cellular immunotherapy on tumours.

李　盈 Lily LI	贝达药业股份有限公司战略合作副总裁 Vice President of Strategic Collaboration of Betta Pharamaceuticals Co., Ltd.	From Insight to Foresight——贝达创新路径与布局 From Insight to Foresight - Betta's Innovation Strategy and Pathway

项目简介

贝达药业自 2003 年成立以来，一直致力于内部自主研发与战略合作引进相结合，扩充公司产品线。今年针对 ALK 突变非小细胞肺癌患者的靶向药恩沙替尼即将在国内上市，其一线全球临床试验达到终点，有望成为贝达第一款全球上市的产品。贝伐单抗生物类似药 MIL60 项目完成注册临床试验，BLA 申报获得受理。三代 EGFR 抑制剂 BPI-D0316 与 CM082 注册临床顺利推进，有望于近期申报 NDA。此外，贝达自主研发多个项目获得临床批件，并推进至早期临床阶段。

贝达今年与 Agenus 签署合作协议，引进 PD-1 和 CTLA-4 两款单抗项目，填补了贝达在大分子肿瘤免疫领域空白。今后贝达将持续打造以肺癌为中心并扩充到其它肿瘤领域的创新药物研发管线，为国内广大癌症患者提供更多治疗方案。

Project Introduction

Since established in 2003, Betta has been focusing on internal R&D and external partnerships to expand its oncology pipeline. Ensartinib, a 2nd-gen ALK TKI will be launched in China this year, while its global PhIII study has reached its primary endpoint and will become Betta's first globally launched product. Bevacizumab biosimilar MIL60 has completed its registrational clinical trial and submitted for BLA. The registrational clinical studies of the 3rd-gen EGFR TKI - BPI-D0316, and the VEGFR TKI - CM-082 have progressed significantly and will file for NDAs in the near future. Furthermore, multiple in-house programs have obtained INDs and moved into clinical stage.

Furthermore, Betta has established a partnership with Agenus, Inc. this year, licensing in PD-1 mAb balstilimab and CTLA-4 mAb zalifrelimab, filling the last missing piece for Betta's lung cancer treating puzzle. Betta will continue to expand its innovative oncology pipeline and benefit cancer patients in China.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
陈　晨 Michael CHEN	康方生物医药有限公司商务拓展副总裁 Business Development VP of Akeso, Inc.	康方生物率先驶入双抗蓝海 Akeso and Bi-specific Antibody

项目简介

AK104 是康方生物自主研发的新型、潜在下一代首创 PD−1/CTLA−4 双特异性肿瘤免疫治疗药物，可同时靶向两个经过验证的免疫检查点分子；因此已显示出 PD− 1 及 CTLA− 4 单克隆抗体联合疗法的临床疗效以及 PD−1 和 CTLA−4 单克隆抗体联合疗法无法提供的良好安全性。AK104 项目是 2017 年国家卫健委及科技部十三五“重大新药创制”科技重大专项支持项目，2017 年广东省“珠江人才计划”引进创新创业团队支持项目。被中国医药生物技术协会和《中国医药生物技术》杂志共同评为“2017 年中国医药生物技术十大进展”之一。

Project Introduction

Akeso, Inc. (9926.HK) is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide. Since our establishment, the Company has established an comprehensive in-house drug development platform (ACE Platform), encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, process development, and GMP-compliant commercial scale manufacturing. AK104 is a potential next-generation, first-in-class humanized IgG1 tetrameric bi-specific antibody drug candidate that is developed in house by Akeso,Inc., is designed to achieve preferential binding to tumor infiltrating lymphocytes rather than normal peripheral tissue lymphocytes. Based on Akeso's proprietary "TETRABODY" technology, AK104 can simultaneously targets two immune checkpoint molecules: PD-1 and CTLA-4. AK104 is in a tetrameric form, which is designed to bind to PD-1 and CTLA-4 simultaneously and have so far displayed the efficacy of PD-1 and CTLA-4 combination blockade with lower toxicity. It is currently in Phase Ib/II and Phase II clinical trials in China and Australia for multiple indications.

张子栋 ZHANG Zidong	上海复宏汉霖生物技术股份有限公司 CFO CFO of Shanghai Henlius Biotech, Inc.	复宏汉霖——可负担的创新 Henlius - Affordable Innovation

项目简介

复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供质高价优的创新生物药，产品覆盖肿瘤、自身免疫疾病等领域。产品涵盖 20 多种创新单克隆抗体，并全面推进基于自有抗 PD−1 单抗 HLX10 的肿瘤免疫联合疗法。截至目前，公司已成功上市国内首个生物类似药汉利康 ®（利妥昔单抗），2 个产品（HLX02 曲妥珠单抗、HLX03 阿达木单抗）上市申请正在审评中，并获得优先审评审批资格，有望于今年上市，并同步就 10 个产品、8 个联合治疗方案于全球范围内开展 20 多项临床试验，产品对外授权覆盖全球近 100 个国家和地区。

Project Introduction

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology and autoimmune diseases. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monocolonal antibodies (mAb) and has continued to explore immuno-oncology combination therapies with proprietary HLX10 (anti-PD-1 mAb) as backbone. Up to date, in addition to 汉利康 ® (HLX01, rituximab) launched commercially and two products (HLX02 trastuzumab and HLX03 adalimumab) under New Drug Application (NDA) review to be potentially launched within 2020, Henlius has conducted over 20 clinical studies for 10 products and 8 combination therapies worldwide. Products have been licensed out to nearly 100 countries and regions. Moreover, the business partner Accord submitted a Marketing Authorisation Application (MAA) for HLX02 to European Medicines Agency (EMA). In May 2020, Henlius received the EMA Committee for Medicinal Products for Human Use (CHMP) positive opinion for HLX02, which is expected to become the first China-manufactured biosimialr to be launched in the EU markets.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
吴劲梓 Jason WU	歌礼制药有限公司董事长 CEO of ASCLETIS PHARMA Inc.	歌礼制药打造病毒性肝炎、脂肪性肝炎、艾滋病三大创新平台 Ascletis Developed its Own Innovative Platform Focusing on Viral Hepatitis, NASH and HIV/AIDS

项目简介

歌礼于 2018 年在香港证券交易所上市（歌礼制药，1672.HK），融资金额 4 亿美金。歌礼公司是本土培育的、中国抗病毒领域最领先的制药企业之一。歌礼公司也是“重大新药创制”国家科技重大专项支持的多个丙肝和艾滋病抗病毒项目的牵头或参与单位。在国家的大力支持及具备深厚专业知识和丰富行业经验的优秀管理团队带领下，歌礼已发展成为一家集研发、生产和销售为一体的平台型制药公司。歌礼的研发管线包括处于不同临床开发阶段的抗体免疫疗法、全球首创或同类最佳的小分子药物和 siRNA 药物。

Project Introduction

Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Ascletis' pipeline is focused primarily on three therapeutic areas: 1. HCV: one commercial stage product, one near commercial stage drug and two R&D stage drug candidates. Ganovo (Danoprevir) is the first direct-acting anti-viral agent for hepatitis C, developed by a domestic firm in China. 2. HBV: one commercial stage product and three R&D stage drug candidates. Pegasys (Peginterferon alfa-2a) is a leading marketed pegylated interferon for hepatitis B & C partnered with Roche. 3. NASH (Non-Alcoholic SteatoHepatitis): three R&D stage drug candidates against three different targets for combination treatments.

俞文冰 YU Wenbing	上海君实生物医药科技股份有限公司 总经理助理 Assistant General Manager, Junshi Biosciences of Shanghai Junshi Bioscience Co., Ltd.	围绕源头创新和患者可及的研发管线介绍 Pipelines Development Focused on Original Innovation and Patient Access

项目简介

君实生物是一家创新驱动型生物制药公司，以开发治疗性抗体为主，专注于创新单克隆抗体药物和其他治疗性蛋白药物的研发与产业化，具有丰富的在研产品管线，包括 19 个创新药，2 个生物类似物，覆盖五大治疗领域，包括恶性肿瘤、自身免疫系统疾病、慢性代谢类疾病、神经系统类疾病及抗感染疾病。君实生物是国内首家获抗 PD−1 单抗 NMPA 上市批准、抗 PCSK9 单抗 NMPA 临床申请批准的中国公司，并取得了全球首个治疗肿瘤抗 BTLA 阻断抗体在中国 NMPA 和美国 FDA 的临床申请批准。今年，君实生物还与国内科研机构携手抗疫，共同开发的 JS016 已作为国内首个抗新冠病毒中和抗体进入临床试验，用本土创新为全球疾病预防控制贡献力量。

Project Introduction

Established in 2012, Junshi Biosciences is committed to developing first-in-class and best-in-class drugs through original innovation and becoming a pioneer in the area of translational medicine to provide patients with effective and affordable treatment options. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK. On July 15, 2020, Junshi Biosciences was listed on the STAR Market of the Shanghai Stock Exchange with the stock code: 688180.SH. The Company has established a diversified R&D pipeline comprising 21 drug candidates with therapeutic areas covering cancer, metabolic diseases, autoimmune diseases, neurologic diseases, and Infectious disease. Product types include monoclonal antibodies, fusion proteins, antibody-drug conjugates, and small molecule drugs. With a combined 33,000L fermentation capacity in two GMP-facilities at Shanghai and Suzhou, Junshi has established the manufacturing infrastructure to support commercialization and provide our partners and patients with high quality products through a global supply chain network.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
张　甦 ZHANG Su	亚盛医药首席财务官 CFO, Ascentage Pharma	亚盛医药——专注细胞凋亡 研发创新药物 Ascentage Pharma - Advancing Therapies that Restore Apoptosis

项目简介

亚盛医药（6855.HK）是一家立足中国、面向全球处于临床开发阶段的原创新药研发企业，致力于在肿瘤、乙肝与衰老相关的疾病等治疗领域开发创新药物。公司已建立有 8 个已进入临床开发阶段的 1 类小分子新药产品管线，包括抑制 BCL−2,IAP 或 MDM2−p53 等抑制剂；新一代针对癌症治疗中出现的激酶突变体的抑制剂等。目前在中国、美国及澳洲开展 30 多项目临床试验。用于治疗耐药性慢性髓性白血病的核心品种 HQP1351 获得美国 FDA 审评快速通道及孤儿药认证资格，并在中国递交新药上市申请。公司的另一重要品种 APG−2575 也获得美国 FDA 孤儿药资格认证。

Project Introduction

Ascentage Pharma(6855.HK) is a globally, clinical-stage biotechnology company in developing novel therapeis for cancers,CHB, and senesce diseases. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. the company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2,and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.Ascentage Pharma is also the only company in the world with active clinical programs targeting all three know classes of key apopotosis regulators. The company is conductiong more than 30 Phase 1/2 clinica trials in the US, Australia, and China. The company's core drug cnadidate HQP1351 was summitted NDA in China and was granted orphan drug and fast track designations by the US Food and Drug Administraion(FDA). APG-2575,another key drug candidate of the company, was recently granted orphan drug designation by the FDA.

谢　炘 Hsin Tse	中国生物制药执行董事、资深副总裁 Executive Director & Senior Vice President, Sino Biopharmaceutical Limited	中国生物制药——以创新力构筑新护城河 Sino Biopharmaceutical Limited - Build a New Moat with Innovation

项目简介

中国生物制药拥有专注于创新药研发的内核、精细化的运营管理并拥抱现代科技及理念。集团同时拓展高端医疗器械领域并加速国际化进程，为长远发展打下更加牢固的基础，更好服务于人类。

Project Introduction

Sino Biopharmaceutical Limited has a core that focuses on innovative drug R&D, maintains refined operation management and embraces modern technology and concepts. At the same time, the group expands the field of high-end medical devices and accelerates the process of internationalization to lay a firmer foundation for long-term development and to better serve mankind.

非上市公司专场
Non-Listed Company Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
陈　悦 CHEN Yue	天津尚德药缘科技股份有限公司总经理 General Manager, Accendatech	抗脑瘤新药的开发 New Drug Targeting Brain Tumour

项目简介

脑胶质瘤母细胞瘤的治疗是世界医学难题，主要原因之一是绝大多数药物难以进入脑部，唯一的标准药物是替莫唑胺，只能延长 2.5 个月的生存期。复发 GBM 无药可治，患者中位生存期仅为 6−7 个月。尚德药缘研发的 ACT001，可以穿过血脑屏障，临床一期的安全性很好，治疗复发 GBM 的最长用药超过 39 个月，其中达到完全缓解的时间超过 20 个月。 平均 PFS 超过 20 周，是欧美治疗复发历史数据（10 周）的两倍。ACT001 获得了欧美孤儿药资格，即将在美国和中国开展针对复发 GBM 的临床试验。ACT001 治疗癌症脑转移的临床试验获得中国 CDE 批准，将联合放疗对照放疗加安慰剂。针对癌症脑转移的临床试验，具有非常广阔的市场前景。

Project Introduction

Glioblastoma(GBM) is one of the most deadly type of cancer. Due to the blood brain barrier (BBB) , most drug are not able to enter the brain, and the best drug (TMZ) for GBM can only extend the life span of 2.5 month. The median life span for recurrent GBM is only 6-7months.
ACT001 is a small molecule developed by Accendatech, it can across the BBB and demonstrated excellent safety profile. The best response observed in a recurrent GBM patient with tumor size close to 4cm, the patient enrolled in March 2017, and reached to complete response after single drug treatment with ACT001 for 19 months. Up to date, the patient continues to take ACT001, and no recurrence was observed. ACT001 obtained the orphan drug designation (ODD) in USA and Europe in 2017 and 2018, respectively, and phase II in USA and China will be carried on separately soon. The clinical trial of combination of ACT001 with radiotherapy in brain metastasis patients will be conducted in 4 months. Treatment of brain metastasis have very abroad application and very urgently medical needs.

罗　文 LUO Wen	索元生物医药（杭州）有限公司首席执行官 CEO, Denovo Biopharma (Hangzhou) Co., Ltd.	中国创新药如何从跟跑到领跑：索元生物借力精准医疗开发全球首创新药模式 From Me-too to First-in-class: Denovo Biopharma's Disruptive Precision Medicine Approach to Developing Novel Drugs

项目简介

索元生物是一家新型的、以快速有效的模式开发一类新药的精准医疗领军企业。索元生物从国际大药厂引进经过临床后期试验证明其安全性且显示对部分患者有效的新药，利用其独创的生物标记物平台技术在残余的临床样本中找到可预测药物疗效的生物标记物。通过这些新发现的生物标记物作为伴随诊断来筛选患者，索元生物能够在敏感患者中重新开展临床试验，从而优化疗效、安全性和耐受性，提高新药开发的成功率，从而达到以较低的成本、较短的时间开发创新药的目的。索元生物目前拥有已开发至临床后期的六个产品 DB102、DB103、DB104、DB105、DB106 和 DB107 的全球权益，均为一类全球首创新药 (First in Class)。

Project Introduction

Denovo Biopharma is a clinical stage biopharmaceutical company that applies novel biomarker approaches to re-evaluate medicines that have failed in broad patient populations. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. The company seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. Denovo then designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo is enrolling patients in the U.S. and China with diffuse large B-cell lymphoma (DLBCL) in a Phase 3 clinical trial and will start a Phase 2B study in Glioblastoma (GBM) for its lead product candidate, DB102, which was in-licensed from Eli Lilly. The company has five additional late stage programs targeting major unmet needs: DB103 for schizophrenia, DB104 for depression, DB105 for Alzheimer's Disease, DB106 for acute myeloid leukemia (AML) and DB107 for recurrent high grade glioma.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
罗　顺 LUO Shun	澳斯康生物制药（海门）有限公司 董事长兼总裁 Chairman & President, Thousand Oaks Biopharmaceuticals	整合性 CMC 组织——生物制药规模化合规整体解决方案 Integrated CMC Organization-Large Scale Solution for Biopharmaceuticals

项目简介

澳斯康生物制药（海门）有限公司由知名生物医药专家罗顺博士创立，公司高层多来自基因泰克、安进、默克等国际知名企业，主要承接创新药的工艺研发及制备、工艺优化、放大生产、注册和验证批生产等 CDMO 服务，在细胞培养基开发、无血清细胞培养工艺技术开发等方面具有核心技术，拥有“健顺生物”细胞培养基品牌，其培养基可使蛋白表达量提高 1.5−3 倍，工业化生产水平达到世界领先，相关工艺技术均具自主知识产权。澳斯康创建了国内首家人工智能 + 生物科技 + 关灯连续生产等技术的一体化平台，具有颠覆性的多行合一智能信息化的工艺工程开发技术和管理体系，于 2019 年通过 ISO9001 质量体系认证并获批。

Project Introduction

Based in Thousand Oaks, CA, Pleasanton, CA, Shanghai, China, Lanzhou, China and Haimen China, Thousand Oaks Pharmaceuticals (“TOBIO”) is a leading global CDMO company committed to providing high quality CDMO services and developing customized cell cultural medium and PD to speed biologics development to clinic. The company combines expertise in biology, cell cultural medium development, and extensive CDMO service capabilities in China to enhance its full range CDMO services that are optimized for biologics pre-clinical and commercial production. The company’s mission is to speed the biologics development to patients in underserved markets via global and region-specific development programs. The company has been working diligently to set up global high standards for the CDMO services. Up to the date, a number of pre-clinical biologics productions including commercial production has been successfully completed. TOBIO is taking advantage of the high-speed growth opportunities in China's biologics development market. TOBIO is one of a few CDMOs in Asian Pacific region, serving the global clients for their biologics pre-clinical and commercial productions. As a trusted partner of the global biological industry, TOBio supplies innovative solutions and partners with biopharmaceutical facilities all over the world to meet tight timelines, drive down cost and provide global compliance.

陈晓光 CHEN Xiaoguang	中国医学科学院北京协和医学院 药物研究所教授 Professor, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College	代谢检查点调节剂治疗重大慢病原创药物研发 The Novel Drug Research and Development of Metabolic Checkpoint Regulators in the Treatment of Major Chronic Diseases

项目简介

人体内存在着一些与脂肪酸、胆固醇和酮体等脂类代谢密切相关的关键限速酶，我们把它称作代谢检查点。代谢检查点异常是肿瘤、自身免疫性疾病等重大慢病和衰老发生发展原始驱动力，代谢检查点调节剂将使慢病治疗进入全新的代谢治疗时代。主要涉及的靶点包括：脂肪酸分解代谢密切相关的关键限速酶 CPT1、与胆固醇酯化代谢密切相关的关键限速酶 SOAT1、与酮体代谢相关的关键限速酶 ACAT1，以及与酮体分解代谢相关的关键限速酶 OXCT1 等。针对这些靶点，研发全球 First−in−class 的创新药物。

Project Introduction

There are some key rate-limiting enzymes which are closely related to the metabolism of fatty acids, cholesterol and ketones in human body. These enzymes are called metabolic checkpoints. Abnormal metabolic checkpoints are the primary driving force of occurrence and progression of chronic diseases including tumor and autoimmune. Additionally, these are also related to aging. Targeting the metabolic checkpoints will make the treatment of major chronic diseases enter a new era of metabolic therapy and make benefits for patients. These metabolic checkpoints include ACAT1 (Acetyl-CoA Acetyltransferase 1), CPT1 (Carnitine palmitoyltransferase I), SOAT1 (Sterol O-Acyltransferase 1) and OXCT1 ((3-Oxoacid CoA-Transferase 1). At present, we have established the enzymatic assay and cells in vitro and animal models in vivo for these targets. The compounds are under screening and modification. We are aiming to develop original innovative drugs for these metabolic checkpoints.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
秦续科 Steve CHIN	科望生物医药科技有限公司首席医学官 CMO, Elpiscience Biopharma Ltd.	深耕肿瘤免疫开发新一代创新型治疗抗体 Driving Cancer Immunotherapy Revolution

项目简介

科望生物医药科技有限公司是一家临床阶段生物医药公司，专注于肿瘤免疫治疗。公司致力于引领新一代肿瘤免疫新药的创新和发展，造福全球癌症患者。科望产品管线中的第一个全球首创的同时靶向 PD-L1 和 4-1BB 的双特异抗体新药 ES101 在临床试验阶段。ES101 实现了对免疫细胞激活的“去闸加油”概念，有望成为新一代肿瘤免疫治疗的基石。管线中第二个创新产品，下一代 OX40 激动剂也已进入临床 I 期，期待和 PD-1 联用产生协同效应。科望医药的临床前管线有 10 余条，广泛覆盖免疫治疗创新靶点，其中重点布局天然免疫和肿瘤微环境领域的新药研发，以期开发出新一代更有效的免疫治疗药物。

Project Introduction

Elpiscience is a clinical stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the innovation and development of the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpiscience's first therapeutic product ES101, is in Phase I clinical study. ES101 is a "First-in-Class" bispecific antibody, targeting 4-1BB and PD-L1. The unique design of the molecule allows for PD-L1 binding dependent activation of 4-1BB, which simultaneously "Removes the brakes and steps on the gas", thereby inducing a stronger anti-tumor immunity. The 2nd molecule ES102, a Next-Generation OX40 antibody with an ingenious design has also entered into clinical trial. It will be used in combination with PD-1 to generate synergistic effects. Furthermore, several differentiated therapeutic antibodies with best-in-class potential, such as ES002 (anti-CD39), ES004 (anti-SIRPα) are currently in CMC stage. Elpiscience has a pipeline of more than 10 innovative molecules in discovery, covering a wide range of targets with a particular focus on innate immunity and tumor microenvironment. Elpiscience's sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies.

窦昌林 DOU Changlin	山东博安生物技术有限公司首席运营官 COO, Shandong BoAn Biotechnology Co., Ltd.	博安生物——中国领先的全球化生物药创新企业 Boan Biological - A Leading Global and Innovative Biopharmaceutical Company in China

项目简介

博安生物是一家全面综合性生物制药公司。从事治疗用抗体的研发，生产和商业化，专注于肿瘤科、糖尿病及免疫疾病等领域。拥有先进的抗体开发平台，覆盖了从靶点验证、抗体药物发现和开发、CMC 的完整流程。抗体生产平台拥有优质的生产能力和严格的质量把控，现有生产设施可满足临床生产的产能需求及未来商业化需求。在研药物中，1 个产品已申报中国上市申请，1 个产品在中国 III 期临床阶段，并已经启动欧美 I 期临床，多个项目获得中国临床研究批准。管理团队在全球知名药企有多年的药物研发和项目管理经验，熟悉生物药产业，能够为药物发现与开发提供专业的综合性解决方案。

Project Introduction

Boan Biotech is a fully-integrated biopharmaceutical company. The company specializes in the research & development, manufacturing and commercialization of therapeutic antibodies, which are mainly focused on key therapeutic areas such as oncology, diabetes and immunological diseases. Boan Biotech has accumulated a wealth of experiences in bio-manufacturing innovation technology in antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.The antibody production platform has high-quality production capacity and strict quality control. Existing production facilities can meet the needs of clinical production capacity and future commercial needs. From the current pipeline, one product candidate has been submitted for marketing authorization in China; another is in Phase III development in China, with Phase I clinical trials initiated in Europe and the United States; and others have been approved for clinical development in China.The management team has many years of experience in drug development and project management in world-renowned pharmaceutical companies, familiar with the biopharmaceutical industry and knowledgeable in advancing professional comprehensive solutions for drug discovery and development.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
王汝涛 WANG Rutao	西安力邦制药有限公司总经理 General Manager, Xi'an Libang Pharmaceutical Co.,Ltd.	抗癫痫一类新药 LMR-101 的 I 期临床试验结果介绍 Introduction of Phase I Clinical Trial Results of LMR - 101, a Novel Antiepileptic Chemical Drug

项目简介

LMR-101 为化药 1.1 类新药，用于治疗癫痫大发作、丛集性癫痫发作或癫痫持续状态。目前已完成 I 期健康人单次给药剂量递增的耐受性和药代动力学临床研究，整个试验中未发生重要和严重不良事件，未出现任何导致试验终止的不良事件，在 0.5 mg/kg-24 mg/kg 剂量范围内，安全且耐受良好，并且在≥ 8mg/kg 剂量组表现出不同程度的靶点相关的药理作用 - 镇静嗜睡。LMR-101 作用靶点为 GABAA 受体，但结合位点与苯二氮卓类药物（西泮、唑仑等）不同，临床前研究显示无药物依赖性，临床试验中未观察到呼吸抑制作用，作为全麻药丙泊酚的结构类似物，在有效抑制癫痫发作剂量下无麻醉活性，对血压无明显影响。

Project Introduction

LMR-101 is a class 1.1 chemical drug for the treatment of grand mal epilepsy, cluster epileptic seizures or status epilepticus. A Phase I, Single-Ascending-Dose Study of LMR-101 in Healthy Subjects has been completed. During the study, there is not any significant AE or serious adverse events, or any adverse events leading to the termination. The drug was safe and well tolerated at doses ranging from 0.5 mg/kg to 24 mg/kg, and showed varying degrees of target-related pharmacologic effect-sedation and lethargy. LMR-101 targets on GABAA receptors, but has a different binding site from that of benzodiazepines. Preclinical studies showed that LMR-101 didn't have drug dependence, and no respiratory inhibition was observed in clinical trials. As a structural analog of propofol, a commonly used general anesthetic, LMR-101 did not exhibit any anesthetic activity under the effective dose for suppressing epileptic seizure, and had no significant effect on blood pressure.

李文斌 LI Wenbin	成都金瑞基业生物科技有限公司临床 PI Principal Investigator, Chengdu Jinrui Foundation Biotech Co., Ltd.	和厚朴酚脂质体 JRF101：脑胶质瘤 I 期临床试验 Honokiol liposome JRF101: Phase I trial for glioblastoma

项目简介

成都金瑞基业生物科技有限公司研发的 JRF101 是从中药厚朴中提取纯化获得的具有显著抗肿瘤活性且能克服肿瘤耐药的高纯度（99.5%）“和厚朴酚”；采用新型载体脂质体包裹制备成能靶向肿瘤组织的“和厚朴酚脂质体冻干粉”，具有自主知识产权，为国际首创新药，获十二五、十三五国家重大新药创制立项支持。2016 年获 NMPA 颁发临床试验批件，2018 年至今在北京天坛医院、北京协和医院开展两项 I 期临床试验。目前脑胶质瘤为主要适应症，临床 I 期试验研究结果显示，和厚朴酚脂质体安全性、耐受性良好，脑胶质瘤受试者获益明显。预计在 2021 年开展 II 期临床研究，金瑞基业将推进 JRF101 国外临床注册工作和国际临床研究。

Project Introduction

JRF101 developed by Chengdu Jinrui Foundation Biotech Co., Ltd. is a high-purity natural compound "Honokiol" which is extracted and purified from Magnolia officinalis with significant anti-tumor activity and can overcome cancer drug resistance. A new carrier liposome is used to prepare the "Honokiol liposome freeze-dried powder" (JRF101) that can target tumor tissues. It has independent intellectual property rights and is a global first-in-class drug for malignant tumor. JRF101 has been supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the 12th and 13th Five-year Plan Period. In 2016, honokiol liposome injection-JRF101 was approved by NMPA for clinical trials. Since 2018, we have carried out phase I clinical trials for lung cancer and glioblastoma in Beijing Tiantan Hospital and Peking Union Medical College Hospital. At present, glioblastoma is the main indication. The results of phase I clinical trial show that honokiol liposome is safe and well tolerated, and subjects benefit significantly. It is expected to carry out phase II clinical research for glioblastoma in 2021, and Jinrui Foundation will promote the foreign clinical registration and international clinical research of JRF101.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
宋　燕 SONG Yan	广州领晟医疗科技有限公司首席执行官 CEO, Link Health Group	3% 褪黑素口腔凝胶防治头颈部肿瘤患者放化疗引起的口腔粘膜炎的 II 期临床研究 Phase II Trial of 3% Melatonin Oral Gel for the Prevention and Treatment of Oral Mucositis in H&N Cancer Patients Undergoing Chemoradiation

项目简介

3% 褪黑素口腔凝胶（LH041）注册分类属于 2 类新药（2.2+2.4），开发适应症为防治肿瘤患者放化疗引起的口腔粘膜炎。本项目目前处于临床 II 期阶段，在全球已完成一项 I/II 期临床试验，共纳入 84 例受试者，研究结果表明：LH041 相对于安慰剂可有效防治头颈部肿瘤患者放化疗引起的严重口腔粘膜炎，特别是联合顺铂化疗的患者。受试者用药后除胃肠道存在一定不适外，总体上，安全性和耐受性良好。放化疗引起的严重口腔粘膜炎，可能造成患者标准抗肿瘤治疗的中断而影响生存期，国内外该适应症均无品种上市，存在迫切的临床需求。LH041 有望成为防治肿瘤患者放化疗引起的口腔粘膜炎的一线用药以及该适应症批准上市的首款药物。

Project Introduction

LH041 is classified as class II new drug (2.2+2.4). The indication to be developed is for the prevention and treatment of oral mucositis in cancer patients caused by radiotherapy or/and chemotherapy and its therapeutic field belongs to the supportive treatment of anti-cancer. It has completed a phaseI/II clinical trial, enrollment of 84 subjects in all together, the results of this study shows that the LH041 can effectively prevent and treat severe oral mucositis in patients with head and neck tumor that caused by radiation or/and chemotherapy, especially in patients combined cisplatin. In addition to some gastrointestinal disorders, the subjects were generally safe and well tolerated. Severe oral mucositis may cause the interruption of standard anti-tumor therapy and affect the survival time of patients. There is no drug approved for this indication in China and abroad at present and it exists an urgent clinical needs.LH041 is expected to be the first-line drug for the prevention and treatment of severe oral mucositis in cancer patients caused by radio-chemotherapy, and may be the first drug to be approved for this indication in China.

韦　德 WEI De	成都惠泰生物医药有限公司董事长兼总经理 Chairman & General Manager, Chengdu Huitai Biomedicine Co., Ltd.	靶向抑制 TGFβ 信号通路的多肽类 1.1 类创新药——抗纤维化和实体肿瘤 Development of Synthetic Peptides Targeting TGF-beta Signaling as First-in-Class Pharma Cotherapies for Fibrosis and Solid Cancer

项目简介

成都惠泰生物医药有限公司是一家创新型生物医药研发企业，致力于抗纤维化与实体肿瘤原研药物。公司开发的全新结构小分子多肽药物拟用于治疗以纤维化为特征的进行性纤维化性间质性肺疾病。该药物是具备全新机制、靶点及药物成分的国家 1 类创新药物。现已完成临床前研究，以及 I 期临床试验申报资料撰写，并于 2020 年 4 月向国家药品审评中心提交国家 1 类新药的 pre-IND 沟通交流会申请，拥有自主知识产权。 本药物仅靶向针对病例条件下开启的关键作用信号通路的上游事件的重要蛋白，从而避免了对正常生理过程的影响。同时，具备活性高、易化学合成优化，代谢产物安全等优势。以期在真正安全和有效药物未被满足的临床需求中发挥价值。

Project Introduction

Chengdu Huitai Biomedcine Co., Ltd. is an innovative biomedical R&D enterprise committed to our own innovative drugs for anti-fibrosis and solid tumors. The Company has developed an innovative small polypeptide (a new molecular entity) proposed for treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) characterized by fibrosis. This drug is a national Class 1 innovative drug with brand-new mechanism, target and composition. The pre-clinical study has been completed, and the application dossier for Phase 1 clinical trial has been prepared. An application for pre-IND meeting on the national Class 1 new drug has been submitted to the Center for Drug Evaluation of NMPA in April 2020. The Company has the independent intellectual property rights of this drug. This drug only targets the important protein in the upstream event of the key signaling pathway that is enabled by the disease, thus avoiding effects on normal physiological processes. Meanwhile, it has such advantages as high activity, easy optimization in chemical synthesis and safe metabolites. It is expected to play a valuable role for the unmet clinical demand due to lack of truly safe and effective drugs.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
郭　箭 GUO Jian	浙江新码生物医药有限公司首席技术官 CTO, NovoCodex Biopharmaceuticals Co.,Ltd.	基于非天然氨基酸定点偶联技术的大分子药物开发 Development of Macromolecular Drugs Based on Unnatural Amino Acids-introduced Site Specific Conjugation

项目简介

浙江新码生物成立于 2017 年 1 月，为浙江医药股份有限公司控股子公司。公司专注于非天然氨基酸定点偶联大分子药物的研发和生产。研发管线中首个项目 NCB001（抗 HER2−ADC，治疗用生物制品 1 类）在乳腺癌 I 期临床研究中表现出良好的安全性和疗效。截止 2020 年 7 月 16 日，入组的 59 例 HER2 阳性晚期乳腺癌受试者中有 26 例 PR，29 例 SD，4 例 PD，在 II/III 期的推荐剂量 1.5mg/kg 下药物相关毒性可控的前提下，ORR 达到了 68.4%（13/19）；目前乳腺癌 II/III 期临床研究已启动。该项目的胃癌 I 期临床研究也即将完成。后续有多个使用定点偶联技术的创新药物处于开发管线中。

Project Introduction

Zhejiang NovoCodex Biopharmaceuticals Co., Ltd., a holding subsidiary of Zhejiang Pharmaceutical Co., Ltd., was established in January 2017. The company is committed to the discovery and development of macromolecular drugs based on unnatural amino acids-introduced site specific conjugation. The phase I clinical study of the leading project, NCB001 (or ARX788, an anti-HER2 ADC), was recently completed. NCB001 showed good safety and efficacy in subjects with advanced breast cancer (BC). As of July 16, 2020, among 59 enrolled BC subjects, there were 26 best response of PR, 29 SD and 4 PD. The ORR of 1.5 mg/kg group (recommended dose of phase II/III clinical study) was 68.4% (13/19) with few cases of grade 3 or above drug related adverse events. Encouraged by the good outcome of NCB001 in BC Phase I study, the phase II/III clinical study of NCB-001 has been initiated. The Phase I clinical study of NCB001 in gastric cancer (GC) is ongoing, with 4 cases of PR, 3 cases of SD, 4 cases of PD and 5 cases of NA among 16 GC enrolled. The overall ORR is 30.8% (4/13, 3 subjects has not reached the evaluation time) in subjects with advanced GC. The company has several innovative site-specific conjugated macromolecular projects that are in the IND or pre-IND development stages.

张世轩 ZHANG Shixuan	大连贝克林医药科技有限公司董事长 Chairman, Dalian BaicaIein Pharmaceutical Technology Co., Ltd.	原创抗癌药物黄芩素哌啶醇研发 R&D of the Original Anticancer Drug Baicalein - Piperidol

项目简介

大连贝克林医药科技有限公司是以大连理工大学精细化工国家重点实验室依托，致力于肿瘤，免疫与炎症的原创新药研发（First-in-class-drug）。黄芩素哌啶醇（BA-j）是以天然黄芩素为先导化合物，经过结构修饰，全合成的一种 CDK1 和 ROS 调控 HIF-α 抑制剂类原创广谱抗癌药物。BA-j 安全，有效，质量可控，药代动力学性质独特，作用机制明确，成药性优良。BA-j 在消除癌症及其放化疗引起的变态免疫有独特疗效。BA-j 已获得专利中国 2 项，美国 2 项，PCT 2 项，发表研究论文 5 篇。BA-j 研发处于临床前晚期，具备国际竞争力，有望开拓国际市场。

Project Introduction

Dalian Baicalein Pharmaceutical Technology Co. LTD focused on R&D of first in class drug about cancer, immune, inflammation based on State Key Laboratory of Fine Chemicals Dalian University. Baicalein-Piperidol (BA-j) is an original broad-spectrum anticancer drug, which is a kind inhibitor of cyclin-dependent protein kinase CDK1 and hypoxia inducible factor HIF-α by regulating reactive oxygen ROS, with natural Baicalein as the lead compound and after structural modification. BA-j is safe, effective and controllable in quality. BA-j has unique pharmacokinetic properties, clear mechanism of action and excellent druggability. By utilizing different mechanisms of redox between normal cells and cancer cells and activated lymphocytes, BA-j selectively induces apoptosis of cancer cells and activated lymphocytes by regulating ROS, inhibits cell necrosis and protects normal cells. It has a unique curative effect in eliminating abnormal immune symptoms caused by cancer and chemoradiotherapy. BA-j has patents of CN 2, US 2 and PCT 2, and 5 published research papers. R&D of BA-j is in the pre-clinical stage with international competitiveness, and is expected to explore the international market.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
郭晓宁 GUO Xiaoning	苏州苏生医药研发有限公司首席医学官 CMO, Suzhou SciClone Pharmaceuticals Research and Development Co., Ltd.	苏生医药研发有限公司产品管线介绍 Pipeline Introduction-Suzhou SciClone Pharmaceuticals

项目简介

1. 苏生医药研发有限公司简介 2. 苏生管线介绍：1) PT-112 是一类创新型的铂类药物，通过细胞凋亡、免疫特性及高耐受性来增强抗肿瘤效果。此药物目前在中国和美国进行 I/II 期临床研究；2) PEN-866 是一款世界首创的小分子偶联药物，其独特桥接设计及细胞毒素释放机理使得 SN-38 可以特异性地在肿瘤部位聚集，同时随着连接分子的持续分解，持久地在肿瘤部位释放，并最终造成 DNA 的破坏及肿瘤的消退。此药物目前在美国进行 Ib/IIa 期的一篮子临床研究；3) ABTL0812 是首个抑制 PI3K/Akt/mTOR 的 Akt/mTOR 轴致癌路径的小分子药物，目前正在欧洲进行 II 期试验；4) 其他

Project Introduction

1. Introduction of SuZhou SciClone Pharma R&D Co. Ltd. 2. Pipeline introduction: 1) PT-112 is an innovative Platinum based drug that has been developing with the specific aim of altering the cellular mechanisms of action of the drug to improve its efficacy while limiting its toxicity. The drug is under Phase I/II clinical trials in both US and China; 2) PEN-866 is a first-in-class miniature drug conjugate that selectively binds to the activated form of HSP90 in solid tumors and is linked to the topoisomerase 1 inhibitor (SN-38), a potent anti-cancer payload. PEN-866 is designed to accumulate and be retained in tumors. As the SN-38 payload is cleaved over time, there is a sustained release of SN-38 in the tumor resulting in prolonged DNA damage and tumor regressions. As a next generation targeted chemo drug, PEN-866 has the potential for benefit in most prevalent solid tumors. This drug is under Phase Ib/IIa basket trial in US; 3) ABTL-0812 is a first-in-class small molecule with anti-cancer activity through PI3K/Akt/mTOR pathway. This drug is under several Phase II trials in EU; 4) Others

王钧源 WANG Jerry	葆元生物医药科技（杭州）有限公司 首席执行官 CEO, AnHeart Therapeutics (Hangzhou) Co., Ltd.	下一代 ROS1/NTRK 抑制剂 Taletrectinib 用于治疗 ROS1 突变的非小细胞肺癌和 NTRK 突变的实体瘤 Next Generation ROS1/NTRK Inhibitor Taletrectinib for ROS1+ NSCLC and NTRK+ Solid Tumors

项目简介

Taletrectinib 是一种下一代的、高效的、高选择性的可以穿过血脑屏障的针对 ROS1 突变和 NTRK 突变的激酶抑制剂。葆元医药从第一三共引进了 Tale 的全球市场的许可。在美国和日本进行的两项一期研究数据初步显示 Tale 具有良好的安全性和有效性。Tale 可抑制 ROS1 融合 WT 和克唑替尼耐药的突变，包括 G2032R。在中国，葆元医药在 2020 年 7 月启动了两项临床二期的患者入组；其中一项临床二期是研究 Tale 用于治疗一线和二线 ROS1+ 非小细胞肺癌，另外一项临床二期是研究 Tale 用于治疗 NTRK+ 实体瘤。其他市场比如美国，日本，和韩国，临床二期试验在准备中。

Project Introduction

AnHeart lead clinical candidate taletrectinib is a next-generation, potent, highly selective ROS1 and NTRK inhibitor that can cross the blood-brain barrier. AnHeart licensed the global rights to taletrectinib from Daiichi Sankyo Company Limited. Two Phase 1 studies in the U.S. and Japan have been reported with promising safety and efficacy data. Taletrectinib inhibits both ROS1 fusion WT and crizotinib-resistant secondary mutations, including G2032R.

The results of two Phase 1 studies in the US and Japan support the potential of taletrectinib to be a next generation ROS1/NTRK inhibitor with durable responses and activity in brain metastases. Based on a data cutoff date in March 2019 from two Phase 1 trials, the mPFS in TKI-naïve and 1 TKI-pretreated patients were 24.9 months and 18.4 months, respectively, with a generally acceptable safety profile. In China, AnHeart got CTA approval in Mar-2020 for two phase 2 trial, one for first line and second line ROS1+ NSCLC, another for NTRK solid tumor; and has initiated patients recruiting. More information about the Phase 1 and ongoing phase 2 trials may be found at clinicaltrials.gov with NCT02279433, NCT02675491 and NCT04395677. In other major markets such as US and Japan, phase 2 clinical trials are under prep. In Korea, AnHeart is co-developing with NewG Lab Pharma who licensed Korea commercial rights from AnHeart in Jul-2020.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
许　恒 XU Heng	中国医学科学院药物研究所研究员 Professor, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College	抗实体肿瘤小分子新药研发 Small-molecule Anti-solid Tumor Drug Discovery and Development

项目简介

本项目主要针对当前抗肿瘤药物研发领域的重要机制与靶点，开展抗实体肿瘤新药研发。具体包括：1）信号转导与转录活化因子 STAT3 的异常与多种实体肿瘤的发生发展密切相关，也是导致肿瘤免疫耐受的原因之一。 STAT3 抑制剂 S−31 体内外抗肿瘤活性强，成药性良好，可针对消化系统肿瘤、前列腺癌、软组织肉瘤等临床适应症进行开发。2）趋化因子受体 CXCR2 是近年来备受关注的肿瘤免疫治疗靶点，CXCR2 拮抗剂 C−7 具有优越体内抗肿瘤活性以及良好的药代性质，具有与免疫检查点抑制剂联用来提高其疗效的潜力。3）第四代 EGFR 抑制剂 E−2，针对 EGFR−C797S 耐药突变，具有良好的抗肿瘤效果。

Project Introduction

With a focus on the current important anticancer mechanisms, we aim to discover novel anticancer therapeutics to address unmet medical needs. Specifically include 1) The abnormality of signal transduction and transcription activator STAT3 is closely related to the occurrence and development of a variety of solid tumors, and is also one of the major causes of tumor immune tolerance. The STAT3 inhibitor S-31 has robust anticancer activity as well as desirable drug-like properties. It could be further developed for clinical indications such as digestive system tumors, prostate cancer, and soft tissue sarcoma. 2) Chemokine receptor CXCR2 is a tumor immunotherapy target that has attracted much attention in recent years. CXCR2 antagonist C-7 has superior in vivo anticancer activity and good pharmacokinetic properties, providing a potential to be combined with immune checkpoint inhibitors to improve their efficacies. 3) The fourth-generation EGFR inhibitor E-2, which targets EGFR-C797S resistant mutations, demonstrates desirable anticancer effects.

程子强 CHENG Ziqiang	苏州赞荣医药科技有限公司董事长 Board of Director, Suzhou Zanrong Phrama Limited	ZN−1041：透过血脑屏障，治疗乳腺癌脑转移的同类最佳 HER2 抑制剂 ZN-1041: A Best-in-class BBB Penetrable HER2 Inhibitor to Treat Breast Cancer with CNS Metastases

项目简介

赞荣医药是一家处于临床阶段的生物技术公司，专注于开发新型小分子抗肿瘤药物。成立于 2018 年，赞荣医药已获得多家知名风险投资机构 3 千万美金的投资。 ZN−A−1041 是赞荣医药开发的具有自主知识产权的可进脑的抗 HER2 小分子药物， 解决未满足的临床需求，给乳腺癌伴有脑转移患者带来福音。ZN−A−1041 的优势在于（1）血脑屏障通透程度高，从而提高中枢系统转移患者的临床疗效；（2）对 HER2 有选择性，对野生型 EGFR 无抑制作用，因此与现有的 TKI 抑制剂相比，减少了不良反应；（3）良好的安全窗口，适合在联合疗法中使用。ZN−1041 在中美两国于 2020 年第三季度启动了一期临床研究。

Project Introduction

Zanrong Pharma Limited is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary compounds focused on therapeutic targets which drive tumor inhibition. The company is well funded having completed three series of financing, with total amount greater than $30 MM in two and half years. led by well-known investors, such as Sherpa Healthcare and Qiming Venture Capital, and including Suzhou Ming Bioventures, Medfine Venture and TF Capital . The company's lead compound, ZN-1041, is a best-in-class, small molecule tyrosine kinase receptor inhibitor targeting HER2; and being developed to address the unmet medical need of CNS metastases associated with metastatic breast cancer. ZN-1041 is expected to be differentiated by its: (1) high degree of brain penetration and therefore increased clinical efficacy in CNS metastases patients; (2) be highly selective to HER2 with no inhibitory effect on wild type EGFR, thus reduced adverse effects compared to existing TKI inhibitors; and (3) good safety margin to allow for use in combination therapies. ZN-1041 has active INDs in both the U.S. and China and has initiated Phase 1 clinical studies in both countries in 3Q2020.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
夏献民 XIA Xianmin	武汉益承生物科技有限公司总经理 General Manager, Wuhan Yicheng Biotechnology Co.	针对新靶点广谱抗炎原研药伊匹乌肽滴鼻液（化药 1 类）人体耐受性和安全性良好 PI3K Isoform Specific Inhibitor Epivotide (First-in-class) Shows Excellent Safety Properties in First Human Clinical Trial

项目简介

利用 PI3K 亚型 p55PIK 抑制剂（伊匹乌肽）开发的原研药（first−in−class）治疗效果好，毒副作用小，为炎症和自身免疫性疾病提供了一种全新的有效治疗手段。伊匹乌肽原料药的第一个制剂治疗鼻炎的滴液 I 期临床研究已经完成，结果表明伊匹乌肽人体耐受性和安全性良好，在试验剂量下没有观察到对人体严重的毒副作用，目前正在开展 II 期临床；伊匹乌肽的第二个制剂治疗眼部炎症的滴液临床批件在年内获得后也将尽快进入临床研究；预期世界上首个伊匹乌肽药物在 2−3 年内上市；除此以外，针对皮肤和黏膜部位炎症的多个伊匹乌肽制剂（乳膏、雾化吸入剂、贴片及外用敷料等）近期将开展临床研究，药品未来几年陆续上市。

Project Introduction

Epivotide developed by Wuhan Yicheng Biotechnology Co. is a cell-penetrating peptide inhibor specifically targeting PI3K isoform p55PIK and shows excellent effectiveness with low side-effects in treating inflammation and aotuimmune diseases. Phase I clinical study of Epivotide Drop (First-in-class drug) to treat rhinitis has been completed and the data show that Epivotide is safe and no serious toxicity on humans have been observed at the experimental doses. Pre-IND study of second Epivotide drug for eye dieseases, such as Conjunctivitis, Keratitis, Trachoma, Dry Eyes, has been finished and its clinical trial is expected to begin early next year. First Epivotide drug will be on the market in 2-3 years. Furthermore, clinical studies of several more Epivotide preparations (Creams, Inhalers, Patches and Dressings/Powders, etc.) to treat inflammation and autoimmune deseases will be carried out in the near future and with drugs coming on the market in the next few years.

麦俊波 MAI Junbo	深圳常元生物医学技术有限公司创始人 & 首席执行官 Founder&CEO, Shenzhen PrePharm Biomedical Tech Co., Ltd.	防治阿尔茨海默病生物创新药 CYPAD01 创制及产业化 An Innovative Biological Medicine CYPAD01 for the Prevention and Treatment of Alzheimer's Disease

项目简介

常元生物致力于防治阿尔茨海默病 (Alzheimer's disease，AD) 生物创新药的研究和开发。我们成功研发防治 AD 的生物创新药 CYPAD01 在防治 AD 方面具有多靶向、一药多能、系统性调节功能和安全有效等创新性。

该创新药已获得国家发明专利和国际发明专利 PCT 授权，美国发明专利公开并将获得授权，具有技术国际先进性、较高的研发可行性和新药研发技术的重大突破性，将成为用于预防和治疗 AD 的安全有效生物创新药物。

CYPAD01 具有巨大的市场需求和广阔的发展前景，每年的销售规模预计可达几十亿至几百亿元，将有效满足全球大量未被满足的防治 AD 临床用药需求。

Project Introduction

Shenzhen PrePharm is committed to the research and development of innovative biological drugs for the prevention and treatment of Alzheimer's disease (AD). It has successfully developed an innovative biological drug CYPAD01 for the prevention and treatment of AD, which has many advantages of multi-targets, multi-functions, systematic regulatory function, safety and effectiveness.

The patent of CYPAD01 has been authorized by both CNIPA in China and the WIPO, and will be authorized by USPTO in USA. It bears the advantages of technology, high feasibility of research and development, and a major breakthrough in the AD drug R&D field. It will become a safe and effective innovative biological medicine for the prevention and treatment of AD.

The scale of annual sales of CYPAD01 is expected to reach over several billions of Yuan. CYPAD01 not only has the enormous market demands and the broad prospects for development, but will also effectively satisfy the vast unmet clinical drug demand for the prevention and treatment of AD in the world.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
王　华 WANG Hua	骨新生医药科技（深圳）有限公司 首席执行官 CEO, Biobone Biotech	骨新生医药科技（深圳）有限公司 ——华南地区骨修复创新领域领军企业 Biobone Biotech (Shenzhen), the Leading Innovation Company in Bone Repair Area of South China

项目简介

骨新生医药科技（深圳）有限公司是一家专注于骨修复创新医药产品的开发和销售型企业，系广州领晟医疗科技有限公司控股子公司。公司产品线全面覆盖了软骨修复和硬骨修复两大细分领域（产品管线如下图），代表产品有国内首个用于修复软骨损伤的Ⅰ类创新药 LH021 和新一代活性骨修复材料固欣生，两大产品当前都处于临床研究阶段。LH021 是国内首个批准进入临床的 DMOAD 药物，固欣生有望 2021 年实现上市销售。公司拥有实力雄厚的医学影像学技术团队和经验丰富的项目管理团队，由国际一流的骨科临床专家参与项目临床研究方案的制定，确保项目在亚太地区乃至全球的顺利开发。

Project Introduction

Biobone Biotech (Shenzhen) Co., Limited is an innovation company committed to develop and promote medical product in bone repair area. Biobone Biotech (Shenzhen) is a holding subsidiary of Link Health Pharma Co., Limited. The pipeline of Biobone Biotech (Shenzhen) covers the two main subdivision of cartilage repair and hard bone repair, and the representative product is the first cartilage regeneration peptide drug LH021 and the next generation bone graft GuXinSheng respectively. Both products are in clinical development stage, LH021 is the first DMOAD (Disease-modifying OA Drug) that in clinical research stage in China and GuXingSheng will be launched in 2021. Biobone Biotech has a strong medical imaging technical team and an experienced project management team. The world-class orthopedics clinical experts participate in the clinical proposal and other research work to ensure the seamless development process of the project in the Asia-Pacific region.

周国庆 ZHOU Guoqing	上海荣瑞医药科技有限公司首席执行官 CEO, Joint Biosciences Ltd.	溶瘤病毒疫苗驱动的 TCR−T 免疫疗法治疗实体瘤 Novel OVV-Drive-TCR-T Combination Therapy for Solid Tumors

项目简介

上海荣瑞医药团队创立的溶瘤病毒疫苗（OVV）驱动过继 T− 细胞（TCR−T）组合治疗实体瘤（OVV−Drive−TCR−T）的突破性技术平台和一系列的自研知识产权，用于开发新一代 First−In−Class 肿瘤免疫治疗新药。目前，在多种不同的肿瘤动物模型中，突破单一免疫治疗药物对 20−30% 的患者有效瓶颈，获得高达 90% 以上的有效率；目前 OVV−Drive−TCR−T 第 1 个新药产品，在 2019 Q4 进入研究者发起的临床 I 期试验。

Project Introduction

Combination therapy may provide a great potential to treat solid tumors and overcome low response rate of immuno-monotherapy, which satisfies unmet medical needs. Joint Biosciences Ltd has a patented breakthrough platform: the novel OVV-Drive-TCR-T combination therapy for solid Tumors, which is used to develop new generation of First-In-Class immune oncotherapy drugs. Our First Oncolytic Virus Vaccine (OVV) is using VSV-based oncolytic virus as vector and inserted tumor associated antigen NY-ESO-1. Which Combines TCR-T cell with NY-ESO-1 receptor. We have completed pre-clinical studies for each of following drugs: (1) Oncolytic Virus Vaccine (OVV); (2) TCR-T cell; (3) OVV-Drive-TCR-T (OVV+TCR-T combo) In our animal model, we showed: (1) OVV or TCR-T alone, only has about 20% response rate; (2) OVV+TCR-T combination therapy, we got over 90% response with CR compared to about 20% of OVV or TCR-T alone; All above 3 drugs have been in Investigator Initiated Trial (IIT) in Q4, 2019.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
包　骏 BAO Jun	南京英派药业有限公司首席执行官 CEO, Impact Therapeutics Inc.	英派药业——小分子，大作用：打造全球领先的合成致死机制产品组合 Impact Therapeutics - Small Molecule, Big Impact: Building Global Leading Synthetic Lethality Product Pipeline

项目简介

英派药业致力于研发具有自主知识产权的靶向抗癌新药，专注于合成致死作用机制。公司由拥有国际药企多年新药研发经验的管理者创立，总部位于中国南京。英派药业以 DNA 损伤修复通路（DDR）自主研发平台为基础，构建了充实独特的产品管线，拥有全球小型生物制药公司中最丰富的 DDR 产品组合。目前所有品种均为自主研发，公司拥有全球权益。首个产品为 PARP 抑制剂 IMP4297，化药 1.1 类新药，正在中国开展三期临床试验，早期临床数据显示了同类更优的安全性及更宽的治疗窗口。至今为止，公司获得包括礼来亚洲基金在内的多家知名风险投资机构的股权投资，并多次获得国家 / 省部 / 市区人才类及科技类项目支持。

Project Introduction

Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has made tremendous progress in several novel drug R&D projects, including PARP inhibitor, Wee1 inhibitor, other novel DDR agents and Hedgehog pathway inhibitor. The lead program PARP inhibitor IMP4297 is in Phase 3 study in China. Preliminary clinical data demonstrated better safety profile and wider therapeutic window. Impact has a unique three-step R&D strategy. Firstly, we selected PARP, a clinically validated target, as the first program to set a foundation for Impact's novel drug discovery and development capability. Secondly, we have assembled most comprehensive global DNA damage response (DDR) pipeline of novel drug candidates generated by in-house discovery platform. Thirdly, we are now expanding to other novel synthetic lethality targets to broaden pipeline coverage. Impact has been invested by recognized venture capital firms including Lilly Asia Ventures.

王奎锋 WANG Kuifeng	勤浩医药（苏州）有限公司首席执行官 CEO, Suzhou GenHouse Pharmaceutical Co.,Ltd.	新型小分子靶向抗肿瘤药物开发 Development of Novel Small Molecule Targeted Antineoplastic Drugs

项目简介

勤浩医药（苏州）有限公司聚焦小分子抗肿瘤药物开发。公司现有研发人员 30 余人，其中博士 6 人，硕士 9 人。依托专业化的研发团队，公司建立了完善的创新药物研发体系，包括基于结构生物学的构效关系研究平台，基于靶点研究的早期药物筛选平台以及涵盖药效、代谢和安全性研究的临床前评价平台。得益于公司高效的研发体系，目前勤浩医药研发管线中有八个处于不同研发阶段的抗肿瘤药物，其中 GH21 项目进展最快，预计 2023 年递交新药申请。GH21 为小分子变构抑制剂，作用机理明确，安全性好，可与多种抗肿瘤药物联用，预期可治疗多种不同类型的肿瘤，具有极大市场价值和社会效益。

Project Introduction

Genhouse Pharmaceutical (Suzhou) Co., Ltd. focuses on the development of small molecule anti-tumor drugs. The company has more than 30 R&D employees, including 6 doctors and 9 masters. Relying on the professional R&D team, the company has established a complete innovative drug R&D system, including a structure-activity relationship research platform based on structural biology, an early drug screening platform based on target research, and a preclinical evaluation platform covering efficacy, metabolism and safety studies. Thanks to the company's efficient R&D system, there are currently eight antineoplastic drugs in different R&D stages in Genhouse R&D pipeline, among which GH21 project is the most advanced and is expected to submit new drug application in 2023. GH21 is a small molecule allosteric inhibitor with clear mechanism of action and good safety. It can be combined with a variety of anti-tumor drugs and is expected to treat a variety of different types of tumors, with great market value and social benefits.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
崔华清 CUI Huaqing	中国医学科学院药物研究所研究员 Professor, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College	hNE/IDO1 单靶及双靶抑制剂的创新药物研发 The Development of Single and Dual Inhibitors Against Human Neutrophil Elastase and Indoleamine 2, 3-dioxygenase

项目简介

吲哚胺 2, 3– 双加氧酶（IDO1）抑制剂能够促进 T 细胞的增殖及活性，有效抑制恶性肿瘤的生长。弹性蛋白酶 (hNE) 由中性粒细胞等免疫细胞分泌，弹性蛋白酶从多个方面影响肿瘤生长的微环境，NE 抑制剂能够阻止肿瘤的生长、侵袭与转移。我们项目组针对 IDO1 和 hNE 分别发展了单靶及双靶的多种小分子抑制剂，并从分子及动物水平评价了其相应的药理活性及药代特征。前期研究表明，多个不同类型的小分子抑制剂均具有理化性质稳定、药代特性良好，且分别针对不同药理模型具有较好的活性和安全性，具有进一步开发的良好前景。

Project Introduction

Indoleamine 2, 3-dioxygenase (IDO1) inhibitors can promote the proliferation and activity of T cells, and effectively inhibit the growth of malignant tumors. Human neutrophil elastase (hNE) is secreted by immune cells such as neutrophils. From various aspects, hNE affects the microenvironment of tumor growth. hNE inhibitors can prevent tumor growth, invasion and metastasis. The research team from Institute of Materia Medica, Chinese Academy of Medical Sciences has developed single-target and dual-target inhibitors against IDO1 and hNE, respectively, and evaluated their corresponding pharmacological activities and pharmacokinetic characteristics from the molecular and animal levels. Preliminary studies have shown that several inhibitors have stable physical and chemical properties, good pharmacokinetic properties, and have good corresponding pharmacological activities and safety, so they have good prospects for further development.

张　涛 ZHANG Tao	深圳善康医疗健康产业有限公司副总经理 Vice President, Shenzhen Sciencare Medical Industries Co.,Ltd.	超长效戒毒药物纳曲酮植入剂临床研究进展 The Research Progress of Controlled Release of Natrexone Implant for Drug Dependence

项目简介

纳曲酮植入剂是化药 2.2 类新药，基于安全可降解高分子材料缓控释技术，用于阿片类毒品依赖患者防复吸治疗。如何防止戒毒后的“复吸”，是戒毒医疗迫切需要解决的关键技术。 纳曲酮是对抗阿片类复吸的特效药物，国内已批准上市仅有口服片剂，需要每日用药，患者依从性差，难以坚持服药，一旦停药后复吸率高达 90% 以上，导致临床疗效不理想而应用非常有限。我司研制的纳曲酮植入剂，植入患者皮下，缓释时间长达 5 个月，能长期阻断海洛因的欣快感，从而可以极大的提高戒毒的成功率。目前已完成临床试验 I 期与 II 期研究，结果显示该品种安全、有效、缓释时间长达 150 天。

Project Introduction

Based on the extended release technology with safe and degradable polymers, naltrexone implant is a modified innovative chemical drug, and the submission classification is type 2.2, which is indicated for the prevention of relapse to opioid dependence, following opioid detoxification. Opioid Use Disorder is a recurrent encephalopathy, which is a serious life-threatening disease and also affects the quality of life. The problems urgently need to be addressed during the clinical practice include how to prevent relapse after detoxification, high relapse rate and gradually increasing drug addict. Naltrexone is an effective medicine to prevention of relapse to opioid dependence, and only the oral tablet was approved for marketing in China. Oral naltrexone needs to be administered daily, so the patients have the poor compliance and can’t take medicines continuously. Once the patient stops taking medicine, the relapse rate will reach up to 90% or above. Naltrexone implant developed by Shenzhen Sciencare Company will be implanted subcutaneously in abdomen, and sustain releasing about 5 months, which can block the euphoria caused by heroin, and greatly decrease the relapse rate. We have completed the phase I and II of clinical trial of naltrexone implant, and the study results showed that naltrexone implant is safe, effective and can sustain releasing about 150 days.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
周文强 ZHOU Wenqiang	长沙泽达医药科技有限公司首席执行官 CEO, Zeta Pharma Inc.	一种治疗前列腺癌的新型 HDAC6 抑制剂小分子创新药物 Zeta55 A Novel Small Molecule HDAC6 Inhibitor Zeta55 as Potential Drug for Prostate Cancer Treatment

项目简介

前列腺癌是发达国家男性新增人数最多的一种癌症。经临床治疗实践确认，前列腺癌细胞内的雄激素受体 AR 是一个前列腺癌生长必须的蛋白，以恩杂鲁胺为代表的 AR 拮抗剂（antagonist）在治疗去势抵抗前列腺癌（CRPC）上展现了良好的效果。我们发现一种新型 HDAC6 抑制剂小分子药物 Zeta55，可以有效地在前列腺癌细胞内积累，导致前列腺癌细胞内 AR 蛋白消融，高效地引发前列腺癌细胞生长停滞，效果几倍于恩杂鲁胺。同时，Zeta55 对其他体细胞的损害能力极低，展现了良好的安全性。因此 Zeta55 是一种很有潜力的治疗前列腺癌的创新药。

Project Introduction

Prostate cancer counts for the largest annual cancer patients in the developed countries. Androgen receptor (AR) is a proven therapeutic target for drug intervention. Enzalutamide has shown great success in treating castration-resistant prostate cancer (CRPC) in clinics, by the pharmacology of AR antagonist. Here we report our discovery of a novel small molecule HDAC6 inhibitor Zeta55 as potential drug for prostate cancer treatment. In the preclinical studies, Zeta55 can be effectively accumulated in the prostate cancer cells, trigger AR degradation, thus lead to growth inhibition of the prostate cancer, a few folds more effective than enzalutamide under the same test conditions. Also, Zeta55 has demonstrated excellent safety profiles towards other somatic cells. The dual activities of AR antagonism, degradation and apoptosis result in significant anticancer effect in cell and xenograft experiments, making Zeta55 a promising drug candidate for treating prostate cancer. Therefore, Zeta55 is excellent drug candidate for treatment of prostate cancer.

肖　凯 XIAO Kai	博和生物科技（成都）有限公司首席科技官 CTO, Bohe Biotechnology(chengdu)Co.,Ltd.	骨靶向递药系统研发及在骨科疾病治疗中的应用 R&D of Bone- Targeted Drug Delivery System and Its Application in the Treatment of Orthopedic Diseases

项目简介

骨组织具有血供、渗透性差等特殊生物学特性，常规给药方式难以使药物转运至骨病灶部位，造成药效低、毒性大等问题。为解决这一未被满足的临床需求，博合生物从骨靶向性分子（“靶头”）和药物制剂（载体）两方面着手，打造系列骨靶向药物递送系统平台。例如，骨靶向脂质体递药平台用于解决骨科临床上骨折延迟愈合、股骨头坏死、骨缺损、骨不连、骨质疏松等刺激骨骼生长问题。骨靶向水凝胶递药平台用于解决骨科炎症问题，如牙周炎、牙龈炎引起的骨丢失和骨缺损等问题。临床前数据表明骨靶向递药系统在大鼠、兔骨折模型和大鼠牙周炎模型中均能靶向递送药物至骨病灶，并显著改善其疗效。

Project Introduction

Bone tissue has special biological characteristics, such as poor blood supply and permeability. It is difficult to transport drugs to bone lesions by conventional administration, resulting in low efficacy and high toxicity. In order to solve this unmet clinical needs, Bohe Biotechnology Co., Ltd. has developed a series of bone targeted drug delivery system platforms based on two approaches: bone targeted molecules ("targeting heads") and drug formulations (carriers). For example, bone-targeted liposome delivery platform is used to treat orthopedics diseasessuch as delayed healing of fracture, femoral necrosis, bone defects, nonunion, and osteoporosis.Bone- targeted hydrogel delivery platform is used to solve orthopaedic inflammation problems, such as bone loss and bone defects caused by periodontitisand gingivitis. Preclinical data have showed that these bone-targeted drug delivery systems could specifically delivery drugs to bone lesions in rats, rabbits and periodontitis models in rats, and significantly improve their therapeutic efficacy.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
金　晶 JIN Jing	中国医学科学院药物研究所副研究员 Associate Professor, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College	靶向 B 细胞淋巴瘤的小分子创新药物研发 R&D of Novel Small Molecular Medicine for the Treatment of B-cell Lymphoma

项目简介

B 细胞淋巴瘤是一种源于 B 淋巴细胞的恶性肿瘤，分型众多且具有高度异质性。因为 B 细胞淋巴瘤的增殖依赖 B 细胞抗原受体（BCR）的信号转导，因此靶向 BCR 通路的的小分子药物对 B 细胞淋巴瘤的治疗具有重要临床应用价值。本项目组针对 PI3K，BTK 等重要 BCR 途径相关信号分子，研发了多个对 B 细胞淋巴瘤具有潜在抑制活性的新型候选及先导化合物。包括新型高选择性 PI3Kδ 小分子抑制剂候选化合物 A128，小分子 PI3K−HDAC 双靶点抑制剂候选化合物 PH−20，以及可逆性 BTK 抑制剂先导化合物 WJ0854，希望为 B 细胞淋巴瘤的治疗提供更多更优的选择。

Project Introduction

B-cell lymphoma is a heterogeneous malignant cancer derived from B lymphocytes with many clinical types. Because the proliferation of B-cell lymphoma is depended on the signal transduction of B cell receptor, small molecular medicines targeting related B cell receptor pathways have great value for the clinical treatment of B-cell lymphoma. Focusing on the important targets related to the B cell receptor signal transduction pathway, such as Phosphoinositide 3-Kinase (PI3K) and Bruton tyrosine kinase (BTK), our group has developed many novel small molecular candidate compounds and leading compounds for the treatment of B-cell lymphoma, including the candidate compound A128, a high selective PI3Kδ inhibitor, candidate compound PH-20, a PI3K- Histone deacetylase (HDAC) inhibitor, and leading compound WJ0854, a reversible Bruton tyrosine kinase inhibitor, which may offer more and better options for the therapy of B-cell lymphoma.

张立国 ZHANG Liguo	广东旋玉健康生物科技有限公司技术总监 CSO, Immunecent Biotechnology, Inc.	治疗 SLE 的新型 IFNAR1 单克隆抗体选择性阻断 IFN−ω 和 IFN−α 但保留 IFN−β 的抗病毒作用 A Unique IFNAR1-targeting mAb that Neutralizes IFN-ω &IFN-α but Preserves the Antiviral Activity of IFN-β, as a Potential Treatment for SLE

项目简介

生物药 / 系统性红斑狼疮 / 临床前 I 型干扰素（IFN−I）的持续表达导致包括 SLE 在内的自身免疫病的发生。AstraZeneca 研发了靶向 IFN−I 受体（IFNAR）的抗体 Anifrolumab，能够阻断所有 IFN−I 的活性，在治疗 SLE 的 III 期临床实验中达到临床终点。然而 Anifrolumab 的临床数据显示带状疱疹病毒的感染率显著升高。针对 IFNAR，我们开发了人源化的抗体 IMN−01，它能阻断致病性的 IFN−ω 和 IFN−α，但保留非致病的 IFN−β 的抗病毒活性，从而降低副反应。另外，IMN−01 结合 IFNAR 上的独特表位，在我们的专利中也已经申请了针对新表位的保护。

Project Introduction

Registrational Category: therapeutic biologics
Therapeutic Area: SLE, auto-immune disease
Development Stage: pre-clinical
Project Description:
Type I interferons (IFN-I) are a family of cytokines that signal through a shared receptor composed of IFNAR1 and IFNAR2. In humans, IFN-I includes IFN-β, IFN-ω and 12 IFN-α subtypes. Type I interferons play important roles in antiviral immune responses, but uncontrol expression of IFN-I leads to over activation of immune system, resulting in autoimmune diseases such as systematic lupus erythematosus (SLE). Anifrolumab (AstraZeneca) is a monoclonal antibody targeting IFNAR1 for treatment of SLE and met it primary endpoint in phase III clinical trial. However, Anifrolumab blocks activity of all IFN-I, leading to impaired antiviral immunity, showing side effects such as zoster virus infection. Here we have developed a differentiated humanized antibody (IMN-01) binding to IFNAR1. Importantly, IMN-01 blocks pathogenic IFN-I including IFN-ω and all IFN-α subtypes but not non-pathogenic IFN-β. This will preserve the antiviral function of IFN-β and minimize the viral infection side effects. Additionally, IMN-01 binds to a unique epitope on IFNAR1 which have been covered in our patent. In summary, IMN-01 is promising antibody for SLE treatment with reduced side effect and robust international patent protection.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
张　洁 ZHANG Jie	成都恩沐生物科技有限公司首席运营官 COO, Chimagen Biosciences, Ltd.	针对 B 细胞血液肿瘤的三特异抗体临床前研究 A Novel Tri-Specific Anti-CD3/CD19/CD20 T cell-Engaging Antibody as A Potentially Better Treatment For B-cell Lymphoma

项目简介

CD20 单抗是目前 B 细胞血液肿瘤标准治疗方案的重要组成部分。然而有研究表明约 25% 的 CD20 阳性 DLBCL 病人，经过 rituximab 治疗后肿瘤细胞表面 CD20 表达水平有不同程度降低。这些病人缺少有效的后续治疗方法，存在巨大的尚未满足的临床需求。1A46 是一个全新的同时靶向 CD19 和 CD20 的三特异 T 细胞介导抗体，对 B 细胞肿瘤有很强的杀伤能力。在体外和体内实验中，1A46 显示出了比传统 1:1 IgG 模式 CD3 x CD20 双抗更好的药效和安全性。食蟹猴中的早期数据显示 1A46 在外周血中具有和传统单抗类似的半衰期，并具有良好可控的安全性。1A46 的 1 期临床试验计划于 2021 年开始。

Project Introduction

CD20 targeted therapy by means of anti-CD20 mAb is currently the most important regimen for treating B cells malignancies. However, 1-2% of B-cell lymphoma patients test negative for CD20. Besides, it has been reported in several studies that CD20 expression was down-regulated in over 20% of CD20-positive DLBCL patients that had relapsed/progressed after R-CHOP regimen. The limited prognosis for these patients poses a substantial unmet medical need. A new class of "1:2" format CD3 x CD20 bispecific antibodies emerged aiming for increased tumor antigen avidity and enhanced tumor cell killing, however, its advantages over conventional "1:1" format CD3 x CD20 antibodies have yet to be revealed in clinical trials. Our studies show that CMG1A46 is a novel CD19/CD20-targeting T cell-engaging tri-specific antibody with very promising anti-tumor activity. In both in vitro and in vivo experiments, CMG1A46 demonstrated superior potency and safety compared to other CD3 x CD20 bispecific antibodies with the conventional "1:1" IgG format. Preliminary study in cyno monkeys suggested IgG-like half-life in serum and manageable toxicity. Taken together, the preclinical data strongly support for clinical testing of CMG1A46 in patients with CD20+ cancers. Phase 1 trial of the molecule is scheduled to start by April 2021.

谢单丹 XIE Dandan	江苏亚虹医药科技有限公司业务拓展副总监 BD, Associate Director, Jiangsu Yahong Meditech Co., Ltd.	全球首个口服治疗非肌层浸润性膀胱癌 APL−1202 项目介绍 The First Oral Medicine to Treat NMIBC_APL-1202

项目简介

APL−1202 是国家“十二五”、“十三五重大新药创制专项”项目，是在引进美国约翰　霍普金斯大学专利技术基础上，进一步研发并拥有新的自有知识产权的成果。1202 是国际上第一个口服、可逆性 MetAP2 抑制剂，既抑制肿瘤细胞的生长，也抑制肿瘤血管新生。我们已完成了开放性、多中心 II 期临床研究，化疗 /BCG 灌注失败的高危性非肌层浸润性膀胱癌。研究结果表明 APL−1202 的疗效优于目前的化疗灌注药物，中位无复发时间翻倍，且安全性良好。 目前正在中国开展多中心、随机、空白对照的 III 期临床研究，并在美国开展与 BCG 灌注联合用药的 Ib 临床研究。

Project Introduction

Asieris' APL-1202 has been awarded as recipient of the "National 12th&13th Five-Year Major New Drug Innovation Program" in China. Asieris licensed the global rights of this technology from the Johns Hopkins University, and evaluate independently its potential as a therapy for the treatment of NMIBC. APL-1202 is the first and only oral methionine aminopeptidase II type (MetAP2) inhibitor currently under clinical development in the world. It has novel mechanisms of action of inhibiting both tumor cell growth and angiogenesis. We have completed a single arm, open-label, multi-center Phase II clinical trial for the treatment of high risk non-muscle-invasive bladder cancer patients who have failed intravesical chemotherapy or BCG. The Phase II data suggested that the efficacy of APL-1202 is better than intravesical chemotherapy with a significantly superior human safety profile. The convenient oral route of administration is considered a breakthrough in the field of bladder cancer treatment. We are currently conducting a multi-center, randomized, placebo-controlled phase III clinical study of APL-1202 in China, meanwhile a phase Ib clinical study of APL1202 with BCG has been conducted in US.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
肖　芳 XIAO Fang	北大未名（上海）生物制药有限公司 首席商务官 CBO, Peking University V-Ming(Shanghai) Biologics Co.,Ltd.	创新药物的最佳伙伴——全产业链的生物制药平台 The Best Partner of Innovative Medicine - the Whole Industry Chain for Biopharmaceutical Platform

项目简介

北大未名（上海）生物制药有限公司在上海张江国际医学园区内建成了 1700 平米的研发和中试生产基地，是国内领先的生物制药 CDMO 专业机构，专门为国内外客户提供高水准的生物医药项目 CRO 服务企业，致力于打造一站式 CDMO 服务平台。致力于为全球的生物制药行业客户提供从产品开发、工艺研发、临床样品生产、国内外注册申报到商业化生产的全过程、定制化服务。我们拥有细致的 CMC 开发和合规的临床生产能力，帮助全球客户提供研发效率，降低研发成本，加速生物药品的研发及上市过程。

Project Introduction

PKU SH is a fully integrated biologics CRO/CDMO dedicated to the whole industry chain from research to commercialization. It built a new 1700 sq.m. R&D and pilot production base in Shanghai's Zhangjiang International Medical Park. So far the company has built a strong R&D team with more than 100 people and invested over $20 million dollars on equipment. We provide standalone technical services for various stages of biological drug development and also end to end support for R&D from discovery to clinical studies. We focus on the establishment of a high quality integrated services platform to support global biopharmaceutical companies. We also provide services for register product in domestic and foreign regions, and have customized support. This high quality integrated service approach including CMC development and qualified production abilities allows our global customers to bring biologics efficiently and cost effectively through the entire development process.

钱雪明 QIAN Xueming	创胜集团首席执行官 CEO, Transcenta Holding Limited	创胜集团 – 一个专注于创新抗体药物开发的全整合型生物药公司 Transcenta - A Fully Integrated Biopharmaceutical Company Focused on Innovative Antibody Drug Development

项目简介

创胜集团是一家在生物药研发、临床和生产方面具有全整合能力的国际化生物制药公司。公司已成功搭建了全球的业务布局：在苏州设有药物发现、临床开发和转化研究中心，在杭州拥有工艺与产品开发中心和药物生产基地，在上海、广州、北京和美国普林斯顿分别设有临床开发中心，并在美国波士顿设立了对外合作中心。公司致力于缩短从药物靶标到 BLA 的时间，并应用高质量的新一代生物制造工厂，支持内部管线和战略合作伙伴管线分子的开发和商业化。目前，公司的研发管线中有十余个创新药品种，涵盖肿瘤、骨科、肾病等疾病领域，多个已进入临床试验阶段。截至目前，公司的融资总额已超过 2.3 亿美元。

Project Introduction

Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. With a Discovery and Translational Research Center in Suzhou, a Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai, and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston, US. Transcenta has established a global footprint. Transcenta aims to shorten the timeline from target to BLA and utilize the next-generation biomanufacturing facility to support the development and commercialization of both in-house and strategic partner's pipeline molecules. Currently, Transcenta has established a pipeline of over 10 biologics programs in oncology, bone disorders and nephrology, many of which have entered clinical trials. Upon the latest financing, the company has raised over $230 million from globally prominent investors.

罕见病专场
Rare Diseases and Orphan Drugs Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
张劲涛 ZHANG Jintao	捷思英达医药技术（上海）有限公司 首席执行官 CEO,JS InnoPharm (Shanghai) Ltd	国际首创 1 类新药 Aurora A 激酶抑制剂 VIC−1911 临床开发 Clinical Development of Aurora Kinase A Inhibitor VIC - 1911 for Myelofibrosis

项目简介

骨髓纤维化 (MF) 是一种罕见病，目前一线疗法 JAK2 抑制剂仅能控制脾脏肿大和改善全身性症状。最新研究表明，抑制 Aurora A 激酶可以促进非典型巨核细胞的正常分化，改善 MF。Aurora A 抑制剂 Alisertib 在临床 1 期试验中看到改善 MF 的初步药效，然而由于其选择性较差，有严重的骨髓抑制毒副作用，限制了临床应用。 VIC−1911 是一个高选择性的 Aurora A 激酶抑制剂，在美国已经完成了临床 1a 期试验，安全性能良好。近期我们将在美国权威机构和临床医生支持下，开展 VIC−1911 在 MF 适应症的临床 1b 研究。VIC−1911 属于国家 1 类新药，中美同步开发，有潜力成为全球首创新药。

Project Introduction

Myelofibrosis (MF) is a rare disease characterized by bone marrow fibrosis. Current therapeutics for MF, JAK2 inhibitors ruxolitinib and fedratinib, mainly relieve symptoms without changes in disease progression. Atypical megakaryocytes are a major source of inflammation and bone marrow fibrosis in MF and had high activity of Aurora A, inhibition of which can promote megakaryocyte differentiation and reverse bone marrow fibrosis. Alisertib, an Aurora kinase inhibitor, was tested in a phase I clinical trial and shown to reduce bone marrow fibrosis. However, alisertib was limited by toxicity such as neutropenia, which was caused by inhibition of Aurora kinase B. VIC-1911 is a novel and highly selective Aurora kinase A inhibitor with first in class potential. It was demonstrated that VIC-1911 has acceptable safety profiles in phase I trials. World class medical advisory board is being formed to support global clinical development of VIC-1911 in myelofibrosis to evaluate safety and efficacy in MF patients.

董　飚 DONG Biao	四川至善唯新生物科技有限公司总经理 CEO,R&B Biotech	利用重组腺相关病毒研制治疗 B 型血友病的基因药物 Genetic medicine: rAAV gene therapy for Hemophilia B

项目简介

重组腺相关病毒（rAAV）基因药物安全性高，“一次治疗，长期有效”，是治疗遗传病的新型生物药。欧美共有三个药物已上市，500 个临床试验正在进行，而我国尚属于空白状态。该类药物难以规模化生产，导致价格昂贵，定价在 100−300 万美元。本项目是利用有自主专利的规模化载体生产技术和高效 IX 因子，建设一个国际领先的生产平台，开发治疗 B 型血友病的 rAAV 药物，并将成本降低 10 倍以上。本项目已经进入临床前生产和安全评估阶段，预计将于 2021 年提交临床批件注册申报资料，力争在 3−5 年内成为中国第一个上市的 rAAV 基因药物。本项目对遗传病的 rAAV 基因药物研发和应用将会产生重要影响。

Project Introduction

rAAV (recombinant adeno-associated virus) is the most promising vector to treat genetic diseases such as Hemophilia B. rAAV gene therapy is safe and has the characteristic “one and done”. Today, there are three approved drugs in the market and more than 500 clinical trials are ongoing in the world, while this field remains nearly blank in China. Since the production is difficult to scale up, such drugs are very expensive which are up to 1M to 3 M $. To address this problem, we invent a scalable production system aiming to lower the price more than 10 times. Also, we identify a highly active Factor IX which would improve the therapy efficiency largely. Both of production system and new molecule have been patented globally or domestically. The rAAV genetic drug for Hemophilia B is on CMC stage and IND will be applied in 2021. It could be the first rAAV drug in China in the coming 3 to 5 years, which would have significant impact on genetic drug exploration.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
郭　夏 GUO Xia	中国医疗集团有限公司执行董事 CEO,China Health Group INC.	应用大数据和真实世界临床研究筛选罕见病和脑科疾病新药和最佳医疗实践 Application of Big Data and Real World Clinical Studies to Screen New Drugs and Best Medical Practices for Rare and Brain Diseases

项目简介

中国医疗集团是一家研发型数字医疗服务集团，联合万全医药，一家研发驱动的数字生态制药集团，打造在罕见病及脑科疾病的新药和临床解决方案。中国第一个罕见疾病用药“万全力太”是十多年前由德众万全罕见病药物研究和阳光万全临床中心首先在国内研制上市。中央电视台在 2019 年专访万全北京研究院和万全海南制造基地。脑科学是继肿瘤后的更大领域，公司的喜恩脑科数字临床研究中心，长期致力于卒中、痴呆、癫痫、帕金森和渐冻症等脑科临床和大数据研究，参与或组织了 60% 以上国家脑科学重大临床研究，其中部分专案还获得了国家科学进步一二等奖。

Project Introduction

China Health Group is a R & D-type digital medical service group, jointly with Wanquan pharmaceutical, a research and development driven digital ecological Pharmaceutical Group, to create new drugs and clinical solutions for rare diseases and brain diseases."Wanquanlitai", the first drug for rare diseases in China, was first developed and marketed in China by Dezhong Wanquan rare disease research and sunshine Wanquan clinical center more than ten years ago. CCTV2 reported an exclusive interview of Wanquan Beijing Research Institute and Wanquan Hainan manufacturing base in 2019. ALS is a rare disease, commonly known as "gradually frozen man". This disease is a very strange term for many people and even medical workers. However, it is one of the five incurable diseases listed by the World Health Organization, which is as famous as cancer and AIDS. Brain science will be a bigger field after tumor. The company's digital clinical research center of brain science has long been committed to clinical and big data research of stroke, dementia, epilepsy, Parkinson's disease, and progressive freezing disease. It has participated in or organized more than 60% of the major clinical studies of national brain science, and some of the projects have also won the first and second prizes of national science progress.

吴振华 WU Zhenhua	杭州嘉因生物科技有限公司首席执行官 CEO,Exegenesis Bio Hangzhou Jiayin Ltd	开发针对罕见病的基因治疗药物 Innovative Gene Therapy Platform for Rare Diseases

项目简介

Exegenesis Bio 成立于 2019 年，是一家创新的基因治疗公司，致力于开发针对眼，血液和中枢神经系统疾病的腺相关病毒（AAV）和基于慢病毒的基因疗法。 Exegenesis Bio 由数位在美国顶级基因治疗公司拥有丰富经验的科学家领导，并得到了君联资本和 K2VC 等一系列风险投资者的大力支持。 Exegenesis Bio 是中国为数不多的具有制造工艺和能力将 GMP 生产规模扩大至 2000L 的公司之一，并且已经建立了符合中国，美国和欧洲 cGMP 标准的 GMP 生产设施，用于生产 1 和 2 期临床材料。

我们的注册分类是针对罕见疾病的生物学和先进疗法。我们关注的治疗领域是眼病，血液病和中枢神经系统疾病。目前，我们正处于发现前的临床阶段，预计将于明年晚些时候提交 IND。

Project Introduction

Exegenesis Bio, founded in 2019, is an innovative gene therapy company specialized in developing adeno-associated virus (AAV) and lentivirus-based gene therapy for ocular, hematological and CNS diseases. Exegenesis Bio is led by a group of scientists with extensive experience in top-tier US gene therapy companies, and has been strongly supported by a series of venture investors such as Legend Capital and K2VC. Exegenesis Bio is one of the few companies in China that has the manufacture process and capability to scale up GMP manufacture to 2000L and has already established a GMP facility, compliant to Chinese, American and European cGMP standards for the manufacture of Phase 1 and 2 clinical materials.Our registration classification is biological and advanced therapy for rare diseases. Our therapeutic areas of focus are ocular, hematological and CNS diseases. Currently we are at preclinical phase of discovery, expecting to file IND later next year.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
戴鲁燕 Connie DAI	天津开心生活科技有限公司 战略与创新副总裁 CRO,Tianjin Happy Life Tech Co., Ltd.	真实世界研究助力罕见病创新药开发 Real World Study Facilitating Innovative Drug Development Treating Rare Diseases

项目简介

罕见病因极低的发病率，临床研究需要强大的经费和人力支撑，中国区域广、分级诊疗未完全实现，患者极度分散且缺乏对临床研究的认知，医生因此也相对缺少临床研究及科研项目的参与经验，患者在寻求罕见病诊疗上极度缺乏有效的治疗方法。2019 年药监局颁布《真实世界证据支持药物研发的基本考虑》，得到了国内研究机构和学者在针对罕见病药物和抗肿瘤药物等高度创新药物领域的高度关注。以患者为中心，开心生活科技打造智能技术，全方位高效的进行真实世界研究与分析，赋能罕见病创新药的开发与证据链条生态的完善，推动诊疗规范化，成为中国药监机构、新药开发者、临床研究者、患者和患者组织各方合力的破局之道。

Project Introduction

Rare diseases have extremely low incidence rates. Due to the geographic sparseness of patient distribution, lack of consensus on treatment guidelines and limited knowledge and practices in clinical research, tremendous resources and efforts need to be made to conduct clinical trials in China, therefore leading to the lack of involvement and experiences in clinical research among physicians and researchers. Consequently, the efficacious treatment options of rare diseases are extremely limited. In 2019, NMPA released the guidance on the general considerations of real-world evidence supporting drug development, which arise great attention and strong interests among clinical research institutes and academic researchers, especially in the area of the guidance applications in rare diseases. The multi-disciplinary collaboration with efficient data capture technologies under patient centricity is acknowledged as the key to the success to empower the clinical development via real world data. Happy Life Technology aim to be the facilitator to complete evidence value chain and nurture health ecosystem for the rare disease therapies in China.

孔令洁 Kong Lingjie	苏州博腾生物制药有限公司首席技术官 CTO,Porton Biologics Ltd.	基因细胞治疗 CDMO 助力罕见病药物研发 Gene and Cell Therapy CDMO in Rare Disease Drug Discovery

项目简介

罕见病超过 7000 种，约有 6–7% 的人有罕见病，但是每种罕见病的病人数却很少，从商业利益的角度，大型制药公司对这一领域的药物研发没有足够的重视和投入。这也给中小型制药公司提供了不可多得的机遇。但是，中小型制药公司缺乏大型制药公司拥有的在产品开发和生产方面的经验和资源，而相应的服务公司可以弥补这方面的不足。大约 80% 的罕见病是由基因突变造成的，基因细胞治疗将有可能成为治愈罕见病的有效工具。博腾生物是一个致力于基因细胞治疗产品开发和生产的 CDMO 公司，我们利用团队的丰富经验和合规的 GMP 设施为客户提供从质粒、病毒载体和细胞类产品的开发、GMP 生产、分析到质量控制的优质服务。

Project Introduction

More than 7000 rare diseases are known that collectively affect some 6-7% of the world's population; however, individually, any single, rare disease may only affects a handful of people making them commercially unattractive for the biopharmaceutical industry to target. This leaves a room for biotech companies. However, unlike big pharmaceutical companies, biotech companies are generally lack of experience and resource in drug development and manufacturing. There is a great need for CDMO services in this area. Approximately 80% of the rare diseases are genetic in origin, gene and cell therapy provides a potential cure for genetic diseases. Here at Porton Biologics, we provide know-how of our experienced teams and our industrial facilities for gene and cell therapy to our customers. Our services include process development, GMP manufacturing, analytical and quality control of plasmid DNA, viral vectors and cell therapy products.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
蒋　鑫 JIANG Xin	北京科信必成医药科技发展有限公司 创新总监 Director, Pipeline & Strategy, CoSci Med-Tech Co., Ltd.	科信必成罕用药 2 类新药研发进展 CoSci Class 2 Orphan Drug RnD Progress

项目简介

科信必成管线中有超过 10 个孤儿药新药在研，其中治疗 I 型糖原累积症的治疗药物 KX−258 是该罕见病适应症全球首个候选治疗药品，目前已经完成全部临床前研究，即将按照 2.2/2.4 类申报临床研究。KX−258 是一个针对新的临床适应症设计的缓释新剂型。目前 I 型糖原累积症没有任何治疗药物，患者尤其是患病儿童需要每日多次服用大量的生玉米淀粉，味道差、口感粗粝，患者尤其儿童患者服药依从性非常差。此外，在夜间患者必须中途起床再次服用凉水混悬的生玉米淀粉，十分痛苦，对于患儿家长更是巨大的负担。KX−258 的缓释时间为 10−12 小时，可以有效解决患者及护理者夜间起床服药的问题。

Project Introduction

CoSci has over 10 new Orphan Drugs in its RnD pipeline. KX-258 is the first medicine for Glycogen Storage Disease type I, and CoSci is going to file it to NMPA by Class 2.2/2.4 route for Clinical Investigation. KX-258 is a new sustained-release dosage form for GSD I, and maybe the first ever medicine for this disease. Currently the patients have to take huge amount of raw corn starch, which has very bad taste and palatability, very frequently, resulting in very bad patient compliance. Especially during night, patients using raw corn starch and their caregivers, such as parents, have to wake up every 4 hours to take raw corn starch suspended with room temperature water, and that cause a lot of inconvenience, even suffer to the patients and their caregivers. KX-258 is a newly designed dosage form with extended release mechanism, that gives the drug 10-12hours acting time, which will effectively solve the dosing problem during the night, and reduce the burden of the family with patients suffering from GSD I.

大数据 + 智慧医疗专场
WIT-MED + Big Data Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
张小栋 Seth ZHANG	上海镁信健康科技 CEO CEO, Shanghai Meditrust Health Co., Ltd.	构建中国医药多层次创新支付模式 Building China's Multi-layer Medical Innovative Payment Model

项目简介

构建多层级医疗保障体系是国家治理的重要方向，但目前患者自费和医保仍然占据了医药支付的绝对主力。考虑到国家提升医保报销水平的总体发展方向，快速增长的医药市场将与医保基金和患者相对有限的支付力形成矛盾，急需快速建立多层次保障体系帮助患者减轻负担，提升医药的可及性。

应对这些挑战，药企及器械厂商开始寻求与商保及其他金融机构的跨界合作。以上海镁信健康为代表的创新医疗支付企业，探索出包括疗效保险、治疗分期、患者福利在内的众多自费支付创新的方向。此外，还有专门针对特定疾病患者的带病体保险，以及混合支付形式，以及通过额外的免费服务来降低患者的整体负担。展望未来，创新支付将在多层次医疗保障能发挥更重要的作用。

Project Introduction

Establishing multi-layer medical security scheme is one of the key issues to China. However, self-funding and medical insurance are dominant in the pharma payments. The rapid growth of pharma expense conflicts with limited payments ability of patients and medical insurance. it is very urgent to establish multi-layer security scheme to reduce patients' financial burden as well as enhance accessibility to pharma.

To overcome these challenges, pharmaceutical and device companies are seeking for cooperation with commercial insurance and financial institutions. Innovative start-ups like Shanghai MediTrust Health, are exploring innovative payments solutions such as efficacy insurance, instalment payment, patients benefit, etc. There are also insurances specialized for patients with specific disease, mixed payments, and additional free service to reduce patients' burden. Looking forward, innovative payments will play more and more important role in the multi-layer medical security scheme.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
周　腾 David ZHOU	思派健康科技有限公司首席财务官及策略官 CFO, Chief of Staff Medbanks Network Technology Co., Ltd.	中国的“联合健康”管理式医疗路径 ——整合医药 + 支付的科技体系 United Health Model in China - An Integration of Providers, Products and Payors

项目简介

从 2014 年起，思派科技即致力于通过做有益于医生和患者的创新，在医疗行业创造社会价值。通过创新性的科技与专业人员“新基建”，思派建立了从服务于创新药临床试验研究者的临床基地网络、新药上市 的特药药房服务网络、到健康险保障计划和药品福利管理的多项业务，形成了整合式的医疗资源网络。思派希望通过帮助健康医疗事业中的所有关键方 – 医疗服务提供方、产品方、及支付方，共同建立整合的管理式医疗模式，更有效率地在中国提供管理式医疗，让更多的人群获益。

Project Introduction

Briefing on Medbanks Since 2014, Medbanks has been focused on creating social value by assisting physicians and helping patients in medical setting and healthcare management. By building new-generation infrastructure of technology and professional workforces across several businesses - from site management network for innovative therapies, specialty pharmacy network and health plan ; PBM, Medbanks aims at helping and empowering all key stakeholders in healthcare community - providers, products and payors - to perform more efficiently in delivering medical benefits and as a result, ultimately provide better managed care for wider population. Medbanks has established a solid position as leading integrated networks across of clinical trial sites for innovative therapies, specialty pharmacies and patient management centers, and health plan ; management providers. Medbanks hopes to help optimize work efficiency for physicians, market access for product innovators, and health management both for payors and insured.

汤　鹏 Rocs Tang	北京量子保科技有限公司品牌经理 Beijing Quantum InsurTech Co., Ltd.	让人人享有普惠精准的健保服务，数据智能助推定制化惠民保险 Health and care service for everyone, Data for benefaction insurance

项目简介

以惠民保险业务为切入，探索以医疗大数据平台为驱动引擎，发展互联网医疗 + 保险服务的居民保障平台，为民众提供便捷的“一站式保险保障 + 医疗服务”。 与各地政府建立长期平等互利的战略合作伙伴关系，针对医疗大数据、人工智能、 市民医疗保障等领域进行合作，加快医疗健康行业创新发展，增速经济产业效能。基于医、药、险、患四方服务，通过服务流、数据流、支付流等创新手段， 致力打造一套四方三流一体的全闭环解决方案，为客户提供全流程的技术服务；以医疗大数据平台为驱动引擎，通过整合当地医疗健康资源，建立当地健康服务平台，打造“新型智慧健康城市”。目前已成功与厦门翔安区政府达成合作。

Project Introduction

Establish long-term , equal and mutually beneficial strategic partnerships with local governments through insurance service to cooperate in areas such as medical big data, artificial intelligence, and citizen medical security, accelerate the innovation, development of the medical and health industry. Based on medical, drug, risk, and patient services and provide customers with full-process technical services through innovative methods such as service flow, data stream, and payment streams. Explore the establishment of health insurance integrated service platform.It has agreed with the Xiang’an government to cooperate and will promote cooperation with more governments. Quantum InsurTech is an internet innovation insurance platform. Established in September 2016 and completed A+ round financing already. With the dynamic premium, big data actuarial, the entire process experience and other technological innovation, Quantum InsurTech provide "insurance + service" multiple custom solutions.

创新研发服务专场
R&D Service Company Roadshow (CRO, CMO, CDMO)

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
李　明 LI Ming	港中科国际生物科技有限公司首席执行官 CEO of ZSHK Laboratories Co., Ltd.	临床前一体化评价服务平台 Integrated Pre-clinical Evaluation Service Platform

项目简介

滬港中科国际生物科技有限公司总部位于中国香港特别行政区，在香港科技园、深圳市坪山区、苏州工业园区建有独立实验室，以生物医药和医疗器械的临床前研究评价服务为主要业务内容，以满足国际申报要求为目标，立志成为中国生物医药与医疗器械研发企业在全球发展和拓展中最有价值的研发合作伙伴。滬港中科公司目前已经在苏州工业园建成药物临床前评价服务实验室，正在香港科技园和深圳坪山区建设新药与医疗器械评价实验室。这些实验室都将具备国家药品监督管理局（NMPA）的 GLP 资格认证和欧盟 OECD 的 GLP 资格认证资格。

Project Introduction

ZSHK Laboratories Limited, headquartered in the Hong Kong Special Administrative Region of China, has established laboratories in Hong Kong Science and Technology Park, Pingshan District, Shenzhen, and Suzhou Industrial Park. Aiming to be the most valuable R&D partner for the global development of bio-pharmaceuticals and medical devices R&D enterprises in China, ZSHK provides pre-clinical study and evaluation on the bio-pharmaceuticals and medical devices and runs a one-stop R&D platform. At present, ZSHK has built laboratories for drug preclinical evaluation in Suzhou Industrial Park and is building laboratories for drug evaluation in Hong Kong Science and Technology Park and Pingshan, Shenzhen. These laboratories will be qualified with GLP certificates issued by National Medical Products Administration (NMPA) and Organization for Economic Co-operation and Development (OECD). ZSHK will become an international enterprise with all-in-one R&D services.

任　峰 REN Feng	上海美迪西生物医药股份有限公司 高级副总裁 Senior Vice President, Shanghai Medicilon Inc.	CRO 加速创新医药的研发 Accelerate the Process of New Drug Discovery

项目简介

1. 合作模式创新

（1）FTE 类型合作：38FTEs 和临床前研究员从 HTS 先导化合物开始，历时约 2 年得到 5 个临床候选化合物，并有 1 个进入临床测试阶段。

（2）项目整体外包：从先导化合物发现到候选化合物临床前研究历时 2 年 6 个月。其中涵盖体外生物活性专利权获得，简单成药性，非 GLP 毒理成药性研究以及 IND 申报。

2. 协同创新案例分享

生物电子等排体；蛋白质降解技术；Protac 平台布局；基于 SPR 技术的高通量筛选；眼科创新药工艺开发；提高难溶性药物生物利用度（＞ 70%）；CRISPR 颠覆性的基因治疗技术；升级版基因编辑技术。

Project Introduction

1. Innovative collaboration models: (1) Integrated services (eg. America client): Starting from the HTS leading compounds, thirty-eight FTEs and preclinical researchers spent around two years to obtain five clinically candidate compounds, and one of them entered the clinical testing phase. (2) Overall project outsourcing: It spends two and a half year from the finding of leading compounds, till the preclinical research of candidate compounds. It covers in vitro biological activity patent rights, simple druggability, non-GLP toxicological druggability research and IND application.

2. Collaborative innovation: Bioisosteres; Protein degradation technology; Protac platform layout; High-throughput screening based on SPR technology; Process development of innovative ophthalmic drugs; Improving the bioavailability of poorly soluble drugs (over 70%); Disruptive gene therapy technology of CRISPR; Upgraded gene editing technology.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
闻丹忆 WEN Danyi	上海立迪生物技术股份有限公司 董事长兼 CEO President & CEO, Shanghai LIDE Biotech. Co., Ltd.	MiniPDX 小鼠体内 7 天肿瘤药敏检测的转化应用 Translational Application of MiniPDX, a 7 Days in Vivo Oncology Drug Efficacy Test

项目简介

对于肿瘤驱动基因不明确的绝大部分肿瘤，分子检测不足以分辨临床的变异，需依赖细胞或动物水平的功能性检测。MiniPDX，7 天小鼠体内肿瘤药敏检测的转化应用，为临床个性化精准医疗提供了新的可能。工信部医疗大数据项目的真实世界研究将在全国以 100+ II−T 形式开展万人 MiniPDX 与临床相关性的研究。多个肿瘤的 MiniPDX II 期前瞻性随机对照试验也在以 II−T（研究者发起的临床试验）形式在多家三甲医院展开。在临床前研究方面，MiniPDX 是新药筛选中界于细胞学实验和 PDX 药效之间的有效筛选工具。MiniPDX Mouse Trial 更为临床前和临床 Biomarker 研究提供了独特的平台。

Project Introduction

For cancer type without clear cancer driver gene, molecule test is not sufficient to distinguish the clinical viable. Next generation of precision medicine relay on functional diagnosis. Translational application of MiniPDX, 7 days in vivo oncology drug efficacy test, enable the personalized oncology. A government funded Big Medical Data RWE project will carry out 100+ II-T (Investigator Initiated Trials) to validate the clinical correlation of MiniPDX. Several prospective, randomized phase II a/b MiniPDX clinical trials are in progress at several 3A hospitals in China. For pre-clinical studies, MiniPDX is an effective screening tool between cellular assay and in vivo PDX pharmacology studies. MiniPDX mouse trail provides unique platform for pre-clinic and clinical biomarker studies. Biotech companies are using MiniPDX for patient stratification on Phase I/IIa clinical trials. Functional diagnosis for patient stratification is the future direction of innovated new drug development.

徐列东 XU Liedong	缔脉生物医药科技（上海）有限公司 首席商务官 Chief Operation Officer, dMed Biopharmaceutical Co., Ltd.	速中求稳的国际化临床研究一站式服务 Doing Clinical Trials the Right Way – One Stop Solution

项目简介

随着中国新药研发高潮的到来，对临床试验的速度、质量、费用以及整体管理都提出了更高的要求。CRO 行业面临的挑战是如何在保证质量的前提下提高速度和降低费用。新技术、新方法、新的管理方式是达到这一目标的保证。缔脉在多年的实践中找到了一条行之有效的一站式服务模式。 缔脉生物医药科技（上海）有限公司是一家立足中国、面向全球的临床合同研究组织 (CRO)。员工中有很多是跨国药企的行业精英和中美两国医药监督管理机构的权威专家，借助多年丰富的药物开发经验，从方案设计到申报策略、从运营执行到质量保证，为客户提供更有价值的建议和更可靠的运营管理。

Project Introduction

The big wave of new drug development has arrived in China. That posted a higher demand on the speed, quality, cost and overall management of clinical trials. The CRO industry is facing the challenge of how to improve speed, control cost, and without compromising quality. New technology, new method and new management approach is essential for success. With many years of practice, dMed has found the right way of one stop service to do clinical trials right.dMed is a full-service Clinical Contract Research Organization (CRO), which provides industry solutions to pharmaceutical and medical device companies in China and across the globe. dMed is led by experts in China and the US who originated from leading multinational pharma companies and regulatory agencies. We are uniquely positioned to leverage and integrate China's new regulatory framework, offer innovative drug development strategies, and help our clients expand globally by tapping into the world's second largest pharmaceutical market. Our creative and flexible collaboration models will help Chinese and global innovative pharma companies effectively raise efficiency in clinical R&D, scientifically shorten research cycle, and boost success rate.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
李　寅 LI Yin	北京春天医药科技发展有限公司 市场营销中心总经理 General Manager of Marketing Center, Proswell Medical Company	创新药临床试验的“春天” Spring of Clinical Trials of Innovative Drugs

项目简介

我国高度重视医药创新，《国家创新驱动发展战略纲要》、《“十三五”国家科技创新规划》等规划指南均提出有关创新药发展的目标，并且设立了专项以推动新药研发。此外，国家药品监督管理局将鼓励创新作为重点改革方向，尤其自 2015 年以来，创新药物的政策环境不断优化，创新活力不断释放。在此背景下，全面剖析我国创新药发展现状，对企业投资决策和监管机构鼓励创新都具有重要意义。春天医药市场营销中心总经理李寅博士将以《创新药临床试验的“春天”》从临床试验涉及到的不同角度等方面展示 进行报告。

Project Introduction

China attaches great importance to pharmaceutical innovation. The National Strategy Outline for Innovation-Driven Development, the National Science and Technology Innovation Plan in the 13th Five-Year Plan, and the Guidelines for the Development of Pharmaceutical Industry all set out the objectives for the development of innovative drugs and set up special projects to promote the development of new drugs. Since 2008, China's implementation of the "new drug creation" major projects in innovative drug research and development has achieved fruitful results. In addition, the State Drug Administration has focused on encouraging innovation as a reform direction, especially since 2015, the policy environment for innovative drugs has been continuously optimized, and innovation vitality has been released. Under this background, it is of great significance to analyze the development of innovative drugs in China, to make investment decisions and to encourage innovation.

The report covers: China's innovative drug R&D market; China's Innovative Drug Development Model; Open innovation in clinical trials; Recommendations for innovative drug development and regulation.

赵　馥 ZHAO Fu	润东医药研发（上海）有限公司副总裁 Vice President, Rundo International Pharmaceutical Research & Development Co., Ltd.	润东医药——打造基于高质量传统 CRO 的数字化和模式化创新平台 Rundo - Build a Digital and Patterned Innovation Platform based on High-Quality Traditional CRO

项目简介

润东医药研发（上海）有限公司成立于 2004 年，是专业提供一站式临床研究外包服务的 CRO 公司。润东医药在行业内首家通过 ISO9001:2008 质量管理体系并结合 CRO 行业规范认证。公司成立的 16 年里，润东执行完成超过 1200 项临床试验，其中 60% 以上是创新药项目。润东医药为中国国内领军的临床 CRO 公司之一，同时也在探索创新模式和数字化技术，不断转型成为创新型、综合型 CRO。润东医药是中国 CRO 联盟（CROU）的主要发起者和推动者，现为 CROU 的理事长单位，中国医药质量管理协会 CRO 分会的会长单位。

服务范围：为客户提供符合 ICH-GCP 和 NMPA 相关法规、专业规范的一站式临床研究全程服务。

Project Introduction

Rundo International Pharmaceutical Research & Development (Shanghai) Co., Ltd. Rundo was founded in 2004, specialized in providing one-stop Clinical Research Organization (CRO) services. Rundo is the first domestic CRO accredited ISO9001: 2008 Quality Management System and CRO Industry Standard Certification in China. In the 16 years since its establishment, Rundo has completed more than 1200 clinical trials, of which over 60% areinnovative drug projects. As one of the leading CRO in China, Rundo is also exploring innovative models and digital technologies to transform itself into an innovative and comprehensive CRO. In addition, Rundo is one of the main founders and facilitators of the Chinese CRO Union (CROU), and currently chairs the board of CROU. Service Scope: One-stop full CRO service to our clients in compliance with ICH-GCP and NMPA relevant regulations and professional standard, including: Regulation Affairs, Medical Affairs, Project Management, Clinical Operations, Biometrics, Pharmacovigilance, SMO, etc.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
董正伟 Harvey DONG	厦门艾德生物医药科技股份有限公司 业务拓展部高级总监 Senior Director of Business Development, Amoy Diagnostics Co., Ltd.	肿瘤精准医疗伴随诊断系统解决方案 Companion Diagnostic Solutions for Precision Oncology

项目简介

厦门艾德生物医药科技股份有限公司（股票代码：300685）由郑立谋教授于 2008 年回国创办，集肿瘤精准医疗诊断产品的研发、生产、销售、服务为一体，同时具备三类体外诊断产品生产 / 经营资质及独立临床医学检验资质。

公司获得国内外发明专利授权 30 余项（核心专利获得中国、美国、欧洲、日本授权），拥有行业内国际先进、完全自主知识产权的 ADx−ARMS®、Super−ARMS®、ddCapture®、digital dual−direction Capture® 等技术平台。基于专利技术，公司陆续研发了十几种基因检测产品，均获得 NMPA 医疗器械注册证书并通过欧盟 CE 认证。

Project Introduction

The company has launched multiple industry-leading proprietary technology platforms, including WuXiBody bispecific antibody technology platform, WuXia cell line development platform, WuXiUP ultra-high productivity continuous processing platform, to enable global partners to develop the next-generation biologics. So far, it has filed more than 300 overseas patent applications and 100 Chinese patent applications. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 280,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

叶伟平 YE Weiping	广东莱佛士制药技术有限公司总经理 CEO, Guangdong Raffles PharmaTech Co., Ltd.	小分子新药开发与产业化关键技术 Key Technologies of New Small Molecule Drug Development and Industrialization

项目简介

小分子新药 API 工艺开发贯穿从研发到临床到产业化的全部过程。以创新工艺路线为核心，系统整合酶催化、有机催化、以及连续流微反应等先进工艺，符合产业化、药品申报、安全、环保等多方面要求，符合国际社会对于绿色制药业的发展趋势。

新化学实体从研发走向产业化，在工艺方面往往面临诸多困境：早期开发阶段如何选择最合适工艺路线？临床后期的工艺变更如何设计考量？生产厂地转移过程中，如何高效实现工艺桥接？与专业、创新的 CDMO 合作，开发适合产业化、工艺风险低的早期工艺，可以有效规避安环风险、技术转移风险等，助力新药成功实现产业化。

Project Introduction

API process development of small molecule new drug runs through the whole flow from preclinical to clinical to industrialization phases. Advanced processes, taking the innovative route as the core, always systematically integrate enzyme catalysis, organic catalysis, continuous flow microreaction etc, which meet the requirements of industrialization, drug application, safety, environmental protection and other aspects, and also meet the development trend of the international community for green pharmaceutical industry.

New chemical entities from R&D to industrialization often face many difficulties in the aspect of process.How to choose a suitable process route in the early development stage? What are the design considerations for process change in the late clinical stage? How to efficiently realize process bridging in the process of site transfer? Cooperating with a professional and innovative CDMO to develop an early process, suitable for industrialization and with low process risk, which can effectively avoid the risks of safety environment and technology transfer, which is benefits to new drugs commercialization.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
郭振荣 GUO Zhenrong	浙江九洲药业股份有限公司首席技术官 CTO, Zhejiang Jiuzhou Pharmaceutical Co., Ltd.	瑞博 CDMO 赋能新药研发 Raybow CDMO, Accelerate Partner New Drug Development

项目简介

浙江瑞博制药有限公司（九洲药业 CDMO 事业部）是浙江九洲药业股份有限公司（股票代码：603456）全资子公司，致力于成为全球领先的 CDMO 服务企业。公司 10 多年来向全球跨国药企和新药研创公司提供全面的委托研发和定制生产服务，内容涵盖新药临床前药学研究、临床及各阶段原料药工艺研发和生产、到商业化生产的全业务链。瑞博制药拥有瑞博台州、瑞博杭州、瑞博美国三个研发中心，以及瑞博台州和瑞博苏州两个生产基地，全球雇员 1500 人。

Project Introduction

The CDMO Division of Jiuzhou Pharma (Raybow Pharmaceutical) has an excellent R&D technology platform for chemical innovative drug and a flexible capacity for commercialization production. As a leading enterprise in the field of global new drug Contract Development and Manufacturing Origination (CDMO), it commits itself to global partners for the supply of "One-Stop Service", covering the stages from new drug preclinical research to commercial production, with high quality, high efficiency, and high flexibility. Our R&D team with resourceful, multi-field experienced and internationalized high talents, over 400 people in total, providing customers with professional solutions for CDMO projects. It committed to the research and development of new pharmaceutical technology, especially in the area of high-end fluorine chemistry, asymmetric chiral synthesis, glycosides and biological enzyme technology, which reflects the high level of technical research and development strength.

陈智胜 Chris CHEN	药明生物首席执行官 CEO of WuXi Biologics	卓越生物技术平台赋能加速全球创新 Global Premier Biologics Platforms to Enable and Expedite Innovations

项目简介

药明生物致力于建立符合国际水准的一体化生物药发现、开发和生产技术平台，加速和变革全球生物药产业发展。经过近十年高速发展，药明生物已服务逾 300 个全球合作伙伴，市值超 2600 亿港币。按收入计算生物药合同定制研发生产服务市场份额，药明生物在全球市场排名第三，中国市场排名第一。

药明生物打造了一系列具有自主知识产权的生物药技术平台，目前提交 300+ 项海外专利申请和 100+ 项中国专利申请。其中双抗技术平台 WuXiBody、细胞系平台 WuXia、超高效连续生产技术平台 WuXiUP 赋能合作伙伴布局新一代生物药浪潮。预计到 2023 年后，公司在中国、爱尔兰、美国、德国和新加坡规划的生物药生产产能将超过 28 万升。

Project Introduction

As the third largest biopharmaceutical CDMO in the world and the largest in China, WuXi Biologics (stock code: 2269.HK) is committed to building open-access technology platforms to offer end-to-end biologics solutions. With the mission to accelerate and transform biologics discovery, development and manufacturing, WuXi Biologics has established comprehensive partnerships with more than 300 pharmaceutical companies around the globe within its 10 years' rapid development, and has reached a market cap of more than $24 billion.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
蔡绪柳 CAI Xuliu	北京经纬传奇医药科技有限公司董事长 Chairman of the Board, Beijing Jingwei Chuanqi Medicine Services Co., Ltd.	第三方稽查与新药投资尽职调查 Third-party Audit and Due Diligence on Investment for New Drug

项目简介

经纬传奇成立于2009年，是专注于临床试验质量的规模化发展的独立第三方稽查公司。服务延伸至药品注册现场稽查，全过程质量管理，咨询与培训，新药投资尽调。已为国内外两百八十余家制药企业规划实施 GCP/GLP/GMP/cGMP 的第三方稽查 770 余项，临床试验机构稽查超过 2700 院次，稽查机构范围已覆盖全国 60% 以上。第三方稽查作为临床试验的协作者，对临床试验操作流程、数据真实性、合规性进行稽查，稽查注册申请中提交的临床试验资料与临床试验机构保存的资料的一致性、临床试验数据溯源、临床试验过程是否符合相关规定要求，帮助发现试验过程中的问题，及早发现、及早纠正和预防，进一步提升临床试验质量，促进药品创新。

Project Introduction

Founded in 2009, Jingwei Chuanqi is an independent third-party audit company focusing on the large-scale development of clinical trial quality. The service extends to on-site inspection of drug registration, quality management throughout the whole process, consultation and training, and due diligence on investment for new drug. More than 770 terms of third-party audits of GCP/GLP/GMP/cGMP have been planned and implemented for over 280 pharmaceutical companies at home and abroad. And more than 2,700 audits of clinical trial institutions have been carried out. More than 60% of audit institutions have been covered in the country. Third-party audit as a collaborator of clinical trial, it checks the operation process, data authenticity, and compliance of clinical trial, checks the consistency between the clinical trial data submitted in the registration application and the data kept by the clinical trial institution, the traceability of clinical trial data, and whether the clinical trial process meets the relevant requirements, in order to find out problems in the trial process, realizing early detection, early correction and prevention and further improving the quality of clinical trials, and promoting drug innovation.

医疗器械专场
Medical Devices Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
郇丹丹 HUAN Dandan	安翰科技（武汉）股份有限公司副总裁、董事会秘书 Vice President & Board Secretary of ANKON Technologies Co., Ltd.	安翰远程胶囊胃镜助力疫情防控 Ankon Remote Capsule Gastroscope Helps COVID-19 Prevention and Control

项目简介

近年，“互联网 + 医疗健康”的概念逐渐进入大众的视野。在此概念的基础上我公司结合现有磁控胶囊胃镜系统（NU-I）和巡航胶囊内窥镜控制系统（AKC-1）开发了可以辅助远程医疗诊断的胶囊内窥镜远程控制台，意在帮助基层和偏远地区的患者就近享受高水平的医疗资源，提高消化道疾病的筛查比例，以实现早筛查早诊断早治疗的目的。COVID-19 新冠疫情防控的需求下，基于互联网平台的胶囊内窥镜远程控制台可以提供无接触的消化道内镜检查的方式，避免医患间的交叉感染和病毒传播。无接触检查方式是现阶段传染病防治防控阶段最为安全有效的诊疗方式，可以极大的满足临床急需要求。

Project Introduction

In recent years, the concept of "Internet + medical health" has gradually entered the public's field of vision. On the basis of this concept, we combined the existing magnetic control capsule gastroscope system (NU-I) and cruise capsule endoscope control system (AKC-1) to develop a capsule endoscope remote console that can assist in remote medical diagnosis. It is intended to help patients in the grassroots and remote areas enjoy high-level medical resources easily. This can increase the screening rate of digestive tract diseases, and achieve the purpose of early screening, early diagnosis and early treatment. Prepared for prevention and control of the COVID-19 new crown epidemic, the remote console of the capsule endoscope based on the Internet platform can provide a non-contact gastrointestinal endoscopy method to avoid cross-infection and virus transmission between doctors and patients. Non-contact inspection is the safest and most effective method of diagnosis and treatment in the prevention and control of infectious diseases at this stage, which can greatly meet the urgent clinical needs.

张亚飞 ZHANG Yafei	迈杰转化医学研究（苏州）有限公司董事长 CEO of MEDx (Suzhou) translational Medicine Co., Ltd.	聚焦生物标志物和伴随诊断的精准医疗创新解决方案 Bringing Integrated Solutions to Precision Medicine: from Biomarkers to CDx

项目简介

迈杰转化医学研究（苏州）有限公司是一个为精准医疗提供完整解决方案的创新型公司。凭借着行业领先的核酸、蛋白、病理以及细胞生物学等综合性转化医学平台和经验丰富的高素质专业化技术团队，迈杰转化医学为肿瘤免疫治疗、靶向治疗等创新疗法提供从生物标志物的发现、验证和检测方法开发，到新药临床试验病人分子检测和分层筛选，以及伴随诊断试剂盒研发和商业化的一站式服务。迈杰转化医学将继续秉承“从生物标志物到伴随诊断产品”的完整解决方案的战略规划，服务世界创新药企和大众健康，助力精准医疗。

Project Introduction

MEDx (Suzhou) translational Medicine Co., Ltd is an Innovative company that provides unique and integrated solutions from biomarker discovery to the development of companion diagnostics (CDx) in addition to clinical testing for precision medicine, in the fields of cancer immune therapy and targeted therapy. With comprehensive Hi-Tech platforms and professional translational scientist teams, we offer profound services with biomarker discovery, diagnostic assay development, CDx commercialization, and patient stratification test for drug clinical trials, as well as one-stop-shop and world class solutions for our clients such as domestic and international pharmaceuticals, independent clinical labs and hospitals. In the future, MEDx will continue to follow the strategy of "from biomarker to CDx products" to bring the integrated solution to precision medicine, and eventually support the innovative pharmaceutical companies and public health.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
周　曜 ZHOU Yao	科瑞百奥生物技术有限公司首席运营官 COO of Cryo Bio Technology Co., Ltd.	同种异体软骨材料临床技术及创新医疗器械产品 Clinical Technology of Allogeneic Cartilage Materials and Innovative Medical Device Products

项目简介

科瑞百奥致力于成为中国领先的生物再生材料整体解决方案提供商。公司打造了国内首家人源性生物再生材料技术平台，通过研发具有生物学活性的外科植入物，如骨科植入物，为更多的患者提供更高效的生物材料解决方案。公司的无冰晶技术填补了国内低温冻存技术的空白，大大提高了捐赠的组织的利用率，延长了保存时间和移植成功率。首先在关节软骨损伤领域应用，针对目前国内快速上升的运动医学和骨关节等领域。目前和国内独家医院签订了战略合作协议，2020 年开始为医院提供限制性临床技术服务。同时公司具有独家专利技术的低温冷藏软骨产品准备申报创新医疗器械。依托于公司的人体组织库和冻存技术平台，与智能化手术机器人， 3D 打印等相结合，可以在半月板，小血管、心脏瓣膜、皮肤、胰岛、生殖、医美等多个组织 / 医学领域应用，未来将有多个产品管线。

Project Introduction

Cryo Bio Technology Co. Ltd is committed to becoming China's leading provider of integrated solutions for biomaterials. The company has built the first domestic technology platform of biological regeneration materials, and provides more efficient biomaterial solutions for more patients by developing surgical implants with biological activity, such as orthopedic implants. The company's ice free technology fills the gap of domestic cryopreservation technology, greatly improves the utilization rate of donated tissues, prolongs the preservation time and transplantation success rate. Firstly, it is applied in the field of articular cartilage injury, aiming at the rapidly rising sports medicine and bone and joint and other fields in China. At present, it has signed strategic cooperation agreement with the exclusive domestic hospitals, and will provide clinical technical services for the hospital from 2020. At the same time, the company has the exclusive patent technology of low temperature cold storage cartilage products ready to apply for innovative medical devices. Relying on the company's human tissue resource and cryopreservation technology platform, it can be applied in many tissue types and multiple medical aeras, such as blood vessels, heart valves, skin, islets, reproduction medicine and beauty, and there will be many product pipelines in the future.

张晓冬 ZHANG Xiaodong	北京天助瑞畅医疗技术有限公司总经理 General Manager of Beijing Angel-Reach Medical Technical Co., Ltd.	新型普适性一一体化主动脉弓修复系统 A Novel Type of Aortic Arch Endovascular Repair System

项目简介

累及主动脉弓部的胸主动脉扩张性疾病（胸主动脉瘤、主动脉夹层），因其在解剖上的特殊性（三分支、弓部弯度、临近主动脉瓣及冠脉开口、弓部形态变异等），成为了主动脉腔内修复技术的一道障碍。本项目结合一体化和覆膜与支架分别置入的理念，制作一款新型的主动脉弓腔内修复系统。产品经体外测试平台测试修改，并于活体猪进行在体试验改进后，形成一款具备普适性特点能够适应各种弓型，减少商业型号的同时解决急性患者的需要，简化操作流程的同时降低输送半径的主动脉弓腔内修复系统，力图有效的改善现有此部位腔内隔绝治疗方案的缺陷，减少并发症并提高疗效，对此领域进行有益的尝试。目前产品已经完成临床前检测及动物实验，即将开展临床试验。

Project Introduction

Thoracic aortic dilatated disease (thoracic aortic aneurysm and aortic dissection)involving the aortic arch has become an obstacle to endovascular aorticrepair (EVAR) because of its anatomical particularity (tri-branch, arch curvature, proximal aortic valve and coronary artery orifice, arch morphological variation,etc.). At present, there are obvious defects in all kinds of technology and equipment in research or marketing. A novel type of aortic arch endovascular repair system is designed and manufactured, which have universal characteristics for adapting to various types of arch, reducing the commercial models, solving the needs of acute patients, simplifying the operation process and reducing the delivery profile. It will effectively improve the defects of the existing endovascular repair systems, reduce the occurrence of complications and improve. At present, preclinical test and animal experiments have been completed, and clinical trials will be carried out soon.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
李广成 LI Guangcheng	苏州梅德厚普医疗科技有限公司董事长 CEO of Suzhou MADEHOPE Medical Technology Co., Ltd.	颅内血肿清除系统 Intracranial Hematoma Clearance System

项目简介

颅内血肿清除系统系苏州梅德厚普医疗科技有限公司自主研发的一款高端医疗器械，主要应用于脑出血的微创清除，适用于自发性脑出血和外伤性脑出血，特别适用于目前难以解决的脑深部血肿的清除。该产品世界首创，在血肿清除方面突破解决了 2 项医学难题：1. 在理论层面解决了血肿清除过程中损伤脑组织的难题；2. 技术上解决了内窥镜在血性液体中无法获得清楚图像的难题。

与现有脑内血肿清除方法相比，具有跨代优势：

安全：从血肿中心清除，不接触脑组织；微创：手术创伤是现有技术的几十分之一；超早期：可在脑组织发生不可逆损伤（6 小时）前进行手术；可视化：世界上首次实现全程内窥镜内可视化清除脑内血肿；精确定位：产品的定位精度在 2mm，告别盲穿操作；适用脑深部血肿：突破目前手术禁区；效率高：手术时间少于 1 小时；清除彻底：一次性血肿清除率 90% 以上。

产品已经完成注册检验，目前正进行临床试验。初步临床结果表明，对于固体血肿的一次性清除率，从对照组的 15% 提高到 95%！

公司拥有此项技术完整知识产权，拥有多项发明专利，已构成完整专利链，其中主要专利都已申报国际专利，并取得包括美国、日本、欧盟等 10 几个国家授权。

Project Introduction

Intracranial hematoma removal system is a high-end medical device independently developed by Suzhou medhoupu Medical Technology Co., Ltd., which is mainly used for minimally invasive removal of cerebral hemorrhage.

Advantages:

Safety: remove from the center of hematoma without contacting brain tissue; Minimally invasive: surgical trauma is less than one tenth of the existing technology; Ultra early stage: the operation can be carried out before irreversible brain injury (6 hours); Visualization: for the first time in the world, the whole process of endoscopic visualization of intracerebral hematoma clearance; Accurate positioning: the positioning accuracy of the product is within 2mm; Suitable for deep brain hematoma: break through the current operation forbidden zone; High efficiency: the operation time is less than 1 hour; Efficient: The one-time clearance rate of hematoma was more than 90%.

The product is in clinical trials. Preliminary clinical results showed that the one-time clearance rate of solid hematoma increased from 15% to 95% !

顾　莹 GU Ying	无锡帕母医疗技术有限公司运营总监 COO of PULNOVO MEDICAL(Wuxi)Co., Ltd.	经皮肺动脉去神经术：治疗肺高压的创新技术 Pulmonary Artery Denervation(PADN): Aninnovative Technique for Treatment of Pulmonary Hypertension(PH)

项目简介

无锡帕母医疗技术有限公司成立于 2013 年，是经皮肺动脉去神经术治疗肺高压的技术首创者和领路人。公司项目组由美国心脏病学院院士（FACC）陈绍良博士带队，基于 PH 治疗现状在国际上首创“经皮肺动脉去神经术（PADN）”，开发的 PADN® 器械属于三类，已斩获国家创新医疗器械，拥有中国、美国、巴西、韩国、日本、印度、欧洲、俄罗斯等国的 PCT 专利和方法学专利，能将特制的导管送到肺动脉分叉近段，损伤浆膜层下的交感神经抑制过度激活。前期开展的动物实验和近 200 例临床研究证实 PADN® 仪器系统能显著改善患者血流动力学和肺动脉重构并提高其活动耐力，相关研究成果共发表 SCI 文章 12 篇，影响因子 IF 合计 66.61。目前正处于报批临床阶段，已完成 50% 的入组。

Project Introduction

Established in 2013, Pulnovo Medical(Wuxi)Co., Ltd. is the pioneer and leader in the treatment of PH through percutaneous pulmonary artery denervation(PADN). The PADN team is led by Dr. Chen Shaoliang, who is currently a fellow of the American College of Cardiology (FACC), fellow of the American Association for Cardiovascular Angiography and Intervention (FSCAI), the executive chairman of the Asian Bifurcation Club (ABC).

Based on the current situation of unsatisfactory and expensive treatment of PH targeted drugs, the PADN team has pioneered "PADN" in the world. The PADN® devices we developed has obtained the national innovative medical devices, have PCT patents and methodological patents in China, the United States, Brazil, South Korea, Japan, India, Europe, Russia, etc.

The PADN® product can deliver a special catheter to the proximal part of the pulmonary artery bifurcation through intervention, which damages the sympathetic nerves under the serosal layer and inhibits over-activation. Animal experiments and nearly 200 clinical studies shown that the PADN® devices can significantly improve the patient's hemodynamics (mPAP and PVR), pulmonary artery remodeling and increase their activity endurance (increase 6 minutes walking distance), related research results have published 12 SCI articles, with a total impact factor of 66.61.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
严光能 YAN Guangneng	暨南大学研究员 Researcher of Jinan University	CT 引导下的穿刺定位装置系统 CT-Guided Puncture Positioning Device

项目简介

微创手术，采用穿刺导管，导丝等介入器官到达病灶进行活检或者进行治疗。从而精确的确定穿刺点，穿刺角度和穿刺深度，避免损伤血管，神经，并以其安全，准确，快速，操作简单，患者痛苦少等优点，与传统手术相比，微创技术无疑是革命性的进步。

精确定位是微创手术的关键。本发明的定位系统由：CT+ 激光器 + 双层标记物组成。经由 CT 的三维成像寻找穿刺最佳路径，并通过激光在标记物上限定穿刺的路径，从而达到精确定位的目的。在此基础上，配合先进半导体探测器，AI 智能技术可以快速获取病灶生物学信息，比如肿瘤的等级和分类。配合靶向药物，对肿瘤的治疗效果更好更快。相对于其他定位装置，该定位系统更精准，成本更低，使用更方便。缩短诊断和治疗时间，提高治疗效果。

本项目已经取得一个发明专利，另一个专利在二审阶段。本装置人员包括了暨南大学的严光能博士，广东医学院的李定教授，中国中医研究院的朱广海教授。

Project Introduction

Minimally invasive surgery, using puncture catheters, guide wires and other interventional organs to reach the lesion for biopsy or treatment. In this way, the puncture point, puncture angle and puncture depth can be accurately determined to avoid damage to blood vessels and nerves. With its advantages of safety, accuracy, speed, simple operation, and less patient pain, compared with traditional surgery, minimally invasive technology is undoubtedly revolutionary improvement.

Precise positioning is the key to minimally invasive surgery. The positioning system of the present invention is composed of CT+laser+double-layer markers. The three-dimensional imaging of CT is used to find the best path of puncture, and the path of puncture is defined on the marker by laser, so as to achieve the purpose of precise positioning. On this basis, with advanced semiconductor detectors, AI intelligent technology can quickly obtain the biological information of the lesion, such as the grade and classification of the tumor. With targeted drugs, the effect of tumor treatment is better and faster. Compared with other positioning devices, the positioning system is more accurate, lower cost, and more convenient to use. Shorten the diagnosis and treatment time, improve the treatment effect,

One invention patent has been obtained for this project, and another patent is in the second trial stage. The personnel of this installation include Dr. Guangneng Yan from Jinan University, Professor Li Ding from Guangdong Medical College, and Professor Guanghai Zhu from China Academy of Chinese Medicine.

高林明 GAO Linming	索思（苏州）医疗科技有限公司总经理 Chief Executive Officer of THOTH (Suzhou) Medical Technology Co., Ltd.	临床级全体征医学传感器 构建数字医疗基础网络 Clinical-Grade Medical Sensor for All Signs Constructing A Basic Digital Medical Network

项目简介

索思医疗（THOTH）成立于 2016 年 1 月，公司总部位于苏州工业园区。公司专注于柔性可穿戴医疗器械的研发及医疗大数据人工智能技术的应用，是集研产销为一体的高新技术企业。索思创新性地设计了类似于“创可贴”的一次性传感器，将产品价值、服务价值融合在传感器当中，用户仅需要为“创可贴”付费，而不需要购买医疗设备或医疗系统。索思专注于为每位用户提供精准、高效、舒适、安全的临床级医疗服务，致力于打造全新的医疗生态系统。

索思自主研发的 7 款产品已获得 NMPA 医疗器械产品注册证，获得专利共 30 项。产品涵盖众多领域，其中核心产品“穿戴式心电传感器”已被 20 个省市 800 余家医院的 50 万患者使用，获得医院及用户的一致认可。

Project Introduction

THOTH (Suzhou) Medical Technology Co., LTD (THOTH), headquartered in Suzhou industrial park, was founded in January 2016. We focuses on the research and development of flexible wearable medical devices and the application of medical big data artificial intelligence technology. It is a high-tech enterprise integrating research, production and sales .We innovatively designed a disposable sensor similar to the "band aid", which integrates the value of the product and service into the sensor. Users only need to pay for the "band aid", but do not need to buy medical equipment or medical system. THOTH focuses on providing precise, efficient, comfortable and safe clinical medical services for each user, and is committed to creating a brand new medical ecosystem.

The 7 products independently developed by THOTH have obtained the NMPA medical device product registration certificates and 30 patents. Products cover many fields, including core product "wearable ECG sensor" has been applied in more than 20 provinces and cities, 800 hospital and 500000 patients. It has won praise of doctors and users alike.

人工智能与生物医药专场
Artificial Intelligence (AI) + BioMed Roadshow

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
马　健 MA Jian	深圳晶泰科技有限公司首席执行官 CEO, XtalPi Inc.	拥抱人工智能，开启药物研发快进模式 Accelerating Drug Discovery & Development with Artificial Intelligence

项目简介

人工智能是一项能够在不同行业、不同领域中使用的，具有全行业共性的新技术。随着算力、算法等技术要素的成熟，以及诸多企业与科研机构的深度参与，人工智能药物研发进入快速发展期。目前中国的新药研发以快速跟进（Fast Follow）为主，同时积极布局首创新药（First-in-class）开发。人工智能方法能够有效探索更广阔的化学空间，规避专利、优化性质、减少合成量、加快迭代速度，是提升药物研发收益的一支“奇”兵。目前，获取高质量数据，实现数据孪生，是该领域面对的重要问题。随着实验技术的进一步挖掘，数字孪生程度的不断提升，人工智能将成为药物化学家最重要的伙伴，双方将共同设计出效果佳、性质优的上市药物。

Project Introduction

Artificial Intelligence (“AI”) is a new technology with broad application in different industries. With the maturity of computational power and algorithms as well as the deep involvement from companies and research institutions, AI drug discovery and development has a rapid development in recent years. Chinese new drug R&D is focusing on Fast Follow and at the same time actively participating in First-in-class drug development. AI drug discovery and development helps explore larger chemical space effectively, avoid patent risks, optimize properties, reduce syntheses and accelerate iterations. It is becoming a disruptive force which boosts the results in drug R&D.

How to obtain data with good quality and realize digital twins is a significant problem in AI drug discovery and development. However, we fully trust that in the near future, with the development of experimental techniques and the increase of the scale of digital twin, AI will become the best partner of pharmaceutical chemists and their collaboration will bring the best drugs to the market.

谭　验 TAN Yan	深圳未知君生物科技有限公司创始人、首席执行官 Founder&CEO, Shenzhen Xbiome Biotech Co., Ltd.	中国首家专注于肠道微生态治疗的 AI 制药公司 The First AI-based Microbiome Drug Development Company in China

项目简介

深圳未知君生物科技有限公司成立于 2017 年，是中国首家专注于肠道微生态治疗的 AI 制药公司，针对当前未被满足的临床需求开发出微生态药物。依托创新型药物开发模式和先进完备的微生态药物研发平台，未知君将“人工智能 + 生物信息分析技术”与肠道微生态技术相结合，实现数据高质量分析、沉淀与产出，打通菌群制药从“数据”向“药物”的转化全链路，提高了药物开发的效率和成功率，可持续产生突破性微生态药物。

未知君的主要药物管线均为自主研发，目前布局的适应症涉及肿瘤、消化系统、神经系统、免疫系统和代谢系统等相关疾病，并已与国内多家知名医疗机构开展了肠道微生态临床研究合作，多款微生态药物在临床研究中表现出显著的治疗效果。

Project Introduction

Shenzhen Xbiome Co. Ltd., established in 2017, is China's first AI-driven microbiome drug development company, dedicated to making the utmost of clinical data and AI technology to break the R&D bottleneck and develop microbiome drugs for current unmet medical needs. Xbiome creates an innovative drug discovery platform that combines industry-leading AI and advanced bioengineering practices with gut microbiome modulation that dramatically speed up the drug development cycle and increase the success rate of drug candidates. Aiming to achieve the prevention and treatment of chronic diseases and subhealth, Xbiome leads the pharmaceutical industry into a new era.

The leading pipelines of Xbiome are mostly developed in-house, covers cancer immunology, digestive system, nervous system, immune system and metabolic system related diseases. Currently, Xbiome has been closely working with top research hospitals in China on human clinical studies with microbiome drugs, and the initial data showed great clinical efficacy in several cases.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
王文佳 WANG Wenjia	天士力国际基因网络药物创新中心有限公司 总经理 General Manager, Genenet Pharmaceutical	星斗云 基于大数据与深度学习的药物机理与重定位研究平台 Cloudphar - A Drug Mechanism and Repositioning Platform Based on Big Data and Deep Learning

项目简介

星斗云是天士力国际基因网络药物创新中心公司在复合药物开发领域的世界领先研发企业法国 Pharnext 公司的独有网络药理学研发技术，以及天士力的现代化中药研发技术及平台的基础之上开发的智能药物研发平台。它通过大数据，人工智能和网络药理学技术驱动的创新药物发现科研协作云平台，旨在为用户提供详尽的智能药物研发支持。星斗云将一系列机器学习技术和自然语言处理技术，应用于分析公开和专有数据源，包括文献、临床试验、专利、药物靶点、化学结构、症状等药物和疾病信息，并通过知识图谱和独有的深度学习网络构建算法，全景式勾画药物和疾病信息，以实现药物特别是中药的精准机理解释，药物重定位，及基于药物重定位的复合药物开发。

Project Introduction

Cloudphar is an is an innovative drug discovery cloud platform developed by Genenet based on the unique network pharmacology technology of pharnext, a world leading company in the field of compound drug development, and the modernized Chinese medicine R&D technology of Tasly. It takes advantage of the latest big data, artificial intelligence and network pharmacology technologies to reshape the drug discovery process and empowers scientists with useful databases and workflows for R&D in precision medicine. Cloudphar integrates large amount of open and proprietary data sources, including literature, clinical trials, patents, drug targets, chemical structures, symptoms and other drug and disease information, and applies a series of machine learning technology and natural language processing technology to sketch drug and disease information in a panoramic way, to enable precise mechanistic interpretation of drugs, especially herbal medicines, drug repositioning, and compound drug development.

沈倩诚 SHEN Qiancheng	上海宇道生物技术有限公司首席执行官 CEO, UCDOM BioTech.(Shanghai) Co., Ltd.	First-in-Class 变构小分子研发平台与管线布局 First in Class Allosteric Molecules: Platform and Pipeline in Drug Discovery

项目简介

本项目自 2009 年以来长期聚焦于变构机制小分子药物研发领域，并开发了具有国际领先水平的变构药物计算发现平台，包括一系列从变构位点识别到变构分子优化相关的计算工具，该平台为使用变构技术克服难成药靶点打下了基础。同时，使用该自主研发的计算平台并经过一段时间的积累， 本项目已针对多个难成药靶点和全新靶点开发了具有变构机制的药物先导分子，目前进度最靠前的分子已经进入了临床前研究阶段，在多个肿瘤相关的适应症中表现出了良好的动物水平活性药效。

Project Introduction

This project reported here has been long focusing on the innovative research of small molecular drugs with allosteric mechanisms since 2009. A globally well-known allosteric drug discovery platform has been gradually developed and continued to be updated, this includes a series of proprietary computational tools and focused databases. The technology allows scientist to identify the possible allosteric site based on the both first principles and machine leaning algorithms, followed by allosteric molecular screen and validation. The platform serves for the foundation for the use of allosteric technology to reach out traditionally non-druggable targets. At the same time, by utilizing the technology in the platform, we have generated our own drug pipeline with novel allosteric mechanisms for multiple new targets, and the most advanced project is now close to the pre-clinical candidate stage. This first in class (FIC) molecule has shown good efficacy in animal models for multiple tumor-related indications, which are aiming to unmet medical needs.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
曹凌霄 CAO Lingxiao	苏州创腾软件有限公司首席执行官 CEO, Suzhou NeoTrident Software Ltd.	致力于创新与品质的数字化智能化转型——基于科学人工智能与数据驱动的 SaaS 平台 Accelerate the Digital Transformation of Intelligent Innovation & Quality - An Artificial - Intelligence - Driven SaaS Platform

项目简介

创腾软件专注生命科学领域实验室信息化综合解决方案。通过云计算、移动互联、AI 等技术，赋予企业更合规的信息化解决方案，提升其在药物早期研发、安全生产、质量控制及检测等多环节的管理、决策和创新能力。国内已有近千家企业用户，包括顶尖药物研发企业，知名医药 CRO 及高校和科研院所。

开创性“双模型 (AI+ 物理)+ 数据驱动”技术，三大自研平台：

· 科研协作平台：专业的科研数据采集和协作创新工具，涵盖研发、生产及检测等全周期

· 科学数据中台：对多维实验数据进行重构重组，形成基于不同应用场景的数据分析流和结果

· 模拟设计平台：实现高通量 / 高并发模拟计算，自动工作流形式实现数据的深度挖掘和计算建模，加速新药研发

Project Introduction

NeoTrident technology focuses on the comprehensive solution of laboratory informatization in the field of life science. Through professional integration of cloud computing, mobile Internet, AI and other advanced technologies, enterprises are given more compliant information solutions to improve their management, decision-making and innovation capabilities in early drug research and development, safety production, quality control and testing. There are nearly a thousand domestic enterprise users, including the top domestic drug R & D enterprises, well-known pharmaceutical CRO and well-known universities and research institutes.

Pioneering introduction of "dual model (AI + Physics) + data-driven" integration technology, three independent software platforms:

1) Mobile research collaboration platform: professional research data collection management and collaboration innovation tools, covering the whole cycle of R & D, production and testing

2) Scientific data middle platform: reconstructs and reorganizes the collected multi-dimensional experimental data to form the data analysis flow and results based on different application scenarios

3) AI simulation design platform: realize high-throughput /concurrent simulation calculation, facilitate deep data mining and calculation modeling in the form of automatic workflow, accelerate new drug research and development

夏荣森 XIA Rongsen	深圳市青云瑞晶科技有限公司首席营销官 CMO, Shenzhen ReadCrystal Technology Co., Ltd.	基于 MicroED 技术的药物研发平台 Pharmaceutical R&D Platform Based on MicroED

项目简介

MicroED（微晶电子衍射）技术被 Science 杂志评为 2018 年度十大突破，是新药研发领域革命性的新技术。我们团队曾在该领域发表包括 Nature，Science，Cell 等一系列世界顶级科学论文。目前，我们已经利用该方法解析了未知蛋白质和蛋白质 – 配体共晶等一系列结构，是该领域全球最领先的研发团队。我们将致力于将利用这项技术，开发针对 GPCR 蛋白和转录因子蛋白等靶点蛋白的 First-in-Class 创新药。

Project Introduction

Readcrystal Technology Co., Ltd is a start-up company founded by a group of researchers worked and graduated from Stockholm University, Sweden. We focus on provide fast and reliable crystallography service (MicroED) to pharmaceutical companies and research institutes.

Characterization of molecule structures and crystal structure of polymorphs are important tasks during new compound discovery phase and preclinical research phase in any pharmaceutical company. But it is often a difficult and time-consuming step which delays the application of IND and NDA and even put unpredictable risks on the patenting of new drugs. Our technology helps chemists in pharmaceutical industry to easily characterize their crystals down to 100 nm in size.

Researchers in our team have published more than 100 scientific papers in the field including several highly impact papers published on top journals e.g. Nature, PANS and Angewante Chemie.

We Provide service of Small Molecule Crystal Structure determination and Protein crystal / Protein-drug cocrystal structure determination.

汇报人姓名 Speaker	单位及职务 Company & Position	汇报题目 Title of Roadshow
靳照宇 JIN Zhaoyu	明济生物制药有限公司创始人、首席执行官 Foundr&CEO, futuregen biopharmaceutical company	计算机辅助的蛋白工程技术及生命组学驱动的创新抗体药物开发 Development of Novel Antibody Therapeutics by Life-omics and Computer-aided Protein Engineering Technologies

项目简介

明济生物制药公司是由前基因泰克资深科学家创立，公司利用计算机辅助的人工智能大分子设计平台针对肿瘤及自体免疫疾病的靶点进行创新药物开发。我们以结构生物学指导下的分子定向进化技术、结合应用先进合成生物学和抗体工程技术的抗体文库构建筛选技术自主开发出了达到世界先进水平的蛋白药物的筛选优化技术平台（STE 平台）。成功筛选优化出针对一系列具有良好功能活性及成药性的单克隆及双特异性抗体。利用 STE 平台开发的用于治疗胃癌的 ADCC 增强型 Claudin18.2 的抗体及新冠病毒抗体已完成大部分临床前实验，目前正在申报临床批件。

Project Introduction

FutureGen Biopharmaceutical Company is founded by experienced returnee scientists focusing on development of novel therapeutics for oncology and inflammatory disease. Our company established state-of-the-art antibody discovery platforms including computer-aided Structure-guided Target Evolution (STE) and Antibody for Membrane Protein by Cell-based panning (AMPC) technologies. With these pioneered tools, the company generated a series of monoclonal or bi-specific antibody drug candidates with great efficacy and manufacturability for the targets selected and validated by genomics, proteomics and immune-oncology research. The ADCC-enhanced anti-Claudin 18.2 antibody for gastric cancer therapy and , neutralizing antibody for SARS-Cov2, developed with our STE technology, are now in the process of IND filling. Most of pre-clinical studies are performed with in-house facilities and technology platform. In vitro study showed our lead candidate is about 100 times more potent than benchmark antibody IMAB362.

许　强 XU Qiang	领星生物科技有限公司创始人、首席执行官 Founder &CEO, GenomiCare Biotechnology	数据驱动赋能新药临床开发 Integration of AI & Clinico-Genomics, Accelerating Clinical Development of New Drugs

项目简介

领星生物为生物技术和制药公司的肿瘤药物研发及商业化提供一个强大而灵活的平台。该平台集成了领星自有的大数据深度整合的真实世界肿瘤患者基因组－临床知识库，以及动态数据智能技术，实现了对于数据问题的灵活方便设问及即时获取答案。领星的自有数据库是基于真实世界临床－分子大数据集，临床试验数据，临床知识库的结合，并使用数据驱动人工智能算法以实现对临床假设的对照组，联合方案，生物标记物，以及适应症拓展等多维度变量的系统整合分析，获得最优临床假设选项，用于临床开发，适应症拓展和市场拓展。

Project Introduction

GenomiCare provides a powerful and flexible platform to pharmaceutical and biopharma companies for oncology drug development and commercialization. It is a proprietary system that integrates genomic-clinical Real World Evidence (RWE) knowledgebase and dynamic Data Intelligence (DI) technology to make dynamic clinical queries straightforward and get answers fast and easy. GenomiCare's data-driven algorithm provides a solution to optimize the clinical hypothesis by combining the real-world clinical-molecular data and comprehensive knowledgebase, with or without prior treatment-specific clinical trial data. It can help in indication expansion, clinical trial design and verification for oncology drug development and commercialization

By utilizing Data Intelligence (DI) technology, which integrates CLIA/CAP clinical laboratory service, the large real world full genomic + clinical history + long-time survival datasets, cloud-based interactive Saas system, and proprietary data-driven algorithm, GenomiCare is helping clients to realize the full potential of the data efficiently. The resulting evidence have been demonstrated in novel biomarker and target identification, mechanism of action study, clinical trial design/prediction, drug combination strategy, fine-tuned patient stratification, and new indications expansion.

非现场路演项目介绍
Candidate Project Introduction

汇报人姓名 Speaker	单位及职务 Company & Position	邮箱 Email Address	汇报题目 Title of Roadshow
陈　玥 CHEN Yue	成都合拓创展生物科技有限公司 总经理 General Manager, Chengdu Bio-HT Co.,Ltd.	yue.chen@bio-ht.cn	合拓创展——专注于医药 / 器械临床前效果评价的 CRO 公司 Bio-HT

项目简介

成都合拓创展生物科技有限公司是研发人类疾病动物模型，输出医学产品功效性评价服务的高科技公司。公司从事医药相关领域的研发服务，创享转化医学平台技术，促进医学产业化进程。

合拓创展秉承了 GLP 标准的实验规范性，对项目的实施进行科学化管理，保证研发结果的真实性、科学性及一致性。可根据研究需要打造定制化的动物模型建立和研究服务，创建了 3 大特色平台，分别是神经系统新药药效评价平台、眼科疾病新药药效评价平台以及心血管系统新药药效评价平台。

Project Introduction

Bio-HT is a global pharmaceutical, medical device preclinical study technologyplatform company active in R&D of experimental animal model. As an innovationdrivenand customer-focused company, Bio-HT provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development cycle and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.

Our core business is preclinical pharmacodynamic evaluation technology services and business consulting services, including one-stop preclinical services for pharmaceutical, medical device and biological products, drug screening with major disease animal model and experimental animal model R&D.

Our team researchers were from RMRC animal experiment platform of West China hospital of Sichuan University, which platform had developed a variety of animal models. Our technical team is proficient in various kinds of experimental animal model and medical diagnostic tests, and has set up multiple products to clinical application.

曲飞寰 QU Feihuan	成都市真实维度科技有限公司 总经理 CEO, Readitec (Chengdu) Co.,Ltd.	richard@readitec.com	真实维度智能微创手术机器人 Readitec Arcbot

项目简介

真实维度研发的微创介入系列解决方案解决微创介入治疗（以粒子植入为例）的两点临床核心问题：1. 术中徒手或模板穿刺精度差、风险高、一致性差、术中容错性差；2. 术前规划效率低、需人工进行放射源布源和穿刺路径计划，对物理师技能要求高。此两点核心问题严重制约了粒子植入的临床普及和广泛推广。

公司与临床专家团队合作研发的 TPS 智能手术规划软件实现了基于深度学习的危及器官自动分割、基于处方剂量的粒子布源、智能针道规划、以及自动化控制等重要功能。基于该 TPS 系统内核，公司输出 3D 打印模板、激光定位系统和智能微创手术机器人三种解决方案，提高了穿刺精度和手术效率。

Project Introduction

The interventional solutions developed by Readitec solve the two core clinical problems of brachytherapy: 1. Intraoperative manual or template puncture has poor accuracy, high risk, poor consistency, and intraoperative fault tolerance still low; 2. The preoperative planning efficiency is low, radioactive source deployment and puncture path planning are required manually, and the physicist's skills are required. These two core issues have severely restricted the clinical popularization and widespread promotion of seed implantation.

The TPS software developed by the company and a team of clinical experts has realized important functions such as the automatic segmentation of endangered organs based on deep learning, the distribution of particles based on prescription dosage, intelligent needle path planning, and automatic control. Based on the core of the TPS system, the company outputs three solutions: 3D printing template, laser positioning system and intelligent minimally invasive surgical robot, which improves puncture accuracy and surgical efficiency.

汇报人姓名 Speaker	单位及职务 Company & Position	邮箱 Email Address	汇报题目 Title of Roadshow
宋世东 SONG Shidong	南京双运生物技术有限公司 董事长 CEO, Nanjing Gemini Biotechnology Co., Ltd.	ssd@zintahealth.com	AI 创新型药物发现平台 AI Innovative Drug Discovery Platform

项目简介

南京双运生物技术有限公司成立于 2012 年，2015 年 8 月转型为 AI 药物研发公司。经过 4 年的研发和投资，AI 药物筛选平台已经成为一个成熟的平台，与多方合作，完成了 30+ 靶点 / 73 个先导化合物的发现。近日，南京双运生物技术有限公司对一种新药进行了验证，证明其为新型冠状病毒突刺蛋白抑制剂，并申请了一项新适应症的专利。

南京双运的 AI 辅助药物发现平台，能将药物临床前发现的时间大大缩短， AI 平台虚拟筛选的命中率高，虚拟筛选命中率已达到 20–30%，并可以直接筛选出细胞实验 nm 级起效的先导化合物。

Project Introduction

Nanjing Gemni Biotechnology Co., Ltd. was established in 2012 and transformed into an AI-based drug discovery company in August 2015. After four years of R&D and investment, the AI drug screening platform has become a well-established platform, cooperated with many parties, and completed the discovery of 30+ targets/ 73 lead compounds.

The AI-assisted drug discovery platform of Nanjing Gemni Biotechnology Co., Ltd. can greatly shorten the time for drug pre-clinical discovery, and the virtual screening hit rate of the AI platform is high, with the virtual screening hit rate reaching 20-30%, and it can directly screen out the lead compounds effective at NM level in cell experiments.

The company's main technologies include a. drug discovery targeting unknown crystal structure b. drug discovery targeting known crystal structure C. Discovery of old drug/new adaptation of active natural product D. Redevelopment of phase 2/3 failed drugs e. AI assisted discovery of new target F. New target confirmation G. AI conducted drug ADMET drugenicity assessment.

朱春明 ZHU Chunming	深圳世纪微创医疗科技有限公司 创始人 Founder, Shenzhen Century Weichuang Medical Technology Co., Ltd.	bjmagnet@vip.sina.com	医用成像芯片及其应用 Medical CMOS

项目简介

致力于“芯片 + 医疗器械”的医疗芯片及其应用领域的自主研发制造，填补国内空白，强化国家核心医药产业链。

发起人（实名股东）：中科院微电子所、美年大健康全国连锁体检机构、深圳世纪微创医疗科技有限公司

核心产品：内窥镜高清成像芯片及其模组、呼吸麻醉可视插管喉镜、便携式一次性宫腔镜

中科医芯以中国科学院微电子所技术为基础，以深圳完善的高新技术产业生态链为依托，以美年大健康全国体检机构的市场应用为出发点，联袂打造成为中国芯片应用类高端医疗器械的行业领导者。

Project Introduction

Committed to independent R&D and manufacturing of "chip + medical device" medical chips and their application fields, filling domestic gaps and strengthening the national core pharmaceutical industry chain.

Promoter (real-name shareholder): Institute of Microelectronics, Chinese Academy of Sciences, National Health Examination Chain, National Century Health, Shenzhen Century Microinvasive Medical Technology Co., Ltd.

Core products: HD imaging chip and its module for endoscope, visual intubation laryngoscope for respiratory anesthesia, portable disposable hysteroscope

Based on the technology of the Institute of Microelectronics of the Chinese Academy of Sciences, relying on Shenzhen's perfect high-tech industrial ecological chain, and based on the market application of the health examination institutions of the United States and the United States, the Chinese Medical Core is jointly built into a high-end medical device for Chinese chip applications. Industry leader.

汇报人姓名 Speaker	单位及职务 Company & Position	邮箱 Email Address	汇报题目 Title of Roadshow
陆满晴 John LUK	艾贝乐医药科技公司公司 创始人兼首席执行官 Head of Corporate Finance, Arbele Limited	jluk@arbelebio.com	用於治療晚期胃腸癌的同類第一 CDH17 靶向 CD3 銜接器的免疫治疗 A First-in-Class, CD3-Engager Targeting CDH17 to Treat Advanced Gastrointestinal Malignancies

项目简介

艾贝乐致力于研发一流的针对晚期胃肠癌的免疫治疗药物及技术，胃肠癌治疗是全球最迫切的未满足医疗需求之一。公司创始人陆满晴博士在 2000 年代初发现了 Cadherin−17（CDH17）并获得了其作为疾病标志物和治疗靶点的全球专利。CDH17 在胃肠癌基因组和肿瘤组织中高度表达，并被证明是胃肠癌的一个真正致癌基因。公司的核心产品包括新型的癌症诊断技术、专利的双特异性抗体生物制剂及 CAR−T 治疗技术。作为香港科技园生物医药科技培育计划和企业飞跃计划的成员，艾贝乐得到政府的大力财务支持，包括迄今创新及科技基金对中小企业的最大拨款，助力推动双特异性抗体 ARB202 进入 IND。

Project Introduction

Arbele develops first-in-class immunotherapy drugs and technologies to treat advanced GI cancers, which present some of the greatest unmet medical needs worldwide. Founder Dr. John Luk discovered and patented Cadherin-17 (CDH17) worldwide as a disease marker and therapeutic target in the early 2000s – CDH17 is highly expressed in GI cancer genomes and tumor tissues (Fig. C), and is shown to be a bona fide oncogene for GI cancers, 2. Genetic knockdown and immuno-targeting of CDH17 inhibits tumor growth, indicating high therapeutic potential.

Arbele has developed a suite of therapeutic and diagnostic products for treating GI cancers surrounding the use of CDH17, core pipeline includes innovative cancer diagnostics, IND-ready proprietary bispecific antibody biologics and CAR-T therapeutics targeted for fast-track biologics license application (BLA) filing with US FDA and China NMPA in 2022.

As a member of HKSTP's Incu-Bio and LEAP programs, Arbele is given substantial governmental financial support, totaling HK$18M to date, e.g. in 2020, Arbele received by far the largest grant to SMEs (HK$7.5M) from HK government's ITF for advancing ARB202 to IND.

Arbele has established strong joint venture/strategic partnerships with leading biotech companies and academic institutions, e.g. Avalon GloboCare (NASDAQ: AVCO), JHL Biotech and Cornell University.

英伟文 YING Weiwen	诺生物医药科技（杭州）有限公司 首席执行官 Chief Executive Officer, Ranok Therapeutics Co., Ltd.	wying@ ranoktherapeutics.com	T-PEACH™：小分子抗肿瘤药物研发的新技术 T-PEACH™: A New Technology for The Development of Small Molecule Antitumor Drugs

项目简介

珃诺生物是一家专注于开发全新一类（First−in−class）小分子抗肿瘤药物的新药研发公司，重点研究的是成药困难的致癌靶标，旨在为过往缺乏治疗手段的特定种类癌症患者提供药物，改善肿瘤患者长期生存质量。目前，公司重点开展的 3 个项目分别处于 IND enabling，PCC 和 lead optimization 阶段。从 2018 年成立至今，项目能较为快速且顺利的推进得益于 T−PEACH™ 这一建立在分子伴侣蛋白相关的拮抗剂和小分子偶联药物的基础上更为优化的技术，最大的特点是靶标结合子选择的灵活性和多样性。因此，该技术能针对不同的癌症和病理而设计高活性和特异性的化合物。

Project Introduction

Ranok Therapeutics Co. Ltd. is a R&D-based pharmaceutical company focused on the development of first-in-class and first-in-class small molecule antitumor drugs.Our development focuses on carcinogenic targets that are difficult to make medicines, and aims to provide drugs for specific types of cancer patients who have historically lacked treatment, improving the long-term quality of life of cancer patients. At present, we have three important projects are during the stages of IND enabling, PCC and lead optimization. Since ranok established in 2018, the project has been able to progress more quickly and smoothly thanks to T-PEACH™, a more optimized technology based on molecular chaperone-related antagonists and small molecule conjugated drugs.Its biggest feature is the flexibility and diversity of target bindings. Therefore, this technology can design highly active and specific compounds for different cancers and pathologies.

汇报人姓名 Speaker	单位及职务 Company & Position	邮箱 Email Address	汇报题目 Title of Roadshow
陈　亮 Michael CHEN	大湾生物控股有限公司 首席执行官 CEO, Great Bay Bio Holdings Ltd.	michael@ greatbay-bio.com	AI 细胞株和培养基开发平台 AI + Cell Line & Media Development Platform

项目简介

大湾生物控股有限公司总部位于香港，是一家以人工智能技术开发生物医药的高新技术企业。公司自主研发的 Klone4.0 平台，专注于细胞株开发的生物技术服务，可显著缩短 80% 的细胞株开发时间和成本。与传统药物研发相比，细胞株筛选的成功率将提高 1.5 倍以上。公司还将 AI 技术、大数据与生物医药相结合，开发了 AlfaMedX，一个细胞培养基开发平台。通过构建生物数据模型，计算培养基中各成分浓度，快速开发优质的定制化培养基。

我们仍不断研究，致力于为生物医药开发提供一站式优质服务，可开发单抗序列、细胞株和细胞培养基，打造大湾生物 CMC 开发主平台。该平台一旦建成，预计能将 CMC 开发时间从传统的 3 年缩短到 6 个月。

Project Introduction

Great Bay Bio Holding Ltd. (GBB) is one of the first companies in the world to utilize a digitalized CMC platform to develop best-in-class biologics for its CDMO customers. Headquartered in Hong Kong, it has gathered high-quality resources from the U.S, Europe, Singapore and Hong Kong/China.

GBB has developed an AI-enabling cell line development platform (Klone4.0) which has been shown to significantly reduce cell line development time by up to 80%, thereby reducing costs and time to market entry for its customers. The platform is also able to increase the probability of selecting high-yield stable cell lines up to 150 times.

Combining AI technology, big data and biomedicine, GBB has also developed AlfaMedX, a cell medium development platform. Constructing a biological data model, it can calculate the ratio of medium components to develop high-quality customized media within a short time.

The company is still committed to provide high-quality and one-stop CMC services, including mAb sequence development, cell line development, and cell culture formulation development, so as to develop GBB's "master" CMC development platform.When complete, it may reduce CMC development time from a typical three years down to a mere six months.

丁海峰 DING Haifeng	苏州澳宗生物科技有限公司 总经理兼首席执行官 General Manager & CEO, Suzhou Auzone Biological Technology CO., Ltd.	dinghf@szauzone.com	中枢神经系统创新药物：p75ECD−FC 和依达拉奉口服制剂 Innovative CNS Drug Candidates: p75ECD-FC and Modified Edaravone

项目简介

p75ECD−FC 是“First−in−Class”1 类创新生物药，拟用于 AD 和脑卒中的治疗。项目由南澳大学周新富教授团队和第三军医大学王延江教授团队联合攻关，在国际知名 SCI 杂志发表论文 40 多篇，研究成果达到国际领先水平。目前已完成初步的药学和药理学研究，预计 2 年内进入临床试验。

依达拉奉口服制剂：依达拉奉注射剂被批准用于脑卒中和渐冻症的治疗，我们应用特有的专利技术开发了依达拉奉口服制剂，极大地提高了生物利用度，具有更好的顺应性和便利性，此外，我们还拓展了阿尔茨海默病和非酒精性脂肪性肝炎两个新适应症，是 2.2+2.4 类化药。目前正在澳大利亚开展 I 期临床研究，预计未来 2−3 年内提交 NDA。

Project Introduction

World Health Statistics 2017 indicated that nearly one in six of the world's population suffer from neurological disorders. CNS drugs held the second largest share in global drugs market, just next to anti-tumor drugs.

p75ECD-FC, a first-in-class biological product of category 1, was developed for Alzheimer's disease(AD) and acute ischemic stroke(AIS) with new mechanisms of action. This project was jointly researched by Professor Xin-Fu Zhou from University of South Australia and Professor Yan-Jiang Wang from The Third Military Medical University, with more than 40 papers published in world-famous journals. The primary CMC andpharmacology studies have been completed, and it is expected to enter the clinical stage within 2 years.

Edaravone injection is widely used for AIS and amyotrophic lateral sclerosis(ALS). We have made a breakthrough to develop the only oral edaravone in the world which dramatically improved the bioavailability with better compliance and convenience, and further creatively developed two new indications of AD and nonalcoholic steatohepatitis(NASH), which should be declared as registration category 2.2+2.4. It is currently undergoing a Phase 1 clinical trial in Australia. It is expected to submit NDA application within 2 years.

In conclusion, the two drug candidates mentioned above are both innovative with obvious clinical advantages.

汇报人姓名 Speaker	单位及职务 Company & Position	邮箱 Email Address	汇报题目 Title of Roadshow
郑　琪 ZHENG Qi	水木未来（北京）科技有限公司 副总裁 VP, Shuimu BioSciences Ltd.	zhengqi@gcdd.life	冷冻电镜 + 计算：加速新药研发 Cryo-EM + Computation: Accelerating Drug Discovery

项目简介

水木未来（北京）科技有限公司于 2017 年底成立，拥有亚太区第一家冷冻电镜商业服务平台，是基于结构和计算的科技服务公司。依托清华大学和自主研发的基于冷冻电镜的革命性结构解析方法学与高性能计算技术，拥有顶级的生命科学专家技术团队，致力于为科研单位和生物科技公司提供靶点验证，化合物库筛选，先导化合物发现，以及治疗性抗体研发等综合性技术服务。我们致力于通过开发创新技术，整合结构数据和基因数据，
改变科学家发现新药的方式，努力改善人类健康，延长预期寿命。

Project Introduction

Shuimu BioSciences Ltd. was founded in 2017 in Beijing, China, to bring the power of Cryo-EM to new therapeutics developers through a differentiated service offering, making the method accessible and affordable for Discovery teams at all stages of method adoption. We are the first commercial full service Cryo-EM platform in Asia, led by top experts from Tsinghua University and experienced industry executives. All of our work is performed with the quality controls and service levels expected of a top tier contract research organization. We are committed to integrating structural and genetic data through the development of innovative technologies, Change the way scientists discover new drugs, strive to improve human health and prolong life expectancy.

CryoEM (coupled with single particle analysis) has become a popular method for high resolution 3D protein structure determination. An aqueous biological sample is frozen rapidly and irradiated with a beam of electrons from a transmission electron microscope. A detector senses how the electrons are scattered and computerized image processing techniques are used to reconstruct the 3D-shape of the molecule. Single particle analysis (SPA) is the most cutting-edge technology of cryo-electron microscope.

蒋争凡 JIANG Zhengfan	启锰生物科技（江苏）有限公司 首席科学家 Chief Scientist, MnStarter Biotechnology (Jiangsu) Co., Ltd.	jiangzf@pku.edu.cn	新型高效锰佐剂——助力疫苗研发和抗体制备 A Novel Manganese (Mn)-Based Adjuvant for Vaccine Development And Antibody Generation

项目简介

本公司自主研发的锰佐剂是一种纳米佐剂，目前处于科研成果转化阶段，尚未进入临床。相比于其他佐剂，锰佐剂的优势有：（1）激活细胞免疫；（2）更强更快地产生抗体；（3）可作粘膜佐剂；（4）对多种抗原具有普适性；（5）可反复冻融；（6）无毒副作用；（7）使用便利。锰佐剂能被应用于各种预防性和治疗性疫苗制作，可以大幅度提高疫苗保护效果和时间，并显著降低抗原用量，在提高疫苗效果的同时极大地降低疫苗成本。该佐剂可以强烈激活细胞免疫，因此可以作为小分子药物应用于抗肿瘤免疫疗法。既可单独成药，又可与现行的肿瘤免疫疗法联合使用，在提高治疗效果的同时显著地降低免疫检查点药物的用量，从而提高已有主流抗癌药物的性价比。

Project Introduction

MnJ, newly invented & developed by the MnStarter Company, is a Manganese (Mn)-based nanoparticle adjuvant. MnJ adjuvant is currently in the stage of scientific research transformation, which has not entered the clinical trial yet. Compared with other adjuvants, MnJ has the following advantages: (1) it activates cellular immunity; (2) it promotes earlier and stronger antibody production; (3) it activates mucosal immunity; (4) it works for any antigens; (5) it can be frozen and thawed repeatedly; (6) it's non-toxic; (7) it's easy and convenient to use. MnJ can be used in the preparation of various preventive and therapeutic vaccines by strongly improving the protection effects of vaccines, but significantly reducing the amount of antigen, and the cost of vaccines. The MnJ adjuvant can be used in antitumor therapies not only as an independent small-molecule drug, but also in combination with various current tumor immunotherapies. It can significantly reduce the dosage of immune checkpoint drugs with improved therapeutic effect, thus improving the cost performance of mainstream anticancer drugs.

汇报人姓名 Speaker	单位及职务 Company & Position	邮箱 Email Address	汇报题目 Title of Roadshow
黎志良 LI Julius	苏州欧赛微科生物医药科技有限公司联合首席执行官 CO-CEO, Suzhou Oswk Bio-Pharm Co., Ltd.	juliusli@oswkbio.com	阴道乳杆菌活菌胶囊联合甲硝唑治疗细菌性阴道病（BV）预防复发的 II 期临床研究 Phase II Trial Study of a Live Lactobacillus Crispatus Capsule to Treat Bacterial Vaginosis (BV) and Prevent Recurrence of BV

项目简介

阴道卷曲乳杆菌活菌胶囊注册分类为 1 类：创新型生物制品，治疗领域为妇科感染性疾病，首选适应症为细菌性阴道病 (BV)。目前已完成 II 期临床试验。本品种作为活体生物药（Live Biotherapeutic Products，LBPs），所用菌株卷曲乳杆菌筛选自中国健康育龄妇女阴道菌群。I 期临床试验数据显示，本品种具有良好的安全性和耐受性。II 期临床试验表明，本品治疗组较安慰剂对照组疗效差异显著，治疗组显著降低患者 BV 复发率（$P < 0.01$）。

Project Introduction

Bacterial vaginosis (BV) is the most common type of gynecologic infection, with a relapse rate of 60% by 6 month post antibiotic treatment. Therefore, a combination therapy with antibiotic and Lactobacillus probiotic has been suggested to improve BV efficacy and prevent relapse rate. Our live Lactobacillus capsule, classified as a live biotherapeutic products(LBPs), contains the strain of Lactobacillus crispatus, the predominant species of vaginal lactobacilli in healthy Chinese women of childbearing age. Phase I trial showed that the live Lactobacillus therapeutic is safe and well tolerated when administrated to vagina of healthy women. Currently, results from Phase II trial indicated that the new combination regimen, e.g., simultaneously adminstration of both oral metronidazole and vaginal live Lactobacillus capsule to BV patients, is safe and resulted in a significantly lower incidence of recurrence of BV than placebo after 3 months post treatment ($P < 0.01$).

路　明 LU Ming	贵州生诺生物科技有限公司 执行副总裁 Executive Vice President, Guizhou Sinorda Biomedicine Co., Ltd.	lum@sinorda.com	新型钾离子竞争性酸阻滞剂与肿瘤免疫产品管线介绍 Introduction of a Novel Potassium-Competitive Acid Blocker And Tumor Immune Products Pipeline

项目简介

生诺医药是一家聚焦于消化道及肿瘤免疫治疗领域的创新型研发企业，由数位中、欧资深科学家团队管理。

公司目前已建立多项产品管线，现拥有一项新型钾离子竞争性酸阻滞剂一类新药（中国临床二期，即将进入临床三期），两项独家的肿瘤免疫细胞药物（欧盟临床二期，即将申报中国 IND），并将建立和优化肿瘤新生抗原 T 细胞平台及溶瘤病毒基因改造平台。

公司现正在寻求合作伙伴，力争三年内一类新药上市，两年左右完成公司上市，成为国内最具价值的创新药企业之一。

Project Introduction

Sinorda is an innovative research and development company focusing on digestion and tumor immunotherapy, jointly managed by several senior Chinese and European scientists.The company also has established extensive cooperation with well-known pharmaceutical companies, R&D institutions, CRPs, CMOs and relevant government departments at China and Oversea to achieve resource sharing, thus amplify existing advantages.

We have established several product pipelines, including a novel potassium-competitive acid blocker, X842 (Chinese clinical phase II, and will soon enter clinical phase III), and two exclusive tumor immunotherapy drugs (EU clinical phase II and will apply for China IND), and will establish and optimize tumor neoantigen T cell platform and oncolytic virus gene modification platform.

We are now looking for partners, and strive to launch the novel PCAB X842 within three years, complete the IPO within two years, and become one of the most valuable innovative drug companies in China.

汇报人姓名 Speaker	单位及职务 Company & Position	邮箱 Email Address	汇报题目 Title of Roadshow
蔡金露 CAI Jinlu	杭州康万达医药科技有限公司 助理总裁 Assistant President, Hangzhou Converd Co., Ltd.	caijinlu@ converd.com.cn	基于肿瘤免疫学的新一代溶瘤病毒药物 / 疗法创制平台 A Platform for Next Generation Oncolytic Virotherapy

项目简介

杭州康万达医药科技有限公司是致力于新一代溶瘤病毒药物和疗法（抗肿瘤生物药）的创新型科技公司。创始人胡放博士曾全程领导世界上第一个溶瘤病毒产品“安柯瑞”的研发，本次创业，其基于多年的溶瘤病毒药物研发和临床经验，开创性地搭建了溶瘤痘苗病毒、腺病毒、单纯疱疹病毒三大病毒类药物开发平台，突破性地解决了病毒 CMC 的关键问题。公司首批项目研发已获得动物实验和临床试验的双重验证，并获得了晨兴创投、华润集团等战略资本的认可和投资。

Project Introduction

ConVerd is an innovative biotech company focused on oncolytic viruses (OV) and other cancer immunotherapies. Dr. Fang Hu, the founder of ConVerd, has led the successful development of the world’s first oncolytic virus drug, Oncorine, which was approved in China in 2005. ConVerd has a team of talented and experienced professionals with expertise that covers the entire new drug development process from bench to bed. Supported by strategic investments from Morningside and China Resources Group, ConVerd has established R&D platforms for three new generation oncolytic virotherapies, including vaccinia virus, adenovirus and HSV. ConVerd has also conquered the key CMC challenges, paving the way of the commercialization of our first oncolytic virus drug. Guided by the rationale for systemic immunotherapy, ConVerd puts great effort into exploring optimal combinations of OV and other immunotherapies, especially, our pilot project is in clinical research.

施　彤 SHI Tong	北京超维知药科技有限公司 商务合作总监 BD Director, Beijing Hyper-D Technology Co., Ltd.	shitong@hyper-d.com	人工智能书写药物发现新篇章 AI Writing a New Chapter in Drug Discovery

项目简介

北京超维知药科技有限公司是一家专注于利用人工智能技术助力创新药研发的科技公司，业务主要聚焦于新药分子的设计。本次汇报分成三个部分：第一部分介绍我国医药行业现状，药物研发存在的痛点，以及国内外人工智能技术在药物研发中的应用情况；第二部分重点介绍本公司自主开发的人工智能药物设计平台的原理、功能定位、与传统药物分子设计方法相比的优势；第三部分将详细介绍超维知药利用人工智能技术进行药物分子设计的成功案例。

Project Introduction

Beijing Hyper-D Technology Co., Ltd. is a technology company focusing on the use of AI (Artificial Intelligence) technology to assist the R&D of innovative drugs. Our business mainly focuses on the design of new drug molecules. We developed a comprehensive drug discovery engine, which utilizes millions of samples and multiple data types to accelerate drug development. This report is divided into three parts: the first part introduces the current status of China's pharmaceutical industry, the existing pain points of drug R&D, and the application of AI technology in drug R&D at home and abroad; the second part presents the principle and functional orientation of the self-developed AI drug design platform, and the advantages compared with traditional drug molecular design methods; the third part introduces the successful cases of drug design using AI technology. We have a great pleasure to work with the leading companies and institutions to provide AI-aided solutions for drug discovery.

汇报人姓名 Speaker	单位及职务 Company & Position	邮箱 Email Address	汇报题目 Title of Roadshow
周天保 ZHOU Tianbao	中国科学院大学 宁波华美医院负责人 Manager, Hwamei Hospital, University of Chinese Academy of Sciences	zhouzp12@21cn.com	新型抗肝移植排斥免疫抑制剂 The New Immunosuppressant to Liver Transplantation Rejection

项目简介

注册分类：原创新药，复合药，化学药

治疗领域：肝移植，其它器官移植

临床阶段及进展结果：临床已应用过，效果良好，将申报临床试验流程

项目显著优势：现行临床上使用的抗肝移植排斥免疫抑制剂是根据经典的 T 细胞介导的细胞免疫应答理论而研制出来的，而拟研发的新型抗肝移植排斥免疫抑制剂是兼顾经典的 T 细胞介导的细胞免疫应答机制和新机制—B 细胞介导的体液免疫应答机制而研制出来的。新药具有诱导自然状态下的免疫耐受，抑制排斥反应的发生，免除终身服用免疫抑制剂，肝移植术后患者能长期存活，安全性有保障等特点，是具有我国自主知识产权的完全原创的颠覆性创新，经济效益及社会效益均十分巨大。

Project Introduction

Registration categories : original new drugs, compound medicine, chemical medicine

Therapeutic areas : liver transplantation , other organ transplantation

Clinical stage and progress Results : Clinical application has had, the effect is very good, will declare clinical trial process

Project significant advantages : Current clinical immunosuppressant to liver transplant rejection is based on the classical theory of cellular immune response mediated by T cell ,while the new immunosuppressant to liver transplant rejection intended to research and develop is both classic cell immune response mechanism mediated by T cell and new mechanism - humoral immune response mechanism mediated by B cell. The new drug possessed characteristics of induction of immune tolerance under natural state, inhibition of rejection reaction, exempt from lifetime use of immune inhibitor, long-term survival of patients after liver transplantation , safety guarantee, which was our country's disruptive innovation with proprietary intellectual property of completely original and had the very big economic and social benefits.

04

参会企业名单
Participating Company List

参会企业名单（截至 2020 年 9 月 10 日）	**List of Participating Companies** (by September 10, 2020)
21 世纪经济报道	The 21st Century Business Herald
香港生物医药创新协会	HK BIO-MED INNOTECH ASSOCIATION
GT Healthcare Capital Partners	GT Healthcare Capital Partners
Morgan Stanley Asia Limited	Morgan Stanley Asia Limited
NEJM 医学前沿	NEJM Frontiers in Medicine
奥博资本	OrbiMed
Protheragen Inc.	Protheragen Inc.
阿斯利康	AstraZeneca
艾昆纬企业管理咨询（上海）有限公司	IQVIA Enterprise Management Consulting (Shanghai) Co., Ltd.
艾美达（北京）医药信息咨询有限公司	iMeta Health Information Cousulting Co.,Ltd.
艾社康健康咨询有限公司	ACCESS Health
艾意凯咨询	L.E.K. Consulting
安图实业集团	Autobio Group Co., Ltd.
安我基因	AndAll Genomics
百放英库	BioFront
百济神州（北京）生物科技有限公司	BeiGene Shenzhou (Beijing) Biotechnology Co., Ltd.
拜耳	Bayer
宝石花医药科技（北京）有限公司	Gem Flower Pharma Tech. (Beijing) Co., Ltd.
北大未名（上海）生物制药有限公司	PEKING UNIVERSITY V-MING(SHANGHAI) BIOLOGICS CO.,LTD
北海康成制药有限公司	CANbridge Pharmaceuticals Inc.
北极光创投	Northern Light Venture Capital
北京北陆药业股份有限公司	beilu pharmacy
北京大数长胜资产管理有限公司	Beijing Greatnumbers Asset Management Company
北京毒物药物研究所	Institute of pharmacology & toxicology of Beijing
北京行远自迩咨询服务有限公司	startpointAdvisors
北京华锣投资管理有限公司	BEIJING HUAE INVESTMENT MANAGEMENT CO., LTD.
北京加科思新药研发有限公司	Jacobio Pharmaceuticals Co., Ltd.
北京康辰药业股份有限公司	Beijing Konruns Pharmaceutical Co., Ltd.
北京科林利康医学研究有限公司	Beijing Clinical Medical Research Co., Ltd.

北京科信必成医药科技发展有限公司	Beijing Cosci-Med Technology Development Co., Ltd.
北京兰璞资本管理有限公司	Jadestonevc Capital
北京诺诚健华医药科技有限公司	INNOCARE Pharma Technology Co., Ltd.
北京泰德制药股份有限公司	Beijing Tide Pharmaceutical Co., Ltd.
北京熙诚金睿股权投资基金管理有限公司	BEIJING XICHENGJINRUI CAPITAL
北京医药卫生经济研究会	Beijing medical and health economic research association
北京医院	Beijing Hospital
北京亦度正康健康科技有限公司	Beijing Yeedozencom Healthcare Science & Technology Co., Ltd.
北京易奇科技有限公司	beijing ekitech co. ,ltd
北京永泰生物制品有限公司	Immunotech Biopharm Ltd
北京煜森股权投资有限公司	BEIJING SUNFOREST CAPITAL CO., LTD.
北京圆心科技有限公司	Beijing Yuanxin Technology Co., Ltd.
北美投资讯息有限公司	NAI Interactive Ltd.
贝达药业股份有限公司	Betta Pharmaceuticals Co., Ltd.
毕马威企业咨询（中国）有限公司苏州分公司	KPMG Advisory (China)Limited Suzhou Branch
勃林格殷格翰生物药业（中国）有限公司	Boehringer Ingelheim Biopharmaceuticals China
亳州市谯城区珍鑫投资管理有限公司	Bozhou Qiaocheng Zhenxin Investment Management Co., Ltd.
博瑞生物医药（苏州）股份有限公司	BrightGene Bio-Medical Technology Co., Ltd.
常州方圆制药有限公司	Changzhou Fangyuan Pharmaceutical Co., Ltd.
成都百裕制药股份有限公司	Chengdu Baiyu pharmaceuticals
成都惠泰生物医药有限公司	Chengdu Huitai Biomedicine Co., Ltd.
成都金瑞基业生物科技有限公司	Chengdu Jinrui Foundation Biotech Co., Ltd.
成都康弘药业集团股份有限公司	Chengdu Kanghong Pharmaceutical Group Co., Ltd.
成都医云科技有限公司	Chengdu Yiyun Technology Co., Ltd.
成都苑东生物制药股份有限公司	Chengdu Easton Biopharmaceuticals Co., Ltd.
达晨财智创业投资管理有限公司	fortunevc
大湾生物控股有限公司	Great Bay Bio Holdings Limited
淡水泉基金	Springs Capital
道远资本管理（北京）有限公司	Tao CAPITAL
德福资本	GL Capital Group
德高信控股集团有限公司	Takson Group Company Limited
缔脉	dMed
鼎晖投资	CDH Investments
东方财富证券股份有限公司	Eastmoney-Securities
东方弘泰资本	Orient Hontai Capital
东曜药业有限公司	TOT Biopharma Co., Ltd.

毒物药物研究所	Institude of Toxicology and Pharmacology
分享投资	Share Capital
复旦大学	Professor of Health Economics, School of Public Health, Fudan University
甘李药业股份有限公司	Gan & Lee Pharmaceuticals.
高特佳弘瑞投资	GTJA HongRui Investment
高特佳投资集团	Gaotejia investment group
歌礼生物科技（杭州）有限公司	Ascletis BioScience Co., Ltd.
工银国际投资有限公司	ICBCI
光大证券股份有限公司	EVERBRIGHT SECURITY
光辉国际	Korn Ferry
光量资本	Photonfund
广东天普生化医药股份有限公司	Guangdong Techpool Biochemical Medicine Co., Ltd.
广东中科药物研究有限公司	Guangdong Zhongke medicine R&D Ltd.
广东中润（集团）医药有限公司	ZORUN PHARMA
广东众生睿创生物科技有限公司	Guangdong Raynovent Biotech Co., Ltd.
广东众生药业股份有限公司	Guangdong Zhongsheng Pharmaceutical Co., Ltd.
广州天普	Techpool
广州元禾原点投资管理有限公司	Oriza Seed Fund Management Co., Ltd.
广州智睿医药科技有限公司	DM Intelligence Limited
国家卫生健康委药物与卫生技术评估中心	National Health Development Research Center
国家药监局	NMPA
国泰君安证券	guitaijunan securities
国投创新投资管理有限公司	SDIC Fund
国新风险投资	CRVC
国药控股分销中心有限公司	Sinopharm Group Distribution Co., Ltd.
国药资本	Sinopharm Capital
海口市制药厂有限公司	Haikou Pharmaceutical Co., Ltd.
海南博鳌乐城国际医疗旅游先行区开发建设有限公司	hainan
海南海药股份有限公司	Hainan Haiyao Co., Ltd.
杭州煌震股权投资有限公司	Huangzhen Venture
杭州嘉因生物科技有限公公司	Exegenesis Bio Hangzhou Jiayin Ltd
杭州康晟健康管理咨询有限公司	Hangzhou Kangsheng Health Management Consulting Co., Ltd.
杭州苓华科技有限公司	Hangzhou Linghua Technology Co., Ltd.
杭州民生药业有限公司	Hangzhou Minsheng Pharmaceutical
杭州索元生物医药股份有限公司	Hangzhou Denovo Biopharma Co., Ltd.

杭州泰格医药科技有限公司	Hangzhou tigermedconsulting Co., Ltd.
杭州医学院	Hangzhou Medical College
杭州憶盛医疗科技有限公司	Hangzhou Yisheng Medical Technology Co., Ltd.
杭州英邈生物科技有限公司	Hangzhou iiMMunity Biotechnology Co., Ltd.
和铂医药	Harbour Biomed
和记黄埔医药（上海）有限公司	Hutchison MediPharm Limited
和其瑞医药（南京）有限公司	Hope Medicine (Nanjing) Co., Ltd.
和玉资本	MSA capital
湖南海药鸿星堂医药有限公司	Hunan Haiyaohongxingtang
华北制药	Huabei Pharma Co., Ltd.
华北制药股份有限公司	North China Pharmaceutical Co., Ltd.
华东理工大学	East China University of Science and Technology
华金大道投资有限公司	HUAJINDADAO INVESTMENT Co., Ltd.
华领医药技术（上海）有限公司	Hua Medicine (Shanghai) Ltd.
华润生命科学集团有限公司	China Resources Life Sciences Group Limited
华润双鹤药业股份有限公司	CR Double-Crane Pharmaceutical Inc.
华泰国际私募基金	HT Private Equity
华夏幸福产业投资有限公司	CFLD
华中科技大学	Huazhong University of Science and Technology
寰信集团（香港）有限公司	WORL FAITH HOLDINGS (HK) LIMITED
辉凌医药咨询（上海）有限公司	Ferring Pharmaceuticals
辉瑞	PFIZER
辉瑞生物制药	Pfizer Biopharm
基石药业（苏州）有限公司	CStone Pharmaceuticals Co., Ltd.
暨南大学	Jinan University of Basic Medicine
嘉会医学研究和教育集团	Jiahui Medical Research & Education Group
嘉兴太美医疗科技有限公司	Jiaxing Taimei Medical Technology Co., Ltd.
江苏艾立康药业股份有限公司	JIANGSU ALICORNPHARMACEUTICAL Co., Ltd.
江苏奥赛康药业有限公司	Jiangsu Aosaikang pharmaceutical Co., Ltd.
江苏豪森药业集团有限公司	Jiangsu Hansoh Pharmaceutical Co., Ltd.
江苏恒瑞医药股份有限公司	Jiangsu Hengrui Medicine Co., Ltd.
江苏集萃新型药物制剂技术研究所有限公司	IADDT
江苏康缘药业股份有限公司	Jiangsu Kanion Pharmaceutical Inc.
江苏柯菲平医药股份有限公司	Jiangsu Carephar Pharmaceutical Co., Ltd.
江苏荃信生物医药有限公司	Qyuns
江苏省产业技术研究院	JITRI

江苏先声药业有限公司	Jiangsu Simcere Pharmaceutical Co., Ltd.
江西济民可信集团有限公司	JIANGXI JEMINCARE GROUP CO., LTD.
界面新闻	JIEMIAN
军事医学研究院	Institute of Military Medicine
军事医学研究院毒物药物研究所	Beijing Institute of Pharmacology & Toxicology
苏州开拓药业股份有限公司	Kintor Pharmaceutical Co., Ltd.
凯莱英医药集团（天津）股份有限公司	Asymchem Laboratories (Tianjin) Co., Ltd.
凯西医药	Chiesi Pharma
康君资本	Bayland capital
科林利康	clinical service
科瑞百奥生物技术有限公司	Cryo Bio Technology Co., Ltd.
科望（上海）生物医药科技有限公司	Elpiscience Biopharma, Ltd.
昆翎医药	ClinChoice
昆山创源科技园管理有限公司	InnoSpring KunShan
来凯医药科技（上海）有限公司	Laekna Therapeutics Shanghai Co., Ltd.
朗玛峰创投	LMF
乐普（北京）医疗器械股份有限公司	Lepu Medical Technology (Beijing) Co., Ltd.
礼新医药科技（上海）有限公司	LaNova Medicines Limited
联新资本	NEW ALLIANCE CAPITAL
零氪科技（北京）有限公司	LinkDoc Co., Ltd.
龙磐投资	LAPAMCAPITAL
鲁南制药集团股份有限公司	Lunan Pharmaceutical Group Corporation
路透社	Reuters News
罗特集团有限公司	Roth Group Co., Ltd.
罗欣药业（上海）有限公司	Luoxin Pharmaceutical Co., Ltd.
绿叶制药集团有限公司	Luye Pharma Group Co., Ltd.
山东绿叶制药有限公司	Shandong Luye Pharmaceutical Co., Ltd.
迈纽斯（苏州）生物科技有限公司	mns
迈哲华投资咨询有限公司	Martec Group
麦克米伦信息咨询服务（上海）有限公司	Macmillan Information Consulting Services (Shanghai) Co., Ltd.
媒音文思	m-events
每日经济新闻	national business daily
美柏医健	MyBioGate
美罗药业股份有限公司	Merro Pharmaceutical Inc.
美天旎中国	Miltenyi
蒙盛投资	Mongrand

米内网	MENET
摩根大通银行（中国）有限公司	JP Morgan
摩根斯坦	JPMS
南方周末报社	Southern Weekly
南京生物医药谷建设发展有限公司	Nanjing Biotech and Pharmaceutical Valley Construction and Development Co., Ltd.
南京圣和药业股份有限公司	Nanjing Sanhome Pharmaceutical Co., Ltd.
南京正大天晴制药有限公司	Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.
南鲨医疗（苏州）科技有限公司	NANYUN
诺华	Novartis
诺辉健康	New Horizon Health
品观科技（武汉）有限公司	pinguan.com
平安海外控股	Ping An Overseas
平安银行股份有限公司	PingAn Bank Co., Ltd.
齐鲁制药有限公司	QILU PHARMACEUTICAL
启明创投	Qiming Venture Partners
前景科学	Prospect Science
前沿生物药业（南京）股份有限公司	Frontier Biotechnologies Inc.
青岛黄海制药有限责任公司	Huanghai Pharmaceutical Co., Ltd.
取势资本	potential capital
荣盛（厦门）投资有限公司	Rongsheng (Xiamen) Investment Co., Ltd.
如文思	RWS Group
瑞石生物医药有限公司	Reistone Biopharma
瑞希奥	KingDoris
瑞致达中国	VISTRA CHINA
润东医药研发（上海）有限公司	Rundo International Pharmaceutical Research & Development Co., Ltd.
赛德思投资	Cedrus Investments
三生制药集团	3S Pharmaceutical Group
三叶草生物制药	Clover Biopharmaceuticals
三一众智（天津）企业管理咨询有限公司	Wisdom & Vision Consulting
厦门大学药学院	School of Pharmaceutical Sciences, Xiamen University
山东方坦思生物制药有限公司	Shandong Fontacea Pharmaceutical Co., Ltd.
山东谷雨春生物科技有限公司	Shandong guyuchun biotechnology Co., Ltd.
山东金城医药集团	Jincheng pharma
山东未名生物医药股份有限公司	Shan Dong Sinobioway Biommedcine Co., Ltd.
山西证券股份有限公司	Shan Xi security Co., Ltd.

杉本思（杭州）科技有限公司	Cenponts healthcare
杉本思欧洲	CENPONTS EUROPE
陕西壹品商务信息科技有限公司	Shanxi Yipin Business Information Technology Co., Ltd.
上海岸迈生物科技有限公司	EpimAb Biotherapeutics Inc.
上海碧博生物医药科技有限公司	Shanghai BiBo Pharma
上海臣邦医药科技股份有限公司	Shanghai Chenpon Pharmaceutical Co., Ltd.
上海东富龙科技股份有限公司	Shanghai Tofflon Science and Technology Co., Ltd.
上海复宏汉霖生物技术股份有限公司	Shanghai Henlius Biotech, Inc.
上海复星医药产业发展有限公司	Shanghai Fosun Pharmaceutical (Group) Limited by Share Co., Ltd.
上海海欣集团股份有限公司	Shanghai Haixin Group
上海昊海生物科技股份有限公司	3Healthcare
上海合全药业	STA
上海和誉生物医药科技有限公司	Abbisko Therapeutics
上海华氏资产经营有限公司	HSCI
上海华旭投资有限公司	china sunlight
上海汇伦生物科技有限公司	Shanghai Huilun Life Science and technology Co., Ltd.
上海健耕医药科技股份有限公司	GENEXT
上海金耕资产管理有限公司	GOLDENHILL ASSET MANAGEMENT CO., LTD.
上海炬睿	Talentorch
上海君实生物医药科技股份有限公司	Shanghai Junshi Biosciences Co., Ltd.
上海醴泽投资管理有限公司	LYZZ Capital
上海量磁资产管理有限公司	shanghai lc assets management Co., Ltd.
上海浦耀信晔投资管理有限公司	Shanghai PUXIN Capital Co., Ltd.
上海硕佑投资	shuoyou
上海特化医药科技有限公司	Topharman Shanghai Co., Ltd.
上海熙华检测技术有限公司	shanghai Xihua Scientific
上海药明巨诺生物科技有限公司	JW Therapeutics (Shanghai) Co., Ltd.
上海药明康德新药开发有限公司	WuXi AppTec Co., Ltd.
上海药明生物技术有限公司	WuXi Biologics
上海药坦药物研究开发有限公司	Shanghai Neutan Pharma R&D Co., Ltd.
上海医药（香港）投资公司	Shanghai pharmaceuticals
上海医药集团股份有限公司	Shanghai Pharmaceuticals Holding Co., Ltd.
上海宇道生物技术有限公司	Nutshell Biotech (Shanghai) Co., Ltd.
上海照友投资管理有限公司	Zhaoyou Investment
上善若水（北京）基金管理有限公司	S.S.R.S. Fund Management(Beijing)Co.,Ltd
上药帛康生物医药（上海）有限公司	SPHBIOCAD

上药博康生物医药（香港）有限公司	SPH-BIOCAD (HK) Limited
深圳贝美药业有限公司	Shenzhen Beimei Pharmaceutical
深圳泛谷药业股份有限公司	Shenzhen Foncoo Pharmaceutical Co., Ltd.
深圳蓝海创业投资基金管理有限公司	BOCG
深圳前海元明资产管理有限公司	Shenzhen Qianhai YuanMing Asset Management Co., Ltd.
深圳清华大学研究院 / 力合科创集团	RITS/Leaguer Group
深圳市东方嘉盛供应链股份有限公司	Shenzhen Easttop Supply Chain Management Co., Ltd.
深圳市泛谷药业股份有限公司	Shenzhen Foncoo Pharmaceutical
深圳市高特佳弘瑞投资有限公司	GTJA Investment Group
深圳市高特佳投资集团	GTGA INVESTMENT GROUP
深圳市新恒利达资本管理有限公司	Shenzhen New Value Capital Management Co., Ltd.
深圳微芯生物科技股份有限公司	Shenzhen Chipscreen Biosciences Co., Ltd.
深圳信立泰药业股份有限公司	Shenzhen Salubris Pharmaceuticals Co., Ltd.
深圳市倚锋投资管理企业（有限合伙）	Shenzhen Efung Venture Capital Co., Ltd.
沈阳三生制药集团	3Sbioinc (Shenyang) Pharma Group
施维雅（天津）制药有限公司	Servier TJ Pharmaceutial Company
施维雅国际研究合作	SERVIER BIOINNOVATION ASIA
石家庄国家高新技术产业开发区投资服务局	SHIJIAHZUANG NATIONAL HI-TECH INDUSTRY DEVELOPMENT ZONE INVESTMENT SERVICE BUREAU
首都医科大学附属北京儿童医院	Beijing Children's Hospital, Capital Medical University
首都医科大学附属北京天坛医院	BeiJing Tiantan hospital, Capital medical university
首正泽富创新投资（北京）有限公司	ShouZheng Zefu Innovation Investment (Beijing) Co., Ltd.
水木未来（北京）科技有限公司	Shuimu BioSciences Ltd.
四川辉阳生命工程股份有限公司	Sichuan Huiyang Life Science and Technology Corporation
四川科伦博泰生物医药股份有限公司	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科伦药业	Sichuan Kelun Pharmaceutical Co., Ltd.
松禾资本医疗健康基金	Pine VC
苏州工业园区产业创新中心	SIPAC Innovation Center
苏州工业园区管委会	SIPAC
苏州工业园区科技招商中心	Suzhou Industry Park Science and Technology Investment Center
苏州工业园区投资促进局	Suzhou industrial park investment promotion board
苏州工业园区中鑫大一投资管理合伙企业（有限合伙）	Innocapital
苏州基金	Suzhou Fund
苏州吉玛基因股份有限公司	Suzhou GenePharma Co., Ltd.
苏州开拓药业股份有限公司	Suzhou Kintor pharmaceutical Co., Ltd.
苏州鲲鹏生物技术有限公司	Suzhou KunPeng Biotech Co., Ltd.

苏州朗科生物技术股份有限公司	SUZHOU LANXITE BIOTECH
苏州隆门创投基金	Suzhou Longmen
苏州绿晖环保科技有限公司	Suzhou Luhui Environmental Protection Technology Co., Ltd.
苏州欧赛微科生物医药科技有限公司	Suzhou Oswk Bio-Pharm Co., Ltd.
苏州瑞博生物技术股份有限公司	Suzhou Ribo Life Science Co., Ltd.
苏州闻天医药科技有限公司	VINTAGENCE BIOTECHNOLOGY, LTD
苏州旭辉检测有限公司	Huhui Analysis Co., Ltd.
苏州泽璟生物制药股份有限公司	Suzhou Zelgen Biopharmaceuticals Co., Ltd.
苏州中科院产业技术创新与育成中心	CAS Innovation and Incubation Center, Suzhou
苏州卓凯生物技术有限公司	Suzhou Joekai Biotechonolgy LLC
太极集团有限公司	Taiji Group Co., Ltd.
泰福资本	TF Capital
泰吉医药	NA
藤济（厦门）生物医药科技有限公司	NUCMITO PHARMACEUTICALS COMPANY LIMITED
天风证券	tianfeng
天镜生物科技（上海）有限公司	I-Mab Biopharma Co., Ltd.
天士力医药集团股份有限公司	Tasly Pharmaceutical Group Co., Ltd.
天士力资本	TASLY capital
天演药业（苏州）有限公司	Adagene (Suzhou) Limited
通德资本	Hermed Capital
万得信息技术股份有限公司	Wind
威尔逊·桑西尼·古奇·罗沙迪律师事务所	Wilson sanshini gucci Rosetti law firm
微医控股（浙江）有限公司	Vice President of We Doctor Group
维亚生物科技控股集团	VIVA BIOTECH HOLDINGS
武汉大学	Wuhan University
武汉唯尔思股权投资基金管理有限公司	Wuhan wealth capital management
武汉誉祥医药科技有限公司	Wuhan Yuxiang Pharmaceutical Technology Co., Ltd.
西安新通药物研究有限公司	Xi'an Xintong Pharmaceutical Research Co., Ltd.
西安杨森制药有限公司	Xian Janssen
西南证券股份有限公司	Southwest Securities Co., Ltd.
香港交易所	Hong Kong Exchanges and Clearing Limited
逍遥资本	J&R Capital
新兴际华海南海药股份有限公司	Xinxing Cathay International Pharmaceutical Holdings Company Limited
信达生物制药（苏州）有限公司	Innovent Biologics (Suzhou) Co., Ltd.
兴鼎投资	Xingding Investment Co., Ltd.

兴业证券	Industrial Securities Co., Ltd.
兴证创新资本管理有限公司	CHINA INDUSTRIAL SECURITIES CAPITAL MANAGEMENT Co., Ltd.
亚盛医药	Ascentage Pharma
扬子江药业集团广州海瑞药业有限公司	YZRiver
扬子江药业集团南京海陵药业有限公司	Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.
耶鲁大学	Yale
野村东方国际证券有限公司	Nomura Orient International Securities Co., Ltd.
一塔资本	itacapital
医渡云技术（北京）有限公司	YIDU CLOUD
医药经济报	Medicine Economic News
义乌市国有资本运营有限公司	Yiwu State owned Capital Operation Co., Ltd.
鹰翅知产有限公司	EAGLE IP LIMITED
赢迪资本	Indaco Capital
远大医药（中国）有限公司	GrandPharma(China) Co., Ltd.
跃科人才	Spring Professional
粤澳中医药科技产业园开发有限公司	TCM Science and Technology Industrial Park of Cooperation between Guangdong and Macao
长风药业股份有限公司	CF Pharmtech, Inc.
招商证券股份有限公司	CMSCHINA
浙江九洲药业股份有限公司	ZHE JIANG JIUZHOUPHARMACEUTICAL Co., Ltd.
浙商创投股份有限公司	Zheshang Venture Capital Co., Ltd.
臻悦生物科技江苏有限公司	Genecast
正大青春宝药业有限公司	Chiataj Qingchunbao Pharmaceutical Co., Ltd.
正大天晴药业集团股份有限公司	CTTQ Group Inc.
智康弘义	BioCity
中国科学院上海药物研究所	Shanghai Institute of Materia Medica, Chinese Academy of Sciences
中国生物制药有限公司	Sino Biopharmaceutical Limited
中国药科大学	China Pharmaceutical University
中国医药创新促进会	China Pharmaceutical Innovation and Research Development Association
中南高科产业集团	zhongnan hightech
中天上海生物科技有限公司	Vitahouse Biotechnology Science and Technology Co., Ltd.
中信证券股份有限公司	CITIC SECUTIRES
中银集团投资有限公司	BOCGI

中誉宏远（北京）投资有限公司	zhongyuhongyuan
重庆金通元股权投资基金管理有限公司	Chongqing Kingdom Equity Investment Fund Management Co., Ltd.
重庆植恩药业有限公司	Zein Pharmaceutical Co., Ltd.
珠海横琴濠麦科技有限公司	Zhuhai Hengqin Hao Mai Technology Co., Ltd.
上海复星医药（集团）股份有限公司	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
中国医学科学院药物研究所	Institute of Materia Medica, Chinese Academy of Medical Sciences
北京协和医院	Peking Union Medical College Hospital
山东齐鲁制药集团有限公司	Shandong Qilu Pharmaceutical Group Co., Ltd.
四川科伦药业股份有限公司	Sichuan Kelun Pharmaceutical Co., Ltd.
再鼎医药	ZAI Lab
浙江华海药业股份有限公司	Zhejiang Huahai Pharmaceutical Co., Ltd.
浙江医药股份有限公司	Zhejiang Medicine Co., Ltd.
珐博进（中国）医药技术开发有限公司	FibroGen (China) Medical Technology Development Co., Ltd.
中天（上海）生物科技有限公司	Microbio (Shanghai) Biotechnology Co., Ltd.
高瓴资本管理有限公司	Hillhouse Capital Management, Ltd.
红杉资本	Sequoia Capital
方恩（天津）医药发展有限公司	Fountain Medical (Tianjin) Co., Ltd.
应世生物科技（上海）有限公司	INxMed (Shanghai) Co., Ltd.
和铂医药（苏州）有限公司	Harbour BioMed Co., Ltd.
亘喜生物科技（上海）有限公司	Gracell Biotechnologies (Shanghai) Co., Ltd.
华平投资	Warburg Pincus
国信医药科技（北京）有限公司	GX Pharma Technology (Beijing) Co., Ltd.
北京大学分子医学南京转化研究院	PKU-Nanjing Joint Institute of Translational Medicine
西湖大学	Westlake University

WARBURG PINCUS
华 平 投 资

拥有全球资源
扎根中国本土的企业成长伙伴

华平投资是全球领先的私募股权投资机构，专注于成长型投资。目前公司在全球 40 多个国家投资于各行各业、处于不同发展阶段的逾 185 家企业。华平投资总部位于纽约，并在 10 个国家有 14 个办公室。

530+ 亿美元
全球资产管理规模

900+ 家
全球累计被投企业总数

54 年
全球投资经验

华平投资是中国和东南亚地区投资规模最大、最活跃的国际私募股权投资机构之一，目前在该地区有 60 多家被投企业。2019 年，华平中国二号基金成功募资 45 亿美元，新增 90 亿美元资金池投向中国和东南亚，这是目前最大的专注于该地区的私募股权投资资金池之一。

140+ 亿美元
中国和东南亚
累计投资金额

140+ 家
中国和东南亚
累计被投企业总数

26 年
中国和东南亚
投资经验

所有数据更新于 2020 年 7 月 10 日

聚焦五大领域，深耕医疗健康主题

在中国和东南亚，华平投资聚焦医疗健康、消费、金融服务、房地产与商业服务和科技、媒体与通信五大领域，围绕万亿级主题持续挖掘投资机会、培养行业龙头。

华平投资在医疗健康领域拥有近50年经验，在全球投资了诸多标杆企业和创新公司。华平投资已累计在中国医疗健康行业投资超过17亿美元，现有被投企业覆盖肿瘤治疗、辅助生殖、创新药、母婴、医美、流通分销等多个细分领域。华平投资在中国医疗健康行业重点关注药品和器械的技术创新、医疗服务升级以及分销/零售渠道整合。

医疗健康领域中国部分被投企业

海和药物 HaiHe Pharmaceutical
药明康德 WuXi AppTec
CTBB 泰邦生物
乐普医疗 LEPU MEDICAL
angelalign 时代天使
安我 AND ALL
华熙大昌 HTDK
锦欣生殖 JINXIN FERTILITY
HYGEIA 海吉亚医疗
amcare 美中宜和医疗集团

华平投资在中国办公地点

北京
北京市朝阳区建国门外大街 1 号国贸大厦三期 A 座 26 层
邮编：100004
+86 10 8529 2688

上海
上海市石门一路 288 号
兴业太古汇香港兴业中心一座 45 楼
邮编：200041
+86 (21) 6069 7388

香港
香港中环金融街 8 号
IFC 二期 6703 室
+852 2536 6183

了解更多信息
请扫描二维码

先声药业 Simcere

让患者早日用上更有效药物

Providing Today's Patients with Medicines of the Future

先声药业是一家快速转型为创新和研发驱动的制药公司，获批建设“转化医学与创新药物国家重点实验室”，致力于“让患者早日用上更有效药物”。先声药业专注于肿瘤（含细胞治疗）、中枢神经和自身免疫三大治疗领域，拥有多元化且领先的创新产品组合。秉持自主研发与合作研发双轮驱动的策略，先声药业与多家全球医药企业及生物技术公司成为战略合作伙伴，促进全球生命科学成果在中国的价值实现。

Simcere Pharmaceutical Group is rapidly transitioning to an innovation and R&D-driven pharmaceutical company, with a mission of "providing today's patients with medicines of the future." It has established a national key laboratory of translational medicine and innovative pharmaceuticals. Simcere focuses on oncology (including cell therapy), central nervous system disease and autoimmune disease therapeutic areas, with a diversified product portfolio and industry-leading capabilities. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading pharmaceutical companies and biotechnology companies, in an effort to bring more global life science breakthroughs to China.

R&D
研发

南京研发中心

专注于创新药和高壁垒仿制药的研发

上海创新中心

专注于创新药的研发

波士顿创新中心

专注于研发以细胞治疗为代表的先进疗法

获国家科学技术部批准建设

转化医学与创新药物国家重点实验室

江苏先声药业有限公司
Jiangsu Simcere Pharmaceutical Co.,Ltd.

No. 699-18, Xuanwu Avenue, Nanjing, 210042
+86 25 8556 6666
www.simcere.com

创新驱动-创新商业模式

西安杨森是强生在华最大的制药子公司，也是改革开放以来最早进入中国的跨国制药公司之一。30 多年来，西安杨森一直致力于引进和生产高质量的创新产品来满足不断增长的医药卫生需求。我们致力成为中国制药行业的领跑者，并专注于九大治疗领域，精神病学，神经病学，感冒咳嗽及发热 / 消化，皮肤病学 / 抗过敏，血液病学，免疫学，实体瘤、传染病和肺动脉高压领域。患者在等待，我们汇聚先进的理念、追求具有发展前景的科学成果，将挽救生命、改善患者生活视为己任。西安杨森，创造没有疾病的未来。

创新驱动-我们的产品研发

针对中国复杂而紧迫的医疗健康需求，我们通过药品研发和医学研究创新为中国医药市场带来了一系列革新性产品，为患者疾病的改善创造新的可能。我们从疾病入手推动研发重点，与本土优秀人才合作，最大化运用优质研发资源；我们提供创新药品及综合医疗解决方案，以确保患者得到更好的产品和相关治疗。

精神科

维思通® 恒德® 善思达®
善妥达® 芮达® 专注达®

神经科

喜普妙® 妥泰® 西比灵®

血液病学

万珂® 达珂® 亿珂®
兆珂®

实体瘤

泽珂®
安森珂®

感冒咳嗽及发热 / 消化

吗丁啉® 泰诺林® 美林®
易蒙停® 安乐士® 泰诺®
力洛® 太宁® 艾舒®

皮科 / 抗过敏

雷诺考特® 达克宁® 皿治林®
金达克宁® 息斯敏® 立复汀®
斯皮仁诺® 派瑞松® 采乐®
妇科达克宁®

免疫学

类克® 喜达诺® 欣普尼®
特诺雅®

传染病

恩临® 斯耐瑞® 普泽力®

肺动脉高压

做朴舒® 优拓比®
全可利® 泽维可®

*此外，他可安®、多瑞吉®、及通安®、及力克雷®等产品，拓展了我们在糖尿病治疗及镇痛等领域的产品线。

宝石花医药科技（北京）有限公司由宝石花医疗集团与安欣泰（北京）医院管理有限公司合资组建。

宝石花医疗集团旗下拥有全资及控股子公司38个，集团所属医疗机构共计174家，其中三级医院7家，二级医院18家，一级医院21家，社区卫生服务中心28家，社区卫生服务站、门诊部100家，总床位数10522张，年门诊量800万人次，年住院量30万人次。

安欣泰（北京）医院管理有限公司由中国科学院院士葛均波和中国医药创新促进会会长宋瑞霖创立，专家资源雄厚。

宝石花医药科技致力于打造全新、高效，以患者为中心，以数据为驱动，赋能人工智能机器学习的开放式一体化临床研究及成果转化综合服务平台。

业务板块

1

健康受试者研究--2个I期临床研究中心，5400㎡，178张床位

2

肿瘤早期研究--与上海东方医院建立战略合作，作为卫星中心参与

3

顶层研究设计--为创新药早期研究提供研究策略咨询服务

4

外院随访--基于宝石花所属医院地域优势为临床研究受试者提供外院随访

5

真实世界研究—基于宝石花医疗集团170多家医院数据资源优势开展各种类型研究

6

临床研究项目管理--为申办方协调各方资源、协助运营临床研究项目，保障项目的质量及进度

联系我们

地　　址：北京市东城区东四十条甲22号南新仓商务大厦A706

联系电话：010-67013860

业务联系：商务部总监 余耀武 18601301790

bioBAY

创业人才 / 企业故事 / 政策解读 / 融资上市 / 精品会议

中国最具有创新力的生命科学故事，都在这里。

关注BioBAY公众号回复“抽奖”，即可获取小礼品，更有机会获得
《后疫情时代中国医药健康领域趋势展望》医药健康行业蓝皮书一份。





Insight
China Pharma Data

免费抽奖

扫码赢 Beats/AirPods

100% 中奖



奖品领取— 博览中心 A 馆 1 层序厅 8 号展位

更多奖品

Beats / AirPods / Insight 大礼盒 / 手持风扇 / 话费 10 元
2020 版药品注册管理办法（纸质书）/ 帆布袋 / 一个月试用

Insight 数据库是国内领先的医药大数据平台
提供专业的医药行业数据情报服务，让决策更精准，让工作更高效

电话：400-6571-918　　官网：db.dxy.cn

CBIIC 2020

第六届中国医药创新与投资大会将于2021年9月25-27日在苏州举办

2021 China BioMed Innovation and Investment Conference

September 25-27, 2021 Suzhou China

会议服务号
CBIIC Official WeChat

开幕式直播
OC Webcast

照片直播
Live Photo

会议微站
Conference Microsite

满意度调查
CBIIC Survey

一对一邀约系统
One-on-One Partnering System